Boca Raton London New York Singapore
Published in 2005 by Taylor & Francis Group 6000 Broken Sound Parkway NW, Suite ...
86 downloads
1664 Views
24MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
Boca Raton London New York Singapore
Published in 2005 by Taylor & Francis Group 6000 Broken Sound Parkway NW, Suite 300 Boca Raton, FL 33487-2742 © 2005 by Taylor & Francis Group, LLC No claim to original U.S. Government works Printed in the United States of America on acid-free paper 10 9 8 7 6 5 4 3 2 1 International Standard Book Number-10: 0-8247-5833-1 (Hardcover) International Standard Book Number-13: 978-0-8247-5833-2 (Hardcover) Library of Congress Card Number 2005041805 This book contains information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to publish reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the consequences of their use. No part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers. For permission to photocopy or use material electronically from this work, please access www.copyright.com (http://www.copyright.com/) or contact the Copyright Clearance Center, Inc. (CCC) 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged. Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe. Library of Congress Cataloging-in-Publication Data Principles and practices in cutaneous laser surgery / editor, Arielle N.B. Kauvar ; associate editor, George J. Hruza. p. ; cm. – (Basic and clinical dermatology ; 33) Includes bibliographical references and index. ISBN 0-8247-5833-1 1. Skin—Laser surgery. I. Kauvar, Arielle N. B. II. Hruza, George J. [DNLM: 1. Laser Surgery—methods. 2. Skin Diseases—surgery. WR 650 P9566 2005] RL120.L37P75 2005 617.4’770598—dc22
Taylor & Francis Group is the Academic Division of T&F Informa plc.
2005041805
Visit the Taylor & Francis Web site at http://www.taylorandfrancis.com
Dedication
To my husband, David R. Kauvar And my three wonderful sons, Ellery, Darien and Hadley Kauvar, For filling my life with love and happiness To my parents, Berta and Harry Bienenstock, For their enduring affection and steadfast guidance Arielle N.B. Kauvar
To my children Stephanie and Paul Hruza For giving my life joy and fulfillment To my parents Judita and Zdenek Hruza For their unwavering support and love George Hruza
Foreword
Almost all clinical texts on skin therapy with lasers and other non-invasive energy sources are in some way out of date, because this fascinating field is prone to making progress (which is discussed a bit more, below). So, read this excellent book as soon as possible. Part of it will be passe´ within a few years, although I don’t know exactly which part. In 25 years, however, this book will still be worth reading. Basic principles inherent in the science and art of medicine do not fade away, and nothing is ever “un-invented”. Indeed, our best stuff is not really new. Arielle Kauvar and George Hruza have given us something built to last, written by colleagues with clinical acumen based on a wealth of ideas and experience. This text should be fun for anyone who wields or thinks about wielding therapeutic photons. I plan to keep it handy for my own use, for residents and students, and for those stunningly inquisitive patients who seem to abound in Boston. Medical professionals have used light to treat skin problems for at least 3000 years. Thermal treatments of skin have been around on a fee-for-service basis for at least twice that long. The recent “explosion” of lasers, intense pulsed light (IPL) sources, lightactivated drugs (photodynamic therapy, PDT), ultrasound, and advanced radiofrequency treatments has occurred during ,1% of this long history, for good reasons. Laser skin surgery is undeniably “high-tech,” and new technology is neat stuff. Lasers are far smaller, more reliable, versatile, efficient, long-lived, and controllable. The recent optical telecommunications “bubble” created many new fiber-based lasers, amplifiers, scanners and detectors that are just beginning to trickle down into medicine. However, new technology is merely a stimulus, and not the primary reason for progress in this field. Very soon after the first laser was invented in 1960—a flashlamp-pumped, longpulsed ruby laser—Leon Goldman, MD and other admirable pioneers widely explored its potential for laser skin surgery. More than 30 years later, the same laser was used to create the “breakthrough” of permanent laser hair removal, which is now available around the world using other lasers and more recently, intense pulsed light sources. Why did it take so long? Intense pulsed light sources were invented long before lasers; why did they appear much more recently than lasers in dermatology? IPLs are xenon flashlamps with optical filters, which have been around for about 60 years. So, if IPLs are a great leap backward—why not keep going? Any sophomore at MIT could show that focused, filtered sunlight can achieve about the same spectrum and brightness as an IPL, because the surface of the sun is a plasma at the same temperature as that in our IPLs. Unless someone in the esthetic device industry with a death-wish does it first, v
vi
Foreword
I hope some day to enjoy making a scanned, focused, solar “photorejuvenator,” just for fun. How ironic it would be to use sunlight for treating skin damage caused by itself. So, if new technology is not the primary limitation to progress in this high-tech corner of medicine—what is? The answer is a humble one, pertinent to this book: we lack the understanding necessary for progress. I do not mean a basic physical or biological science understanding. What we lack most is the ability to pose clinical connections with existing science and technologies. The readership of this book (yes, you!) is in a position to contribute something to that kind of understanding. As a group of biomedical professionals we are no more or less intelligent, and no more or less naı¨ve, than those before us during millennia of using light to treat skin disease. Oddly enough, it is probably the most recent info in this book that runs the greatest risk of early obsolescence. The trick, apparently, is to do something both new and long-lasting. I like this book because it brings the attentive reader to the brink of our lack of understanding. Bon appetit! R. Rox Anderson, MD Prof. of Dermatology Director, Wellman Center for Photomedicine Harvard Medical School
Preface
Lasers have become integral to the modern practice of medicine in the fields of dermatology, plastic surgery, otolaryngology, and phlebology. With the skin being the most accessible organ in the body, many cutaneous disorders and conditions are ideally suited to treatment by laser technology. Lasers are safely used to destroy or alter epidermal and dermal processes and lesions comprising blood vessels or pigment. With the development of the principles of “selective photothermolysis” by Drs. R. Rox Anderson and John Parrish in the 1980s, selective site-specific destruction of skin lesions became a reality. The appropriate combination of laser wavelength and exposure time enabled the removal of blood vessels and pigment without affecting the surrounding tissue. For the first time in medical history, port wine stains were gradually lightened with a series of noninvasive treatments leaving these patients with normalappearing skin. Similarly, tattoos and melanocytic lesions could be targeted by pigmentabsorbing lasers without altering the normal skin pigmentation. The same basic principles have been used to create lasers that selectively damage leg veins and hair follicles. More recently, new technology has led to the development of skin resurfacing lasers and to the development of a whole new approach to facial rejuvenation and the treatment of wrinkles, photodamage, and scars. Dramatic clinical results and a low incidence of adverse side effects have generated much enthusiasm among physicians and patients for these procedures. Laser technology and its application to the treatment of skin disorders has developed at a rapid pace in recent years. Multiple types of laser systems are now available to treat a wide variety of cutaneous lesions, including vascular and pigmented lesions, tattoos, hair, leg veins, scars, and wrinkles. Clinicians using lasers as well as residents and fellows in training are faced with a perplexing array of technology with few resources for obtaining background knowledge and practical information necessary to perform these treatments. The purpose of this text is to provide an up-to-date, comprehensive yet straight-forward approach to understanding lasers and performing laser treatment for cutaneous disorders. The book is intended for use by practicing physicians. For convenience and clarity, information is readily available about each laser system as well as specific treatment indications. Section I provides the fundamentals for understanding laser instrumentation and physics. A comprehensive review of each laser system, its interaction with tissue and treatment indications are presented in Section II of the book. Existing technologies are compared and the details of operation are reviewed. Section III offers a step-by-step approach to laser treatment of specific skin disorders, with an emphasis on the selection vii
viii
Preface
of the appropriate laser for each clinical situation, treatment guidelines, and possible pitfalls. In Section IV, a guide to patient selection, appropriate education, and credentialing, as well as establishing a laser surgical unit is provided for clinicians new to the practice of laser surgery. The comprehensive scope of this text with its in-depth analysis yet practical approach make it a useful reference and teaching tool for both the novice and the experienced laser surgeon in the fields of dermatology, plastic surgery, otolaryngology, and phlebology. Arielle N. B. Kauvar
Acknowledgment
We are grateful to our many colleagues and friends whose hard work and dedication helped make this book a reality. This project would not have been possible without the patience, understanding, and support of our families and office staff. We sincerely appreciate the invaluable assistance and guidance of Sandra Beberman and the support staff at Marcel Dekker and Taylor & Francis. Arielle N.B. Kauvar and George J. Hruza
ix
Contents
Foreword . . . . . . . Preface . . . . . . . . . Acknowledgment . . List of Contributors
. . . .
. . . .
.. .. .. ..
. . . .
. . . .
.. .. .. ..
. . . .
.. .. .. ..
. . . .
. . . .
.. .. .. ..
. . . .
. . . .
.. .. .. ..
. . . .
. . . .
.. .. .. ..
. . . .
. . . .
.. .. .. ..
. . . .
.. .. .. ..
. . . .
. . . .
.. .. .. ..
. . . .
. . . .
.. .. .. ..
. . . .
. . . .
.. .. .. ..
. . . .
.. .. .. ..
. . . .
v vii ix xv
1. Cutaneous Laser Surgery: Historical Perspectives . . . . . . . . . . . . . . . . . . . . . Gary J. Brauner
3
Section I: Understanding Lasers
2. An Introduction to Lasers and Laser –Tissue Interactions in Dermatology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . J. Stuart Nelson 3. Laser Safety Measures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Christie Travelute Ammirati and George J. Hruza
59
79
Section II: Laser Science and Instrumentation 4. Continuous Wave Lasers: Argon, Dye, KTP, Copper Vapor, Krypton . . . . . . 105 Thomas O. McMeekin 5. Continuous Wave and Pulsed CO2 Lasers E. Victor Ross
. . . . . . . . . . . . . . . . . . . . . . . . . . 129
6. Er:YAG Lasers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 181 Ulrich Hohenleutner and Michael Landthaler 7. Pulsed Dye Lasers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 199 Kristen A. Richards and Jerome M. Garden 8. Clinical Uses of the Long Pulse Duration Pulsed Dye Laser . . . . . . . . . . . . . 219 Eric F. Bernstein 9. Pulsed KTP and Diode (532 nm) Lasers . . . . . . . . . . . . . . . . . . . . . . . . . . . . 245 Robert M. Adrian, Emil Tanghetti, and Arielle N. B. Kauvar xi
xii
10. Q-Switched Ruby Laser Vic A. Narurkar
Contents
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 259
11. The Q-Switched Nd:YAG (1064 þ 532 nm) Laser . . . . . . . . . . . . . . . . . . . . 265 Suzanne L. Kilmer, Macrene R. Alexiades-Armenakas, Vicki J. Levine, and Robin Ashinoff 12. Q-Switched Alexandrite Lasers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 285 Christopher A. Nanni 13. Long-Pulsed Alexandrite Laser . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 297 Cathy A. Slater, John B. Newman, and David H. McDaniel 14. Diode Lasers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 317 Murad Alam, David A. Wrone, and Beatrice Berkes 15. Long-Pulsed Nd:YAG (1064 nm) Lasers Neil Sadick and Arielle N. B. Kauvar
. . . . . . . . . . . . . . . . . . . . . . . . . . . 337
16. Noncoherent Light Source . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 355 Robert A. Weiss and Margaret A. Weiss 17. Excimer Lasers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 375 James M. Spencer 18. Photodynamic Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 387 Shirley Jean-Baptiste, David A. Wrone, and Murad Alam 19. Skin Cooling in Laser Dermatology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 403 Kristen M. Kelly and J. Stuart Nelson 20. Reflectance Confocal Microscopy for Basic and Clinical Dermatology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 415 Salvador Gonza´lez, Robert H. Webb, R. Rox Anderson, and Milind Rajadhyaksha
Section III: Lasers Treatment of Cutaneous Disorders 21. Laser Treatment of Port Wine Stains . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 441 Arielle N. B. Kauvar 22. Lasers and the Treatment of Hemangiomas Milton Waner and Jay Kincannon
. . . . . . . . . . . . . . . . . . . . . . . . . 461
23. Laser Treatment of Acquired Vascular Lesions Tina B. West
. . . . . . . . . . . . . . . . . . . . . . 475
24. Lasers in the Treatment of Pigmented Lesions . . . . . . . . . . . . . . . . . . . . . . . 489 Jeffrey S. Dover, Kenneth A. Arndt, and Richard J. Ort
Contents
xiii
25. Laser Treatment of Tattoos . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 505 Suzanne L. Kilmer 26. Carbon Dioxide Laser Treatment of Epidermal and Dermal Lesions in Principles and Practices in Cutaneous Laser Surgery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 519 Leslie C. Lucchina and Suzanne M. Olbricht 27. Skin Resurfacing with CO2 Lasers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 535 Richard E. Fitzpatrick and Elizabeth Rostan 28. Skin Resurfacing with Erbium:YAG Lasers . . . . . . . . . . . . . . . . . . . . . . . . . 553 Kucy Pon, Vivek Iyengar, and Thomas Rohrer 29. Combined Laser Resurfacing Techniques . . . . . . . . . . . . . . . . . . . . . . . . . . . 569 Mitchel P. Goldman and Elizabeth Roston 30. Combining Laser Resurfacing with Facial Surgery . . . . . . . . . . . . . . . . . . . . 589 Cynthia Weinstein 31. Laser Treatment of Scars and Striae . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 619 Tina S. Alster and H. L. Greenberg 32. Nonablative Skin Rejuvenation and Acne Therapy . . . . . . . . . . . . . . . . . . . . 637 David J. Goldberg and Arielle N. B. Kauvar 33. Laser Treatment of Leg Veins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 653 Arielle N. B. Kauvar 34. Laser Hair Removal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 677 Christine C. Dierickx 35. Laser Assisted Hair Transplantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 703 Marc R. Avram 36. Treatment of Nonwhite Skin with Lasers . . . . . . . . . . . . . . . . . . . . . . . . . . . 717 Woraphong Manuskiatti and Mitchel P. Goldman Section IV: Considerations in the Practice of Laser Surgery 37. Legal Considerations in Laser Surgery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 749 David J. Goldberg 38. Establishing a Laser Unit Elizabeth I. McBurney
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 757
39. Anesthesia Options for Laser Surgery John A. Carucci and David J. Leffell Index
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 775
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 789
List of Contributors
Robert M. Adrian, M.D., F.A.C.P. Murad Alam, M.D. Illinois, USA
Center for Laser Surgery, Washington, DC, USA
Department of Dermatology, Northwestern University, Chicago,
Macrene R. Alexiades-Armenakas, M.D., Ph.D. New York, USA
Private Practice, New York,
Tina S. Alster, M.D. Dermatology and Pediatrics, Georgetown University Medical Center, Washington Institute of Dermatologic Laser Surgery, Washington, DC, USA Christie Travelute Ammirati, M.D. Division of Dermatology, Penn State University College of Medicine, Pennsylvania, USA R. Rox Anderson, M.D. Department of Dermatology, Wellman Laboratories of Photomedicine, Massachusetts General Hospital, Massachusetts, USA Kenneth A. Arndt, M.D. SkinCare Physicians of Chestnut Hill, Chestnut Hill and Clinical Professor of Dermatology, Harvard Medical School, Massachusetts, and Clinical Professor of Dermatology, Yale University School of Medicine, Connecticut, USA Robin Ashinoff, M.D. Department of Dermatology, Hackensack University, Hackensack, New Jersey, USA Marc R. Avram, M.D. Department of Dermatology, Weill-Cornell Medical Center, New York, New York, USA Beatrice Berkes, M.D. California, USA
Department of Dermatology, Loma Linda University,
Eric F. Bernstein, M.D. Laser Surgery and Cosmetic Dermatology Centers, Marlton, New Jersey, USA; University of Pennsylvania, Pennsylvania, USA Gary J. Brauner, M.D. Department of Dermatology, Mount Sinai School of Medicine, New York, New York, USA John A. Carucci, M.D., Ph.D. Medicine, Connecticut, USA
Department of Dermatology, Yale University School of xv
xvi
List of Contributors
Christine C. Dierickx, M.D. Wellman Laboratories of Photomedicine, Massachusetts General Hospital, Massachusetts, USA; Department of Dermatology, University of Ghent, Belgium Jeffery S. Dover, M.D. F.R.C.P.C. SkinCare Physicians of Chestnut Hill, Chestnut Hill, Massachusetts and Associate Clinical Professor of Dermatology, Yale University School of Medicine, Connecticut, USA Richard E. Fitzpatrick, M.D. San Diego, California, USA
Dermatology Associates of San Diego County, Inc.,
Jerome M. Garden, M.D. Department of Dermatology, Northwestern University Medical School and Divisions of Dermatology and Plastic Surgery, Children’s Memorial Hospital, Chicago, Illinois, USA David J. Goldberg, M.D., J.D. Department of Dermatology, Mount Sinai School of Medicine, New York, New York, USA Mitchel P. Goldman, M.D. Cosmetic Laser Associates of La Jolla, Inc., La Jolla and University of California, San Diego, California, USA Salvador Gonza´lez, M.D., Ph.D. Massachusetts General Hospital, Harvard Medical School and Department of Dermatology, Wellman Laboratories of Photomedicine, Massachusetts General Hospital, Massachusetts, USA Washington Institute of Dermatologic Laser Surgery,
H. L. Greenberg, M.D. Washington, DC, USA Ulrich Hohenleutner, M.D. Regensburg, Germany George J. Hruza, M.D. Medicine, Missouri, USA Vivek Iyengar, M.D.
Department of Dermatology, University of Regensburg,
Division of Dermatology, St. Louis University School of
SkinCare Physicians of Chestnut Hill, Massachusetts, USA
Shirley Jean-Baptiste, M.D.
Northwestern University, Chicago, Illinois, USA
Arielle N. B. Kauvar, M.D. New York Laser & Skin Care, Department of Dermatology, New York University School of Medicine and Department of Dermatology, SUNY Downstate Medical Center, New York, New York, USA Kristen M. Kelly, M.D. Department of Dermatology and Surgery, Beckman Laser Institute, University of California, California, USA Suzanne L. Kilmer, M.D. Laser & Skin Surgery Center of Northern California, Sacramento, California, USA Jay Kincannon, M.D. Department of Dermatology and Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA Michael Landthaler, M.D. Regensburg, Germany David J. Leffel, M.D. cine, Connecticut, USA
Department of Dermatology, University of Regensburg,
Department of Dermatology, Yale University School of Medi-
Vicki J. Levine, M.D. Department of Dermatology, New York University School of Medicine, New York, New York, USA
List of Contributors
xvii
Leslie C. Lucchina, M.D. Department of Dermatology, Brigham and Women’s Hospital and Department of Dermatology, Harvard Medical School, Massachusetts, USA Woraphong Manuskiatti, M.D. Department of Dermatology, Siriraj Hospital, Mahidol University, Bangkok, Thailand Elizabeth I. McBurney, M.D. Department of Dermatology, Lousiana State University School of Medicine, Tulane University School of Medicine, Lousiana, USA David H. McDaniel, M.D. Laser Skin & Vein Center of Virginia, Virginia Beach, Virginia and Eastern Virginia Medical School, Norfolk, Virginia, USA Thomas O. McMeekin, M.D. Department of Dermatology and Pediatrics, University of Rochester and Department of Dermatology, State University of New York at Buffalo, New York, New York, USA Christopher A. Nanni, M.D.
Private Practice, Glendore, California, USA
Vic A. Narurkar, M.D. Bay Area Laser Institute and Department of Dermatology, University of California at Davis, California, USA J. Stuart Nelson, M.D., Ph.D. Department of Surgery, Dermatology and Biomedical Engineering, Beckman Laser Institute, University of California, California, USA John B. Newman, M.D. Laser Skin & Vein Center of Virginia, Virginia Beach, Virginia and Department of General Surgery, Naval Medical Center Portsmouth, Portsmouth, Virginia, USA Suzanne M. Olbricht, M.D. Department of Dermatology, Lahey Clinic and Department of Dermatology, Harvard Medical School, Massachusetts, USA Richard J. Ort, M.D. SkinCare Physicians of Chestnut Hill and Department of Dermatology, Beth Israel Deaconess Medical Center, Massachusetts, USA Kucy Pon, M.D.
SkinCare Physicians of Chestnut Hill, Massachusetts, USA
Milind Rajadhyaksha, Ph.D. Department of Dermatology, Wellman Laboratories of Photomedicine, Massachusetts General Hospital, Harvard Medical School, Massachusetts, USA; Lucid, Inc., New York, New York, USA Kristen A. Richards, M.D.
Scripps Memorial Hospital, California, USA
Thomas Rohrer, M.D. SkinCare Physicians of Chestnut Hill, Chestnut Hill and Associate Clinical Professor of Dermatology, Boston University School of Medicine, Massachusetts, USA E. Victor Ross, M.D., C.D.R., M.C., U.S.N. Dermatology Department, Naval Medical Center San Diego and Division of Dermatology, University of California, San Diego, California, USA Elizabeth Rostan, M.D. California, USA
Dermatology Associates of San Diego County, Inc., San Diego,
Neil S. Sadick, M.D., F.A.C.P., F.A.A.C.S. Department of Dermatology, Weil Medical College of Cornell University, New York, New York, USA Cathy A. Slater, M.D., M.P.H. Laser Skin & Vein Center of Virginia, Virginia Beach, Virginia and Boice-Willis Clinic, Rock Mount, North Carolina, USA
xviii
List of Contributors
James M. Spencer, M.D., M.S. Department of Dermatology, Mount Sinai School of Medicine, New York, New York, USA Emil Tanghetti, M.D.
Private Practice, Sacramento, California, USA
Milton Waner, M.D., F.C.S. Department of Otolaryngology, St. Lukes—Roosevelt Hospital, New York, New York, USA Robert H. Webb, Ph.D. Department of Dermatology, Wellman Laboratories of Photomedicine, Massachusetts General Hospital, Massachusetts, USA Cynthia Weinstein, M.B.B.S., F.A.C.D., F.R.A.C.P. Australia.
Private Practice, Melbourne,
Margaret A. Weiss, M.D. Department of Dermatology, Johns Hopkins University School of Medicine, Maryland, USA Robert A. Weiss, M.D. Department of Dermatology, Johns Hopkins University School of Medicine, Maryland, USA Tina B. West, M.D.
Private Practice, Chevy Chase, Maryland, USA
David A. Wrone, M.D. Chicago, Illinois, USA
Department of Dermatology, Northwestern University,
Section I: Understanding Lasers
1 Cutaneous Laser Surgery: Historical Perspectives Gary J. Brauner Mount Sinai School of Medicine, New York, New York, USA
1. 2. 3. 4.
5.
6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19.
Finding the Right Thread in the Cloak It Takes a Nobel Prize Winner to Think of it Ruby Other New Lasers 4.1. Argon Laser 4.2. CO2 Laser Multidisciplinary Societies 5.1. Laser Institute of America 5.2. International Society for Laser Medicine and Surgery 5.3. American Society for Laser Medicine and Surgery Laser safety—The American National Standards Institute Personnel and Patient Safety—Plume Patient Safety—SCAR Postoperative Wound Care Selective Photothermolysis Wellman Lab and Beckman Lab Nd:YAG LASER 12.1. Q-switching Pigment Lasers Serendipity Resurfacing Laser-Assisted Hair Transplantation Pulsed Light Sources Laser Hair Removal Chilling and Wrinkles
4 4 9 9 9 12 15 15 15 15 16 17 17 22 23 24 25 25 26 27 28 30 31 31 33 3
4
Brauner
20. Biostimulation 21. Photodynamic Therapy 22. Return of the Scientific Method—The Charge for the Future References
1.
34 35 36 39
FINDING THE RIGHT THREAD IN THE CLOAK
A proper history of lasers in dermatologic surgery requires not just a chronological recitation (1 – 3) of what we know as published fact by the sequential appearance of peer-reviewed and dated articles and Congress presentations but also an attempt to find the thread of true progress weaving through the fabric of the “cloak of magical claims.” The use of light and its many colors, both visible and invisible, for the treatment and healing of cutaneous disease is a true analog of Joseph’s multicolored cloak. How does the laser-surgeon-turned-historian achieve a sense of perspective over the laser miracles of the past 40 years while sitting in the midst of them? Is he/she woven too tightly into the woof and warp to see above it? This author’s selection of a few articles and concepts as seminal ones will trace this thread but it does not negate the importance of many other legitimate contributions in our cloak (Table 1.1). There is a sense and a nonsense to our history. The relentless march of technical, industrial, and military genius in developing new lasers after 1960 was at first random and certainly unrelated to dermatologic surgery at least until 1983 (4). But there were clearly identifiable and critical seminal events which brought about the flowering of cutaneous laser surgery. These events define the thread this author will trace—they span theoretical physics, inventive genius of laser manufacture, optical modeling schema of the skin and its chromophores to direct development of appropriate lasers to treat cutaneous disease (4–13), accidental discoveries, the advertising kingdom, the medical–industrial complex, and ethics of the marketplace and of the practice of medicine. All of these elements and events must be elaborated and reflected upon before a full though pro tem view of the evolution of cutaneous laser surgery is understood and hopefully utilized to direct its future. For spatial considerations the ever-expanding spectrum of laser technology for medical communication by fiberoptic networks, holographic reconstructions, or laser microsurgical manipulations of subcellular organelles or genes will not be reviewed.
2.
IT TAKES A NOBEL PRIZE WINNER TO THINK OF IT
Albert Einstein (Fig. 1.1) (14 –18), Time Magazine’s outstanding persona of the 20th century, also had the first insight into what has become our 21st century world of lasers. He elaborated the concept of stimulated emission of radiation in 1917 (19,20) wherein he postulated that if an electron were in an already excited state and were hit by a photon of the proper energy, instead of rising to a still higher energy level, it would fall to a lower level and emit a second photon of precisely the same wavelength as the initial photon, and the initial photon would also continue on without having been absorbed. Theoretically, one could then have a stream of unique and uniform photons arising in an incremental but massive exponential cascade (21). Laboratory experiments in the 1920s confirmed this postulate of stimulated emission but even in the experiments spontaneous emission of radiation and not stimulated emission predominated (21). According to Itzkan and Drake (22) Dirac’s theory of quantum electrodynamics in the
Cutaneous Laser Surgery: Historical Perspectives
5
Table 1.1 Seminal Events and Personae Albert Einstein Schawlow and Townes Theodore Maiman Leon Goldman, MD Argon laser-D Apfelberg, K. Arndt “Nonsense” science CO2 Laser Hyperbole and unreproducible results Interdisciplinary societies: LIA, ISLMS, ASLMSa Laser safety: ANSI standards Personnel and patient safety: plume Patient safety: scar Minimal dose: B. Cosman, scanners Chilling: C. Chess Postoperative wound care: G. Brauner, A. Schliftman Photothermolysis: R. Anderson, J. Parrish Wellman Lab and Beckman Lab Hyperbole? Corruption of scientific method Pigment lasers Q-switched lasers Serendipity: scars: T. Alster Resurfacing: R. Fitzpatrick, R. Kaufmann, A. Kauvar, J. Dover, R. Adrian Serendipity redux and hair removal: R. Anderson, M. Grossman Thermokinetics: J. Nelson, R. Anderson Biostimulation and “cool” lasers Real scientific method: side-by-side studies; Report of complications Nonphysician use of medical lasers a
LIA, Laser Institute of America; ISLMS, International Society for Laser Medicine and Surgery; ASLMS, American Society for Laser Medicine and Surgery.
1920s established the nature of coherence whereby the stimulated photons would not only have the same frequency as the inciting photon but phase and direction as well. In order to have a scenario where stimulated emission predominated, a population inversion of more excited atoms or molecules than unexcited ones had to be produced. Charles H. Townes (Fig. 1.2) was the first to manufacture such a functioning prototype which produced microwaves, thus the first MASER microwave amplified stimulated emission of radiation. He had been involved with radar in World War II and became interested in microwaves (21). Townes had first thought of the mechanism for amplification of the radiation on a park bench in Franklin Park in Washington in April 1951 (21,23). Also, in 1951 the Russian physicist V. A. Fabrikant applied for a Soviet patent on amplifying stimulated emission but it was not published until 1959 and did not influence the course of American laser physics (21). In the USA in 1953 Joseph Weber was the first to propose stimulated emission. Townes’ research group recognized in 1953 (23 – 25) that ammonia molecules in the ground state would be attracted by an electrical field and those in an excited state would be repelled and thus these researchers could separate out excited ammonia molecules and force them through a small hole into a cavity into a true population inversion. In their doing so, stimulated emission of 1.25 cm microwaves
6
Brauner
Figure 1.1 Albert Einstein in 1905 in the Swiss patent office in Berne (Lucien Chavan). (Courtesy, The Albert Einstein Archives, The Jewish National and University Library, The Hebrew University of Jerusalem, Israel.)
spontaneously occurred. In 1957 Schawlow (Fig. 1.3) and Townes (26,27) first elaborated their concept of an optical resonator which could amplify stimulated emission in a chamber with parallel opposing reflective mirrors and thus produce waves coherent in space, all in phase and of uniform frequency (and thus wavelength) (21). Townes and Schawlow thought that the first practical “optical maser” (i.e., “laser”) would be an electric
Figure 1.2 Charles Townes, coinventor of the maser. (Courtesy, Bell Labs/Lucent Technologies.)
Cutaneous Laser Surgery: Historical Perspectives
7
Figure 1.3 Theodore Schawlow, coinventor of the maser with the ruby optical maser (i.e., laser). (Courtesy, Bell Labs/Lucent Technologies.)
current pumping or energizing a gas but the first effective laser was made in Hughes Labs by Maiman (Fig. 1.4) in 1960 by surrounding a 4 cm long ruby crystal rod with a spiral flashlamp, which excited the chromium in the ruby crystal when it absorbed blue-green light and produced a chromium population inversion.
Figure 1.4 Theodore Maiman, inventor of the first laser, the ruby. (Courtesy, Hughes Research— Labs HRL.)
8
Brauner
The development of lasers 50 years after Einstein’s’ first conceptualization was of such importance to the scientific community that Townes as well as the Russian physicists Nikolai Basov and Aleksander Prokhorov received the Nobel Prize in 1964. Shawlow, who had collaborated in 1958 with Townes to obtain the first laser patents (27), shared the 1981 Nobel Prize for using lasers to study the nature of atoms and molecules (21). Hecht and Teresi provide a fascinating blow-by-blow account of the 20-year patent controversy between Gordon Gould and Townes and Schawlow and the race to produce the first laser in the late 1950s—the first of many laser controversies. Interestingly, Maiman’s seminal contribution, announced on July 7, 1960, in a brief four-paragraph article—the very first laser—was refused publication in the prestigious Physical Review Letters but was finally presented in Nature (28,29). Although “LASER,” as used now, is an acronym for light amplified stimulated emission of radiation, Orazio Svelto, an Italian professor of quantum electronics and laser pioneer (30) reflected on an ancient (1st century AD) but apparently timeless reference from Pliny the Elder in “Natural History XXII,” 49 that “the laser is numbered among the most miraculous gifts of nature and lends itself to a variety of applications.” Pliny was not prescient or more brilliant than Einstein or Townes and Schawlow; however, his “laser” was a celebrated, commercially important, but extinct since the 2nd century, plant raised in North Africa and used as a culinary dressing but more importantly also as a cure for a variety of diseases, even injuries such as scorpion stings or arrow wounds. A 1960s timeline (21) shows that rapid progress in laser research began around 1962 in scientific laboratories and commercial manufacture of lasers began at about the same time. The US military had a significant interest in laser development very early on; in fact, this interest and its associated elements of secrecy led to much of Gould’s problems with others’ recognition of his early contributions since he was under contract with the government. The first gas laser was also invented in 1960 but by 1965 laser activity had been found in gases in over 1000 different wavelengths. In the early 1960s Dr. Leon Goldman (Fig. 1.5), a Cincinnati dermatologist, started a center for medical laser research at the University of Cincinnati where he, also Chief of Dermatology, often used himself as the first human guinea pig at which to aim a newly developed laser and became thereby the father of laser medicine and surgery—another seminal event. He had originally been given a grant in 1961 to study the safety of lasers by the National Institute of Health and Occupational Medicine and so opened the laboratory to study the ruby laser. It was Leon Goldman who first realized the possibilities of therapeutic uses of lasers as medical instruments but he was unable to interest the Surgeon General in funding his research. The John A. Hartford Foundation did come up with support for him, enabling him to run a multidisciplinary laboratory of biologists, safety engineers, and physicians from other surgical disciplines (31) from 1961 to 1976. It was only because of the ingenuity and persistence of this one man that lasers finally were made applicable to the treatment of human malformation and disease and degenerative changes (32). Since the ruby laser was the only one available, it was that which he turned on himself, laboratory animals, and other humans (33). Goldman first exposed normal white and black skin and also white and black human skin covered with various black dyes to the ruby laser (34) and then attempted to treat cutaneous lesions such as seborrheic keratoses and superficial hemangiomas (33,35,36) and tattoos (37). Histologically, nonspecific thermal destruction of the cutaneous target occurred; clinically, there was long-lasting oozing and crusting, usually resulting in scarring, which was fortunately only rarely hypertrophic. By
He also experimented artistically and performed laser sculpting on a variety of media, which he exhibited at dermatologic meetings.
Cutaneous Laser Surgery: Historical Perspectives
9
Figure 1.5 Leon Goldman, MD, “father” of laser medicine and surgery. (Courtesy, American Society for Laser Medicine and Surgery.)
1967 (38) he had concluded that both long-pulsed ruby and “neodymium” (?Nd:YAG) laser were specifically absorbed more by colored tattoo pigments than by the surrounding normal skin and this distinguished laser surgery from techniques such as electrosurgery, which produced nonspecific coagulation necrosis. His first experiment with a Q-switched ruby laser in 1964 showed craters on normal and tattooed skin for focused beams as he had obtained with the normal mode ruby laser. With nonfocused impacts he noted a selective difference with no damage to normal skin but transient whitening of the tattooed area without significant damage to the skin but with only edema and spongiosis apparent (37). His contributions were the first to suggest the concept of selective targeting by lasers. 3.
RUBY
The ruby laser was first used on the eye by Zweng et al. (39) in 1962. It was the principal laser studied by Dr. Leon Goldman in his earliest work (40–48). Almost 15 years passed before others took up Goldman’s mantle and began in earnest to perform cutaneous laser surgery. Ohshiro’s extensive work with normal mode ruby laser and nevi and other dyschromias including port-wine stains (49) did not begin until 1975. Studies of Q-switched ruby lasers for treatment of tattoos took a full 20 years and FDA approval, still another decade. 4.
OTHER NEW LASERS
Javan developed the first gas laser, He–Ne, in 1961 (50). Johnson produced an infrared laser beam from a Nd-doped yttrium–aluminum–garnet rod (Nd:YAG) also in 1961 (51). By 1964 Goldman was using this laser for experiments on tattoos and normal skin (37,52). 4.1.
Argon Laser
Bennett et al. (53) invented the blue-green argon laser in 1962. It was first used on the eye by L’Esperance (54) in 1967. This laser became commercially available in 1971 (55) and
10
Brauner
was the first laser to be widely used for treatment of cutaneous disease once the initial excitement, and unfortunately concurrent disappointment, with the ruby laser had passed, which had proven to be uncontrollably too destructive for skin disease in its original industrial format. Reports by Apfelberg and coworkers (56 – 60) begining in 1976 about their experiences with the argon laser since 1972 were the stimulus and seminal event for the upsurge in interest by dermatologists and plastic surgeons, though Leon Goldman’s group (61 – 65) had earlier published data on its usefulness. The mid- to late-1970s, after now a second decade, were the formative years for cutaneous laser surgery. Numerous dermatologists and plastic surgeons began to use the argon laser (66) and a flood of laser-related papers began. Arndt and Noe and their coworkers in Boston (67) in a series of papers began the first formal introduction to the dermatologic readership of laser terminology and to the histologic, clinical, and spectrophotometric analysis of what argon lasers could perform on a variety of vascular lesions (68 –70). By the late 1970s and early 1980s these reports as well as thermal models to help understand the dynamics of laser –port-wine stain interaction were formulated in rapid succession. Concurrently, the carbon dioxide laser appeared in the cutaneous surgeon’s armentarium and the American Society for Laser Medicine and Surgery (ASLMS) was founded. What the argon laser allowed for the first time was a therapy for widespread telangiectasia that was sensible in that destruction proceeded from the vessel outward rather than from the surface of the skin inward as by electrodesiccation or electrofulguration, then the standard treatment. In practice, with early argon laser surgical techniques there was thin second-degree burn injury involving the papillary dermis and the entire epidermis. Still, since the maximal energy dissipation was in the vessel itself rather than on the surface of the skin it seemed more reliable particularly for more deeply situated and resistant spider angiomas and for treating networks of fine vessels extending over large areas of the cheeks as in extensive rosacea. For congenital port-wine stain this treatment was miraculous. Ten percent of patients could expect entire clearance of their vascular malformation and 75% of the remaining patients would have dramatic and long-lasting or permanent and significant lightening with only one treatment. With further treatments the stains continued to lighten further (71,72). Alternatives prior to laser included mutilating procedures such as cryosurgery in which nonspecific and unquantifiable damage led to improvement with scarring, or tattooing with skin-colored pigments which only lightened the areas slightly in an artificial-appearing manner, superficial radiation (Fig. 1.6) with progressively worsening radiation dermatitis and development of skin cancer, or excision with grafting (Fig. 1.7) which was often more of a technical than a cosmetic triumph. There were several historically relevant adverse sequelae that began with this instrument. The first was a seminal event whose importance took almost 20 years to gain recognition, the use of nonphysicians, in this instance, nurses, to perform argon laser surgery. In the “reproducible” or “sense” technique—which meant using a standard protocol of power setting, spot size, pulse duration, and prechilling (Gilchrest) or postchilling, and postoperative wound care appropriate for a second-degree burn injury, or one that could be repeated reliably from patient to patient and physician to physician and also could be quantifiably studied and reported in a series of patients treated with the same or precise but differing parameters—intense monotony was the rule. Imagine 5000 bursts of laser energy clicking off second by second for 1 h merely to cover a 2 by 3 in. square of port-wine stain! To some laser surgeons it seemed more appropriate to use one’s trained skills for “real surgery” whereas a trained assistant could hold a handpiece when given standard parameters and perform “laser surgery.” This time-saving assistance
Cutaneous Laser Surgery: Historical Perspectives
11
Figure 1.6 Port-wine stain, years after radiotherapy.
was used by Apfelberg (56 –60,73) but he also reported an acknowledged incidence of hypertrophic postoperative scarring of 16%, which was 3 –15 times higher than the experience of other laser surgeons (68,70,74 – 77). The question of nonphysicians performing laser surgery (vide infra) became a major issue by 1998 (78,79). Monotony of this technique and its slowness in covering large areas had many more aggressive laser surgeons using the nonreproducible or nonsense technique—passing the laser in a continuous beam rapidly by hand or “air-brushing” over the area to be treated.
Figure 1.7 Port-wine stain, after split thickness skin grafting.
12
Brauner
This could be a masterful and quick way of treating a port-wine stain without requiring multiple return visits but as a nonreproducible technique it was not universally reliable—not from patient to patient, not teachable and usable from physician to physician (certainly not from a printed article) and not even in the same patient in the same area since hand speed varied especially on turning corners. This was only surgical artistry at work. Avoiding excessive thermal damage and excessive flat or hypertrophic scarring required great skill. In addition, the lack of standard postoperative wound care consistent with the known care of burn injury in this technique made understanding literature and clinical abstracts a frustrating quest. Laser surgical interpretation was muddled by tremendously differing techniques and incomparability of results and style. The art of laser surgery flourished but the science lagged behind. A price was paid by patients for the lack of rigorous “reproducible” literature and the seeds of discord and controversy were laid down. Because of misinterpretation of the literature (70,74,76) only few laser surgeons (71,72,77,80) would treat children by argon laser; some would treat none under age 8, some arbitrarily none under age 12, assuming, in error, a 38% risk of scar, thus denying therapy to the age group in which the greatest emotional impact of having a port-wine stain was occurring (81 –85). A third adverse sequel of argon laser surgery reflected, in retrospect, poor judgment by the underreporting of scarring. The definition of only cosmetically unacceptable hypertrophic scar as “scar” was too limiting but was almost uniformly applied by cutaneous laser surgeons, who wished to focus instead on the dramatic overall beneficial results of argon laser surgery. 4.2.
CO2 Laser
The CO2 laser was invented by Patel (86 – 88) (Fig. 1.8) of Bell Labs in 1964, but the first surgical CO2 laser was developed by Polanyi et al. (89) in 1965 and was first exhibited in 1967. Jako (90) noted that the earliest laser work in otolaryngology was by Stahle and Hoegberg (91) in 1965, using a pulsed laser for inner ear irradiation, Conti and Bergomi (92) in 1966 for the posterior labyrinth, and Sataloff (93) in 1967 for otosclerotic stapes. About the same time in 1965 he first began studies with Polanyi on cadaveric vocal cords with the pulsed Nd:YAG laser hoping to find that the laser could be used to cut tissue, but it was able to produce only small lesions. By 1967 Jako and Polanyi
Figure 1.8 C.K.N. Patel, inventor of the CO2 laser. (Courtesy, Bell Labs/Lucent Technologies.)
Cutaneous Laser Surgery: Historical Perspectives
13
were examining the absorption of CO2 laser by human cadaveric vocal cords; they developed an endoscopic delivery system in 1968. Soon after, Strong, Jako, and Polanyi (94 –98) initiated laser laryngeal surgery. Jako (90) performed vocal cord nodule removal in a dog soon thereafter and first operated on a human in 1970. Jako described the “precision of the CO2 laser beam and good wound healing subsequent to its impacts” (94). Hall et al. (99) described incisional surgery by laser in 1971. For gynecologists serendipity (or better, foresight) initiated the specialty into laser surgery when Joseph Bellina (100 – 102), the father of the gynecologic laser, realized the potential of this instrument in treating neoplasia of the cervix when he observed CO2 laser surgery used to remove laryngeal lesions (103). Despite work by others such as Kaplan and coworkers (104 – 106), who in 1973 first used the CO2 laser on the cervix (104 – 106). Fischer claims that Bellina had great difficulty convincing other American surgeons to perform such surgery. The Gynecologic Laser Society was founded in 1979 and thereafter authors such as Dorsey and Diggs (107) and Baggish and coworkers (108,109) began to publish prolific studies on cervical, vaginal, and vulvar diseases. Cerullo and Burke (110) noted that experiments with laser on neural tissue began as early as 1964 but the laser was too destructive for the meticulous surgery required in neurosurgery; only when microsurgery also matured by the late 1970s did laser neurosurgery begin. Heppner and Ascher (111) initiated CO2 laser neurosurgery in 1976. The laser was ready and waiting but the rest of the technology for appropriate delivery was not. A similar hiatus between the development of lasers and their practical use in gastroenterology had occurred while the field waited for the development of appropriate fiberoptic technology for laser delivery—for such lasers as argon, Nd:YAG, and tunable dye (112 –116). Nd:YAG was first used for GI disease with fiberoptics in 1973 (112,113); Keifhaber et al. (113) reported its first use in GI bleeding in 1975. It was the early 1970s before cutaneous applications of CO2 laser began in studies by Goldman et al. (31,117,118) on skin cancer. Kaplan helped to develop the commercial Sharplan laser in 1972, which became a standard mass-produced surgical device. Among the early authors, Frishman et al. (119) and Kaplan and coworkers (105,106,120) also published on skin cancer, Kaplan et al. (121) on other plastic surgical applications, and, Stellar et al. on decubitus ulcers (122) and on excision of third-degree burns (123,124). Among dermatologists McBurney (125,126) pioneered its use in 1978, also after a hiatus of almost a decade, as a vaporizing instrument for the treatment of warts and tattoos. Adams and Price (127) decribed its use in treating basal cell carcinoma in 1979. Bailin’s group (128 –132) at the Cleveland Clinic authored numerous early anecdotal reports on tattoos and a variety of epidermal tumors and port-wine stains. Interestingly, Reid , a gynecologist, and Muller (133,134) were the first to use the CO2 laser on a large series of tattoo patients and the first to suggest that this laser had to be used in multiple stages with incomplete treatment in each stage since a .16% risk of hypertrophic scarring arose in their patients if the tattoo had been removed by laser in one visit. These observations were compatible with what was by then long known about removal of tattoos in multiple sessions by dermabrasion. Nevertheless, the authors exhibited an experience contrary to the innovative but conservative wisdom of Leon Goldman who advised repeatedly, and even framed a placard on his wall for emphasis, “If you don’t need the laser, you don’t use it” (31,135,136). Overzealous use of laser on cutaneous lesions here reflected the worst practice of experimenting with a new device merely because it was new and high-tech but without a total understanding of the nature of the destruction which would ensue (Fig. 1.9).
14
Brauner
Figure 1.9 Severe hypertrophic scars after CO2 laser surgery for port-wine stain by inexperienced laser surgeon.
A singular, but fortunately nonscarring, abuse of Goldman’s maxim took place in the early evolution of podiatric laser surgery where fees of thousands of dollars were charged for laser debridement of diseased nails (i.e., an expensive laser analog of a nail clipper), giving patients a sour taste about the ethics of laser surgeons. Another adverse side of this laser’s history is that it was the first cutaneous laser about which unreproducible results were first reported in the literature and heated controversy first began to appear at laser meetings, particularly with claims made for healing of keloids. Though initial reports were overwhelmingly enthusiastic (131,137), claiming almost universal and persistent clearing with laser alone subsequent authors found a significant recurrence rate even with adjunctive therapy (138 – 141). Also, the laser’s “basic advantages” were subject to hyperbole and were promoted as 1. 2. 3. 4. 5. 6. 7. 8.
Noncontact surgery Dry-field, almost bloodless surgery Highly sterile surgery Highly localized and precise microsurgery Clear field of view and easy access in confined areas Prompt healing with minimal postoperative swelling and scarring Apparent reduction in postoperative pain No electromagnetic interference with monitoring instrumentation (120)
The number of times the same Kodachrome of this table was shown by dozens of laser lecturers became countless and laser dogma with little or no basis in critical anecdotal or peer-reviewed science became well instilled early in cutaneous CO2 laser surgery. This instrument was wonderful in that it was noncontact surgery and could be
Cutaneous Laser Surgery: Historical Perspectives
15
used as a vaporizing or excisional tool in patients wearing electronic devices or on anticoagulants. However, it could not stop freely running blood from vessels greater than 0.5 mm in diameter. In fact, hemostasis was often better in wart surgery with topical application of hemostatic Monsel’s solution than by laser charring and overburning the base of the wart. On digits a tourniquet or digital compression could produce equal hemostasis without the need for the laser. The field was not necessarily sterile, particularly at low fluences when less that 500 W/cm2 was applied. With high fluences it was found useful to sterilize wound bases in decubitus ulcers, synergistic gangrene, burns, and osteomyelitis (120,142– 144). Healing was not prompt; in fact, it was slower than traditional cold steel surgery or dermabrasion (145,146). Furthermore, the subsequent re-epithelialized area of a vaporization site was often fragile for months, capable of producing spontaneous bullae and hypertrophic scarring if that new surface had broken down. Pain was not reduced since nerve endings were not neatly sealed (147). When employed appropriately (148) the CO2 laser can safely and effectively treat dozens of cutaneous conditions, often better than older techniques including vaporization of actinic cheilitis and actinic keratoses, adenoma sebaceum, angiokeratomas, appendageal tumors, Bowenoid papulosis, condyloma acuminata, digital mucous cysts, epidermal nevi, Hailey –Hailey disease, ingrown nails, lichen myxedematosus, lichen sclerosus, lymphangioma circumscriptum, neurofibromas, nodular amyloidosis, pyogenic granulomas, rhinophyma, rhytids, sebaceous hyperplasia, xanthelasma, as well as cosmetic applications of resurfacing. Excisional applications for blepharoplasty or for patients compromised by anticoagulation or electronic devices such as pacemakers are widely employed.
5. 5.1.
MULTIDISCIPLINARY SOCIETIES Laser Institute of America
In 1968, partly at the instigation of Arthur Shawlow, a group of laser researchers in California founded the Laser Institute of America. This first meeting was attended by 75 members and now has grown to 200 corporate and almost 2000 individual members. Based now in Orlando, Florida (www.LaserInstitute.org) this group focuses mostly on laser science and safety and credentialling standards. It also is the secretariat and publisher of the ANSI standards, the latest of which is Z136.3 last revised in 1996. It sponsors a variety of courses and both the annual International Congress on Applications of Lasers and Electro-Optics (ICALEO) and the biennial International Laser Safety Conference (ILSC). 5.2.
International Society for Laser Medicine and Surgery
In 1975 Israeli surgeon, Dr. Isaac Kaplan, and others founded the first major interdisciplinary medical-surgical laser society, the International Society for Laser Medicine and Surgery (ISLMS), and held the First International Symposium on Laser Surgery in Jerusalem in November 1975. 5.3.
American Society for Laser Medicine and Surgery
In March 1979 in the USA, Drs. Ellet Drake and Leon Goldman set about establishing a multidisciplinary group of physicians and scientists who might be interested in exchanging
16
Brauner
knowledge and exploring uses for lasers in medicine and surgery and invited 280 renowned scientists from around the world, of whom about half attended, to an organizational meeting in San Diego in January 1981, where the ASLMS was founded. This seed organization (Fig. 1.10) has blossomed into one with now over 3000 physicians, veterinarians, nurses, industrial innovators, and laser researchers, and is the largest of its type in the world. This group (www.aslms.org) has met annually since then, running several full-day single-subject symposia as well as providing the largest forum for presentation of original abstracts on laser medicine and surgery in the USA. It sponsors the journal Lasers in Surgery and Medicine, the sixth “most cited” surgical journal, and has established ethical standards for the use of lasers and also formulated general guidelines for hospitals to use in credentialling laser surgeons. The happy concurrence of publications of unique results of argon laser surgery, the availability of the CO2 laser, and now a society dedicated to promoting laser use and widespread education produced the first tidal wave of interest in lasers by cutaneous surgeons.
6.
LASER SAFETY—THE AMERICAN NATIONAL STANDARDS INSTITUTE
Although Leon Goldman had initiated studies on laser–tissue interaction in 1961 as a means of exploring laser hazards and safety precautions, it was not until 1975 that the FDA established a performance standard for laser products as a supplement to the Radiation Control for Health and Safety Act of 1969 (102). Four classes of risk (I through IV) were established. Safety features and labels required for each of these classes of lasers were outlined in the Federal Register (149) and are best summarized and explained in the manual from the American National Standards Institute (ANSI). Interestingly, hazards were concerned with the work environment and accidental human exposure—relative risks of accidental damage to the eye and skin defined the classification schema (150–153). Hazards and
Figure 1.10 American Society for Laser Medicine and Surgery group photograph of the second annual meeting, 1982. (L. Goldman, first row center; G. Brauner, third row, center.)
Cutaneous Laser Surgery: Historical Perspectives
17
controls cited by ANSI in document Z136.3 include engineering controls, administrative controls, procedural controls, and protective equipment (154,155). Strict protocols were formulated by hospital laser safety committees for patient and personnel safety. They reviewed electrical hazards, eye and skin burn hazards, protective eyewear of specific optical density and absorbance of the appropriate wavelength, protective clothing and absorbent wet drapings of flame-resistant materials, nonreflective instruments and anesthesia ventilation systems, and the ready presence of fire extinguishers (156,157). Communication patterns between the laser-operating technician and the surgeon for on– off and standby modes were formalized. Laser-specific in-servicing for nurses and technicians were made compulsory. Treatment of pathologic processes in a patient and hazards of incorrect or inappropriate use were not addressed and to this day have still not been written into law (vide infra).
7.
PERSONNEL AND PATIENT SAFETY—PLUME
Since lasers used in cutaneous surgery until the most recent thermally “cool” devices essentially generate much focal heat or mechanico-acoustic waves, either splatter debris or smoke are often generated. The presence of acrid smoke generated from boiling and charred skin by the CO2 laser and the need to remove such obvious pollution (158 –161) led to seminal discoveries of the nature of operative-generated smoke and splatter debris (162). Even though electrosurgical apparatuses used for decades produced visible smoke it had been tolerated without comment. This was clearly not so with the laser. Laser smoke or debris may contain tumor cells (163,164), blood, blood-borne pathogens such as papilloma virus or HIV (165 – 169), bacteria (170,171), particulates as small as 0.1 mm in diameter, and toxic gases including benzene, formaldehyde, and acrolein (154,158,160). For slower-moving particulates, such as those generated by CO2 laser, not only masks which filtered less than 0.3 – 0.1 mm (167,172,173) but also vacuum evacuators held within 1 cm of the target area became necessary (161). For faster-moving particulates such as those generated by the immensely energetic Q-switched lasers the value of suction and the speed required have not been ascertained since the velocity of ablated material is 10,000 m/s (174); physical obstructions and traps such as plastic cylinders attached to ruby or Nd:YAG handpieces or clear membranes applied directly to the skin surface and shot through have been used. Jako (164) notes that various pioneering researchers including himself who had first experimented with the Nd:YAG laser on tissue in the mid-1960s found that it exploded tissue and that scattered cells and tissue fragments were found in the operative area. Nevertheless, Fader and Ratner (173), citing several authors such as Gloster and Roenigk (175), who suggested that CO2 laser surgeons should have had a larger incidence of wart contamination, and Hughes (176) and Hughes who could not find human papilloma viral DNA in Er:YAG wart plume, de-emphasize the inherent risk of plume infection.
8.
PATIENT SAFETY—SCAR
The argon laser had not been developed specifically for the treatment of cutaneous disease but was used mostly for spectroscopy. Most manufacturers were supplying instruments with 1 or 2 mm spot sizes with 0.1 s being the shortest pulse duration (shutter speed). Even with the “minimal dose” technique of Cosman (71,72), wherein one selected the
18
Brauner
lowest power setting to produce a visible whitening of the skin after laser impact, one had to depend on this visual signal which reflected not vascular obliteration alone but that plus coagulation of the dermis and perhaps even the epidermis with a change in light reflectance, so-called “blanching.” Thus, an inside-out second-degree burn injury was produced. The necrotic collagen as well as the obliterated vessel had to be replaced by new collagen, which might end up as transparent as normal collagen or which frequently, even without excess elevation, became dense enough so that the area became opacified and lighter than normal skin color. For at least its first 12 years Leon Goldman’s laboratory deemed the desirable end point of treating PWS by long-pulsed ruby laser treatment (136) as an improvement by “producing collagen damage with superficial fibrosis [to] . . . change the optical quality of tissue.” In other words the end point was production of scar tissue but it was not ever called so except by Brauner (75) and Schliftman concerning argon laser, who also recognized the similarity of this “opacification” to the appearance of an opaque collagen skin test in transparent skin (Figs. 1.11 –1.13). Such opacification was later cited as an adverse effect by Geronemus (177) but was mistakenly thought to be hypopigmentation. It was not a reflection of total and permanent destruction of melanocytes by the argon laser since these areas did tan in sunlight and even hyperpigmented without sun but represented a true scar. As a typical example, in a large review as late as 1986, Apfelberg and McBurney (60) cited a 14% incidence of “scarring” in port-wine stains treated by argon laser with a variety of parameters and a 35% risk in strawberry hemangiomas. Nevertheless, photodocumentation of their results, even those reported as good results, clearly showed scars, but these were mischaracterized as not only “no change in sebaceous skin” but also exhibiting mild scarring in nasal telangiectases, “flattening and blanching . . . of strawberry mark” but with a densely opaque and hypertrophic lip scar, “lightening” but with a dense slightly hypertrophic scar on a treated tattoo, “without scarring” of a pyogenic granuloma which does have a small hypertrophic scar, “resolution of trichoepithelioma”
Figure 1.11
Flat opaque scars after argon laser surgery and appropriate dressing.
Cutaneous Laser Surgery: Historical Perspectives
Figure 1.12
19
Almost invisible opacification of an argon laser test area.
without mention of an opaque atrophic hairless patch on the lip. The results were so good in many authors’ experience as compared to their prior attempts at improvement that small amounts of scarring were similarly overlooked and certainly underreported by most laser surgeons who reserved the term “scarring” to mean real hypertrophic scarring. The reader of a paper or the audience of a lecture was led to believe that this instrument was not only wonderfully effective—which it was—but that it was also not as problematic as it really
Figure 1.13 Same area after stretching, exhibiting flat opacification and not true hypopigmentation.
20
Brauner
turned out to be. Time and time again, even with photographic documentation showing scarring, authors mentioned only improvement of the primary lesion and left it up to the reader to deduce that scarring was more prevalent than reported. A variety of methods were attempted to minimize hypertrophic scarring. Apfelberg tried to treat only small areas assuming that a larger second-degree burn injury would be more likely to hypertrophy. He spaced his treated areas with parallel untreated areas in a “banded” or “striped” pattern but eventually discarded the technique since scars continued to appear (73,178,179) (Fig. 1.14). Cosman tried to minimize the amount of thermal damage by using the lowest possible power setting to be effective. Unfortunately, the visible end point used in port-wine stains without magnification was not watching the vessel disappear or coagulate but watching the dermis and epidermis coagulate. With this minimal dose technique, Cosman used the lowest power setting to produce discrete whiteness of the epidermis after laser impact for each individual patient and used that dose uniquely for the patient with 0.2 s bursts. Many surgeons, including Cosman, used the dot-by-dot intermittent technique with slight or no overlap of the 1 or 2 mm bursts to produce uniform as well as reproducible injury. Scheibner and Wheeland (180,181) used the continuous wave tunable dye laser tuned to 577 nm with magnification by 8-power optical loupes to trace out vessels and observe them constrict and coagulate as the visual end point. Tracing was done in a continuous fashion but with the surgeon’s hand moving quickly. This meticulous and incredibly laborious method was thus more sparing of the epidermis and the dermis surrounding the vessels. Since the minimal achievable pulse duration was 50– 100 ms scanners were developed (182) which could move a beam so quickly over an area that the effective time of injury was 1 ms and much more focal to the vessel (183,184). Scanners were also developed for use in gynecologic surgery and by 1982 for the cutaneous CO2 laser with a microslad coupled to the Sharplan 733 laser (Fig. 1.15) and later a Sharplan 777 scanner; these scanners were not used primarily for vascular lesions but for more precise vaporization of large areas such as tattoos and for resurfacing of scarring from acne, varicella, or trauma and other contour defects such as rhytids. Robotized hexagonal scanners were introduced by Rottoleur et al. (185) in 1988 initially for use with the argon laser, but later they were used with continuous wave dye and copper vapor lasers (Fig. 1.16) which had appeared commercially. The release of pulsed dye lasers for vascular and pigmented lesions dimmed the aura and popularity of hexagonal scanners (186) but scanners appeared again in the mid-1990s as adjuncts for laser resurfacing with carbon dioxide and Er:YAG lasers.
Figure 1.14 Hypertrophic scarring after argon laser “stripe” technique and an undressed wound.
Cutaneous Laser Surgery: Historical Perspectives
21
Figure 1.15 Sharplan microslad scanner for CO2 laser cutaneous resurfacing and tattoo ablation. (Courtesy, Am J Cosmet Surg.)
Chilling heat-injured skin was long known to diminish the extent of overall burn injury so that postlaser cooling of the treated area became a common afterthought. Perhaps more importantly, if local anesthesia had not been used, it would have helped relieve the symptomatic burning pain. Preoperative chilling was attempted (187) to
Figure 1.16 Hexascan scanner, the first American application by Alan Schliftman, MD, of the most widely used scanner for continuous or quasi-continuous lasers (argon, continuous dye, copper vapor, copper bromide) for vascular and pigmented lesions. (Courtesy, Am J Cosmet Surg.)
22
Brauner
slow down and pool targeted erythrocytes in port-wine stains and not to diminish burn injury. Unfortunately, no pooling was statistically demonstrable and the main “benefit” was a lower incidence of atrophic scarring, scarring which could just as well have been caused by lack of closed dressings. Even intraoperative chilling (188 – 191) was attempted in the hope of preserving the epidermis so that there would be no open wound to become potentially infected and to preserve the upper papillary dermis. Since an inside-out thermal injury was produced by the laser, a lower set temperature point for the epidermis meant that the temperature rise from spread of heat from the injured vessel would still be below a necrosis threshold of 708C (9). Chess (190,191) has promulgated for years the importance of intraoperative chilling for a variety of lasers and invented the first practical “icing” device. Landthaler (189) had used an ice cube to chill the epidermis as he moved his deeply burning continuous Nd:YAG for hemangiomas. Leon Goldman (188) had toyed with a variety of unusual chilling implements in his laboratory. A deeper understanding of the thermokinetics of laser injury has led to resurgent interest in chilling in the late 1990s for maximal thermal injury to targets such as deeper or larger telangiectases (192) and venules, deeper or resistant port-wine stains (193 –202), and the hair follicle. A concurrent approach to greater selectivity of the laser for its target in the mid- to late-1980s centered on the greater relative absorption by oxyhemoglobin than melanin of yellow wavelengths (203). The argon-laser-pumped continuous tunable dye laser tuned to 577 nm (204), the quasi-continuous copper vapor laser (205 –210) at 578 nm, and the pulsed dye laser at 577 nm, had better absorption and deeper penetration so that theoretically deeper vessels could be targeted and more energy could be delivered to destroy vessels with less or no epidermal injury. The continuous dye and copper vapor were both found to be somewhat more effective than the blue-green argon but their clinical thermal effect was essentially unchanged from the argon experience (206) whether made freehand or by scanner. They were followed shortly in the cutaneous surgical marketplace by the quasi-continuous copper bromide laser (211,212) and the quasi-continuous krypton laser (7). Interestingly, the pulsed dye laser was shifted to 585 nm, which is less well absorbed than 577 nm, and now is also used at 595 nm (213).
9.
POSTOPERATIVE WOUND CARE
As noted before, interpretation of adverse events when continuous wave lasers were employed for cutaneous laser surgery and epidermal necrosis ensued became obscured by the fact that scarring was underreported or redefined and postoperative care was not standardized, not mentioned in the literature or in lectures, and sometimes not given. Second-degree thermal wounds all scar and it is likely that the absence of postoperative dressings over the necrotic wound in early argon laser surgery was responsible for much of the incidence of hypertrophic scars. With proper postoperative dressings and antibacterial ointment the incidence of such scarring dropped to less than 1% (75,77) from a range of 3 –16% or more (60,68,71,73,74,178,214,215) (Figs. 1.11 and 1.17). Brauner and Schliftman were early proponents of scrupulous postoperative wound care. Unfortunately, there was an accompanying and unexpected large incidence of contact dermatitis to bacitracin with large areas of coverage (216 –218). Though the need for scrupulous postoperative care is now well established for this type of laser induced wound, the most appropriate type of dressing has been controversial in the past half-decade as facial resurfacing became the leading example of cutaneous laser surgery (218 – 227).
Cutaneous Laser Surgery: Historical Perspectives
Figure 1.17
10.
23
Hypertrophic scars after argon laser surgery and an undressed wound.
SELECTIVE PHOTOTHERMOLYSIS
Leon Goldman was seminal in beginning and motivating the use of medical and surgical lasers but the direction of laser use was related to the industrial lasers provided to us. Micromanipulators, fiberoptics, scanners, and microscopic couplers were all cleverly invented accessories for the main item but the main item was never designed from the ground up for altering specific pathogenic targets, that is, not until 1983. The second most remarkable seminal event for laser surgery was the optical construct, which allowed us to understand the nature of the amount of thermal or acoustic alteration that was minimally necessary to produce our biologic result. Not only could we select a target and an appropriate laser using the target’s relative absorption characteristics but we could also construct a laser putting out a burst of light corresponding in its duration to the thermal relaxation time of the target. This combination of selection by absorption and by size became the theory of selective photothermolysis as elaborated by Anderson and Parrish (4,5) (Fig. 1.18). It was the first of many modeling constructs around which medical lasers would be manufactured. The courtship of laser industry and laser surgeons, which had begun after the institution of ASLMS, was now ready for the full-fledged partnership of marriage. Now laser surgeons could request industry machines capable of specific tasks. The pulsed dye laser for vascular lesions was the first of these many instruments (228 –235). Though shifted from its original experimental format of 577 nm (236,237), 360 ms pulses, and 5 mm spot size to 585 nm (235,238 – 244) and 450 ms and now up to 600 nm and 20 ms pulses with 5, 7, and 10 mm spot sizes, it allowed for rapid treatment of large areas—perhaps 100 times faster than the argon laser had been. Pain was usually not severe enough to require anesthesia except in children. There was almost no thermal damage to the epidermis except mild crusting by days 3– 4 postoperative and thus no second-degree burn injury and essentially no risk of either hypertrophic or flat opaque scar. In the mid- to late 1980s it very quickly became the vascular laser of choice despite the simultaneous appearance of other quasicontinuous yellow lasers (205 – 207,245 –248). Because of its greater safety and specificity it was widely offered to children who for the most part (74,76,77,80,241,249,250) had been denied continuous or quasi-continuous laser treatments. The dramatic impact of a laser able to treat deformed children without scarring and with a “100% cure rate” (240) was earth-shaking.
24
Brauner
Figure 1.18 R. Rox Anderson, MD, conceptualizer of “selective photothermolysis.” (Courtesy, Wellman Laboratories of Photomedicine.)
What actually happened was unfortunate as this drama had an adverse side as well. Tan et al.’s enthusiastic report in the widely publicized New England Journal of Medicine had the public convinced that the laser was painless and 100% effective, thus putting all cutaneous laser surgeons on the spot trying to re-explain that neither scenario was true. This laser has been documented to clear PWS in only 40% of patient populations (251) with repeated treatments, though the remainder of patients are very significantly improved. As initially with the carbon dioxide laser, hyperbole was fashioning unrealistic public demand. The second adverse sequel was that this industry –surgeon marriage meant that there was an increasingly important role that the medical – industrial complex would play, not just in the delivery of care, but also in its cost since the new lasers represented hundreds of thousands of dollars in investment to be paid off by the laser surgeon. There was, as well, the possible perversion of scientific methodology and reporting by not-so-subtle conflicts of interest such as special deals in pricing of lasers, free or loaned lasers, research grants, surgeons acting as spokespersons in advertising routines for companies; these same laser surgeons would then be called upon to present or publish new data in what the audience was supposed to think represented no conflict of interest. For the first time it would not be egos or ideas under attack by skeptical laser audiences but the very ethics and truthfulness of the presenters. This was a nasty and unexpected challenge to honest scientific methodology; vocal controversy and insult became an unfortunate coparticipant at laser meetings as evidenced by chairmen’s forewarning to their panelists at the 1998 ASLMS about personal (ad hominem) attacks.
11.
WELLMAN LAB AND BECKMAN LAB
Although Rox Anderson first immersed himself in lasers as an undergraduate student in 1976, in the Wellman Labs of Photomedicine (www.wellman.mgh.harvard.edu), of
Cutaneous Laser Surgery: Historical Perspectives
25
which he is now the research director, had opened at Massachusetts General Hospital (MGH) in Boston in 1974 as a multidisciplinary research laboratory devoted to basic and applied research in human photobiology. It is now the world’s largest biomedical laser research facility as well. In 1988 a laser applications research laboratory to develop specific medical laser applications was formalized. In 1992 the MGH laser center, a hospital-wide multispecialty center to deliver care by laser therapy to a variety of patients, was established in coordination with the Wellman Labs. In 1982 the Beckman Lab (www.bli.uci.edu) was founded by Drs. Michael Berns and Hugh Beckman, both bioengineering scientists. This institute is now part of the University of California, Irvine, and houses multidisciplinary basic research groups, as well as having a clinical laser surgical center for patient care. It, along with the Wellman Lab, are unique facilities in the USA for fundamental laser research. The rest of laser progress has essentially been the fruit of individual practicing laser surgeons or research grantees in concert with clever industrial invention.
12.
Nd:YAG LASER
The Nd:YAG laser was first used by Goldman in studies on tattoos shortly after its invention in 1961. Though used primarily in endoscopic gastrointestinal laser surgery, particularly for bleeding, since it had such deeply penetrating nonselective thermal necrosis of almost 4 mm when used in normal mode, Landthaler et al. (189) in Germany in the mid-1980s first advanced its use for therapy of large vascular cutaneous tumors. These cavernous hemangiomas (252–258) or large blebs of port-wine stains (52,215) were too thick to be affected by the available argon laser or even the pulsed dye laser when it appeared. Intraoperative chilling by moving an ice cube quickly over the skin just prior to single or a group of widely spaced bursts was necessary to attempt to preserve epidermal integrity. David and coworkers (253) noted that the scarred resultant area might then be excised in a secondary procedure with minimal bleeding for an even better cosmetic result. Apfelberg et al. (254,256,257) and Waner and coworkers (259,260) promoted the use of the Nd:YAG laser in the USA with both noncontact and contact surgery with a sapphire tip, (261,262). The laser heated the tip, which then acted as a hot hemostatic scalpel (254). With Q-switching (vide infra) this laser became widely employed worldwide for treatment of tattoos and pigmented lesions in the 1990s. Adaptation of the normal mode Nd:YAG laser by doubling its frequency and thus halving its wavelength to 532 nm makes it particularly applicable for the treatment of vascular lesions with a similar therapeutic profile compared to other continuous wave lasers such as argon (263). Only recently, in the late 1990s, when combined with a chill-tip, has its use been expanded again for the treatment of vascular lesions but now without epidermal thermal damage and mostly without purpura (vide infra). 12.1. Q-switching In 1967 Leon Goldman (38) published his 3-year experience with the long-pulsed 1.8 ms ruby laser and the neodymium laser to treat tattoos, producing nonspecific histologic necrosis and subsequent fibrosis with decreased pigment. In 1964 Goldman had already first compared the normal mode and the “new” Q-switched ruby laser (37) on tattoos. By increasing the power density, he was able to show permanent tattoo pigment removal with the Q-switched ruby laser by 1967 (38). In 1967, a full 15 years before Reid, Laub and coworkers (264) showed that Q-switched ruby laser with 10 ns pulses
26
Brauner
and 5.4 mm spot sizes with 2 – 4 J output could destroy tattoo pigment without epidermal damage (265). Kitzmiller (136) in 1974, reviewing Goldman’s Cincinnati experience, also claimed that Q-switched ruby laser in nanosecond bursts had been found to be more effective than normal mode ruby laser in tattoo removal. In 1983, Reid et al. (266,267) described the first series of patients treated successfully with Q-switched ruby laser without scarring. Another historical laser hiatus occurred, this time almost a decade before American publications on tattoo removal (268,269) and Polla et al. (270) and Dover et al. (271) on melanocyte destruction followed by FDA approval in 1989 (3), which allowed American use of commercial Q-switched ruby lasers for hyperpigmentation and tattoos, 25 years after Leon Goldman first used it. Q-switching is compatible with the principle of selective photothermolysis since the thermal relaxation time of targeted melanosomes or tattoo pigment granules are within the nanosecond range emitted by a Q-switched device. Soon after the appearance of the “new” Q-switched ruby laser, the Q-switched Nd:YAG laser emitting at both 1064 and 532 nm (272 – 274) and the Q-switched alexandrite (275 – 277) lasers were marketed in the early 1990s for treating similar conditions (Fig. 1.19). A non-Q-switched but nanosecond pulse flashlamp-excited dye laser (PLDL) for hyperpigmentation also appeared; its wavelength of 510 nm was close to the most effective wavelength for melanosome destruction (514 nm) (278,279).
13.
PIGMENT LASERS
The high prevalence of unsightly pigmented lesions such as solar lentigines, flat seborrheic keratoses, cafe´ au lait macules, and even nevi offered a large spectrum of potentially treatable lesions and spurred the boom in the use of pigment-targeting lasers. Q-switching was not essential for melanocyte destruction but allowed for more intense focal melanosome injury and lesser risk of scarring, but continuous wave green argon, KTP, krypton, and copper vapor lasers had been widely used in the 1970s through the early 2000s for benign pigmented lesions with acceptable results (280 – 283). Hyperbole reigned here too. Initial reports of very high success rates (284,285) for cafe´ au lait macules were tempered by frequent recurrences reported by subsequent investigators (276,279,286 – 288). Even the use of progressively deeper penetrating red alexandrite or ruby lasers seemed no more permanently effective than the more shallow-penetrating green lasers.
Figure 1.19 First observation of dermal holes immediately after tattoo pigment explosion in minipigs produced by alexandrite laser by Gary Brauner, MD, and Alan Schliftman, MD.
Cutaneous Laser Surgery: Historical Perspectives
27
“Nonsense” science also played a role when these lasers were used to treat lentigo maligna. Arndt’s initial anecdotal case report of success with the shallowly penetrating argon laser for lentigo maligna had to be retracted 2 years later by the recurrence of the melanoma since it was too deep to be entirely eradicated (289,290). Such nonsense application of laser was potentially life-threatening since obliteration of only the superficial component of a lentigo maligna allows deeper melanoma to metastasize (J. Spencer, personal communication). Treatment of tattoos and nevus of Ota (291) temporarily but inadequately moved the focus of laser – tissue interaction from merely the physics of light absorption by skin and adnexae to the equally pertinent subsequent biologic behavior of the injured tissue. These two conditions continued to improve and recede long after therapy—the rush to treat them as quickly as possible and maintain patient satisfaction undermined proper side-by-side studies to ascertain biologically appropriate treatment intervals. Unfortunate counterpoints in the 1990s were the unsettling discoveries of unanticipated very delayed (months) opacification of CO2-resurfaced areas or even of pulsed dye or continuous dye laser-treated poikiloderma of Civatte (292) as well as the fortuitous discovery of beneficial tightening of rhytids seen after CO2 resurfacing. Treatment of nevocellular nevi by lasers has reached no consensus or historical conclusion. Some of Leon Goldman’s first attempts with laser were centered on the treatment of melanoma (41,47). Much of Ohshiro’s early work in Japan in the late 1970s involved destruction of nevi by long-pulsed ruby lasers (49). Brauner and Schliftman (286) first raised the question of the “angry melanocyte” in discussing idiosyncratic hyperpigmentation of a cafe´ au lait patch as a result of the first use of the pulsed 510 nm PLDL laser for treating hyperpigmentation. Postinflammatory hyperpigmentation (293) was by then long known to occur after CO2 , argon, copper vapor, and now after Q-switched Nd:YAG (288), 1320 Nd:YAG (294), Q-switched ruby, and long-pulsed ruby hair removal lasers. Brauner’s was the first clinical recapitulation of Dover et al.’s (271) first experiments with pigmented guinea pig skin showing that guinea pigs treated at less than a “threshold” of 0.3 J/cm2 developed hyperpigmentation and Hruza et al.’s (295) 1991 electronmicroscopic studies of normal human skin showing subthreshold stimulation of melanogenesis, which was precisely the opposite of what was intended. Attempts to debulk congenital nevocellular nevi, which can be very unsightly, may be of a size or location where a mutilating scar might be left after excision, and among which the giant ones are considered potentially premalignant seemed reasonable. Multiple treatments with well-absorbed Q-switched alexandrite or ruby lasers are required for debulking and a significant though nonpigmented residue of dermal melanocytes may still be histologically present (296 –298). If these melanocytes retain latent subthreshold stimulation precisely what risks are latent?
14.
SERENDIPITY
In the early 1990s within a decade of the marriage of surgeon and industry serendipity reminded us that not all laser developments are predetermined rationally. In 1993, Alster reported that, when treating hypertrophic, persistently red scars for the erythema with a pulsed dye laser, she obtained not just improvement of the erythema but a distinct textural improvement, so much so that the scars flattened, occasionally dramatically, after several sessions (299). At first argon laser induced scars, then hypertrophic scars of other cause, facial acne scars, and even keloidal sternotomy scars responded. When Alster considered atrophic scars she found a similar result. The scar texture improved to the eye.
28
Brauner
The scar became less depressed and the surface was demonstrably changed on skin surface topographic textural analysis by optical profilometry, erythema reflectance spectrometry, scar height measurements, and pliability scores (300 – 306). The pulsed dye laser rapidly became an instrument widely used for scar treatment or as adjunctive therapy. McDaniel reported in 1995 and 1996 (307,308) his results with striae distensae, which are in some ways histologic equivalents of atrophic scars. Use of the pulsed dye laser with a 10 mm spot size and a low energy fluence of 3 J/cm2 showed clinical improvement and measurable improvement of skin texture by optical profilometry. These results are reproducible in some capable hands (306) but not in others (309,310). Since striae are not made to disappear but only contract slightly, hyperbole by the lay press played a prominent and unnecessary role.
15.
RESURFACING
Focal laser ablation of acne scars was one of the earliest procedures performed by cutaneous laser surgeons in the early 1980s. Although the freehand airbrush technique could be performed on tattoos and still leave a cosmetically acceptable scar on the trunk and extremities, the artistry required made laser resurfacing of large areas of acne scarring or rhytids on the face potentially more hazardous than dermabrasion. It was especially worrisome because the latter healed within a 2-week time frame while laser wound healing was prolonged often beyond the 2-week window of healing after which unsightly scars could develop. Though scanners had been coupled earlier to the CO2 laser for gynecologic cervical ablation, only in 1982 did Brauner and Schliftman first introduce to the USA the Sharplan microslad scanner (182) which allowed precise controllable movement of the beam in an X –Y grid pattern with uniform though Gaussian ablation. Such uniformity not only led to better results in tattoo removal but also allowed for more controlled ablation for resurfacing the face for acne scarring. Although this was the first mechanically assisted laser resurfacing, it did not gain widespread popularity for rhytid removal because the healing time still was slower than that for dermabrasion, presumably because of residual thermal damage. Focal laser resurfacing was done for treatment of rhinophyma since 1980 (132,311) and for actinic cheilitis for much of the 1980s (312 – 314). In 1989 David et al. (315) presented the first report of 4 years’ experience on “laser resurfacing” for facial wrinkles by a CO2 laser with clinical and histologic improvement. Their technique really represented a 50% trichloroacetic acid peel supplemented by focal epidermal and upper dermal coagulation without visible vaporization of the deeper rhytids by the defocused 0.1 s gated hand-held laser. Healing took 5– 14 days. Studies on superpulse CO2 laser had been done in the late 1980s (316,317), but in 1993 Fitzpatrick (318) presented studies showing that the principles of selective photothermolysis could be applied to the CO2 laser, that a re-engineered “ultrapulse” laser delivering up to 500 mJ in a single pulse with a pulse duration of less than 1 ms, which is the calculated thermal relaxation time of skin, would produce the most precise vaporization and leave the smallest possible thermal damage of 50 – 100 mm. With such a small residue, more rapid tissue healing could be expected and the collagen to be laid down would more likely be thinner and less likely opaque. Whereas more traditional CO2 laser resurfacing could take 2 or even 3 weeks to re-epithelialize and even David et al.’s combined trichloroacetic acid (TCA) –laser process took up to 2 weeks to heal this, new laser allowed for healing after two or three passes in about 10 days. Traditional dogma of wound healing had indicated that a wound taking longer than 2 weeks to heal
Cutaneous Laser Surgery: Historical Perspectives
29
was much more likely to result in a visible or even unsightly scar. Since Fitzpatrick’s technique was used alone to treat entire faces, it was the seminal event in laser resurfacing (319,320). The appearance commercially of both the scanner-driven SilkTouch laser by Sharplan (with much more precise ablation than its older-generation scanning microslad device) and the Coherent UltraPulse laser which provided individual ultrashort pulses and the clinical and histologic reports of Kauvar and coworkers (321 – 324), David et al. (325), Dover and Hruza (326,327), Cotton et al. (328), Ross et al. (329,330), Chernoff et al. (331,332), Lowe et al. (333), and Lask et al. (334) led to an unprecedented avalanche of cosmetic surgeons beginning to perform laser surgery mostly for actinic damage and rhytids but also for acne scarring (335). Although chemical peeling and dermabrasion were long-established and safe techniques for the treatment of wrinkles, the ability to easily remove wrinkles to a precise and uniform depth (unlike peels), to remove the need for artistry (unlike dermabrasion and peels), to remove the risk of exposure to sprayed blood (unlike dermabrasion) and the high-tech appeal of the laser instrumentation compounded interest in the laser (227). Serendipity gave a coup-de-grace to the older techniques when it was soon noted that improvement in laser-treated wrinkling continued as the healed areas tightened and contracted over a period of months (319). Competing claims of efficacy of scanned vs. Ultrapulse lasers in numerous anecdotal reports were based on experience with one or other laser. Comparative studies of side-by-side treatments, not just randomized or anecdotal surveys, were needed and were much delayed by the costs involved in having more than one equivalent laser. These competing claims were laid to rest by studies such as those by Burns (336) on half-faces and by Alster et al. (337) with four randomized CO2 lasers for quarter-face resurfacing. The perception by industry of the huge potential market spurred on marketing and advertising unprecedented with other lasers. The whole direction of cutaneous laser surgery shifted dramatically from a medical –scientific discipline to a medical – industrial commercial one (338). Courses were now driven not by medical interest in academic settings but by almost weekly promotional courses directly by laser companies using guest laser lecturers. Roving laser rental companies first appeared with a “have laser (and technician), will travel” motto. In-hospital laser peer credentialling became a practical though not a moral irrelevancy. The early 1990s saw a new federal administration with health care as its priority and fostering HMOs as its club to beat down costs. In 1992 Medicare law drastically cut physician reimbursements. With the appearance of safe cosmetic laser surgery as an alternative for diminished income, not only traditional cutaneous surgeons (dermatologists, otolaryngologists, and plastic surgeons) but even family practitioners, dentists, oral surgeons, and gynecologists began to perform cosmetic cutaneous laser surgery. A sudden influx of large numbers of cosmetic surgeons into ASLMS changed its balanced multidisciplinary format to a predominantly cutaneous surgical forum. Preceding the explosion of interest in laser resurfacing in the USA, Kaufmann and coworkers (339 – 343) in Ulm, Germany, had been studying since 1988 (almost a full decade earlier) the erbium:YAG laser, which held the potential for much more precise cutaneous ablation since its absorption by water was an order of magnitude greater than that of CO2 . It had been first researched in the USA in the mid-1980s for ophthalmologic use (344,345). Walsh and coworkers (346,347) published the first American cutaneous studies showing the markedly diminished zone of residual thermal dermal damage after erbium:YAG pulses. Kaufmann’s initial studies were not followed by American cutaneous laser surgeons until 1997 when Teikemeier (also German) and Goldberg published the first preliminary study on 20 patients (348). Immediately, the laser pendulum began to swing away from the CO2 laser (which had been so heavily touted as safer and more efficacious
30
Brauner
than all prior resurfacing modalities) to the erbium; the CO2 laser was suddenly no longer viewed as such a “safe” instrument. The precision of the Er:YAG laser and the much smaller demonstrable degree of thermal damage left behind was hyped by industry and speaker alike. The simultaneous discovery that delayed opacification, misconstrued as hypopigmentation (349,350), could occur with some frequency in CO2-resurfaced patients helped accelerate the swing. The faster healing and decreased postoperative erythema of the Er:YAG laser was considered powerful evidence of its effectiveness and safety but at the same time laser surgeons also reported that results did not seem as good with this laser (351 – 354). Qualified statements about its use for shallow rhytids rather than significant ones now had to be employed to explain the poorer results. The lack of controlled side-by-side studies permitted the hyperbole to sweep away much interest in the CO2 laser and dozens of manufacturers got on the Er:YAG bandwagon. Hyperbole was again marching at a much faster pace than true science. Authors such as Alster and Adrian with systematic side-by-side studies brought order to the scene. Alster (355) reviewed laser resurfacing by six randomized Er:YAG lasers in her patients. Adrian (351,352) in his seminal histologic studies had earlier admonished other laser surgeons using the CO2 laser for resurfacing that they had misunderstood the nature of vaporization and thermal damage, that with the parameters of UtraPulse 500 microsecond pulses, unlike older traditional CO2 laser vaporization, dermal ablation was limited to the upper reticular dermis and further applications of the CO2 laser only produced more thermal damage and increased the risk of scarring. With the waters muddied by conflicting claims of Er:YAG’s efficacy vs. CO2 , it was again Adrian who showed with his careful histologic studies that equally deep destruction by Er:YAG and CO2 lasers would produce equal clinical results with equal healing times and equal erythema. He clearly unmasked the errors of the initial excitement as due to the laser surgeon’s not truly understanding the nature of the the two types of injury and basically not performing equivalent surgery with each laser. Commercial adaptations, including variable pulse durations, of the Er:YAG laser, to more closely resemble the CO2, have evolved over the past 4 years (356 –358). Combination therapies (359) relying on the virtues of each of these lasers were employed, producing faster ablation and leaving less residue by using CO2 first then erbium or more precise ablation but better hemostasis by using erbium first then CO2 (360) or even using both lasers through the same handpiece in the same laser device (361,362). Even the variable-pulse Er:YAG followed by shortpulse Er:YAG has been tried and seems to work even better than CO2 followed by short Er:YAG (360).
16.
LASER-ASSISTED HAIR TRANSPLANTATION
Concurrent with resurfacing technology was the suggestion that a narrow band of thermally damaged tissue should be hemostatic and might allow for rapid and bloodless hair transplantation by insertion of thin slits of hair-bearing skin or individual follicular units into slits or holes made by one of these lasers. Although with the CO2 laser a bloodless wound can be produced by either an UltraPulse laser or laser with rapid scanning, the amount of oxygen diffusion through this area and the rapidity of establishment of a vascular supply to the hair matrix was questionable and so, yet another controversy (363 –366) began in the mid-1990s. Walter Unger (367 –370), a prominent hair transplant surgeon, first reported his experience in 1994 with the UltraPulse laser. He thought that laser-recipient sites had good hair growth but that it was delayed compared to control cold steel grafts. Fitzpatrick
Cutaneous Laser Surgery: Historical Perspectives
31
(371) found that the laser-assisted procedure was 50% faster than control cold steel grafting but healing was slower and graft take was not as good. Ho et al. (372) claimed that slit placement with the UltraPulse laser was 50% faster than cold steel and thought growth in lased slits was good. Grevelink and coworkers (373,374) first reported on the use of a CO2 laser with the Sharplan SilkTouch scanner to develop recipient sites. Smithdeal (375) in 1997 employed the Sharplan scanner with good results and Tsai et al. (376) using a similar scanner said that his patients thought the laser-prepared sites looked more natural and had better density than cold steel sites. Neidel et al. (377) recently reported a single case of Er:YAG laser-assisted transplantation with a good results. A small number of physicians are still promoting laser methodology (366,368,370,372, 376,378) but cold-steel surgery is still the predominant method of graft recipient design (365).
17.
PULSED LIGHT SOURCES
Though not true lasers, intense broad-band pulsed light sources with a wavelength range of 590 – 1200 nm have recently found widespread use as epilating devices (379 – 383). The first generation of these machines with 550 –1200 nm bandwidth have been used for the treatment of vascular lesions since M. Goldman’s work (384 –387) in 1994. Since these devices were also approved by the FDA in a different category from lasers, they have been a focus of controversy, especially when marketed and administered by lay personnel (78). Bitter’s (388) seminal article on “Fotofacials” by intense pulsed light treatments launched the huge demand for nonablative techniques for cosmetic facial improvement by lasers or light sources. He claimed “wrinkling, skin coarseness, irregular pigmentation, pore size and telangiectases showed visible improvement in more than 90% of subjects.” His optimistic observations were matched by some (389,390) but met with skepticism from many others. While most laser surgeons now agree that dyschromias are readily improved by this technique it is not clear that significant clinical improvement in wrinkling is effected (391) despite evidence of new papillary dermal collagen formation histologically (392).
18.
LASER HAIR REMOVAL
When Q-switched ruby lasers were employed in large numbers in cutaneous laser surgery another serendipitous enlightenment occurred. The immensely powerful though short bursts of energy generated to fragment tattoo particles were noted not only to vaporize darkly pigmented hairs but also to bleach them below their follicular exit and even to inhibit their reappearance. Studies by Dover et al. (271) in 1989 had shown selective pigment cell damage in follicles from this laser, which caused the leukotrichia. It seemed that laser energy had reached a portion of the pigmented hair bulb and disrupted it enough so that it might act also as a depilatory, or better still, a nonscarring permanent or epilatory instrument. The financial appeal of entering the 6 billion dollar-a-year industry of cosmetic hair removal was too enticing for laser manufacturers to avoid. Truly medical applications such as treating disfiguring hirsutism in women or pseudofolliculitis barbae in men (and rarely women) were an additional potential benefit. Thermally nonselective but effective destruction of hair follicles in hair-bearing grafts, or for trichiasis, had been reported as early as the 1970s (393 – 396) but hair
32
Brauner
removal by thermal damage confined to the hair follicle governed by the principle of selective photothermolysis had not been attempted. The first FDA-approved laser for hair removal did not depend on the pigmented hair as a target but instead a patented mineral oil lotion was used containing carbon-based material, which was presumed to seep into the follicles after waxing immediately prior to massaging of the lotion and thus provide a target for the laser. Presumably, the mechanico-acoustic wave appearing after the laser impact would then disrupt the base of the follicle so that the loosened hair would fall out and the damaged follicle would no longer produce hair. In 1995 Goldberg and coworkers (397,398) presented the first studies showing very short-term efficacy. Hyperbole from the mass media was unfortunately not countered immediately; neither the short 12 week duration of the study nor the low 25% hair loss at that time was widely publicized. The hairs grew back, in fact most of them by 3 months, although more slowly in lased sites, and all of them grew back (399) by 6 months. Nanni and Alster (399) also demonstrated that the scientific principle behind this laser was flawed in that the carbon suspension was not required for hair removal since, at 1 month, waxing plus laser alone was equivalent to carbon-assisted laser removal. Nevertheless, these flawed data became a public mantra that laser removes hair. The public was led to believe by the mass media that this was permanent hair removal done quickly, painlessly, and without potential for scarring, all unlike traditional electrolysis. The public again had unrealistic expectations driven by laser hyperbole and many patients became dissatisfied with this very expensive and temporary procedure. When educated properly about the relative long-lasting effects and the apparent diminution of caliber of hair, most of the treated public was content. Also in 1995, Grossman et al. (400) reported their preliminary results with normal mode ruby laser in black-haired dog skin and found that this laser with a pulse duration of 0.297 ms, shorter than the estimated thermal relaxation time for a 200– 300 mm hair follicle of 40 –100 ms (401), could produce selective thermal damage to the hair follicle. They soon followed this abstract with a published report on 13 patients treated only once with normal mode ruby laser (402), noting that four of them had less than 50% regrowth after 6 months. They also claimed that “selective thermal injury to follicles was observed.” Unfortunately, only horizontal sections of the upper follicle were shown. It was years before any investigator presented vertical sections exhibiting the nature of damage to the hair bulb and still no one has shown the numbers of scarred or atretic follicles on vertical section. Controversy again reigned because of the claims of “permanent” hair loss by these and other authors and the lack of both clinical and histologic proof (403). In mouse studies the Wellman Lab showed in 1998 that only anagen hairs were affected by ruby laser. This suggests that at least for mice the pigmented bulb and not the stemcell-containing bulge was the ruby laser’s target (404). Only one of Grossman et al.’s original 13 patients had lost all hair at 2 years’ follow-up and the four with diminished hair had no decrease in actual hair counts; histology showed hair follicles but with evidence of some miniaturization with vellus hairs replacing terminal hairs (405). Subsequent studies demonstrated long-term hair reduction with several long-pulse lasers, though patients required a series of treatments. The long-pulsed ruby, alexandrite, diode (810 nm), and Nd:YAG (1064 nm) are widely used for long-term hair reduction (406). In 1999 the word “permanent” was redefined in an Orwellian fashion by the FDA to no longer mean “forever” but, for the hair follicle, to mean absence of a visible hair for a period longer than one estimated anagen–telogen growth cycle for a particular body region. Such language manipulation served as a marketing ploy that only confused the public more. One positive redirection concurrent with attempts to make hair removal safer was a renewed interest in thermokinetics and protection of tissues not by selectivity of
Cutaneous Laser Surgery: Historical Perspectives
33
absorption and nonabsorption but protection even in the face of absorption by both the target and the nontarget. Because the thermal relaxation time of the pigmented epidermis is estimated at 3 – 10 ms, the epidermis is also a target for the ruby laser and with high fluences of 20 J/cm2 or more required for hair removal, significant destruction of the epidermis would occur if simultaneous cooling devices were not used. If two tissues shared too many common absorbents but were either physically different in size or were separated by some distance in the skin one could select pulse durations intermediate between each tissue’s estimated thermal relaxation time. One could preferentially heat smaller targets faster and larger targets slower to spare inversely their corresponding larger or smaller coabsorbers. One type of thermokinetically set alexandrite hair removal laser was manufactured which lengthened its pulse duration in order to deliver its energy over a longer period to the hair bulb and follicle and over too long a period to appreciably affect epidermal melanin in light-complexioned patients. Unfortunately, this theoretical enhancement did not provide a marked clinical difference (407). Such selectivity of longer pulse durations for larger targets to also protect smaller targets has more recently been employed for long-pulsed diode hair removal lasers for very darkly pigmented patients (408).
19.
CHILLING AND WRINKLES
Laser technologies seem to have a knack for recapitulating. Just as the ruby laser reappeared in the late 1980s after a 20-year hiatus, so renewed interest in green lasers for vascular lesions and a renewed understanding of the importance of chilling reappeared in the mid- to late 1990s, particularly by Wellman Lab (199,200) and Beckman Lab. Part of the interest in chilling was fostered by the large amounts of energy required to destroy or alter hair follicles and the need to protect the epidermis even better than theoretical thermokinetics alone. In 1994 Nelson’s group (193) at the Beckman Institute began a series of theoretical (194) and clinical (193,195 – 198,409) studies and first described the use of a spray cooling device using 20 – 80 ms bursts of a cryogen to cool and protect the epidermis during port-wine stain therapy. They saw no blistering appear after even 20 –36 J/cm2 with cooling spray but both blistering and necrosis without it. With this apparatus they could not only diminish intraoperative pain (197) and diminish epidermal injury with the 585 nm pulsed dye laser and with the 532 nm solid state laser (202) but, with the continuous Nd:YAG laser applied for thick vascular lesions in a cockscomb model (410), they could produce deep thermal effects to 6 mm without epidermal injury. Such dynamic cooling was adapted also for long-pulsed alexandrite hair removal systems. In the late 1990s, doubled-frequency 532 nm Nd:YAG laser with intermediate pulse widths of 2 – 10 ms and coupled with a sapphire water-cooled chill tip was introduced for treatment of vascular lesions without purpura. The chill tip was able to protect the epidermal integrity by keeping epidermal temperature at 5 – 5.58C and fluences of 9.5 –15 J were employed (190). Chill tips were consolidated with various long-pulsed ruby and diode lasers for hair removal also. Chilling by spray can be used just prior to, during, or even after the laser burst as a type of “thermal quenching.” Despite the dramatic and novel benefit of laser resurfacing, public demand has been driven by market forces as fast as development of the Web. Yesterday’s technology even for laser surgery rapidly and unjustifiably really becomes considered yesterday’s practice. Marketing forces the public to search for newer and quicker medical “fixes,” hence the appearance of the “lunchtime peel,” the “lunchtime microdermabrasion” and ultimately the lunchtime (i.e., no “downtime”) laser resurfacing by nonablative lasers (411,412).
34
Brauner
The public is confused into believing that these techniques all produce the same results as a true wounding resurfacing and without any hazard. Kelly et al. (294) in 1999 and Nelson et al. (409) showed that a small but statistically evident improvement in rhytids could be safely achieved with a 1320 nm Nd:YAG and dynamic cooling; there was rare blistering and hyperpigmentation and rarer pitted scarring. However, Ross et al. (413) thought that this process is too variable and prone to deep dermal collagen injury with resultant granulomatous inflammation, fibrosis, and pitted scarring. Muccini et al. (414) reported 18% shrinkage of collagen and new collagen synthesis without epidermal destruction in treating rhytids with a 980 nm diode laser with a spherical optical handpiece that focused the energy into the dermis. Goldberg and Whitworth (415) discovered subtle yet visible improvement of rhytids after slight epidermal ablation with uncooled Q-switched Nd:YAG laser, and Goldberg and Cutler (416) found that intense pulsed light sources with a precooled light guide did the same without epidermal ablation. Patients treated with pulsed dye laser for vascular lesions also report improved skin textures as have those treated for atrophic and hypertrophic scars. Nonablative skin remodeling has ballyhooed the promise of reduction of wrinkles, pore size, and oiliness, improvement of skin texture, and removal of pigmentary dyschromias, both brown and red, with no epidermal damage, no downtime from work, and no morbidity (417). Amazingly, the lasers and light sources touted to produce these changes have included the entire spectrum from 532 to 1540 nm—clinical improvement or histologic evidence of procollagen, new collagen synthesis or deposition was noted for 532 nm, 2 ms laser (418), 585 nm, 450 ms pulsed dye laser (419), low-fluence 595 nm long-pulse chilled pulsed dye laser (420), 585 nm, 360 ms pulsed dye laser (421), chilled 1320 nm Nd:YAG laser (422, 423), and chilled 1540 nm Er:glass laser (424). Similar claims were made for intense pulsed light (389,392). More realistic assessments of improvement indicated that though most subjects showed some improvement, it was at most minimal—only 18% by grading in Rostan’s study (420)—and could lead to patient dissatisfaction as for 80% of Trelles patients (423) even though they had histologic evidence of new collagen.
20.
BIOSTIMULATION
Numerous European authors, most prominently E. Mester in Hungary, have studied biostimulatory effects of lasers on cutaneous tissues in vivo and in vitro since the mid-1960s (425 –428). Beginning with the long-pulse ruby, then the He – Ne and argon lasers, he performed studies on 15 different biologic systems, such as Erlich’s ascites tumor cells, hair growth in mice, rat marrow hemoglobin synthesis, human fibroblast RNA and DNA protein synthesis, and wound healing, first reporting his results in 1968 (425). In general, he found that lower-intensity lasers produced biostimulatory effects while higher doses were inhibitory. In the mid-1980s a short burst of interest by American authors Abergel, Castro, and coworkers (429 – 437) showed that Nd:YAG laser could inhibit or stimulate fibroblast collagen production without destruction of the cells and without thermal effect and that He – Ne and Ga – As lasers could stimulate collagen production in vivo and in vitro. The Nd:YAG laser was also shown to inhibit keloidal fibroblasts in culture and to clinically shrink keloids. For the most part though, the American cutaneous surgical community did not follow Mester’s lead perhaps because of very few pertinent English language articles, or more likely the great difficulty of performing controlled clinical trials when the strict definition of biostimulation meant that no measurable immediate tissue changes (i.e., thermal) took effect. As a further
Cutaneous Laser Surgery: Historical Perspectives
35
example, although ASLMS annual meetings have always had a section on biostimulation, the papers presented most recently invariably are not from the USA. In the 1980s the gallium –arsenide laser was removed from cutaneous study protocols by the FDA. The He – Ne laser attained unfortunate notoriety at the same time when it was fraudulently promoted by lay practitioners and some chiropractors as a laser nonsurgical facelift. Ultimately, renewed interest in minimal thermal or acoustic damage inciting fibroblastic repair will undoubtedly spill over into biostimulation as well and, hopefully, more American literature will be forthcoming.
21.
PHOTODYNAMIC THERAPY
Photochemotherapy depends on an external light source activating an exogenous photosensitizer. This process has been employed to treat disease for over 3000 years, first used for vitiligo with plant extracts containing psoralens acting as the sensitizers. Modern studies of photosensitizers began with Raab (438) and his professor, von Tappeiner (439) just 100 years ago, who found that acridine and other dyes would kill paramecia when exposed to light. von Tappeiner (440) published the first text on the subject in 1907 and named the process photodynamic action. Interestingly, one of the first therapeutic applications he published was with the dermatologist Jesionek (441) on the use of eosin as a photosensitizer to treat cutaneous diseases including skin cancer (442). In 1942 Auler and Banzer (443) first exhibited the retention of hematoporphyrin by rat tumor tissue and the tumor’s selective destruction by subsequent quartz lamp radiation. Diamond et al. (444) in 1972, Dougherty (445) in 1974, and Tomson et al. (446) in 1974 started the modern era of photodynamic therapy, Diamond with hematoporphyrin derivative (HpD) and rat gliomas, Dougherty with fluorescein and mouse mammary carcinomas, and Tomson with acridine orange and mouse epithelial tissue where argon laser was the illuminating source. Dougherty’s report in 1975 of HpD injected intraperitoneally in animal models with application of deeply penetrating red light initiated intense study of HpD (441,447 –452). Both noncoherent light sources and lasers have been employed in the past several decades, although the laser’s monochromaticity and coherence would seem to make it a preferable choice. Since HpD and its purified product Photofrin (porfimer sodium) have been the most widely studied compounds, red light sources have been their complement. The continuous wave tunable dye laser tuned to red wavelengths from 630 to 690 nm and the quasi-continuous gold vapor laser at 628 nm were the lasers of choice. Photofrin and laser technique was approved for general use by the FDA (451,453) in 1995 but with limitations to pulmonary, gastrointestinal, and urologic malignancies. Only a few select experimental centers such as Dougherty’s in Buffalo were able to continue to provide information on applications for cutaneous carcinoma. Thus, 25 years of American studies of these photosensitizers and benzoporphyrin derivative, tin ethyl etiopurpurin, and monoaspartyl chlorin e6 have been retarded. Allison et al.’s (454) recent literature review and their own data showed enticing remission rates with clinical cures of up to 100% claimed by various authors (Table 1.2). Topical 5-aminolevulinic acid (with a nonlaser blue light source) has been approved in 2000 in the USA for cutaneous premalignancies (455). Bissonette and Lui’s (453) review showed that complete response of actinic keratoses ranged from 81% to 100%, which bodes well for a promising future for photodynamic therapy and skin disease.
36
Brauner
Table 1.2 Photodynamic Therapy of Cancer Involving the Skin Photodynamic therapy
Complete remission
Basal cell carcinoma Wilson, 151 BCC (125 primary, 26 recurring) Wilson, 588 lesions in Gorlin’s syndrome Warloe lesions ,2 mm thick lesions .2 mm thick
IV PDT 88% IV Photofrin 95% Topical ALA 90% Topical ALA 45%
Squamous cell carcinoma Hernnijton, 32 lesions Robinson, 500 lesions Jones, 6 Bowen’s
IV PDT 81% IV Photofrin 100% IV Photofrin 100%
Kaposi’s sarcoma Bernstein Allison, 121 lesions
IV Photofrin 33% IV SnET2 75%
Breast adenocarcinoma metastasis Allison, 86 lesions
IV SnET2 92%
Source: Adapted from Allison et al. (454).
However, when it comes to invasive cancer, another picture emerges. Warloe and coworkers (456 –458) obtained mediocre results with topical therapy of even thin 2 mm tumors; only with combined aggressive approaches were cure rates comparable to those of traditional therapy. Sacchini et al.’s (459) experience with topical TPPS in azone and 630 nm light in 14 cases of basal cell carcinoma (BCC) evidenced biopsy-proven complete remission in all tumors less than 2 mm thick but also only partial remission in those more than 2 mm thick. Biel’s (452) review of his own and others’ experience found poor results from systemic photodynamic therapy uniformly for tumors more than 5 mm thick.
22.
RETURN OF THE SCIENTIFIC METHOD—THE CHARGE FOR THE FUTURE
Industrial hyperbole and the seeming need by many cutaneous laser surgeons to be the first “kid on the block” by presenting anecdotal evidence for a new use of a particular laser (148), whether justifiable biologically or financially for the patient, swung the pendulum of laser activity and continues to do so at a violent pace toward the nonsense pole antithetical to Leon Goldman’s maxim. In recently reviewing laser skin resurfacing, Kauvar (324) bemoaned and warned that “rapid development of novel instrumentation is outpacing our ability to study fully their biological effects in tissue.” The immense cost of purchasing several similar lasers to compare their efficacy and the unlikely provision of loaned or free competing lasers by a laser manufacturer (anxious to market a new product) complicated interpretation of new data and even made those presented for one laser system only suspect and continued to foster divisiveness and antagonism even in the public arena. Even with panels of experts presenting their data, too often listeners would query, “Well, which of these very expensive instruments should I purchase?” Fortunately, a number of laser surgeons could occasionally swing the pendulum back toward “sense” science by doing side-by-side or randomized comparisons (Fig. 1.20) (186,192,197,205,207,208,329,337,352 –356,415,459,460). For example, Schliftman and
Cutaneous Laser Surgery: Historical Perspectives
37
Figure 1.20 Two comparative side-by-side studies of argon, copper vapor, and continuous dye lasers on a port-wine stain by Drs. Schliftman and Brauner.
Brauner (205,207) in 1990 showed that equivalently dosed copper vapor laser was more effective than continuous wave dye laser or argon laser on side-by-side test areas of port-wine stain after one treatment. In 1993 Waner et al. (208) compared two yellow lasers, the copper vapor and pulsed dye, for facial telangiectases. Upon side-by-side comparison the former laser healed more quickly and was more cosmetically acceptable to the patients but both gave equivalent clinical improvement. In 1995 Dover et al. (186) compared port-wine stains treated with hexascan-assisted continuous dye laser with those treated with matched side-by-side pulsed dye laser and found both lasers effective, with the pulsed dye more so. A minimal and equivalent side effect profile for both sites was shown. Waldorf et al. (197) compared dynamically cooled sites with uncooled sites on pulsed dye laser-treated paired sites in port-wine stains, illustrating the epidermal sparing and pain relief effects of this device. Adrian and Tanghetti (192) paired pulsed dye laser and sapphire-tip-chilled 532 nm Nd:YAG laser for facial telangiectasia. Leuenberger et al. (460) had better results with Q-switched ruby laser on black tattoos than sideby-side Q-switched Nd:YAG and Q-switched alexandrite, although all worked well. McDaniel et al. (356) compared CO2 laser for perioral rhytid resurfacing to combined sequential CO2 and then Er:YAG resurfacing and found no significant clinical differences. Alster et al. (337) found no significant clinical differences in four randomized simultaneous CO2 resurfacing lasers and in a second study (355), in six randomized Er:YAG resurfacing systems. Khatri et al. (353) found quicker recovery but lesser therapeutic effect in Er:YAG than in CO2-laser-resurfaced areas. Goldberg and Whitworth (415) compared side-by-side char-free CO2 lasers and QS Nd:YAG laser for periorbital rhytid removal. Grossman et al. (461) studied side-by side flashlamp-pulsed light source, two types of long-pulsed ruby laser, long-pulsed alexandrite, and long-pulsed diode lasers for hair removal. Determining optimal intervals for therapies requiring multiple treatments (as mentioned previously concerning pigmented lesion removal) requires paired side-byside comparisons as well, but the rush to publication and for rapid treatment obscured the need for understanding the biology of laser healing and tissue restoration. The emergence of on-line Internet laser discussion groups and even journals such as lasernews.net (http://lasernews.net) and Dermatology Online Journal (http://matrix. ucdavis.edu/DOJdesk/desk.html) fosters rapid communication and helps disseminates more quickly new insights and possible complications but accelerates the speed of what we think is laser “science” perhaps faster than the biology of healing and repair is willing to provide us with correct information. Time tempers judgment but accelerated internet time may only interfere with a cautious laser surgeon’s perspective.
38
Brauner
In a similar vein, hyperbole (308 –338) masked the true incidence of complications. Some cautious but perhaps courageous laser surgeons did report side effects and preached thoughtful reflection and methodology (222,319,349,355,462 – 469). This author raised the question of underreporting of scarring and the role of wound dressings in preventing hypertrophic scarring in 1984 (75). In a 1987 review Olbricht et al. (463) surveyed laser surgeons, 69% of whom had seen at least one case of hypertrophic scarring after argon laser and 64% after CO2 laser surgery, but no true incidence of scarring was tabulated. Lent and David (464) noted hyperpigmentation in 16% of laser-resurfaced patients postoperatively and Fitzpatrick et al. (319), 25%. Nanni and Alster (466) found a 37% incidence, more common in darker patients (up to 100% of Fitzpatrick type IV and V patients) (355,466), but this is reversible particularly with postoperative hydroquinones. Bernstein et al. (349) first made known the previously unreported late onset of hypopigmentation with CO2-laser-resurfaced patients, which may have represented both melanocyte destruction and delayed opacification. This delayed side effect, which seemed to correlate with prolonged erythema, was largely responsible for the shift to Er:YAG laser resurfacing systems. Rendon-Pellerano et al. (467) reviewed the rare but expectable early and late complications seen after laser resurfacing but reported four worrisome unpredictable outcomes, disseminated herpes simplex without prior clinical history of herpes, delayed wound healing with spontaneous breakdown of previously healed skin and protracted healing with scarring thereafter, granulomatous response of the lip margins, and a case of staphylococcal parapharyngeal abscess. Our past history, short as it has been in cutaneous laser surgery, has been one of brilliance, bringing unimaginable benefits to our patients with deformity, as well as convenience and safety for cosmetic surgery. Our future will undoubtedly continue in a similar vein. In an era of high technology we can only expect more extraordinary technical innovations and new seminal events. Hopefully, as physicians first, we will be mindful of the cautions laid down by Leon Goldman and by our sense of honest scientific inquiry and our ethos of “primum non nocere.” Hopefully, we will continue to view the potential of cutaneous laser surgery with the same excitement and joy that Leon Goldman did at laser’s very inception in 1960 as a potential for healing. Hopefully, future historians of cutaneous laser surgery will not record how our professionalism was swept away by a tidal wave of marketing hyperbole. Timeline of the Development of Cutaneous Laser Surgery Early 20th century 1906– 1917 1920s 1951 1957
Einstein’s conceptualization of stimulated emission of radiation Theory of coherence—Dirac Theory of amplification—Townes (USA), V. A. Fabrikant (USSR) Optical resonator—Schawlow and Townes
1960s 1960 1961 1961 1961 1961 1962 1962 1962 1962
First Laser, ruby—Maiman First gas laser, He-Ne, at Bell Labs Nd:YAG laser—Johnson and Naussau Ruby laser used on port-wine stain—Leon Goldman Nd:YAG laser for tattoos—Goldman Microscope coupled with ruby laser—Bessis and Coll Ruby laser used on eye by Zweng Argon laser invented First commercial production of lasers
Cutaneous Laser Surgery: Historical Perspectives 1962 1963 1964 1964 1964 1965 1966 1967 1967 1968 1970s 1970 Early 1970s Early 1970s 1971 1972 1974 1974 Late 1970s Late 1970s
39
Laser research laboratories founded Low-power lasers and wound healing—Endre Mester First article on laser surgery of the skin—Leon Goldman Q-switched ruby laser on tattoo—Goldman CO2 laser invented—Patel Nd:YAG to cut human tissue—Jako First surgical CO2 laser—Polanyi First commercial CO2 laser—American Optical Co. Argon laser used on eye—L’Esperance First CO2 laser use in urology—Mulvaney and Beck CO2 laser on human larynx—Jako Fiberoptics developed for lasers Photodynamic therapy of malignancy—Dougherty First commercial argon laser First use of CO2 laser for disease of cervix—Kaplan CO2 laser on vaginal tissue, cervical dysplasia, condylomas—Bellina Wellman Lab founded Argon laser for cutaneous disease—Apfelberg, Arndt, Noe, and others CO2 laser for cutaneous disease—McBurney and others
1980s Early 1980s Early 1980s 1981 1981 1982 1983 Mid 1980s Late 1980s to early 1990s 1988 1989
Intraoperative and postoperative wound care Mechanized scanners American Society of Laser Medicine and Surgery founded Q-switched ruby laser for tattoos—Reid Beckman Lab founded Theory of selective photothermolysis—Anderson and Parrish Continuous Nd:YAG laser for cutaneous vascular tumors “Yellow lasers”: pulsed dye, continuous wave dye, copper vapor, copper bromide, krypton Er:YAG for resurfacing—Kaufmann First commercial American Q-switched ruby laser for tattoos
1990s Early 1990s 1993 1993 1993 1994 1995 1997 1999 1999
Q-switched Nd:YAG, Q-switched alexandrite Pulsed dye laser treatment of scars Ultrapulse and high-speed-scanned CO2 laser resurfacing Pulsed light sources for vascular lesions Q-switched Nd:YAG laser-assisted hair removal Long-pulse ruby laser for hair removal First American Er:YAG laser for resurfacing Long-pulse diode laser for hair removal Long-pulse 1320 nm Nd:YAG laser for thermal remodeling
Source: Adapted partially from “The Development of Laser Medicine” (monograph, American Society for Laser Medicine and Surgery, 1987), Hecht and Teresi (21), and Bellina et al. (102).
REFERENCES 1. Enderby C. Laser instrumentation. In: Dixon J, ed. Surgical Application of Lasers. 2nd ed. Chicago: Yearbook Medical Publisher’s, 1987:52 – 78. 2. Alster T, Kohn S. Dermatologic lasers: three decades of progress. Int J Dermatol 1992; 31:601 – 610. 3. Wheeland R. History of lasers in dermatology. Clin Dermatol 1995; 13:3– 10.
40 4. 5. 6. 7. 8.
9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34.
Brauner Anderson R, Parrish J. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science 1983; 220:524 – 527. Anderson R, Parrish J. The optics of human skin. J Invest Dermatol 1981; 77:13 – 19. Anderson R, Parrish J. Microvasculature can be selectively damaged using dye lasers: a basic theory and experimental evidence in human skin. Lasers Surg Med 1989; 1:263– 276. van Gemert M, Henning J. A model approach to laser coagulation of dermal vascular lesions. Arch Dermatol Res 1981; 270:429– 439. Hulsbergen Henning J, van Gemert M, Lahaye C. Clinical and histological evaluation of portwine stain treatment with a microsecond-pulsed dye-laser at 577. Lasers Surg Med 1984; 4:375 – 380. van Gemert M, Welch A, Amin A. Is there an optimal laser treatment for port wine stains? Lasers Surg Med 1986; 6:76 – 83. van Gemert M, Welch A, Tan O et al. Limitations of carbon dioxide lasers for treatment of port-wine stains. Arch Dermatol 1987; 123:71 – 73. van Gemert M, Nelson J, Milner T et al. Non-invasive determination of port wine stain anatomy and physiology for optimal laser treatment strategies. Phys Med Biol 1997; 42:937–950. Smithies D, van Gemert M, Hansen M et al. Three-dimensional reconstruction of port-wine stain vascular anatomy from serial histological sections. Phys Med Biol 1997; 42:1843 – 1847. Pfefer T, Barton J, Smithies D et al. Modeling laser treatment of port wine stains with a computer-reconstructed biopsy. Lasers Surg Med 1999; 24:151 – 166. American Institute of Physics. Albert Einstein (1879– 1955). http://www.aip.org/history/ esva/exhibits/ein.htm. Albert Einstein online. http://www.westegg.com/einstein. F. Einstein’s Legacy. Forward pp1– 2. http://www.achilles.net/%7Ejtalbot/history/ einstein.html. Hughes Research Labs. Our History: Published Highlights 1960’s. http://www.hrl.com/ tradition/Tradition.1960s.html. Laser Stars—Laser History (1917 – 1996). pp 1 – 2. http://www.achilles.net/%7Ejtalbot/ history/index.html. Einstein A. Zur Quanten Theorie der Strahlung. Physikal Zeitschr 1917; 18:121 – 128. Einstein A. Ideas and Opinions. Reprint ed. New York: Modern Library, 1994. Hecht J, Teresi D. Laser: Supertool of the 1980’s. New Haven, CT: Ticknor and Fields, 1982. Itzkan I, Drake E. History of lasers in medicine. In: Arndt K, Dover J, Olbricht S, eds. Lasers in Cutaneous Medicine and Surgery. Boston, MA: Little Brown, 1997:3 – 9. The Invention of the LASER at Bell Laboratories: 1958– 1998. pp 1 –9. http://www.belllabs.com/history/laser/invention. Gordon J, Zeigler H, Townes C. The MASER- new type of amplifier, frequency standard and spectrometer. Phys Rev 1955; 99:1264 – 1274. Townes CH. The Invention of the LASER at Bell Laboratories: 1958– 1998. pp 1 – 3. http://www-out.bell-labs.com/history/laser/invention/townes-bio.html. Schawlow AL. The Invention of the LASER at Bell Laboratories: 1958– 1998. pp 1 – 2. http://www-out.bell-labs.com/history/laser/invention/schawlow-bio.html. Schawlow A, Townes C. Infrared and optical masers. Phys Rev 1958; 112:1940 – 1949. Maiman T. Stimulated optical radiation in ruby. Nature 1960; 187:493– 494. Optical Laser. http://www.achilles.net/%7Ejtalbot/history/ruby.html. Svelto O. Principles of Lasers. 2nd ed. New York: Plenum Press, 1982. Goldman L. The CO2 laser in dermatology: the perspective of Leon Goldman, M.D. “Father of laser surgery”. Xanar Surgical Monograph, 1988. Goldman L. http://www.lasertraining.org/leon.htm. Goldman L, Blaney D, Kindel D et al. Effect of the laser beam on the skin. J Invest Dermatol 1963; 40:121 – 122. Goldman L, Blaney D, Kindel D et al. Pathology of the effect of the laser beam on the skin. Nature 1963; 197:912 – 914.
Cutaneous Laser Surgery: Historical Perspectives 35. 36. 37.
38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61.
62. 63. 64.
41
Tan O, Morelli J. Lasers in dermatology. Curr Probl Dermatol 1989; 1:1 – 26. Alster T, Kohn S, Dermatologic lasers: three decades of progress. Int J Dermatol 1992; 31:601 – 610. Goldman L, Wilson R, Hornby P et al. Radiation from a Q-switched ruby laser. Effect of repeated impacts of power output of 10 megawatts on a tattoo of man. J Invest Dermatol 1965; 44:69 – 71. Goldman L, Rockwell R, Meyer R et al. Laser treatment of tattoos: a preliminary survey of three years clinical experience. J Am Med Assoc 1967; 201:841 – 844. Zweng H, Flocks M, Kapany N et al. Experimental laser photocoagulation. Am J Ophthalmol 1964; 58:355. Goldman L, Hornby P, Long C. Effect of the laser on the skin. III. Transmission of laser beams through fiber optics. J Invest Dermatol 1964; 42:231 – 234. Goldman L, Igelman J, Richfield D. Impact of the laser on nevi and melanomas. Arch Dermatol 1964; 90:71 – 75. Goldman L. Comparison of the biomedical effects of the exposure of human tissues to low and high energy lasers. Ann NY Acad Sci 1965; 122:802 – 831. Goldman L et al. Laser radiation of malignancy in man. Cancer 1965; 18:533 –545. Goldman L. Dermatologic manifestations of laser radiation. Fed Proc 1965; 14:592– 593. Goldman L, Rockwell R. Lasers in Medicine. New York: Gordon and Breach, 1971. Goldman L. Laser surgery for skin cancer. NY State J Med 1977; 77:1897 – 1900. Goldman L. Surgery by laser for malignant melanoma. J Dermatol Surg Oncol 1979; 5:141 – 144. Goldman L, ed. The Biomedical Laser: Technology and Clinical Applications. New York: Springer-Verlag, 1981. Ohshiro T. Laser Treatment for Nevi. Tokyo: Medical Laser Research Co., 1980. Javan A, Bennett W, Herriot D. Population inversion and continuous optical maser oscillator in a gas discharge containing a He– Ne mixture. Phys Rev 1961; 6:106 – 110. Johnson L. Optical maser characteristics of rare-earth ions in crystals. J Appl Physiol 1961; 34:897 – 909. Goldman L, Nath G, Schindler G et al. High-power neodymium – YAG laser surgery. Acta Dermatol Venereol 1973; 53:45 – 49. Bennett W, Faust W, McFarlane R et al. Dissociative excitation transfer and optical maser oscillation in NeO2 and ArO2 rf discharges. Phys Rev 1962; 8:470 – 473. L’Esperance F. An ophthalmic argon laser photocoagulator system: design, construction and laboratory investigation. Trans Am Ophthalmol Soc 1968; 66:827 –904. Bloom L, Brucker A. Lasers in ophthalmology. Surg Clin North Am 1984; 64:1013 –1024. Apfelberg D, Maser M, Lash H. Argon laser management of cutaneous vascular deformities. A preliminary report. West J Med 1976; 124:99 – 101. Apfelberg D, Kosek J, Maser M et al. Histology of port-wine stains following argon laser treatment. Brit J Plast Surg 1979; 32:232– 237. Apfelberg D, Maser M, Lash H. Extended clinical use of the argon laser for cutaneous lesions. Arch Dermatol 1979; 115:719 – 721. Apfelberg D, Maser M, Lash H et al. The argon laser for cutaneous lesions. J Am Med Assoc 1981; 245:2073 – 2075. Apfelberg D, McBurney E. Use of the argon laser in dermatologic surgery in lasers. In: Ratz J, ed. Cutaneous Medicine and Surgery. Chicago: Yearbook Medical Publishers, 1986:31–71. Solomon H, Goldman L, Henderson B et al. Histopathology of the laser treatment of port-wine lesions: biopsy studies of treated areas observed up to three years after laser impacts. J Invest Dermatol 1968; 50:141 – 146. Goldman L. Effects of new laser systems on the skin. Arch Dermatol 1973; 108:385 – 390. Goldman L et al. Treatment of port-wine marks by an argon laser. J Dermatol Surg Oncol 1976; 2:385 – 388. Goldman L, Dreffer R, Rockwell J et al. Treatment of portwine marks by an argon laser. J Dermatol Surg 1976; 2:385 – 388.
42 65. 66. 67. 68.
69. 70. 71. 72. 73.
74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90.
91.
Brauner Goldman L, Dreffer R. Laser treatment of extensive mixed cavernous and port-wine stains. Arch Dermatol 1977; 113:504 – 505. McBurney E, Leonard G. Argon laser treatment of port-wine hemangiomas: clinical and histologic correlation. South Med J 1981; 74:925 – 927. Arndt K, Noe J, Northam D et al. Laser therapy: basic concepts and nomenclature. J Am Acad Dermatol 1981; 5:649 – 654. Noe J, Barsky S, Geer D et al. Port-wine stains and the response to argon laser therapy: successful treatment and the predictive role of color, age and biopsy. Plast Reconstr Surg 1980; 65:130 – 136. Finley J, Barsky S, Geer D et al. Healing of port-wine stains after argon laser therapy. Arch Dermatol 1981; 117:486 – 489. Noe J. Complications of argon laser surgery for skin. In: Fried M et al. ed. Complications of Laser Surgery of the Head and Neck. Chicago: Yearbook Medical Publishers, 1986:124. Cosman B. Experience in the argon laser therapy of port-wine stains. Plast Reconstr Surg 1980; 65:119 – 129. Cosman B. Role of retreatment in minimal-power argon laser therapy for port-wine stains. Lasers Surg Med 1982; 2:43. Apfelberg D, Smith T, Maser M et al. Dot or pointillistic method of improvement in results of hypertrophic scarring in the argon laser treatment of portwine hemangiomas. Lasers Surg Med 1987; 6:552– 558. Dixon J, Huether S, Rotering R. Hypertrophic scarring in argon laser treatment of port-wine stains. Plast Reconstr Surg 1984; 73:771 –777. Brauner G. Scarring from laser surgery. In: Lasers in Dermatology (Course). American Academy of Dermatology Annual Meeting, Washington, DC, Dec 1984. Dixon J, ed. Surgical Application of Lasers, 2nd ed. Chicago: Yearbook Medical Publishers, 1987. Brauner G, Schliftman A, Cosman B. Evaluation of argon laser surgery in children under 13 years of age. J Plast Reconstr Surg 1991; 87:37 – 43. Gold M, Brauner G. Point/counterpoint: should surgeons delegate laser procedures to ancillary staff?—Only physicians should be laser surgeons. Skin Aging 2000; 8:57– 59. Wagner R, Brown T, Archer R et al. Dermatologists’ attitudes toward independent nonphysician electrolysis practice. Dermatol Surg 1998; 24:357 –362. Brauner G, Schliftman A. Laser surgery for children. J Dermatol Surg Oncol 1987; 13:178–186. Geronemus R, Ashinoff R. The medical necessity of evaluation and treatment of port-wine stains. J Dermatol Surg Oncol 1991; 17:76– 79. van der Horst C, Koster P, de Borgie C et al. Effect of the timing of treatment of port-wine stains with the flash-lamp-pumped pulsed-dye laser. N Engl J Med 1998; 338:1028 – 1033. Troilius A, Wrangsjo B, Ljunggren B. Potential psychological benefits from early treatment of port-wine stains in children. Br J Dermatol 1998; 139:59– 65. Miller A, Pit-Ten Cate I, Watson H et al. Stress and family satisfaction in parents of children with facial port-wine stains. Pediatr Dermatol 1999; 16:190 – 197. Troilius A, Wrangsjo B, Ljunggren B. Patients with port-wine stains and their psychosocial reactions after photothermolytic treatment. Dermatol Surg 2000; 26:190 –196. Patel CKN, McFarlane R, Faust W. Selective excitation through vibrational energy transfer and optical maser action in N2 –CO2. Phys Rev 1964; 136:617– 619. Patel CKN. High-power carbon dioxide lasers. Sci Am 1968; 219:23. Patel CKN, Wood O. In: Baggish M, ed. History of the Laser in Basic and Advanced Laser Surgery. Gynecology, Norwalk: Appleton-Century-Crofts, 1985:1 – 22. Polanyi T, Bredemeier H, Davis T. A CO2 laser for surgical research. Med Biol Eng Computs 1966; 8:541 – 548. Jako G. Laser biomedical engineering: clinical applications in otolaryngology. In: Goldman L, ed. The Biomedical Laser: Technology and Clinical Applications, New York: Springer-Verlag, 1981:175– 198. Stahle J, Hoegberg L. Laser and the labyrinth. Acta Otolaryngol 1965; 85:367– 374.
Cutaneous Laser Surgery: Historical Perspectives 92. 93. 94. 95. 96. 97. 98.
99. 100. 101.
102. 103. 104. 105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119.
43
Conti A, Bergomi A. Irradiazione laser del labirinto posteriore. Arch Ital Biol 1966; 77:546 – 567. Sataloff J. Experimental use of laser in otosclerotic stapes. Arch Otolaryngol 1967; 85:614 – 616. Jako G. Laser surgery of the vocal cords: an experimental study with carbon dioxide lasers on dogs. Laryngoscope 1972; 82:2204– 2216. Strong M, Jako G. Laser surgery in the larynx. Ann Otol Rhinol Laryngol 1972; 81:791 – 798. Strong M, Jako G, Polanyi T et al. Laser surgery in the aerodigestive tract. Am J Surg 1973; 126:529 – 533. Strong M. Laser management of premalignant lesions of the larynx. Can J Otolaryngol 1974; 3:560 – 563. Jako G, Vaughn C, Strong M et al. Surgical management of malignant tumors of the aerodigestive tract with carbon dioxide laser microsurgery. Int Adv Surg Oncol 1979; 1:265 – 284. Hall R, Beach A, Baker E et al. Incision of tissue by carbon dioxide laser. Nature 1971; 232:131 – 132. Bellina J. Gynecology and the laser. Contrib Gynecol Obstet 1974; 4:24– 34. Bellina J, Polanyi T. Management of vaginal adenosis and related cervicovaginal disorders in DES-exposed progeny by means of carbon dioxide laser surgery. J Reprod Med 1976; 16:295 – 296. Bellina J, Fick A, Jackson J. Lasers in gynecology: an historical/developmental overview. Lasers surg Med 1985; 5:1– 22. Fisher J. The Laser Education Foundation Syllabus on Basic Laser Biophysics and Safety and Resurfacing of Skin with the Carbon-Dioxide Laser. 1998:vi. Kaplan I, Goldman L, Ger R. The treatment of erosions of the uterine cervix by means of the CO2 laser. Obstet Gynecol 1973; 41:795 – 796. Kaplan I, Ger R. The carbon dioxide laser in clinical surgery Israel. J Med Sci 1973; 9:79– 83. Kaplan I, Sharon U, Ger R. The carbon dioxide laser in clinical surgery. In: Wolbarsht M, ed. Laser Applications in Medicine and Biology. Vol. 2. New York: Plenum Press, 1974:295–308. Dorsey J, Diggs E. Microsurgical conization of the cervix by carbon dioxide laser. Obstet Gynecol 1979; 54:565– 570. Baggish M, Keye W. Lasers in gynecology. In: Dixon J, ed. Surgical Application of Lasers, 2nd ed. Chicago: Yearbook Medical Publishers, 1987:183 – 217. Baggish M, ed. Basic and Advanced Laser Surgery in Gynecology, Norwalk, CT: Appleton-Century-Crofts, 1989. Cerullo L, Burke L. Use of the laser in neurosurgery. Surg Clin North Am 1984; 64:995 – 1000. Heppner F, Ascher P. Uber den Einsatz des Laserstrahls in der Neurochirurgie. Medizinalmarkt 1976; 12:424. Nath G, Gorisch W, Kiefhaber P. First laser endoscopy via a fiberoptic transmission system. Endoscopy 1973; 5:208 – 213. Keifhaber P, Nath G, Moritz K. Endoscopic control of massive gastrointestinal hemorrhage by irradiation with a high-power neodymium– YAG laser. Prog Surg 1977; 15:140– 155. LaForet E, Berger R, Vaughn C. Carcinoma obstructing the trachea; treatment by laser resection. New Engl J Med 1976; 294:941. Casey K, Unger M. Laser bronchoscopy. In: Dixon J, ed. Surgical Application of Lasers, 2nd ed. Chicago: Yearbook Medical Publishers, 1987:287 – 309. Toty L, Personne C, Colchen A et al. Bronchoscopic management of tracheal lesions using the neodymium yttrium aluminum garnet laser. Thorax 1981; 36:175– 178. Goldman L, Rockwell R, Naprstek Z et al. Some parameters of high output CO2 laser experimental surgery. Nature 1970; 228:1344 – 1345. Goldman L et al. CO2 laser surgery for cancer of man. Laser J 1971; 3:21– 23. Frishman A et al. Excision of subcutaneous fibrosarcoma in mice. Isr J Med Sci 1974; 10:637 – 641.
44 120.
121. 122. 123. 124. 125. 126. 127. 128. 129. 130. 131. 132. 133. 134. 135. 136. 137. 138. 139. 140. 141. 142.
143. 144. 145.
146.
Brauner Kaplan I, Raif J. The Sharplan carbon dioxide laser in clinical surgery: 7 years’ experience. In: Goldman L, ed. The Biomedical Laser, Technology and Clinical Applications. New York: Springer-Verlag, 1981:89– 97. Kaplan I, Ger R, Sharon U. The carbon dioxide laser in plastic surgery. Brit J Plast Surg 1973; 26:359 – 362. Stellar S, Meijer R, Walia S et al. Carbon dioxide laser debridement of decubitus ulcers: followed by immediate rotation flap or skin graft closure. Ann Surg 1974; 79:230– 237. Stellar S et al. Laser excision of acute third degree burns followed by immediate autograft replacement: an experimental study in the pig. J Trauma 1973; 13:45 – 53. Stellar S, Levine N, Ger R et al. Carbon-dioxide laser for excision of burn eschars. Lancet 1971; 1:945. McBurney E. Carbon dioxide laser surgery of dermatologic lesions. South Med J 1978; 71:795 – 797. McBurney E. Dermatologic laser surgery. Otolaryngol Clin North Am 1990; 23:77 – 97. Adams E, Price N. Treatment of basal cell carcinomas with a carbon-dioxide laser. J Dermatol Surg Oncol 1979; 5:803 – 806. Bailin P, Ratz J, Levine J. Removal of tattoos by CO2 laser. J Dermatol Surg Oncol 1980; 6:977 – 1001. Bailin P, Ratz J, Lutz-Nagey L. CO2 laser modification of Mohs’ surgery. J Dermatol Surg Oncol 1981; 7:621– 623. Ratz J, Bailin P, Levine H. CO2 laser treatment of port-wine stains: a preliminary report. J Dermatol Surg Oncol 1982; 8:1039– 1044. Ratz J. Laser applications in dermatology and plastic surgery. In: J Dixon J, ed. Surgical Application of Lasers. 2nd ed. Chicago: Yearbook Medical Publishers, 1987:160 – 182. Wheeland R, Bailin P, Ratz J. Combined carbon dioxide laser excision and vaporization in the treatment of rhinophyma. J Dermatol Surg Oncol 1987; 13:172– 177. Reid R, Muller S. Tattoo removal with laser. Med J Aust 1978; 1:389. Reid R, Muller S. Tattoo removal by CO2 laser dermabrasion. Plast Reconstr Surg 1980; 65:717 – 728. Goldman L. Laser medicine: when you need it, when you don’t. Ohio Med 1987; 83:861– 865. (Published erratum appears in Ohio Med 1988; 84:168). Kitzmiller W. Laser treatment of angiomas and tattoos. Cutis 1974; 13:251 – 254. Kantor G, Wheeland R, Bailin P et al. Treatment of earlobe keloids with carbon dioxide laser excision: a report of sixteen cases. J Dermatol Surg Oncol 1985; 11:1063– 1067. Apfelberg D, Maser M, Lash H et al. Preliminary results of argon and carbon dioxide laser treatment of keloid scars. Lasers Surg Med 1984; 4:283– 290. Apfelberg D, Maser M, White D et al. Failure of carbon dioxide laser excision of keloids. Lasers Surg Med 1989; 9:382 – 388. Stern J, Lucente F. Carbon dioxide laser excision of earlobe keloids. A prospective study and critical analysis of existing data. Arch Otolaryngol Head Neck Surg 1989; 115:1107 – 1111. Norris J. The effect of carbon dioxide laser surgery on the recurrence of keloid. Plast Reconstr Surg 1991; 87:44 –49, discussion 50– 53. Madden J, Edlich R, Custer J et al. Studies in the management of the contaminated wound. IV. Resistance to infection of surgical wounds made by knife, electrosurgery and laser. Am J Surg 1970; 119:222 – 224. Hishimoto K, Rockwell R, Epstein R et al. Laser wound healing compared with other surgical modalities. Burns 1975; 1:13. Brauner G, Schliftman A, Sottile E. Lasers in dermatologic surgery. Infect Sur 1987; 6:242 – 247. Hambley R, Hebda P, Abell E et al. Wound healing of skin incisions produced by ultrasonically vibrating knife, scalpel, electrosurgery, and carbon dioxide laser. J Dermatol Surg Oncol 1988; 14:1213 –1217. Molgat Y, Pollack S, Hurwitz J et al. Comparative study of wound healing in porcine skin with CO2 laser and other surgical modalities: preliminary findings. Int J Dermatol 1995; 34:42–47.
Cutaneous Laser Surgery: Historical Perspectives 147. 148. 149. 150. 151. 152. 153. 154. 155.
156. 157. 158. 159. 160. 161. 162. 163. 164.
165. 166. 167.
168. 169. 170. 171. 172. 173.
45
Strohecker J, Piotrowski W, Lametschwandtner A. Ultrastructural findings after the use of a CO2 laser in carpal tunnel surgery. Lasers Surg Med 1985; 5:123 – 128. Dover J, Arndt K, Dinehart S et al. Guidelines of care for laser surgery. J Am Acad Dermatol 1999; 41:484 – 495. Department of Health, Education and Welfare/Food and Drug Administration. Report on Laser Products. Federal Register 40(148):Part II, July 1975. Sliney D. Safety with biomedical lasers. In: Goldman L, ed. The Biomedical Laser: Technology and Clinical Applications. New York: Springer-Verlag, 1981:11 – 24. Lundergun D, Rockwell R. ANSI medical laser standards. Clin Laser Monthly 1984; 2:99 – 100. Ossoff R. ANSI standards for clinical laser safety. Clin Laser Monthly 1986; 4:7– 9. ANSI Z 136.3 for the Safe Use of Lasers in Health Care Facilities. New York: American National Standards Institute, 1996. Smalley P. Laser safety—more than goggles and signs. Plas Surg Prod 1998; Nov/Dec:66–68. Holmes J. A summary of safety considerations for the medical and surgical practitioner. In Apfelberg D, ed. Evaluation and Installation of Surgical Laser Systems. New York: Springer Verlag, 1987. Fretzin S, Beeson W, Hanke C. Ignition potential of the 585-nm pulsed-dye laser. Review of the literature and safety recommendations. Dermatol Surg 1996; 22:699 – 702. Rohrich R, Gyimesi I, Clark P et al. CO2 laser safety considerations in facial skin resurfacing Plast Reconstr Surg 1997; 100:1285 – 1290. Baggish M, Elbakry M. The effects of laser smoke on the lungs of rats. Am J Obstet Gynecol 1987; 156:1260 – 1265. Nezhat C, Winer W, Nezhat F et al. Smoke from laser surgery: Is there a health hazard? Lasers Surg Med 1987; 7:376 – 382. Baggish M, Baltoyannis P, Sze E. Protection of the rat lung from the harmful effects of laser smoke. Lasers Surg Med 1988; 8:248– 253. Smith J, Moss E, Bryant C et al. Evaluation of a smoke evacuator used for laser surgery. Laser Surg Med 1989; 9:276 – 281. Wentzell J, Robinson J, Wentzell J et al. Physical properties of aerosols produced by dermabrasion. Arch Dermatol 1989; 125:1637 – 1643. Hoye R, Ketcham A, Riggle G. The air-borne dissemination of viable tumor by high energy neodymium laser. Life Sci 1967; 6:119 –125. Jako G. Laser biomedical engineering: clinical applications in otolaryngology. In: Goldman L, ed. The Biomedical Laser: Technology and Clinical Applications. New York: Springer-Verlag, 1981:175. Garden J, O’Banion K, Shelnitz I et al. Papillomavirus in the vapor of carbon dioxide laser-treated verrucae. J Am Med Assoc 1988; 259:1199– 1202. Garden J. The hazards of laser plume: a mid-year committee report. Am Soc Laser Med Surg 1989, 3:6. Sawchuck W, Weber P, Lowy D et al. Infectious papillomavirus in the vapor of warts treated with carbon dioxide laser or electrocoagulation: detection and protection. J Am Acad Dermatol 1989; 20:41 – 49. Baggish M, Poiesz B, Doret D et al. Presence of human immunodeficiency virus DNA in laser smoke. Lasers Surg Med 1991; 11:197– 203. Ziegler B, Thomas C, Meier T et al. Generation of infectious retrovirus aerosol through medical laser irradiation. Lasers Surg Med 1998; 22:37 –41. Capizzi P, Clay R, Battey M. Microbiologic activity in laser resurfacing plume and debris. Lasers Surg Med 1998; 23:172 – 174. Frenz M, Mathezloic F, Stoffel M et al. Transport of biologically active material in laser cutting. Lasers Surg Med 1988; 8:562– 566. Beeson W. Laser safety—effective risk management and outcomes monitoring. 8th International Symposium for Cosmetic Laser Surgery, New Orleans, LA, Mar 1999. Fader D, Ratner D. Principles of CO2/erbium laser safety. Dermatol Surg 2000; 26:235 – 239.
46 174. 175. 176. 177. 178.
179. 180.
181. 182. 183. 184.
185. 186.
187. 188. 189. 190. 191.
192. 193. 194. 195.
196.
197.
Brauner Hughes P. Boiling and splattering liquid with the Er:YAG laser. Lasers Surg Med 1998; 23:248. Gloster H, Roenigk R. Risk of acquiring human papillomavirus from the plume produced by the carbon dioxide laser in the treatment of warts. J Am Acad Dermatol 1995; 32:436 – 441. Hughes P, Hughes A. Absence of human papillomavirus DNA in the plume of erbium:YAG laser-treated warts. J Am Acad Dermatol 1998; 38:426 –428. Geronemus R. Argon laser surgery in children under 13 years of age. Plast Reconstr Surg 1991; 87:37 – 43. Apfelberg D, Flores J, Maser M et al. Analysis of complications of argon laser treatment for portwine hemangiomas with reference to striped technique. Lasers Surg Med 1983; 2:357 – 371. Apfelberg D. Biophysics, advantages, and installation of laser systems. In: Evaluation and Installation of Surgical Laser Systems. New York: Springer Verlag, 1987:1. Scheibner A, Wheeland R. Argon-pumped tunable dye laser therapy for facial port-wine stain hemangiomas in adults: a new technique using small spot size and minimal power. J Dermatol Surg Oncol 1989; 15:277 – 282. Scheibner A, Wheeland R. Use of the argon-pumped tunable dye laser for port-wine stains in children. J Dermatol Surg Oncol 1991; 17:735 – 739. Brauner G. Laser scanners in dermatologic surgery. Am J Cosmet Surg 1992; 9:197 – 203. Itzkan I, Bourgelais D. Established Dermascan treatment parameters using cherry angiomas as a model. SPIE 1986; 712:206– 208. (Abstract.) Tang S, Arndt K, Gilchrest B et al. Clinical comparisons of millisecond versus conventional argon laser treatment of in vivo vascular skin lesions. Laser Med Surg 1985; 5:177 – 178. (Abstract.) Rotteleur G, Mordon S, Buys B et al. Robotized scanning laser handpiece for the treatment of port-wine stains and other angiodysplasias. Lasers Surg Med 1988; 8:283– 287. Dover J, Geronemus R, Stern R et al. Dye laser treatment of port-wine stains: comparison of the continuous-wave dye laser with a robotized scanning device and the pulsed dye laser. J Am Acad Dermatol 1995; 32:237 – 240. Gilchrest B, Rosen S, Noe J. Chilling port-wine stains improves the response to argon laser therapy. Plast Reconstr Surg 1982; 69:278 – 283. Goldman L, Stefanovsky D, Gregory R et al. Research and development of additional aids for dermatologic and plastic surgery. Lasers Surg Med 1983; 2:323 – 330. Landthaler M, Haina D, Brunner R et al. Neodymium-YAG laser therapy for vascular lesions. J Am Acad Dermatol 1986; 14:107 – 117. Chess C, Chess Q. Cool laser optics treatment of large telangiectasia of the lower extremities. J Dermatol Surg Oncol 1993; 19:74– 80. Chess C. Does simultaneous contact cooling reduce intravascular temperature during laser irradiation and impinge on selective vascular destruction? Dermatol Surg 1997; 23:657 – 662; Dermatol Surg 1998; 24:404– 405. Adrian R, Tanghetti E. Long pulse 532-nm laser treatment of facial telangiectasia. Dermatol Surg 1998; 24:71 –74. Nelson J, Milner T, Anvari B et al. Dynamic cooling of the epidermis during laser port-wine stain therapy. Laser Surg Med 1994; (suppl 6):48. (Abstract.) Anvari B, Milner T, Tanenbaum B et al. Selective cooling of biological tissues: application for thermally mediated therapeutic procedures. Phys Med Biol 1995; 40:241 –252. Nelson J, Milner T, Anvari B et al. Dynamic epidermal cooling during pulsed laser treatment of port-wine stain. A new methodology with preliminary clinical evaluation. Arch Dermatol 1995; 131:695 – 700. Nelson J, Milner T, Anvari B et al. Dynamic epidermal cooling in conjunction with laser-induced photothermolysis of port-wine stain blood vessels. Lasers Surg Med 1996; 19:224 – 229. Waldorf H, Alster T, McMillan K et al. Effect of dynamic cooling on 585 nm pulsed dye laser treatment of port-wine stain birthmarks. Dermatol Surg 1997; 23:657 – 662.
Cutaneous Laser Surgery: Historical Perspectives 198. 199. 200. 201. 202. 203. 204. 205.
206.
207. 208.
209.
210.
211. 212. 213. 214. 215. 216. 217. 218.
219. 220.
221.
47
Anvari B, Milner T, Tanenbaum B et al. A comparative study of human skin thermal response to sapphire contact and cryogen spray cooling. IEEE Trans Biomed Eng 1998; 45:934 – 941. Altshuler G, Zenzie H, Erofeev A et al. Contact cooling of the skin. Phys Med Biol 1999; 44:1003 – 1023. Zenzie H, Altshuler G, Smirnov M et al. Evaluation of cooling methods for laser dermatology. Lasers Surg Med 2000; 26:130 – 144. Pfefer T, Smithies D, Milner T et al. Bioheat transfer analysis of cryogen spray cooling during laser treatment of port wine stains. Lasers Surg Med 2000; 26:145 – 157. Anvari B, Ver Steeg B, Tanenbaum B et al. Cryogenic spray cooling: a preliminary study during 532 laser irradiation of port wine stains. Cosmet Dermatol 2000; 13:22– 26. Ross B, Levine V, Ashinoff R. Laser treatment of acquired vascular lesions. Dermatol Clin 1997; 15:385 – 396. Keller G, Doiron D, Keller R. Treatment of vascular lesions with a CW yellow dye laser— initial trials. Otolaryngol Head Neck Surg 1986; 95:527– 530. Schliftman A, Brauner G. The comparative tissue effects of copper vapor laser (578 nm), argon/dye laser and argon laser (488,514 nm) on vascular lesions. Lasers Surg Med 1988; 8:188. (Abstract.) Brauner G. Comparison of argon, Argon Dye, Copper Vapor Lasers in the Treatment of Telangiectases and Port-Wine Stains. Little Rock, AR: University of Arkansas for Medical Sciences, 1990. Schliftman A, Brauner G. Test results comparing copper vapor and flashlamp pumped dye laser. Lasers Surg Med 1991; (suppl 3):69. (Abstract.) Waner M, Dinehart S, Wilson M et al. A comparison of copper vapor and flashlamp pumped dye lasers in the treatment of facial telangiectasia. J Dermatol Surg Oncol 1993; 19:992 – 998. Sheehan-Dare R, Cotterill J. Copper vapour laser treatment of port-wine stains: clinical evaluation and comparison with conventional argon laser therapy. Br J Dermatol 1993; 128:546 – 549. Sheehan-Dare R, Cotterill J. Copper vapour laser (578 nm) and flashlamp-pumped pulsed tunable dye laser (585 nm) treatment of port wine stains: results of a comparative study using test sites. Br J Dermatol 1994; 130:478 – 482. McCoy S, Hanna M, Anderson P et al. An evaluation of the copper-bromide laser for treating telangiectasia. Dermatol Surg 1996; 22:551 – 557. McCoy S. Copper bromide laser treatment of facial telangiectasia: results of patients treated over five years. Lasers Surg Med 1997; 21:329 – 340. Bernstein E, Lee J, Lowery J et al. Treatment of spider veins with the 595 nm pulsed-dye laser. J Am Acad Dermatol 1998; 39:746 –750. Dixon J, Rotering R, Huether S. Patients’ evaluation of argon laser therapy of portwine stain, decorative tattoo, and essential telangiectasia. Laser Surg Med 1984; 4:181 – 190. Dixon J, Gilbertson J. Argon and neodymium YAG laser therapy of dark nodular port wine stains in older patients. Lasers Surg Med 1986; 6:5 –11. Fisher A, Lasers and allergic contact dermatitis to topical antibiotics, with particular reference to bacitracin. Cutis 1996; 58:252– 254. David L, Ruiz-Esparza J. Fast healing after laser skin resurfacing. The minimal mechanical trauma technique. Dermatol Surg 1997; 23:359– 361. Ruiz-Esparza J, Barba-Gomez J, Gomez-de-la-Torre O. Wound care after laser skin resurfacing. A combination of open and closed methods using a new polyethylene mask. Dermatol Surg 1998; 24:79 –81. Fitzpatrick R. Laser resurfacing of rhytids. Dermatol Clin 1997; 15:431 – 447. Trelles M, Rigau J, Mellor T, Garcia L. A clinical and histological comparison of flashscanning versus pulsed technology in carbon dioxide laser facial skin resurfacing. Dermatol Surg 1998; 24:43 – 49. Weinstein C, Ramirez O, Pozner J. Postoperative care following carbon dioxide laser resurfacing. Avoiding pitfalls. Dermatol Surg 1998; 24:51 –56.
48 222. 223. 224. 225. 226.
227. 228.
229. 230. 231. 232.
233. 234.
235. 236. 237. 238. 239. 240. 241. 242. 243. 244. 245. 246.
Brauner Fulton J. Complications of laser resurfacing. Methods of prevention and management. Dermatol Surg 1998; 24:91 –99. Shim E, Tse Y, Velazquez E et al. Short-pulse carbon dioxide laser resurfacing in the treatment of rhytides and scars. A clinical and histopathological study. Dermatol Surg 1998; 24:113–117. Suarez M, Fulton J. A novel occlusive dressing for skin resurfacing. Dermatol Surg 1998; 24:567 – 570. Geronemus R, Alster T, Brandt F et al. Table talk: common questions about laser resurfacing. Dermatol Surg 1998; 24:123 –124. Davis S, Badiavas E, Rendon-Pellerano M et al. Histological Comparison of postoperative wound care regimens for laser resurfacing in a porcine model. Dermatol Surg 1999; 25:387 – 393. Ratner D, Tse Y, Marchell N et al. Cutaneous laser resurfacing. J Am Acad Dermatol 1999; 41:365 – 389. Greenwald J, Rosen S, Anderson R et al. Comparative histological studies of the tunable dye (at 577 nm) laser and argon laser: the specific vascular effects of the dye laser. J Invest Dermatol 1981; 77:305 – 310. Nakagawa H, Tan O, Parrish J. Ultrastructural changes in human skin after exposure to a pulsed laser. J Invest Dermatol 1985; 84:396 –400. Garden J, Tan O, Kerschmann R et al. Effect of dye laser pulse duration on selective cutaneous vascular injury. J Invest Dermatol 1986; 87:653 –657. Morelli J, Tan O, Garden J et al. Tunable dye laser (577 nm) treatment of port-wine stains. Lasers Surg Med 1986; 6:94 – 99. Tan O, Carney J, Margolis R et al. Histologic responses of port-wine stains treated by argon, carbon dioxide, and tunable dye lasers. A preliminary report. Arch Dermatol 1986; 122:1016 – 1022. Garden J, Polla L, Tan O. The treatment of port-wine stains by the pulsed dye laser. Analysis of pulse duration and long-term therapy. Arch Dermatol 1988; 124:889 – 896. Tan O, Whitaker D, Garden J et al. Pulsed dye laser (577 nm) treatment of port-wine stains: ultrastructural evidence of neovascularization and mast cell degranulation in healed lesions. J Invest Dermatol 1988; 90:395 – 398. Tan O, Murray S, Kurban A. Action spectrum of vascular specific injury using pulsed irradiation. J Invest Dermatol 1989; 92:868 – 871. Nakagawa H, Tan O, Parrish J. Ultrastructural changes in human skin after exposure to a pulsed laser. J Invest Dermatol 1985; 84:396 –400. Garden J, Tan O, Kerschmann R et al. Effect of dye laser pulse duration on selective cutaneous vascular injury. J Invest Dermatol 1986; 87:653 –657. Garden J, Polla L, Tan O. The treatment of port-wine stains by the pulsed dye laser. Analysis of pulse duration and long-term therapy. Arch Dermatol 1988; 124:889 – 896. Kurban A, Sherwood K, Tan O. What are the optimal wavelengths for selective vascular injury? Lasers Surg Med 8:189, 1988. Tan O, Sherwood K, Gilchrest B. Treatment of children with port-wine stains using the flashlamp-pulsed tunable dye laser. N Engl J Med 1989; 320:416 – 421. Garden J, Burton C, Geronemus R. Dye laser treatment of children with portwine stains. N Engl J Med 1989; 321:901 – 902. Tan O, Morrison P, Kurban A. 585 nm for the treatment of port-wine stains. Plast Reconstr Surg 1990; 86:1112 – 1117. Garden J, Bakus A, Paller A. Treatment of cutaneous hemangiomas by the flashlamp-pumped pulsed dye laser: prospective analysis. J Pediatr 1992; 120:555 – 560. Garden J, Bakus A. Laser treatment of port-wine stains and hemangiomas. Dermatol Clin 1997; 15:373 – 383. Walker E, Butler P, Pickering J et al. Histology of port wine stains after copper vapour laser treatment. Br J Dermatol 1989; 121:217– 223. Pickering J, Walker E, Butler P et al. Copper vapour laser treatment of port-wine stains and other vascular malformations. Br J Plast Surg 1990; 43:273– 282.
Cutaneous Laser Surgery: Historical Perspectives 247. 248. 249. 250. 251. 252. 253. 254. 255. 256. 257. 258. 259. 260. 261. 262. 263. 264. 265. 266. 267. 268. 269. 270. 271. 272. 273.
49
Dinehart S, Waner M, Flock S. The copper vapor laser for treatment of cutaneous vascular and pigmented lesions. Lasers Surg Med 1990; 10:52 – 53. Neumann R, Knobler R, Leonhartsberger H et al. Comparative histochemistry of port-wine stains after copper vapor laser (578) and argon laser treatment. J Invest Dermatol 1992; 99:160–167. Reyes B, Geronemus R. Treatment of port-wine stains during childhood with the flashlamppumped dye laser. J Am Acad Dermatol 1990; 23:1142 – 1148. Garden J, Bakus A. Laser treatment of portwine stains and hemangiomas. Dermatol Clin 1997; 15:373 – 383. Renfro L, Geronemus R. Anatomical differences of port-wine stains in response to treatment with the pulsed dye laser. Arch Dermatol 1993; 129:182 – 188. Rosenfeld H, Sherman R. Treatment of cutaneous and deep vascular lesions with the Nd:YAG laser. Lasers Surg Med 1986; 6:20– 23, 50– 51. Shapshay S, David L, Zeitels S. Neodymium-YAG laser photocoagulation of hemangiomas of the head and neck. Laryngoscope 1987; 97:323 –330. Apfelberg D, Smith T, Lash H et al. Preliminary report on use of the neodymium – YAG laser in plastic surgery. Lasers Surg Med 1987; 7:189 – 198. Achauer B, Vanderkam V. Capillary hemangioma (strawberry mark) of infancy: comparison of argon and Nd:YAG laser treatment. Plast Reconstr Surg 1989; 84:60 –69, discussion 70. Apfelberg D, Maser M, Lash H et al. YAG laser resection of complicated hemangiomas of the hand and upper extremity. J Hand Surg Am 1990; 15:765– 773. Apfelberg D, Maser M, White D et al. Benefits of contact and noncontact YAG laser for periorbital hemangiomas. Ann Plast Surg 1990; 24:397 – 408. Landthaler M, Hohenleutner U, el Raheem T. Laser therapy of childhood haemangiomas. Br J Dermatol 1995; 133:275 – 281. Suen J, Waner M. Treatment of oral cavity vascular malformations using the neodymium:YAG laser. Arch Otolaryngol Head Neck Surg 1989; 115:1329 –1333. Waner M, Suen J, Dinehart S. Treatment of hemangiomas of the head and neck. Laryngoscope 1992; 102:1123– 1132. Hukki J, Krogerus I, Casteren M et al. Effects of different contact laser scalpels on skin and subcutaneous fat. Lasers Surg Med 1987; 7:189– 198. Daikuzono N, Joffe S. Artificial sapphire probe for contact photocoagulation and tissue vaporization with the Nd:YAG laser. Med Instrument 1988; 19:173. Apfelberg D, Bailin P, Rosenberg H. Preliminary investigation of KTP/532 laser light in the treatment of hemangiomas and tattoos. Lasers Surg Med 1986; 6:38 – 42, 56 – 57. Yules R, Laub D, Honey R et al. The effect of Q-switched ruby laser radiation on Dermatolal tattoo pigment in man. Arch Surg 1967; 95:179– 180. Laub D, Yules R, Arras M et al. Preliminary histopathologic observation of Q-switched ruby laser radiation on Dermatolal tattoo pigment in man. J Surg Res 1968; 8:220– 224. Reid W, McLeod P, Ritchie A et al. Q-switched ruby laser treatment of black tattoos. Brit J Plast Surg 1983; 36:455 – 459. Reid W, Miller I, Murphy M et al. Q-switched ruby laser treatment of tattoos: a 9-year experience. Br J Plast Surg 1990; 43:663 –669. Taylor C, Gange R, Dover J et al. Treatment of tattoos by Q-switched ruby laser. Arch Dermatol 1990; 126:893 – 899. Taylor C, Anderson R, Gange R et al. Light and electron microscopic analysis of tattoos treated by Q-switched ruby laser. J Invest Dermatol 1991; 97:131– 136. Polla L, Margolis R, Dover J et al. Melanosomes are a primary target of Q-switched ruby laser irradiation in guinea pig skin. J Invest Dermatol 1987; 89:281 – 286. Dover J, Margolis R, Polla L et al. Pigmented guinea pig skin irradiated with Q-switched ruby laser pulses. Arch Dermatol 1989; 125:43– 49. Kilmer S, Lee M, Grevelink J et al. The Q-switched Nd:YAG laser (1064 nm) effectively treats tattoos: a controlled, dose-response study. Arch Dermatol 1993; 129:971 – 978. Kilmer S, Anderson R. Clinical use of the Q-switched ruby and Q-switched Nd:YAG (1064 and 532 nm) lasers for the treatment of tattoos. J Dermatol Surg Oncol 1993; 19:330–338.
50 274. 275. 276. 277. 278. 279.
280. 281. 282. 283. 284. 285. 286. 287. 288. 289. 290. 291.
292. 293. 294. 295. 296. 297.
298. 299. 300.
Brauner Kilmer S. Laser treatment of tattoos. Dermatol Clin 1997; 15:409– 417. Brauner G, Schliftman A. Treatment of pigmented lesions of the skin with alexandrite laser. Lasers Surg Med 1992; (suppl 4):72. (Abstract.) Fitzpatrick R, Ruiz-Esparza J, Goldman M. The alexandrite laser for tattoos: a preliminary report. Lasers Surg Med 1992; 4S:321. Fitzpatrick R, Goldman M. Tattoo removal using the alexandrite laser (755 nm, 100 ns). Arch Dermatol 1994; 130:1508 – 1514. Sherwood K, Murray S, Kurban A et al. Effect of wavelength of cutaneous pigment using pulsed irradiation. J Invest Dermatol 1989; 92:717 – 720. Fitzpatrick R, Goldman M, Ruiz-Esparza J. Laser treatment of benign pigmented epidermatolal lesions using a 300 ns pulse and 510 nm wavelength. J Dermatol Surg Oncol 1993; 19:341 – 347. Murphy G, Shepard R, Paul B et al. Organelle-specific injury to melanin- containing cells in human skin by pulsed laser irradiation. Lab Invest 1983; 49:680 – 685. Margolis R, Dover J, Polla L et al. Visible action spectrum for melanin-specific selective photothermolysis. Lasers Surg Med 1989; 389– 397. Goldberg D. Benign pigmented lesions of the skin. Treatment with the Q-switched ruby laser. J Dermatol Surg Oncol 1993; 19:376– 379. Goldberg D. Laser treatment of pigmented lesions. Dermatol Clin 1997; 15:397– 407. Alster T. Complete elimination of large cafe-au-lait birthmarks by the 510 nm pulsed dye laser. Plast Reconstr Surg 1995; 96:1660 – 1664. Alster T, Williams C. Cafe-au-lait macule in type V skin: successful treatment with a 510 nm pulsed dye laser. J Am Acad Dermatol 1995; 33:1042 – 1043. Brauner G, Schliftman A. Treatment of pigmented lesions with the flashlamp pumped PLDL (brown spot) laser. Lasers Surg Med 1992; (suppl 4):73. (Abstract.) Grossman M, Anderson R, Farinelli W et al. Treatment of cafe au lait macules with lasers. a clinicopathologic correlation. Arch Dermatol 1995; 131:1416 – 1420. Levy J, Mordon S, Pizzi-Anselme M. Treatment of individual cafe´ au lait macules with the Q-switched Nd:YAG: a clinicopathologic correlation. J Cutan Ther 1999; 1:217 – 223. Arndt K. Argon laser treatment of lentigo maligna. J Am Acad Dermatol 1984; 10:953 – 957. Arndt K. New pigmented macule appearing four years after argon laser treatment of lentigo maligna. J Am Acad Dermatol 1986; 14:1092. Suzuki H, Kobayashi S, Yamamoto K et al. The optimal age to begin and optimal interval for treatment of nevus of Ota with the Q-switched Nd:YAG laser. Lasers Surg Med 1996; (suppl 8):39. Haywood R, Monk B. Treatment of poikiloderma of Civatte with the pulsed dye laser: a series of seven cases. J Cutan Laser Ther 1999; 1:45– 48. Nanni C, Alster T. Complications of cutaneous laser surgery. A review. Dermatol Surg 1998; 24:209 – 219. Kelly K, Nelson J, Lask G et al. Cryogen spray cooling in combination with non-ablative laser treatment of facial rhytids. Arch Dermatol 1999; 135:691 – 694. Hruza G, Dover J, Flotte T et al. Q-switched ruby laser irradiation of normal human skin. Histologic and ultrastructural findings. Arch Dermatol 1991; 127:1799 – 1805. Waldorf H, Kauvar A, Geronemus R. Treatment of small and medium congenital nevi with the Q-switched ruby laser. Arch Dermatol 1996; 132:301 – 304. Rosenbach A, Williams C, Alster T. Comparison of the Q-switched alexandrite (755 nm) and Q-switched Nd:YAG (1064 nm) lasers in the treatment of benign melanocytic nevi. Dermatol Surg 1997; 23:239 –244, discussion 244– 245. Ueda S, Imayama S. Normal-mode ruby laser for treating congenital nevi. Arch Dermatol 1997; 133: 355 –359. Alster T, Kurban A, Grove G et al. Alteration of argon laser-induced scars by the pulsed dye laser. Lasers Surg Med 1993; 13:368 –373. Alster T. Improvement of erythematous and hypertrophic scars by the 585 nm pulsed dye laser. Ann Plast Surg 1994; 32:186 – 190.
Cutaneous Laser Surgery: Historical Perspectives 301. 302. 303. 304. 305. 306. 307. 308. 309. 310. 311. 312. 313. 314. 315. 316. 317.
318. 319. 320.
321.
322. 323. 324. 325. 326. 327. 328.
51
Alster T. Laser treatment of erythematous/hypertrophic pigmented scars in 26 patients. Plast Reconstr Surg 1995; 95:91. Alster T, Williams C. Treatment of keloid sternotomy scars with 585 nm flashlamp-pumped pulsed-dye laser. Lancet 1995; 345:1998 – 2001. Dierickx C, Goldman M, Fitzpatrick R. Laser treatment of erythematous/hypertrophic and pigmented scars in 26 patients. Plast Reconstr Surg 1995; 94:84 – 90. Goldman M, Fitzpatrick R. Laser treatment of scars. Dermatol Surg 1995; 21:685 – 687. Alster T, McMeekin T. Improvement of facial acne scars by the 585 nm flashlamp-pumped pulsed dye laser. J Am Acad Dermatol 1996; 35:79 – 81. Alster T. Laser treatment of hypertrophic scars, keloids and striae. Dermatol Clin 1997; 15:419 – 429. McDaniel D. Laser resurfacing of stretch marks. Laser Surg Med 1995; S7:52. (Abstract.) McDaniel D, Ash K, Zukowski M. Treatment of stretch marks with he 585 nm flashlamppumped pulsed dye laser. Dermatol Surg 1996; 22:332 – 337. Nehal K, Levine V, Ashinoff R. Treatment of mature striae with the pulsed dye laser. Lasers Surg Med 1998; s10:41. (Abstract.) Nehal K, Lichtenstein D, Kamino H et al. Treatment of mature striae with the pulsed dye laser. J Cutan Laser Ther 1999; 1:41– 44. Shapshay S, Strong M, Anastasi G et al. Removal of rhinophyma with the carbon dioxide laser: a preliminary report. Arch Otolaryngol 1980; 106:257 – 259. David L. Laser vermilion ablation for actinic cheilitis. J Dermatol Surg Oncol 1985; 11:605–608. Whitaker D. Microscopically proven cure of actinic cheilitis by CO2 laser. Lasers Surg Med 1987; 7:520 – 523. Zelickson B, Roenigk R. Actinic cheilitis. Treatment with the carbon dioxide laser. Cancer 1990; 65:1307 – 1311. David L, Lask G, Glassberg E et al. Laser abrasion for cosmetic and medical treatment of facial actinic damage. Cutis 1989; 43:583 – 587. Hobbs E, Bailin P, Wheeland R et al. Superpulsed lasers: minimizing thermal damage with short duration, high irradiance pulses. J Dermatol Surg Oncol 1987; 13:955 –964. Fitzpatrick R, Goldman M, Ruiz-Esparza J. Clinical advantage of the CO2 laser superpulsed mode. Treatment of verruca vulgaris, seborrheic keratoses, lentigines, and actinic cheilitis. J Dermatol Surg Oncol 1994; 20:449 –456. Fitzpatrick R. The ultrapulse CO2 laser: selective photothermolysis of epidermatolal tumors. Lasers Surg Med 1993; (suppl 5):56. (Abstract.) Fitzpatrick R, Goldman M, Satur N et al. Pulsed carbon dioxide laser resurfacing of photoaged facial skin. Arch Dermatol 1996; 132:395 – 402. Fitzpatrick R, Tope W, Goldman M et al. Pulsed carbon dioxide laser, trichloroacetic acid, Baker Gordon phenol, and Dermatolabrasion: a comparative clinical and histologic study of cutaneous resurfacing in a porcine model. Arch Dermatol 1996; 132:469 – 471. Kauvar A, Geronemus R, Waldorf H. Char free tissue ablation: a comparative histopathological analysis of new carbon dioxide (CO2) laser systems. Lasers Surg Med 16 1995; (suppl 7):50. Waldorf H, Kauvar A, Geronemus R. Skin resurfacing of fine to deep rhytides using a char-free carbon dioxide laser in 47 patients. Dermatol Surg 1995; 21:940 – 946. Kauvar A, Geronemus R. Histology of laser resurfacing. Dermatol Clin 1997; 15:459 – 467. Kauvar A. Laser skin resurfacing: perspectives at the millennium. Dermatol Surg 2000; 26:174 – 177. David L, Sarne A, Unger W. Rapid laser scanning for facial resurfacing. Dermatol Surg 1995; 21:1031 – 1033. Dover J, Hruza G. Laser skin resurfacing. Semin Cutan Med Surg 1996; 15:177 – 188. Hruza G, Dover J. Laser skin resurfacing. Arch Dermatol 1996; 132:395 – 402. Cotton J, Hood A, Gonin R et al. Histologic evaluation of preauricular and postauricular human skin after high-energy, short-pulse carbon dioxide laser. Arch Dermatol 1996; 132:425 – 428.
52 329.
330. 331. 332. 333. 334. 335. 336. 337. 338. 339. 340. 341. 342. 343. 344. 345. 346. 347. 348. 349. 350. 351. 352. 353. 354.
Brauner Ross E, Grossman M, Anderson R. Treatment of facial rhytides: comparing a pulsed CO2 laser with a collimated beam to a CO2 laser enhanced by a flashscanner. Lasers Surg Med 15 1995; (suppl 7):50. (Abstract) Ross E, Grossman M, Duke D et al. Long-term results after CO2 laser skin resurfacing: a comparison of scanned and pulsed systems. J Am Acad Dermatol 1997; 37:709 – 718. Chernoff W, Schoenrock L, Cramer H et al. Cutaneous laser resurfacing. Int J Aesthet Restor Surg 1995; 3:57– 68. Chernoff G, Slatkine M, Zair E et al. Silk touch: a new technology for skin resurfacing in aesthetic surgery. J Clin Laser Med Surg 1995; 13:97 – 100. Lowe N, Lask G, Griffin M et al. Skin resurfacing with the Ultrapulse carbon dioxide laser. Observations on 100 patients. Dermatol Surg 1995; 21:1025 –1029. Lask G, Keller G, Lowe N et al. Laser skin resurfacing with the SilkTouch flashscanner for facial rhytides. Dermatol Surg 1995; 21:1021 – 1024. West T. Laser resurfacing of atrophic scars. Dermatol Clin 1997; 15:449 –457. Burns A. Combined use of lasers in facial resurfacing. Laser skin resurfacing. American Society for Laser Medicine and Surgery Annual Meeting, Phoenix AK, Apr 1997. Alster T, Nanni C, Williams C. Comparison of four carbon dioxide resurfacing lasers. A clinical and histopathologic evaluation. Dermatol Surg 1999; 25:153 – 158. Field L. Laser resurfacing hysteria. The media, the marketers, the companies and us. Dermatol Surg 1998; 24:684 –686. Kaufmann R, Hibst R. Pulsed Er:YAG and 308 nm UV-Excimer laser: an in vitro and in vivo study of skin-ablative effects. Lasers Surg Med 1989; 9:132– 140. Kaufmann R, Hibst R. Pulsed Erbium:YAG laser ablation in cutaneous surgery. Lasers Surg Med 1989; 19:324– 330. Kaufmann R, Hibst R. Pulsed 2.94 mm erbium:YAG laser skin ablation: experimental results and first clinical application. Clin Exp Dermatol 1990; 15:389– 393. Hibst R, Kaufmann R. Effects of laser parameters on pulsed erbium:YAG laser skin ablation. Lasers Med Sci 1991; 6:391– 397. Kaufmann R, Hartmann A, Hibst R. Cutting and skin-ablative properties of pulsed midinfrared laser surgery. J Dermatol Surg Oncol 1994; 20:112 – 118. Wolbarsht M, Esterowitz L, Tran D et al. A mid-infrared (2.94) surgical laser with an optical fiber delivery system. Lasers Surg Med 1986; 6:257 – 258. Wolbarsht M, Foulks G, Esterowitz L et al. Corneal surgery with an Er:YAG laser at 2.94 um. Lasers Surg Med 1986; 6:241. Walsh J, Flotte T, Deutsch T. Er:YAG laser ablation of tissue: effect of pulse duration and tissue type on thermal damage. Lasers Surg Med 1989; 9:314 – 326. Walsh J, Deutsch T. Er:YAG laser ablation of tissue: measurement of ablation rates. Lasers Surg Med 1989; 9:327 – 337. Teikemeier G, Goldberg D. Skin resurfacing with the erbium:YAG laser. Dermatol Surg 1997; 23:685 – 687. Bernstein L, Kauvar A, Grossman M et al. The short- and long-term side effects of carbon dioxide laser resurfacing. Dermatol Surg 1997; 23:519– 525. Schwartz R, Burns A, Rohrich R et al. Long-term assessment of CO2 facial laser resurfacing: aesthetic results and complications. Plast Reconstr Surg 1999; 103:592– 601. Adrian R. Pulsed carbon dioxide and erbium-YAG laser resurfacing: a comparative clinical and histologic study. J Cutan Laser Ther 1999; 1:29– 35. Adrian R. Pulsed carbon dioxide and long pulse 10-ms erbium-YAG laser resurfacing: a comparative clinical and histologic study. J Cutan Laser Ther 1999; 1:197– 202. Khatri K, Ross V, Grevelink J et al. Comparison of erbium:YAG and carbon dioxide lasers in resurfacing of facial rhytides. Arch Dermatol 1999; 135:391 – 397. Newman J, Lord J, Ash K, McDaniel D. Variable pulse erbium:YAG laser skin resurfacing of perioral rhytides and side-by-side comparison with carbon dioxide laser. Lasers Surg Med 2000; 26:208 – 214.
Cutaneous Laser Surgery: Historical Perspectives 355. 356.
357.
358. 359. 360. 361. 362. 363. 364. 365. 366. 367. 368. 369. 370. 371. 372. 373. 374. 375. 376. 377. 378. 379. 380. 381. 382. 383.
53
Alster T. Clinical and histologic evaluation of six erbium:YAG lasers for cutaneous resurfacing. Lasers Surg Med 1999; 24:87– 92. McDaniel D, Lord J, Ash K et al. Combined CO2/erbium:YAG laser resurfacing of peri-oral rhytides and side-by-side comparison with carbon dioxide laser alone. Dermatol Surg 1999; 25:285 – 293. Newman J, Lord J, Ash K et al. DH.Variable pulse erbium:YAG laser skin resurfacing of perioral rhytides and side-by-side comparison with carbon dioxide laser. Lasers Surg Med 2000; 26:208 – 214. Zachary C. Modulating the Er:YAG laser. Lasers Surg Med 2000; 26:223 –226. Alster T, Lupton J. Erbium:YAG cutaneous laser resurfacing. Dermatol Clin 2001; 19:453–466. Rostan E, Fitzpatrick R, Goldman M. Laser resurfacing with a long pulse erbium:YAG laser compared to the 950 ms pulsed CO(2) laser. Lasers Surg Med 2001; 29: 136 – 141. Trelles M, Allones I, Luna R. One-pass resurfacing with a combined-mode erbium:YAG/ CO2 laser system: a study in 102 patients. Br J Dermatol 2002; 146: 473 – 480. Weinstein C, Scheflan M. Simultaneously combined ER:YAG and carbon dioxide laser (Dermatola K) for skin resurfacing. Clin Plast Surg 2000; 27:273– 285, xi. Comment in: Dermatol Surg 1995; 21:564– 565 on Unger W, David L. Laser hair transplantation. J Dermatol Surg Oncol 1994; 20:515 – 521. Dzubow L. Hair transplantation. Process and product. [(Published erratum appears in J Dermatol Surg Oncol 1994; 20:571.) J Dermatol Surg Oncol 1994; 20:509 – 510.] Bernstein R, Rassman W. Laser hair transplantation: is it really state of the art? Lasers Surg Med 1996; 19:233– 235, discussion 236– 238. Fitzpatrick R, Marchell N. Laser hair transplantation II. Dermatol Surg 2000; 26:419– 424. Unger W, David L. Laser hair transplantation. J Dermatol Surg Oncol 1994; 20:515 – 521. Unger W. Laser hair transplantation. Dermatol Surg 1995; 21:186– 187. Unger W. Laser hair transplantation II. Dermatol Surg 1995; 21:759– 765. Unger W. Laser hair transplantation III. Computer-assisted laser transplanting. Dermatol Surg 1995; 21:1047 – 1055. Fitzpatrick R. Laser hair transplantation. Tissue effects of laser parameters. Dermatol Surg 1995; 21:1042 – 1046. Ho C, Nguyen Q, Lask G et al. Mini-slit graft hair transplantation using the Ultrapulse carbon dioxide laser handpiece. Dermatol Surg 1995; 21:1056– 1059. Grevelink J, Brennick J. Hair transplantation facilitated by flashscanner-enhanced carbon dioxide laser operative techniques. Otolaryngol Head Neck Surg 1994; 5:278 – 280. Grevelink J, Farinelli W, Bua D et al. Hair transplantation aided by CO2 lasers. Lasers Surg Med 1995; S7:S47. Smithdeal C. Carbon dioxide laser-assisted hair transplantation. The effect of laser parameters on scalp tissue—a histologic study. Dermatol Surg 1997; 23:835 – 840. Tsai R, Chen D, Chan H et al. Experience with laser hair transplantation in Orientals. Dermatol Surg 1998; 24:1065 – 1068. Neidel F, Fuchs M, Krahl D. Laser-assisted autologous hair transplantation with the Er:YAG laser. J Cutan Laser Ther 1999; 1:229 –231. Grevelink J. Laser hair transplantation. Dermatol Clin 1997; 15:479 – 486. Gold M, Bell M, Foster T et al. Long term epilation using the Epilight broad band, intense pulsed light hair removal system. Dermatol Surg 1997; 23:909 – 913. Schroeter C. Hair removal with the PhotoDermatol VL as an intense light source: a histopathological study. Lasers Surg Med 1998; (suppl 10):3. Lask G, Eckhouse S, Slatkine M et al. The role of laser and intense light sources in photoepilation: a comparative evaluation. J Cutan Laser Ther 1999; 1:3 – 14. Sadick N, Shea C, Burchette J et al. High-intensity flashlamp photoepilation: a clinical, histological, and mechanistic study in human skin. Arch Dermatol 1999; 135:668–676. Johnson F, Dovale M. Intense pulsed light treatment of hirsutism: case reports of skin phototypes V and VI. J Cutan Laser Ther 1999; 1:233– 237.
54 384. 385. 386. 387. 388. 389.
390. 391. 392. 393. 394. 395. 396. 397. 398. 399.
400. 401. 402. 403. 404. 405. 406.
407. 408. 409. 410.
Brauner Goldman M. Leg veins and laser. Lasers Surg Med 1994; (suppl 6):48. Schroeter C, Neumann H. An intense light source. The photoderm VL-flashlamp as a new treatment possibility for vascular skin lesions. Dermatol Surg 1998; 24:743 – 748. Dover J, Sadick N, Goldman M. The role of lasers and light sources in the treatment of leg veins. Dermatol Surg 1999; 25:328 – 336. Raulin C, Schroeter C, Weiss R et al. Treatment of port-wine stains with a noncoherent pulsed light source: a retrospective study. Arch Dermatol 1999; 135:679 – 683. Bitter P. Noninvasive rejuvenation of photodamaged skin using serial, full-face intense pulsed light treatments. Dermatol Surg 2000; 26:835 – 842, discussion 843. Hernandez-Perez E, Ibiett E. Gross and microscopic findings in patients submitted to nonablative full-face resurfacing using intense pulsed light: a preliminary study. Dermatol Surg 2002; 28:651 –655. Negishi K, Tezuka Y, Kushikata N et al. Photorejuvenation for Asian skin by intense pulsed light. Dermatol Surg 2001; 27:627 – 631, discussion 632. Goldberg D, Cutler K. Nonablative treatment of rhytids with intense pulsed light. Lasers Surg Med 2000; 26:196– 200. Goldberg D. New collagen formation after dermal remodeling with an intense pulsed light source. J Cutan Laser Ther 2000; 2:49– 61. Berry J. Recurrent trichiasis: treatment with laser photocoagulation Ophthalmic Surg 1979; 10:36 – 38. Kuriloff D, Finn D, Kimmelman C. Pharyngoesophageal hair growth: the role of laser epilation. Otolaryngol Head Neck Surg 1988; 98:342– 345. Finkelstein L, Blatstein L. Epilation of hair-bearing urethral grafts using the neodymium: YAG surgical laser. J Urol 1991; 146:840 – 842. Gossman M, Yung R, Berlin A et al. Prospective evaluation of the argon laser in the treatment of trichiasis. Ophthalmic Surg 1992; 23:183 – 187. Goldberg D. Topical solution—assisted laser hair removal. Lasers Surg Med 1995; 7S:47. Goldberg D, Littler C, Wheeland R. Topical suspension-assisted Q-switched Nd:YAG laser hair removal. Dermatol Surg 1997; 23:741 –745. Nanni C, Alster T. Optimizing treatment parameters for hair removal using a topical carbonbased solution and 1064-nm Q-switched neodymium:YAG laser energy. Arch Dermatol 1997; 133:1546 – 1549. Grossman M, Farinelli W, Flotte T et al. Laser targeted at hair follicles. Lasers Surg Med 1995; S7:47. Wheeland R. Laser-assisted hair removal Dermatol Clin 1997; 15:469– 477. Grossman M, Dierickx C, Farinelli W et al. Damage to hair follicles by normal-mode ruby laser pulses. J Am Acad Dermatol 1996; 35:889– 894. Anderson R, Burns A, Garden J et al. Multicenter study of long-pulse ruby laser hair removal. Lasers Surg Med suppl 1999; 11:56. (Abstracts.) Lin T, Manuskiatti W, Dierickx C et al. Hair growth cycle affects hair follicle destruction by ruby laser pulses. J Invest Dermatol 1998; 111:107 – 113. Dierickx C, Grossman M, Farinelli W et al. Permanent hair removal by normal-mode ruby laser. Arch Dermatol 1998; 134:837 –842. Nanni C, Alster T. A practical review of laser assisted hair removal using the Q-switched Nd:YAG, long-pulsed ruby and long-pulsed alexandrite lasers. Dermatol Surg 1998; 24:1399 – 1405. Goldberg D, Ahkami R. Evaluation comparing multiple treatments with a 2-msec and 10-msec alexandrite laser for hair removal. Lasers Surg Med 1999; 25:223– 228. Battle E. Hypertrichosis [treatment modalities for dark skin types]. American Academy of Dermatology Annual Meeting, San Francisco, CA, Mar 14, 2000. Nelson J, Milner T, Dave D et al. Clinical study of non-ablative laser treatment of facial rhytides. Lasers Surg Med 1997; 95:32– 33. Hoffman W, Anvari B, Said S et al. Cryogen spray cooling during Nd:YAG laser treatment of hemangiomas. A preliminary animal model study. Dermatol Surg 1997; 23:635– 641.
Cutaneous Laser Surgery: Historical Perspectives 411. 412. 413.
414. 415. 416. 417. 418.
419. 420.
421. 422. 423. 424.
425. 426. 427. 428. 429. 430. 431. 432. 433.
434. 435.
55
Goldman M. Non-ablative laser treatment of wrinkles. Cosmet Dermatol 2000; 13:17 – 20. Menaker G, Wrone D, Williams R et al. Treatment of facial rhytids with a non-ablative laser: a clinical and histologic study. Dermatol Surg 1999; 25:440– 444. Ross E, Sajben F, Hsia J et al. Nonablative skin remodeling: selective dermal heating with a mid-infrared laser and contact cooling combination. Lasers Surg Med 2000; 26:186 – 195. Muccini J, O’Donnell F, Fuller T et al. Rapid report; laser treatment of solar elastosis with epithelial preservation. Lasers Surg Med 1998; 23:121– 127. Goldberg D, Whitworth J. Laser skin resurfacing with the Q-switched Nd:YAG laser. Dermatol Surg 1997; 23:903 –906, discussion 906 – 907. Goldberg D, Cutler K, Nonablative treatment of rhytids with intense pulsed light. Lasers Surg Med 2000; 26:196 – 200. Hardaway C, Ross EV. Nonablative laser skin remodeling. Dermatol Clin 2000; 20:97 – 111,ix. Bernstein E, Ferreira M, Anderson D. A pilot investigation to subjectively measure treatment effect and side-effect profile of non-ablative skin remodeling using a 532 nm, 2 ms pulseduration laser. J Cosmet Laser Ther 2001; 3:137– 141. Zelickson B, Kilmer S, Bernstein E et al. Pulsed dye laser therapy for sun damaged skin. Lasers Surg Med 1999; 25:229 – 236. Rostan E, Bowes L, Iyer S et al. A double-blind, side-by-side comparison study of low fluence long pulse dye laser to coolant treatment for wrinkling of the cheeks. J Cosmet Laser Ther 2001; 3:129 – 136. Bjerring P, Clement M, Heickendorff L et al. Selective non-ablative wrinkle reduction by laser. J Cutan Laser Ther 2000; 2:9– 15. Goldberg D. Non-ablative subsurface remodeling: clinical and histologic evaluation of a 1320-nm Nd:YAG laser. J Cutan Laser Ther 1999; 3:153– 157. Trelles M, Allones I, Luna R. Facial rejuvenation with a nonablative 1320 nm Nd:YAG laser: a preliminary clinical and histologic evaluation. Dermatol Surg 2001; 27:111– 116. Fournier N, Dahan S, Barneon G et al. Nonablative remodeling: clinical, histologic, ultrasound imaging, and profilometric evaluation of a 1540 nm Er:glass laser. Dermatol Surg 2001; 27:799 –806. Mester E et al. Laserstrahlenwirkung auf das Wachstum des Erlichsen Ascitestumor. Arch Geschwultsforsch 1968; 32:201. Mester E et al. Stimulation of wound healing by laser rays. Acta Chir Acad Sci Hung 1972; 13:315. Mester E, Mester A, Mester A. The biomedical effects of laser application. Lasers Surg Med 1985; 5:31 – 39. Wheeland R. Lasers for the stimulation or inhibition of wound healing. J Dermatol Surg Oncol 1993; 19:747 –752. Castro D, Abergel R, Meeker C et al. Effects of the Nd:YAG laser on DNA synthesis and collagen production in human skin fibroblast cultures. Ann Plast Surg 1983; 11:214 – 222. Abergel R, Meeker C, Dwyer R et al. Nonthermal effects of Nd:YAG laser on biological functions of human skin fibroblasts in culture. Lasers Surg Med 1984; 3:279– 284. Abergel R, Dwyer R, Meeker C et al. Laser treatment of keloids. Lasers Surg Med 1984; 4:291 – 295. Abergel R, Meeker C, Lam T et al. Control of connective tissue metabolism by lasers; recent developments and future prospects. J Am Acad Dermatol 1984; 11:1142– 1150. Castro D, Saxton R, Fetterman H et al. Biostimulative effects of Nd:YAG Q-switch dye on normal human fibroblast cultures: study of a new chemosensitizing agent for the Nd:YAG laser. Laryngoscope 1987; 97:1454 – 1459. Abergel R, Lyons R, Castel J et al. Biostimulation of wound healing by lasers: experimental approaches in animal models and in fibroblast cultures. J Dermatol Surg Oncol 1987; 13:127–133. Lyons R, Abergel R, White R et al. Biostimulation of wound healing in vivo by a helium-neon laser. Ann Plast Surg 1987; 18:47 – 50.
56 436.
437. 438. 439. 440. 441. 442. 443. 444. 445. 446. 447. 448. 449. 450. 451. 452. 453. 454. 455. 456. 457. 458.
459. 460. 461. 462. 463.
Brauner Castro D, Saxton R, Fetterman H et al. Bioinhibition of human fibroblast cultures sensitized to Q-switch II dye and treated with the Nd:YAG laser: a new technique of photodynamic therapy with lasers. Laryngoscope 1989; 99:421 – 428. Saxton R, Haghighat S, Plant D et al. Dose response of human tumor cells to rhodamine 123 and laser phototherapy. Laryngoscope 1994; 104:1013 – 1018. Raab O. Uber die Wirkung fluorescierendes stoffe und Infusorien. Z Biol 1900; 39:524. Tappeiner H. Uber die Wirkung fluorescierender Stoffe auf Infusorien nach versuchen von O. Raab. Munch Med Wochenschr 1900; 47:5. Tappeiner H, Jodlbauer A. Die sensibilisierende Wirkung fluorescierender Substanzen. In: Vogel F, ed. Gesammelte Untersuchungen uber die photodynamische Erscheinung. Leipzig, 1907. Jesionek A, Tappeiner H. Zur Behandlung der Hautcarcinome nmit fluorescierenden Stoffen. Arch Klin Med 1905; 82:223. Straight R. Photodynamic therapy in laser surgery and medicine. In: Dixon J, ed. Surgical Application of Lasers. 2nd ed. Chicago: Yearbook Medical Publishers, 1987:310 – 349. Auler H, Banzer G. Untersucheungen uber die Rolle der Porphyrine bei geschwulstkranken Menschen und Tieren. Z Krebsforsch 1942; 53:65. Diamond I, McDonagh A, Wilson C et al. Photodynamic therapy of malignant tumors. Lancet 1972; II:1175 – 1177. Dougherty T. Activated dyes as antitumor agents. J Natl Cancer Inst 1974; 52:1333 – 1336. Tomson S, Emmett E, Fox S. Photodestruction of mouse epithelial tumors after acridine orange and argon laser. Cancer Res 1974; 34:3124 – 3127. Dougherty T, Grindey G, Fiel R et al. Photoradiation therapy. II. Cure of animal tumors with hematoporphyrin and light. J Natl Cancer Inst 1975; 55:115– 121. Dougherty T. Photoradiation therapy for cutaneous and subcutaneous malignancies. J Invest Dermatol 1981; 77:122 – 124. Dougherty T. Hematoporphyrin as a photosensitizer of tumors. Photochem Photobiol 1983; 38:377 – 379. Daniell M, Hill J. A history of photodynamic therapy. Aust NZ J Surg 1991; 61:340 – 348. Lui H, Anderson R. Photodynamic therapy in dermatology: recent developments. Dermatol Clin 1993; 11:1 – 13. Biel M. Photodynamic therapy and the treatment of head and neck cancers. J Clin Laser Med Surg 1996; 14:239 –244. Bissonette R, Lui H. Current status of photodynamic therapy in dermatology. Dermatol Clin 1997; 15:507 – 519. Allison R, Mang T, Wilson B. Photodynamic therapy for the treatment of nonmelanomatous cutaneous malignancies. Semin Cutan Med Surg 1998; 17:153 – 163. Henney J. First drug device to treat actinic keratoses. J Am Med Assoc 2000; 283:596. Peng Q, Warloe T, Moan J et al. Distribution of 5-aminolevulinic acid-induced porphyrins in noduloulcerative basal cell carcinoma. Photochem Photobiol 1995; 62:906 – 913. Peng Q, Warloe T, Berg K et al. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 1997; 79:2282– 2308. Soler A, Warloe T, Tausjo J et al. Photodynamic therapy by topical aminolevulinic acid, dimethylsulphoxide and curettage in nodular basal cell carcinoma: a one-year follow-up study. Acta Dermatol Venereol 1999; 79:204 – 206. Sacchini V, Melloni E, Marchesini R et al. Preliminary clinical studies with PDT by topical TPPS administration in neoplastic skin lesions. Lasers Surg Med 1987; 7:6– 11. Leuenberger M, Mulas M, Hata T et al. Comparison of the Q-switched alexandrite, Nd:YAG, and ruby lasers in treating blue-black tattoos. Dermatol Surg 1999; 25:10 – 14. Grossman M, Lou W, Kauvar A et al. Comparison of different lasers and light sources hair removal. Lasers Surg Med 1999; (suppl 11):14. (Abstracts.) Fried M, Kelly J, Strome M. Complications of Laser Surgery of the Head and Neck. Chicago: Yearbook Medical Publishers, 1986. Olbricht S, Stern R, Tang S et al. Complications of cutaneous laser surgery. A survey. Arch Dermatol 1987; 123:345 – 349.
Cutaneous Laser Surgery: Historical Perspectives 464. 465. 466. 467. 468. 469.
57
Lent W, David L. Laser resurfacing: a safe and predictable method of skin resurfacing. J Cutan Laser Ther 1999; 1:87 – 94. Nanni C. Complications of laser surgery. Dermatol Clin 1997; 15:521 – 534. Nanni C, Alster T. Complications of carbon dioxide laser resurfacing. An evaluation of 500 patients. Dermatol Surg 1998; 24:315 – 322. Rendon-Pellerano M, Lentini J, Eaglstein W et al. Laser resurfacing: usual and unusual complications. Dermatol Surg 1999; 25:360 – 367. Anderson R, Geronemus R, Kilmer S et al. Cosmetic tattoo ink darkening: a complication of Q-switched and pulsed laser treatment. Arch Dermatol 1993; 129:1010 – 1014. Nanni C, Alster T. Laser-assisted hair removal: side effects of Q-switched Nd:YAG, long-pulsed ruby, and alexandrite lasers. J Am Acad Dermatol 1999; 41:165– 171.
2 An Introduction to Lasers and Laser –Tissue Interactions in Dermatology J. Stuart Nelson Beckman Laser Institute, University of California, Irvine, California, USA
1. 2. 3. 4. 5. 6. 7. 8. 9. 10.
Introduction Electromagnetic Radiation Light Bulb vs. a Laser Basic Laser Principles Lasers in Dermatology Continuous Wave vs. Pulsed Lasers Q-Switching Laser Delivery Dosimetry Basic Laser – Tissue Interactions: Reflection, Scattering, Transmission, and Absorption 11. The Process of Absorption 12. Chromophores in Human Skin 13. Heat 14. Ablation of Human Skin 15. Selective Photothermolysis 16. Selective Photothermolysis of Cutaneous Blood Vessels 17. Selective Photothermolysis of Tattoos 18. Selective Photothermolysis of Pigmented Lesions 19. Selective Photothermolysis and Laser Assisted Hair Removal 20. Skin Cooling 21. Photochemistry and Photodynamic Therapy 22. Fluorescence 23. Conclusion References
60 60 61 62 64 65 66 66 67 67 68 69 71 71 72 73 74 74 74 74 76 76 76 77 59
60
1.
Nelson
INTRODUCTION
Dermatologic laser surgery is regarded as one of the fastest growing areas in the emerging fields of photomedicine and biomedical optics. The unique properties of lasers create an enormous potential for specific therapy of skin diseases. As with any device, the most efficacious and appropriate use requires an understanding of the basic photobiological and photophysical principles of laser –tissue interaction as well as the properties of the laser itself. Modifications of current lasers and innovative advances in biomedical laser instrumentation may eventually allow the physician to match optimally the laser and treatment procedure with the lesion. This chapter provides a brief description of the nature of the laser, how it works, and the fundamental mechanisms of its interaction with human skin.
2.
ELECTROMAGNETIC RADIATION
Electromagnetic radiation is a fundamental form of energy that exhibits both wave properties, because of alternating electric and magnetic fields, and particle properties, comprising packets of energy called photons. A relationship exists between the energy of the photon (E) and the speed of light (c), and frequency (n) and wavelength (l) of the radiation. The constant of proportionality (h) is Planck’s constant. E ¼ hn and E ¼ hc=l
n ¼ c=l
(2:1) (2:2)
These equations show that the energy of an electromagnetic wave is proportional to its frequency and inversely proportional to wavelength. Long-wavelength photons carry less energy than short-wavelength photons as expressed by Planck’s law. The electromagnetic spectrum is portrayed in Fig. 2.1. It can be seen that visible light lasers
Figure 2.1 The spectrum of electromagnetic radiation.
Lasers and Laser –Tissue Interactions
61
occupy a relatively small region of the entire spectrum. However, with the continued development of the free-electron laser, the region occupied by lasers eventually might be extended into the near-X-ray part of the spectrum with wavelengths as short as 10 nm.
3.
LIGHT BULB
VS .
A LASER
Photons are the fundamental units of light, and they are the same whether produced by a light bulb or a laser (Fig. 2.2). The laser and the light bulb differ in how their photons are organized. Light from a light bulb radiates in all directions, and there is a direct mathematical relationship between the loss of light intensity and the distance one moves away from the bulb. In the laser, photons are emitted parallel (or nearly parallel) to, and in phase with, each other as they travel toward infinity. This property is known as coherence and explains why the light intensity of a laser does not decrease very much with distance. Another feature of light from a light bulb is that it is white or yellow-white in color because it contains all the different colors and wavelengths in the visual portion of the electromagnetic spectrum and, hence, is polychromatic. A glass prism placed in front of a light bulb refracts the different wavelengths and allows the constituent colors to be seen. With the laser, the prism produces light of one wavelength and one color. The light from the laser is therefore pure or monochromatic. This property, under some circumstances, allows for selective absorption of laser energy by a targeted chromophore within human skin—structures with high absorption at a laser wavelength can be selectively altered or destroyed. Another difference between the two light sources is their intensity. The number of photons per unit area of emission produced by the laser is much greater than for any
Figure 2.2 Characteristics of light from a conventional light bulb and from a laser.
62
Nelson
other light source. In fact, millions more photons are emitted by a laser than by a comparable surface area of the sun. For example, peak powers of 1012 W can be obtained with certain short-pulsed lasers. Laser power can also be varied over a wide range to achieve quite different tissue effects. For example, a low-power laser may be used to heat gently a tissue, with perhaps the only change being an increase in metabolic rate. A high-power pulsed laser may be used to achieve nonlinear optical effects (e.g., optical breakdown) causing explosions within the tissue (1). As a result of these three basic differences—coherence, monochromaticity, and intensity—the laser produces a highly unique form of electromagnetic radiation. Otherwise, photons from the light bulb and the laser obey the same basic laws and principles governing their interaction with human skin.
4.
BASIC LASER PRINCIPLES
The word laser is an acronym derived from light amplification by the stimulated emission of radiation. The amplification of the stimulated emission of radiation is the actual physical process that goes on within the laser device (2 – 5). Figure 2.3 illustrates the process of lasing: the stimulated emission of one photon by the action of another photon. To understand the acronym, it is necessary to examine some basic atomic physics. Figure 2.3(a) illustrates two atoms existing in what is termed the ground state, the lowest possible energy level. If by some mechanism the electrons of these atoms are excited from the ground state by the input of energy, they move to a higher energy level called the excited singlet state [Fig. 2.3(b)]. The source of this energy or “pumping system” can be electrical, chemical, radiofrequency waves, or light from a flashlamp or another laser. When these atoms are in the excited singlet state, they very quickly drop down to an in-between, long-lived energy level called the metastable state [Fig. 2.3(c)]. This state may last as long as a few seconds, as compared
Figure 2.3 Energy transitions characteristic of atoms in stimulated emissions. (a) Two groundstate atoms (1,2). (b) Excitation to the singlet state by input of energy (black arrows). (c) Transition to the metastable state. (d) Atom 1 spontaneously drops to the ground state, emitting a photon that stimulates atom 2 also to drop to the ground state. Both photons (yellow arrows) from atoms 1 and 2 have the same wavelength and travel parallel to each other and in phase.
Lasers and Laser –Tissue Interactions
63
with 1026 – 1029 s for most excited states. This explains why some materials can go through the lasing process and others cannot. Only atoms and molecules with a metastable state in their energy structure can achieve what is called a population inversion and undergo stimulated emission. What happens next is a spontaneous event. Those atoms existing in the metastable state spontaneously, and by random action, return to the ground state with the loss of some energy. This loss of energy occurs in the form of light—the release of a photon [Fig. 2.3(d)]. If the photon is in close proximity to another atom still in the metastable state (recall that the metastable state is long-lived so that there are going to be many atoms still at that energy level at a given moment), it collides (interacts) with that atom. This interaction stimulates the second atom to return to its ground state and, in the process, emit another photon of light. This phenomenon is termed stimulated emission of radiation. It is a basic principle of physics that since both photons come from identical energy levels, they are of the same wavelength (color) and are moving parallel and in phase with each other (the property of coherence). The first laser built in 1960 used synthetic red ruby, which is an aluminum trioxide crystal doped with chromium atoms. It was the chromium atoms inside the aluminum trioxide crystal that underwent the lasing process to produce red light. Figure 2.4 presents the foregoing on a much grander scale. Here, the atoms in the lasing medium in the ground state are represented by violet circles and those in the metastable state, by red circles [Fig. 2.4(a)]. Most of the atoms initially are in the ground state and are subsequently excited to the singlet state by a flash of light. They rapidly drop
Figure 2.4 Schematic of laser action illustrating photon cascade. (a) Unstimulated crystal; a few atoms (red circles) are spontaneously in the singlet or metastable state, but most are in the ground state (violet circles). (b) Energy input excites ground-state atoms to the singlet state whence they drop down to the metastable state. (c) Stimulated emission of excited atoms by photons of stimulated emitting atoms. (d) Photon cascade is produced by reflection at reflecting ends of the laser cavity; stimulated emission continues. (e) Further photon cascade occurs and laser light passes out the partially reflective end of the laser cavity.
64
Nelson
down to the metastable state [Fig. 2.4(b)]. Following this event, spontaneous emission occurs as described previously. The two emitted photons strike other atoms in the metastable state causing them to emit photons in parallel and in phase with those already present [Fig. 2.4(c)]. All this occurs within a fraction of a second creating an intense buildup of many photons, or a photon cascade. If the laser cavity has opposing reflective surfaces, the photons are oscillated through the medium at the speed of light, stimulating the emission of more photons [Fig. 2.4(d)]. This buildup of intensity by oscillation between two reflecting surfaces results in the final process in lasing: amplification. By permitting the release of some photons through a partially reflective surface at one end of the cavity, the result is a bright, intense monochromatic beam of light: a laser beam [Fig. 2.4(e)].
5.
LASERS IN DERMATOLOGY
Different kinds of lasers (Fig. 2.5) are identified by the type of material that undergoes the lasing process (e.g., the argon laser has argon gas as the lasing medium) inside the device. There are four types of lasing materials: solid, gas, liquid, or semiconductor. It is possible to obtain lasing action from any of these types of lasing materials provided that their atomic structures have metastable states that permit the stimulated emission process to occur. Examples of solid-state lasers are the ruby, alexandrite, and neodymium yttrium –aluminum – garnet (Nd:YAG) lasers. Examples of gas lasers are the excimer, argon, and carbon dioxide lasers. An example of a liquid laser is the pulsed dye laser. Liquid lasers employ complex organic dyes, such as rhodamine or coumarin, in solution or suspension. Diode lasers use two layers of a semiconductor material, such as gallium arsenide. Some diode lasers are tuneable over a broad wavelength range. They can be operated on battery power and, due to their small size which provides for efficient packaging, are useful for remote operation.
Figure 2.5 Identification of different types of medical lasers.
Lasers and Laser –Tissue Interactions
65
Generally and by convention, a medical laser is referred to in terms of its wavelength in either nanometers (nm) or micrometers (mm). There are also ways to modify the wavelengths obtainable from lasers. The simplest of these is frequency doubling or harmonic generation, where high-intensity light propagating through a nonlinear, asymmetric crystal generates laser light at twice the input frequency (Fig. 2.6). For example, light from high-power Nd:YAG lasers can be doubled in frequency by placing a KTP (potassium-titanyl-phosphate) crystal inside the laser cavity itself and focusing the beam into the crystal. Since the frequency of light is inversely proportional to wavelength, the result is light emitted from the crystal with twice the frequency or half the wavelength of the incident light. In practice, invisible near-infrared 1064 nm wavelength light is passed through a KTP crystal producing green visible light at a wavelength of 532 nm. The resulting laser is sometimes referred to as a KTP laser. Similar complicated physical processes can be used to double, triple, or quadruple the wavelengths from the primary laser source. Dye lasers contain a tube filled with flowing dye solution that is excited within the laser cavity. The output wavelength may be “tuned” from 400 to 1000 nm as desired by changing the dye. Precise wavelength tuning is controlled by the individual dye’s fluorescence, typically in the 30 –100 nm range, and is accomplished through the use of prisms, diffraction gratings, or birefringent filters placed within the cavity. By choosing different dyes, laser light of virtually any wavelength in the visible spectrum can be produced. Unfortunately, all of the dye lasers must contend with photoinduced dye disintegration, necessitating frequent changes of the dye after a certain number of pulses. In summary, there are a wide range of lasers available for clinical use. The dye lasers, and in the future the free-electron laser, can be precisely tuned to emit photons at wavelengths that match absorption peaks of tissue chromophores, thus permitting their selective destruction and subsequent tissue ablation.
6.
CONTINUOUS WAVE vs. PULSED LASERS
A continuous wave (CW) laser may be differentiated from a pulsed laser, which provides bursts of energy. In the CW mode, the laser delivers a continuous beam of light with little or no variation in power output over time In CW operation, laser output is controlled by the physician, typically by depressing a foot pedal. A pulsed laser delivers its energy in the form of a single pulse or a train of pulses. The frequency or pulse repetition rate is the number of pulses emitted in 1 s (Hertz).
Figure 2.6 Frequency doubling by passing an Nd:YAG laser beam through an asymmetric potassium-titanyl-phosphate (KTP) crystal.
66
Nelson
The duration of the pulse, or pulse width, is defined as the total time required for the pulse to rise from zero intensity, build to a maximum, and then return to zero intensity. An alternative definition for pulse width (used for short pulses) is the time between the 50% points on the pulse curve. This is called full width at half maximum. “Superpulse” is a term specific to some carbon dioxide lasers that have been modified to produce very short pulses with high peak powers in a repetitive fashion, commonly several hundred pulses per second. From the physician’s point of view, superpulse is most useful for incisional surgery with a focused beam. High peak power maximizes tissue vaporization, and short pulse duration minimizes adjacent thermal injury.
7.
Q-SWITCHING
Q-switching of lasers is a mechanism often used to control the light output by concentrating all the energy into a single, intense pulse with a duration on the order of nanoseconds and an energy of 10 J or more. With Q-switching (the Q-factor stands for “quality factor,” used in electronics theory terminology), a fast electromagnetic switch (Pockel’s cell) in the laser cavity causes excitation of the active medium to buildup far in excess of the level of the medium when the shutter is open. In operation, the flashlamp is turned on and the population inversion gradually grows. Lasing is prevented by the shutter. When the population inversion is at a maximum, the shutter is opened so that lasing occurs and a large burst of energy is emitted as the cavity rapidly depletes the population inversion. The net result is an extremely high peak power (greater than 106 W) nanosecond duration pulse or series of pulses. Several methods are available to create laser pulses with pulse widths on the order of femtoseconds (10215 s). Because the techniques can be quite complicated, especially for producing very short pulse widths, they are not discussed here.
8.
LASER DELIVERY
Transmission of laser energy from the laser cavity to the tissue is provided by one of three devices: articulated arms, optical fibers, or micromanipulators. Articulated arms direct laser energy from the laser cavity to the desired location through a series of hollow, rigid tubes with reflecting mirrors at each connection. The series of mirrors is chosen to be reflective of the laser wavelength being transmitted so that coherence and power are maintained, allowing the fine focusing of the exiting beam. A hand piece at the end of the arm contains a lens that focuses the beam to various spot sizes with uniform light intensity. Several limitations remain in articulated arm systems. Despite recent advances to improve their mobility, articulated arms are somewhat cumbersome to use in a clinical setting. The mirrors are easily misaligned when either the laser device or the articulated arm is disturbed. Despite the aforementioned limitations, carbon dioxide or Er:YAG lasers almost exclusively utilize articulated arms because their infrared wavelengths are not transmissible along currently available optical fibers. The most common and convenient way of delivering laser energy to the skin is through flexible optical fibers. Most visible light can be transmitted along optical fibers which are composed of two or more concentrically arranged optical materials and light is carried through the fiber by total internal reflection. Most optical fibers contain a quartz core surrounded by a silicone rubber cladding. Optical fibers can be hand-held or coupled to a hand piece with a focusing lens for cutaneous applications.
Lasers and Laser –Tissue Interactions
67
Both articulated arms and optical fibers can be coupled through a microscope with a micromanipulator which provides a controlled means of moving the laser beam across the surface of human skin. The micromanipulator can also be coupled with a computer for completely preprogrammed and precise skin irradiation. 9.
DOSIMETRY
Laser light is a form of energy that is subject to certain fundamental physical laws defined by a set of equations. An understanding of these relationships is required in order to properly use the laser as a medical device (6). Laser light emitted from the customized medical device is generally characterized in terms of power, measured in watts. The energy (stated in Joules) is defined as the power times the time interval during which light is emitted: Energy (J) ¼ power (W) time (s)
(2:3)
The power density or irradiance is then defined as the power applied per unit area of target tissue: Power density ¼ power (W)=p r 2 (cm2 )
(2:4)
Fluence is defined as the energy applied to an area of target tissue: Fluence (J=cm2 ) ¼ power density (W=cm2 ) time (s)
(2:5)
It can readily be appreciated that the effect of the laser beam on human skin can be affected by any of three variables: power, time, and spot size. The effects of power and time are proportional whereas that of spot size (radius) is an inverse square. If either the power or time is doubled, fluence increases by a factor of 2. However, if the spot size is decreased by a factor of 2, fluence increases by a factor of 4. Doubling the spot size results in a fourfold reduction in fluence. 10.
BASIC LASER – TISSUE INTERACTIONS: REFLECTION, SCATTERING, TRANSMISSION, AND ABSORPTION
How can this intense, pure beam of light be used in the clinical management of patients? The successful applications of lasers to dermatologic surgery rely upon an adequate appreciation of the principles of light interactions with human skin. It is important to recognize that these interactions are complex phenomena influenced not only by laser parameters, such as power, spot size, pulse duration, repetition rate, and wavelength, but also by properties of the tissue itself. If a laser beam is directed at the skin, light may be reflected back to the source or to another undesired surface. Reflection occurs as a result of changes in the indices of refraction at the air – skin interface. When light strikes the skin surface, approximately 5% is reflected. Since tissues reflect light, their reflectance properties are important considerations. Instruments in the operative field may also reflect the light, creating potential health hazards for the patient and attending medical personnel. If reflectance is adequately controlled and light enters human skin, the ultimate determinant affecting that tissue is the absorption of light. However, two things can happen other than absorption. Light can scatter from particles and structures in the skin to places where it is not wanted. Scattered energy is a major reason for the spread of tissue damage around the focused spot because it changes the direction of the incident
68
Nelson
beam. In human skin, collagen fibers are particularly important scattering structures. The degree of scatter is heavily dependent on the wavelength of the light and the composition of the tissue. Light scattering in human skin is greater and more random at shorter wavelengths. Light scattering at longer wavelengths is less and more forward directed. Finally, light might be transmitted through the tissue with only a minimal amount being absorbed. Since every tissue has reflective, scattering, and transmissive properties, understanding these tissue characteristics is an important aspect of knowing how to use the laser. 11.
THE PROCESS OF ABSORPTION
When photons enter the tissue, those that are not reflected, scattered, or transmitted are absorbed. Without absorption, there is no response. Absorption is the key to effective laser use (Fig. 2.7). Absorption refers to a process that occurs when energy supplied by electromagnetic radiation (e.g., light) is transferred to an absorbing molecule, M, so that a more energetic, excited-state species, M , is produced. This excitation can be depicted by the equation: M þ hn ! M
(2:6)
where hv represents the amount of energy absorbed. Within 1026 –1029 s following excitation, the energy is lost, most often as heat, and the species relaxes to its former state: M ! M þ heat
(2:7)
Relaxation may also result from decomposition of M to form a new species; such a process is called photochemical decomposition (see section on Photochemistry and Photodynamic Therapy). Alternatively, relaxation may involve fluorescent or phosphorescent re-emission of a photon (see section on Fluorescence). It is important to
Figure 2.7 Laser –tissue interactions.
Lasers and Laser –Tissue Interactions
69
note that the lifetime of M is so short that its concentration at any instant is ordinarily negligible. All molecules contain a unique energy level structure. In order to have light energy absorbed, the energy level structure of the absorbing molecules in the tissue must correspond to the energy of the incident radiation (light). These energy-absorbing molecules in human skin are generally referred to as chromophores. When light is absorbed by a chromophore, energy is transferred from the incoming photon to the chromophore in the skin that is to be altered or changed. Once this energy is absorbed, the energy has to go somewhere, and this is really the key to producing the changes seen in human skin after laser irradiation. Normally, we think of lasers as producing heat, and most laser dermatologic procedures initiate a local thermal event. Radiation, from high-energy sources such as X-rays and gamma rays, ionizes molecules in the tissue and results in relatively nondiscriminant tissue damage. The nonionizing wavelengths, which include visible light electromagnetic radiation, can cause electronic excitations in specific atoms or molecules in the skin which permit selective targeting of chromophores with specific wavelengths of light. Although not demonstrating the same degree of target specificity as visible energy, infrared energy excites vibrational modes in certain tissue molecules that result in a generalized heating of human skin.
12.
CHROMOPHORES IN HUMAN SKIN
Hemoglobin has significant light absorption in the violet, blue/green, and yellow portions of the spectrum (7,8). This absorption starts to decline in the red region. These absorption features permit the scattering and transmission of red light thus causing hemoglobin to appear red in color. In the case of laser treatment of cutaneous blood vessels, the wavelengths suitable for consideration are the hemoglobin Soret absorption band at 418 nm and the absorption bands at 542 and 577 –595 nm (Fig. 2.8). Despite the higher extinction coefficient of the Soret band, this wavelength can be rejected for clinical use because penetration of photons into the dermis in insufficient. However, if one takes advantage of the longer-wavelength hemoglobin absorption band at 577 – 595 nm, where tissue penetration is increased and melanin absorption is reduced, less heating of the epidermis should occur and more incident light energy is transmitted to the blood vessels. For these reasons, the pulsed dye laser (577 – 595 nm) has been the mainstay of treatment for multiple cutaneous vascular lesions. The yellow light is absorbed by hemoglobin in these lesions causing thermal damage and thrombosis of targeted vessels. Melanosomes are the fundamental sites for melanin synthesis and occur as organelles within melanocytes. Absorption is the dominant process by epidermal melanin. Although highest in the ultraviolet portion of the spectrum, melanin absorption is also significant in the visible and near-infrared wavelengths. For these reasons, Q-switched green (KTP), red (ruby, alexandrite), and near-infrared wavelengths have been utilized for the treatment of certain epidermal and dermal pigmented lesions. Water has no light energy absorption in the visible portion of the spectrum and very minimal absorption in the near-infrared portion. However, further out in the infrared (beyond 2 mm), water in the tissue has significant absorption. The Er:YAG and carbon dioxide lasers are currently the most frequently used surgical lasers. Since human skin contains water as a major constituent, the Er:YAG (2.94 mm) and carbon dioxide (10.6 mm) lasers producing infrared photons that are specifically absorbed by water can have a direct effect on the epidermis and dermis. If used properly, the
70
Figure 2.8
Nelson
Chromophores in human skin—absorption spectra of hemoglobin, melanin, and water.
Er:YAG and carbon dioxide lasers are clinically equivalent to dermabrasion because the laser gradually removes cell layer after cell layer through volatilization of water present in human skin. Photons emitted by the Nd:YAG laser (at a wavelength of 1.06 mm), on the other hand, are very poorly absorbed by hemoglobin, melanin, water, and other chromophores in human skin. Light penetration into skin is very deep (4 – 6 mm) resulting in a large volume of coagulated tissue—substantially larger than that created by either the Er:YAG or the carbon dioxide laser. Because of the extensive penetration of the Nd:YAG laser into skin, its use in the continuous mode is somewhat limited in cutaneous surgery. For example, the Nd:YAG laser cannot be used to ablate superficial lesions like the Er:YAG or carbon dioxide laser. Recently, however, Nd:YAG lasers pulsed in the millisecond domain have been used to target telangiectasia and reticular veins of the legs. These lasers take advantage of the small peak in the hemoglobin absorption curve, with relatively no competition from melanin or water. Wavelengths suitable for nonablative laser skin rejuvenation must have low melanin absorption, which favors the choice of longer wavelengths (i.e., near- and mid-infrared) over visible light (9). Therefore, most attempts at nonablative laser skin regeneration have used wavelengths with low (650 – 1100 nm) or intermediate tissue water absorption to deposit laser energy nonselectively in the upper (100 – 400 mm) dermis. Wavelengths from 1.3 to 1.8 mm meet this need, which currently limits the selection of light sources to the 1.32 and 1.44 mm Nd:YAG lasers, the 1.45 mm diode laser, and the 1.54 mm Er:glass laser. Because deposited heat is redistributed within the skin by heat diffusion, the ultimate depth of thermal injury is affected not only by the optical penetration of the selected wavelength but also by a multitude of other variables beyond the scope of this chapter.
Lasers and Laser –Tissue Interactions
71
In summary, selection of the correct laser for a particular clinical procedure requires an understanding of the absorptive as well as the reflective, scattering, and transmissive properties of the target tissue. 13.
HEAT
Given that one goal of laser therapy is the precise control of thermal energy, a thorough understanding of the sequelae of tissue heating is required. Ideally, from the clinical point of view, the physician should be able to confine the heating process to produce the desired result. Physicians experienced in laser therapy acquire the ability to discern these tissue changes visually so that the heating process can be stopped at the desired point. It is therefore important that physicians planning to use lasers take a basic course in laser theory and clinical management and complete a preceptorship with an experienced instructor who can help them develop the requisite skills. Figure 2.9 shows the effect of a rise in temperature in human skin during laser irradiation. As the tissue is heated and the temperature rises to between 378C and 608C, the skin starts to retract and conformational changes occur. At a temperature above 608C, there is protein denaturization and coagulation. From 908C to 1008C, drying and shrinkage of the skin occur. Above 1008C, the skin is carbonized and subsequently vaporized and ablated.
14.
ABLATION OF HUMAN SKIN
The Er:YAG and carbon dioxide lasers are currently the lasers of choice for human skin ablation. Since light is absorbed so intensely by water, penetration depths are only a few micrometers. Absorption of many photons in such a small volume of tissue produces a
Figure 2.9 Thermal interaction of laser irradiation with human skin.
72
Nelson
rapid rise in skin temperature. As energy is added, the temperature of water is raised to its boiling point. Internal vapor pressure builds up until a microexplosion occurs. The rapid expansion created by this excitation give rise to the actual ejection of microscopic tissue fragments at high velocities. Since most of the energy of the laser pulse goes into the thermal phase change associated with tissue vaporization, ablated fragments ejected from the skin surface carry most of the energy with them, leaving little energy in the form of heat to damage surrounding tissue. Because vaporization is such a rapid process, thermal damage to adjacent tissue, although varying with the duration of exposure, is usually limited to a zone of 100–200 mm (carbon dioxide) or less (Er:YAG) in human skin.
15.
SELECTIVE PHOTOTHERMOLYSIS
The laser has many inherent properties that contribute to its ability to effect a specific biological outcome. Most important, from a clinical point of view, are the properties of emitted wavelength and pulse duration. If the clinical objective is to cause selective destruction of a specific chromophore, the wavelength chosen should match the highest absorption of the targeted chromophore relative to other optically absorbing molecules. Given that one goal of treatment is the precise control of thermal energy, the pulse duration of laser irradiation is just as important as optical and tissue factors. One way to maximize the spatial confinement of heat is to use a laser with a pulse duration on the order of the thermal relaxation time (Tr) of the target chromophore (10). Tr is defined as the time required for the heat generated by the absorbed light energy within the target chromophore to cool to half of the original value immediately after the laser pulse. During a lengthy laser exposure, most of the heat produced diffuses away despite its origin in the target structure. The target does not become appreciably warmer than its surroundings because the absorbed energy is invested almost uniformly in heating of the tissue during exposure. As a result, longer pulse durations offer a more generalized heating and, therefore, less spatial selectivity resulting in nonspecific thermal damage to adjacent structures regardless of how carefully one has chosen a wavelength. However, if the laser pulse is suitably brief, its energy is invested in the target chromophore before much heat is lost by thermal diffusion out of the exposure field. A transient maximum temperature differential between the target and adjacent structures is then achieved. Shorter pulse durations confine the laser energy to progressively smaller targets with more spatial selectivity. The transition from specific to nonspecific thermal damage occurs as the laser exposure equals and then exceeds Tr . Therefore, selective target damage depends on delivering a pulse of light of shorter duration than Tr , which can be estimated because the latter is directly proportional to the square of the diameter of the target and inversely proportional to the thermal diffusivity of the tissue (Table 2.1). A laser emitting at a Table 2.1 Relationship of Target Chromophore Diameters and Their Thermal Relaxation Times (Tr) Target Microvessel Blood vessel Tattoo pigment Melanosome Melanocyte
Diameter (mm)
Tr
50 150 0.5 – 100 0.5– 1.0 7
1.4 ms 12.8 ms 20 ns – 3 ms 20– 40 ns 1 ms
Lasers and Laser –Tissue Interactions
73
selectively absorbed wavelength with a pulse duration less than Tr can be expected to cause highly selective target damage (Fig. 2.10). This process, termed selective photothermolysis, was introduced in 1983 as a means of achieving target chromophore destruction by careful selection of wavelength and pulse duration.
16.
SELECTIVE PHOTOTHERMOLYSIS OF CUTANEOUS BLOOD VESSELS
The pulsed dye lasers at 577 – 595 nm, wavelengths well absorbed by the targeted hemoglobin molecule relative to other optically absorbing structures, cause selective thermal damage to dermal blood vessels while minimizing epidermal melanin absorption. Furthermore, because the Tr for cutaneous blood vessels 50 –150 mm in diameter is between 1.4 and 12.8 ms, the 0.45– 50 ms pulse duration produced by these lasers matches the Tr for dermal blood vessels, thus confining the laser energy to the targeted vessel before much heat is lost by thermal diffusion out of the exposure field (11). Patients with a wide range of vascular abnormalities, such as port wine stains, hemangiomas, telangiectasias, angiomas, venous lakes, poikiloderma of Civatte, and angiokeratomas, have benefited from pulsed dye laser therapy (12). The green light (532 nm) produced by the frequency-doubled Nd:YAG laser (KTP laser) is also preferentially absorbed by hemoglobin. Although melanin absorption is higher and light penetration into human skin is less at this shorter wavelength, the KTP laser has been approved by the FDA for many of the same procedures as the pulsed dye laser.
Figure 2.10 Selective photothermolysis. With relatively long laser exposure times, selective target damage is followed by thermal diffusion and damage to adjacent structures. Selective thermal damage can be confined to the tissue target by choosing a pulse duration that is shorter than Tr .
74
17.
Nelson
SELECTIVE PHOTOTHERMOLYSIS OF TATTOOS
Amorphous carbon, graphite, India ink, and organometallic dyes, typically found in dark blue-black amateur and professional tattoos, have a broad absorption in the visible and near-infrared portions of the spectrum. At visible wavelengths longer than 600 nm, hemoglobin and melanin light absorption is minimized and tattoo dyes can be targeted selectively (13). The pigment granules characteristically found in tattoos have diameters of 0.5– 100 mm, which correspond to Tr of 20 ns to 3 ms. With the development of the Q-switched ruby (694 nm), alexandrite (755 nm), and Nd:YAG (1.06 mm) lasers, tattoo removal without scarring can be achieved. The frequency-doubled, Q-switched Nd:YAG laser (KTP laser) emits at a wavelength of 532 nm, which provides improved removal of red dye.
18.
SELECTIVE PHOTOTHERMOLYSIS OF PIGMENTED LESIONS
Although highest in the ultraviolet portion of the spectrum, melanin absorption is also significant in the visible and near-infrared wavelengths. The diameters of individual melanosomes (0.5 –1.0 mm) and melanocytes (7 mm) correspond to Tr of 20 –1000 ns. Therefore, Q-switched green, red, and near-infrared wavelengths have been utilized for this indication. Studies have shown that the effects of Q-switched lasers are melanosome dependent, and vacuolization of pigment-laden cells has been seen immediately after laser irradiation on examination by light and electron microscopy (14). Disruption of melanosomes at pulse widths less than Tr presumably resulted from a shock wave or cavitation induced by thermal expansion or by the temperature gradient generated across the pigmented cells. Q-switched lasers have been used successfully to treat a wide variety of pigmented lesions including lentigines, ephelides, and nevus of Ota (12).
19.
SELECTIVE PHOTOTHERMOLYSIS AND LASER ASSISTED HAIR REMOVAL
The human hair follicle is a complex structure derived from both epidermal and dermal components. The target chromophores, primarily melanin-rich hair shafts, are located deep in human skin (bulge around 1.5 mm and bulb at 2 –7 mm). At this depth, only red and near-infrared wavelengths are useful (690 –900 nm). The follicular structure responsible for regeneration has not been conclusively identified and, therefore, current systems target the entire follicle. As a result, long pulse widths on the order of milliseconds and high fluences capable of heating large volumes of tissue are required (15). Millisecond-domain ruby, alexandrite, diode, and Nd:YAG lasers using high light doses can produce selective injury to human hair follicles resulting in prolonged growth delay and, in some cases, permanent hair loss after a single treatment.
20.
SKIN COOLING
The clinical objective of laser therapy is to maximize thermal damage to target chromophores while minimizing injury to overlying skin. Unfortunately, for many skin types, the threshold light dosage for epidermal injury due to melanin absorption can be very close to
Lasers and Laser –Tissue Interactions
75
that for permanent removal of target chromophores. A valuable method to overcome this problem is to cool selectively the superficial layers of the skin during laser therapy which prevents thermal injury despite some melanin absorption. Rapid and spatially selective epidermal cooling can be achieved by active skin cooling (16). The first and intuitively simple objective of skin cooling is to decrease epidermal damage. So long as the epidermis is prevented from reaching a temperature in response to laser exposure that is above its threshold for denaturation (60 – 658C), the epidermis and upper dermis can be preserved. The second objective is to permit the use of higher light dosages for treatment of laser resistant lesions. The third objective is the treatment of patients with all skin types. For patients with darker skin types (types IV – VI), it is not possible to treat lesions without cooling due to epidermal damage with a sufficiently high light dosage. The fourth objective is reduction of pain and posttreatment swelling or edema. Several different methods have been developed for cooling human skin in conjunction with laser therapy. All methods utilize a precooled medium brought in contact with the skin surface. Deeper skin layers are cooled by heat diffusion toward the cooled surface with subsequent transfer to the cooling medium. The rate of heat transfer across the interface between the skin and the cooling medium depends primarily on the temperature difference between the two adjacent materials, as well as other parameters, specific to each cooling method. Therefore, cooling efficiency using any method can be adequately characterized by the proportionality constant, termed heat transfer coefficient (h), regardless of the physical mechanisms involved. Contact cooling (CC) of human skin is achieved by heat conduction into an adjacent precooled solid body, usually an optically transparent plate, kept at constant temperature (210 to 48C) by a cooling system. Laser exposure is delivered through the plate, which is pressed against the patient’s skin. CC can be very efficient especially when a highly conductive material, such as sapphire, is used for the cooling plate. However, in practice, the thermal resistance at the interface of the intervening layer between the skin and the plate inevitably impairs the rate of heat extraction with CC. Air, bubbles, hair, or other substances may impede the direct contact between the skin surface and the cooling plate. Human skin can also be cooled by air precooled (AC) and blown onto or across the surface at temperatures as low as 2308C. Despite the low air temperature used, AC is characterized by the lowest cooling rate since the heat transfer coefficient for forced convection in gas is very low. As a result, long cooling times (on the order of several seconds) are necessary to induce significant temperature reductions in the basal layer. Therefore, the final outcome is inevitably general (“bulk”) cooling of the entire skin with minimal spatial selectivity. Rapid and spatially selective epidermal cooling can be achieved by active cooling using a cryogen spray (CSC) or dynamic cooling (17). Tetrafluoroethane (TFE) is the only cryogenic compound currently FDA approved for use in dermatologic laser surgery. TFE is a nonflammable, nontoxic, environmentally compatible freon substitute which does not deplete atmospheric ozone or contribute to global warming (18). CSC’s main cooling mechanism is rapid evaporation of cryogen, which extracts the necessary latent heat from the skin. Liquid cryogen is “atomized” into a fine spray and directed toward the skin surface. During flight, spray droplets cool rapidly due to cryogen evaporation. Therefore, the droplet temperature when impinging on the skin surface is typically between 2408C and 2608C. As a result, CSC provides a rapid, large, and spatially selective epidermal temperature reduction. A layer of liquid cryogen can remain on the skin surface after spurt termination. Consequently, cooling continues for a much longer time than the actual user-specified spurt duration. The presence of liquid
76
Nelson
cryogen on the skin surface after spurt termination constitutes de facto skin cooling during and after the laser exposure. Cryogen spurt duration and delay between spurt termination and the laser pulse can be controlled electronically, which results in predictable cooling with reproducible spatial selectivity. The development of skin cooling methodology has definite advantages for patients receiving laser therapy: (1) cooling permits safe and effective laser treatment by increasing the threshold for epidermal damage, (2) cooling permits the use of higher-incident light doses for treatment of resistant lesions, (3) cooling permits the treatment of patients with all skin types, and (4) for all patients, particularly children, pain and distress associated with laser therapy are significantly reduced.
21.
PHOTOCHEMISTRY AND PHOTODYNAMIC THERAPY
Photon energy may also be dissipated by photochemistry. The basic concept of photochemistry is that certain molecules (natural or applied) can function as photosensitizers. The presence of these photosensitizers in certain cells makes them vulnerable to light at wavelengths absorbed by the chromophore. The excited photosensitizer subsequently reacts (transfers its energy) with a molecular substrate, such as oxygen, to produce highly reactive singlet oxygen which causes irreversible oxidation of some essential cellular component. All of this occurs without the generation of heat. Although photodynamic therapy (PDT), using porphyrin derivatives and visible light, has primarily focused on the treatment of skin cancer, PDT is also being used for the clinical management of selected nonmalignant, dermatological indications, such as actinic keratosis, psoriasis, and PWS (19).
22.
FLUORESCENCE
Photon energy may be dissipated as the re-emission of light. If this happens within 1026 s after absorption, it is called fluorescence. The fluorescent photon is emitted as the excited atom returns to the ground state. However, because some energy is lost by collisions with other atoms in the excited state, the energy of the fluorescent photon is lower (and therefore the wavelength is longer) than that of the absorbed photon. It appears that many of the photosensitizing dyes used to induce photochemistry are also fluorescent. If in the case of porphyrins, 400 nm blue-violet light from a krypton laser is used with an appropriate filter and image intensifier, fluorescence can be observed (19). Clinical trials are now in progress in which the effectiveness of fluorescence for detection and localization of certain premalignant and malignant skin lesions is being evaluated.
23.
CONCLUSION
Since the laser was first developed in 1960, it has found many uses in dermatology. Moreover, lasers are now the treatment of choice for several clinical entities for which no reliable or effective modality was previously available. Research into increasing our understanding of the optical characteristics of skin has made it possible to concentrate not on the effects of any particular laser system but on the basic biological and physical principles of laser – tissue interaction. Modern technology allows us to manipulate the physical characteristics of lasers and design them for specific therapeutic purposes.
Lasers and Laser –Tissue Interactions
77
REFERENCES 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11.
12.
13. 14.
15. 16. 17.
18. 19.
Boulnois JL. Photophysical processes in recent medical laser developments. A review. Lasers Med Sci 1986; 1:47– 66. Elion HA. Laser Systems and Applications. New York: Pergamon Press, 1967. Hitz CB. Understanding Laser Technology. Tulsa, OK: PennWell Publishing, 1985. O’Shea DC, Callen WR, Rhodes WT. Introduction to Lasers and Their Applications. Menlo Park, CA: Addison-Wesley Publishing, 1978. Siegman AE. Lasers. Mill Valley, CA: University Science Books, 1986. Sliney D, Wolbarsht M. Safety with Laser and Other Optical Sources. New York: Plenum Press, 1985. Anderson RR, Parrish JA. Optical properties of skin. In: Regan JD, Parrish JA, eds. The Science of Photomedicine. New York: Plenum Press, 1982:147 – 194. Anderson RR, Parrish JA. The optics of human skin. J Invest Dermatol 1981; 77:13– 19. Kelly KM, Majaron B, Nelson JS. Nonablative laser and light rejuvenation. Arch Facial Plast Surg 2001; 3:230– 235. Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. Science 1983; 220:524 – 529. Dierickx CC, Casparian JM, Venugopalan V, Farinelli WA, Anderson RR. Thermal relaxation of port-wine stain vessels probed in vivo: the need for 1– 10 millisecond laser pulse treatment. J Invest Dermatol 1995; 105:709 – 714. Kelly KM, Nelson JS. Critical review of lasers in dermatology. Critical reviews of optical science and technology. In: Ryan TP, ed. Matching the Energy Source to the Clinical Need. Vol. CR75. Bellingham, WA: SPIE Optical Engineering Press, 2000:3 – 23. Cesario-Kelly KM, Nelson JS. Q-switched laser treatment of tattoos. Lasers Med Sci 1997; 12:89 – 98. Anderson RR, Margolis RJ, Watenabe S, Flotte T, Hruza GJ, Dover JS. Selective photothermolysis of cutaneous pigmentation by Q-switched Nd:YAG laser pulses at 1064, 532, and 355 nm. J Invest Dermatol 1989; 93:28– 32. Ross EV, Ladin Z, Kriendel M, Dierickx CC. Theoretical considerations in laser hair removal. Dermatol Clin 1999; 17:333 – 355. Nelson JS, Majaron B, Kelly KM. Active skin cooling in conjunction with laser dermatologic surgery. Semin Cutan Med Surg 2000; 19:253– 266. Nelson JS, Milner TE, Anvari B, Tanenbaum BS, Kimel S, Svaasand LO, Jacques SL. Dynamic epidermal cooling during pulsed laser treatment of port-wine stain. A new methodology with preliminary clinical evaluation. Arch Dermatol 1995; 131:695 – 700. Nelson JS, Kimel S. Safety of cryogen spray cooling during pulsed laser treatment of selected dermatoses. Lasers Surg Med 2000; 26:2 – 3. Nelson JS, McCullough JL, Berns MW. Principles and applications of photodynamic therapy in dermatology. In: Arndt KA, Dover JS, Olbricht SM, eds. Lasers in Cutaneous and Aesthetic Surgery. Philadelphia, PA: Lippincott-Raven Publishers, 1997:349 – 382.
3 Laser Safety Measures Christie Travelute Ammirati Penn State University College of Medicine, Hershey, Pennsylvania, USA
George J. Hruza St. Louis University School of Medicine, St. Louis, Missouri, USA
1. Introduction 2. Laser Safety Organizations and Regulations 2.1. American National Standards Institute 2.2. The Center for Devices and Radiological Health 2.3. Occupational Safety and Health Administration 2.4. The National Institute for Occupational Safety and Health 3. Laser Hazard Classification 4. Eye Hazards 4.1. Eye Anatomy 4.2. Electromagnetic Spectrum 4.3. Retinal Injury 4.4. Corneal Injury 4.5. Lenticular Injury 5. Eye Protection 5.1. Patient Protection 5.2. Medical Surveillance 6. Skin Hazards 7. Teeth Hazards 8. Fire Hazards 8.1. Fire Prevention 8.2. Fire Containment 9. Electrical and Mechanical Hazards 9.1. Controlled Access 10. Chemical Hazards 10.1. Chemical Protection 11. Accoustic Hazards
80 80 80 82 82 82 82 83 84 85 87 87 88 88 90 90 91 91 91 91 92 93 93 95 95 95 79
80
Ammirati and Hruza
12. Laser Plume Hazards 12.1. Organic Compounds 12.2. Particulate Debris 12.3. Pathogenicity 12.4. Protection and Evacuation 12.5. Smoke Evacuators 12.6. Laser Masks References
1.
95 95 96 96 97 97 98 98
INTRODUCTION
Lasers produce intense monochromatic, collimated, and coherent light. These properties, which allow for the highly selective destruction of target chromophores, also carry significant safety concerns. There are an ever-increasing number of cutaneous lasers available today and it can prove challenging to remain current with the unique safety issues of each system. Overall, surgical lasers have a good safety record but their potential hazards can cause significant injury and even death (1). This chapter provides an overview of laser safety issues as they apply to the patient, laser surgeon, and staff. It augments, but cannot hope to replace, formal instruction.
2.
LASER SAFETY ORGANIZATIONS AND REGULATIONS
There are several organizations that concern themselves with laser safety. In the USA these organizations include the American National Standards Institute (ANSI), the Center for Devices and Radiological Health (CDRH), the Occupational Health and Safety Administration (OSHA), and the National Institute for Occupational Safety and Health (NIOSH). Many of these organizations publish laser safety manuals that are available free of charge (see Table 3.1).
2.1.
American National Standards Institute
The ANSI is a consensus group of industry, university, and government laser experts who developed the ANSI-Z136 series. This set of standards provides recommendations for the safe use of lasers and laser systems. There is no inherent requirement for adherence to their guidelines and compliance is voluntary unless mandated by an employer or organization. The American National Standard for Safe Use of Lasers (ANSI-Z136.1) and the American National Standard for Safe Use of Lasers in Health Care Facilities (ANSI-Z136.3) are the expected standards of care in the USA and are often cited in litigation. OSHA and the Joint Commission for Accreditation of Healthcare Organizations (JCAHO) reference these standards when evaluating laser-related occupational safety issues. The ANSI-Z136 series provides information on laser classification, safety calculations, and control measures. These standards of care apply to all laser operators, regardless of the clinical application or practice setting. Specifically, private office-based laser centers are expected to have training policies and safety protocols similar to those used in hospitals.
Laser Safety Measures
81
Table 3.1 Laser Safety Resources Laser safety source University of Waterloo “Laser Manual” OSHA Technical Manual Section III: Chapter 6 “Laser Hazards” OSHA PUB 8-1.7 “Guidelines for Laser Safety and Hazard Assessment” Berkely Lab Health and Safety Manual Chapter 16 “Lasers” NIOSH Hazard Control “Control of Smoke from Laser/Electrosurgical Procedures” LaserFX “Basic Laser Safety” Rockwell Laser Institute “Statistical Data for Laser Accidents” Laser Institute of America “Laser Generated Air Contaminants (LGAC)” Laser Institute of America “Laser Safety Information Bulletin” American Society for Lasers in Medicine and Surgery “Smoking Guns” Lawrence Livermore National Laboratory “Environment, Safety and Health Manual” Center for Devices and Radiological Health “21CFR 1040.10 and 1040.11” University of Illinois “UIUC Laser Safety Tutorial” Navy Laser Safety Page U.S. Army Laser/Optical Radiation Program Oklahoma State University Optical Radiation Branch (AFRL/HEDO) Air Force Canadian Centre for Occupational Health & Safety (CCOHS) “Lasers in Health Care” University of Pennsylvania Laser Safety
Website www.adm.uwaterloo.ca/infohs/lasermanual/documents www.osha-slc.gov/dts/osta/otm_iii/otm_iii_6.html
www.osha-slc.gov/OshDoc/Directive_data/PUB_8-1_7.html
ehssun.lbl.gov/ehsdiv/pub3000/CH16.html
www.cdc.gov/niosh/hc11.html
www.laserfx.com/sci4.html www.iac.net/rli/accidents/stat_dat.html
www.rli.com/lgac.html
www.laserinstitute.org/safety_bulletin
www.aslms.org/general-smokegunsl.html
www.llnl.gov/es_and_h/hsm/chapter_28
www.fda.gov/cdrh/index.html
phantom.ehs.uiuc.edu/rad/laser/laser.html www.nswc.navy.mil/safety/laser chppm-www.apgea.army.mil/laser/laser.html www.pp.okstate.edu/ehs/links/laser.html www.brooks.af.mil/AFRL/HED/HEDO www.ccohs.ca/oshanswers/phys_agents/lasers.html
www.oehs.upenn.edu/laser/laser_manual.html
Note: There are many laser safety resources available on the Internet. Many have safety manuals that can be downloaded free of charge.
82
2.2.
Ammirati and Hruza
The Center for Devices and Radiological Health
The CDRH U.S. Federal Laser Product Performance Standard (FLPPS) regulates the manufacture of commercial lasers. Under guidelines 21 CFR Part 1040.10 and 1040.11, the manufacturer is required by federal law to classify and appropriately label a laser with its hazard class. These regulations are designed to insure product safety and do not pertain to or regulate laser use once they have been purchased. 2.3.
Occupational Safety and Health Administration
OSHA is a federal regulatory agency concerned with safety and health conditions in the workplace. While it does not have a comprehensive standard for medical lasers, it has issued several regulations that pertain to laser safety. The Eye and Face Protection Standard (29CFR 1926.102) and Personal Protective Equipment Standard (29CFR 1910.132-138) mandate that employees who are exposed to laser beams by occupation or assignment be provided with appropriate laser-specific eye protection. The BloodBorne Pathogen Standard (29CFR 1910.1030) addresses employee protection from potentially infectious exposures and has been extrapolated to include laser-generated debris (2). The OSHA Technical Manual and, Guidelines for Laser Safety and Hazard Assessment are available free of charge from OSHA (see Table 3.1). These manuals provide an excellent overview of laser safety and are highly recommended. 2.4.
The National Institute for Occupational Safety and Health
NIOSH is a federal agency responsible for conducting research and making recommendations for preventing work-related illness and injury. In 1996, NIOSH published Control of Smoke from Laser/Electric Surgical Procedures (HC11). This hazard control discusses the rationale for controlling the smoke from laser or electrosurgical procedures and makes recommendations for optimal smoke evacuation. 3.
LASER HAZARD CLASSIFICATION
In general, lasers are classified according to their relative hazards. The basis for this classification scheme is the ability of the laser beam to cause unintended injury to the eye or skin (2). The ANSI classification, which is the most commonly cited standard, stratifies risk from I to IV (Table 3.2). Class I lasers are very low-power lasers that do not emit hazardous radiation (typically ,0.4 mW) and are considered to be safe for continued viewing. Few lasers function at this very low level and most Class I lasers are in this category by virtue of an enclosure that prevents access to their radiation (embedded). An example of an embedded laser would be a laser printer. Class I lasers are exempt from control measures or warning labels. The Class IIa subclassification was developed for bar-code scanners, which emit visible light and are not intended for viewing. They have an upper power limit of 4 mW and are considered safe unless viewed directly for .1000 s. Class IIa lasers are required to carry the label, “Avoid Long-Term Viewing of Direct Laser Radiation” but are exempt from other hazard controls. Class II lasers emit ,1 mW of visible (400–760 nm) light. The human eye will blink and look away within 250 ms when exposed to a bright visible light. This is known as the blink reflex or aversion response and it is usually sufficient to protect the eye from Class II laser injury (4). With intentionally prolonged viewing (.250 ms), these lasers are capable of damaging the eye (5). Alignment beams or low-power helium–neon laser pointers are
Laser Safety Measures
83
Table 3.2 ANSI Classification of Risk Class
Energy (mW)
Exposure limits
I IIa II
,0.0004 ,0.004 ,1
IIIa
1 –5
Hazardous in ,0.25 s when viewed with collecting optics
IIIb
5– 500
IV
.500
Direct beam or specular reflection hazardous in ,0.25 s Direct beam, specular or diffuse reflection hazardous in ,0.25 s
None Safe for ,1000 s Safe for ,0.25 s
Comments Safe for viewing Not intended for direct viewing Do not purposely stare into the beam Do not view through collecting optics without protective eyewear Do not view direct beam or specular reflection without protective eyewear Do not view direct beam, specular or diffuse reflection without protective eyewear; skin and fire hazard as well
Source: Refs. (2,3).
examples of Class II lasers. They require a “CAUTION” warning with the phrase, “LASER RADIATION—DO NOT STARE INTO BEAM.” Class III lasers, which include ultraviolet (UV), visible, and infrared lasers are divided into subclasses IIIa and IIIb. Class IIIa lasers, such as diode aiming beams, emit 1–5 mW of energy (6). These lasers are safe for brief viewing (,250 ms) but can be hazardous when viewed through collecting optics (i.e., microscope or endoscope). All Class IIIa lasers require a “CAUTION” warning with the phrase, “LASER RADIATION—DO NOT STARE INTO BEAM OR VIEW DIRECTLY WITH OPTICAL INSTRUMENTS.” (Note: Prescription eyewear is not considered to be a collecting optic.) Class IIIb lasers, such as retinal photocoagulators, produce 5– 500 mW and exposure to their direct or reflected beam can cause eye and skin damage (7). Class IIIb lasers are not considered to be fire hazards but they are subjected to all other control measures outlined in this chapter. They require a “DANGER” warning with the phrase, “LASER RADIATION—AVOID DIRECT EXPOSURE TO THE BEAM.” Almost all medical lasers are designated as Class IV and have power levels greater than 500 mW (continuous wave) or generate more than 10 J/cm2 in 250 ms (pulsed system). Even brief exposures to their direct, reflected, or scattered emissions pose eye, skin, and fire hazards. These lasers require a “DANGER” warning with the phrase, “LASER RADIATION—AVOID EYE OR SKIN EXPOSURE TO DIRECT OR SCATTERED RADIATION.”
4.
EYE HAZARDS . . . I was not wearing protective goggles at the time, although they were available in the laboratory. When the beam struck my eye, I heard a distinct popping sound, caused by a laser-induced explosion at the back of my eyeball. My vision was obscured almost immediately by streams of blood floating in the vitreous humor. It was like viewing the world through a round fish bowl full of glycerol into which a quart of blood and a handful of black pepper have been partially mixed. Decker, CD. Laser accident victim’s view. Laser Focus August 1977.
84
Ammirati and Hruza
The above account was written by a researcher who suffered permanent eye damage from a 1064 nm Nd:YAG laser beam. The eye is an intricate and complex organ, comprising several structures, each with their own absorption spectrum. As with all laser – tissue interactions, photon energy must be absorbed to have an effect (Grothus –Draper Law) and the ocular structure at risk will vary with the wavelength in use (8). To understand how this selective injury can occur, eye anatomy and basic principles of optical physics should be reviewed.
4.1.
Eye Anatomy
The cornea is the main focusing element for vision and is protected from the environment by its tear film and numerous sensory receptors (9) (Fig. 3.1). The cellular turnover of the outer corneal layers is approximately 48 h and allows most of the superficial injury to heal without residual damage. Permanent corneal scarring will occur if the damage extends to the deeper layers. The lens performs fine focusing of images onto the retina. Normally, the lens is transparent but changes in its proteins can produce a cataract. The space between the cornea and lens is filled with the aqueous humor and the interior of the eyeball is filled with the gelatinous vitreous humor. The cornea and lens, along with the aqueous and vitreous humors, comprise the anterior segment of the eyeball. The retina is divided into two major components. The pigmented monolayer is called the retinal pigmented epithelium and the multilayered neural component is called the neural retina. The rods and cones, which function as photoreceptors, are located adjacent to the neural retina. Rods are mainly concerned with low light vision and are found predominantly in the periphery of the retina. Cones are responsible for color perception and visual acuity. They are concentrated centrally within the macula. The fovea is in the center of the macula and is responsible for fine focusing activities such as
Figure 3.1 Anatomic structures of the human eye.
Laser Safety Measures
85
reading. The retina, which is rich in photoreceptors, does not contain pain receptors. The choroid is a vascular layer that is separated from the retina by Bruch’s membrane.
4.2.
Electromagnetic Spectrum
The divisions between the different portions of the electromagnetic spectrum (EMS) are somewhat arbitrary and the regions tend to overlap (10) (Fig. 3.2). The EMS includes radiation that extends from cosmic rays to radiowaves. The UV spectrum includes radiation from 100 to 400 nm and is divided into four subdivisions: vacuum UV (100 –200 nm), UV-C (200 –290 nm), UV-B (290 – 315 nm), and UV-A (315 –400 nm). The visible
Figure 3.2 Diagrammatic representation of the electromagnetic spectrum and the specific sites of laser-induced ocular damage. The optical spectra used for cutaneous lasers are expanded to present more detail. [Adapted from Refs. (8,10,11,13– 15).]
86
Ammirati and Hruza
spectrum is often referred to as visible light and extends from 400 to 760 nm. The infrared (IR) spectrum spans from 760 to 106 nm and has three subdivisions: near-IR (760 – 1400 nm), mid-IR (1400 – 3000 nm), and far-IR (3000 –106 nm). The term specular describes mirror-like reflections, which can reflect close to 100% of incident light (11). Specular reflection by a flat surface will not change a fixed beam’s diameter, only its direction (Fig. 3.3). Convex surfaces will cause beam divergence and concave surfaces will make the beam converge. Diffuse reflections result when surface irregularities scatter light in all directions. Whether the reflection is specular or diffuse will depend on the wavelength of light that strikes the surface (12). A given surface, which will diffuse visible light, may produce specular reflections when struck by longer IR wavelengths. Although oversimplified, wavelengths in the UV, mid- and far-IR regions are primarily absorbed by the anterior segment while the posterior segment absorbs the majority of visible and near-IR wavelengths. There are two transition zones in which both segments of the eye may be damaged. These zones are found at the transition from UV to visible light and where near-IR light becomes mid-IR (2). An example would be the Nd:YAG laser at 1340 nm, which can simultaneously damage the cornea, lens, and retina (13).
Figure 3.3 Diagrammatic representation of reflections by various specular and anodized surfaces. Convex specular surfaces cause beam convergence. Concave specular surfaces cause beam divergence. Flat specular surfaces change a fixed beam’s direction but not its diameter. Anodized, brushed or matte surfaces cause beam diffusion. [Adapted from Refs. (11,12,16).]
Laser Safety Measures
4.3.
87
Retinal Injury
Light of 400– 1400 nm wavelength poses the most serious risk to the retina and is known as the retinal hazard zone (8). For Class IV lasers, the blink reflex is not protective, as by the time it can engage, the damage has already occurred. The human eye can focus collimated laser light down to a 10– 20 mm spot (11). The law of the conservation of energy applies to this convergence and the energy density will increase geometrically as the spot diameter decreases. Thus, normal focusing by the eye results in a 100,000-fold increase in energy fluence. This can be likened to a magnifying lens focusing sunlight onto paper and causing it to burn. The eye focuses and intensifies the laser beam in a similar fashion onto the retina. Visible and near-IR lasers can produce retinal injury via thermal and photoacoustic mechanisms (8). Thermal injury may remain confined to the dimensions of the laser spot or if the energy is excessive, heat may extend the damage peripherally. Q-switched lasers produce powerful nanosecond pulses that create shock waves (photoacoustic effects) within the retina. This type of mechanical damage forcibly expels burned debris into the vitreous and due to its global effect on the retina often produces more destruction than thermal damage alone (17,18). The location and extent of the damage within the retina determines the degree of perceived visual loss. A small lesion, at the periphery of the fundus, may go unnoticed while damage to even the smallest portion of the fovea will produce a decrease in visual acuity and color perception. Since retinal tissue does not regenerate, any damage will be permanent. Unprotected eye exposure to visible (400 – 760 nm) laser light produces an intense flash of colored light followed by an after-image. Exposure to near-IR (760 –1400 nm) laser light may not be initially apparent because wavelengths much longer than 760 nm are invisible to the human eye (14). Since there are no pain receptors in the retina and the beam is invisible, accidental exposure to a near-IR beam may go unnoticed until the damage is severe. By far, the most common laser associated with retinal injury is the 1064 nm Nd:YAG laser (19). Symptoms from Nd:YAG laser injury can range from a headache to the audible “pop” and appearance of “floaters” as described by Decker (20). Treatment for laser-induced retinal injury is largely anecdotal but the majority of the literature supports observation or the use of corticosteroids (21,22). Apparently, as long as the fovea is not damaged, the potential for spontaneous recovery of vision is favorable (23,24).
4.4.
Corneal Injury
The cornea is susceptible to damage from radiation within the UV spectrum and above 1400 nm (13,15). As with all laser – tissue interactions, the extent of injury will depend on the wavelength, energy, and duration of exposure. Since amplification by the lens is not involved, injury thresholds for the cornea are significantly higher than those that cause retinal injury (11). Corneal injury from wavelengths beyond 2800 nm (i.e., 2940 nm Er:YAG and 10,600 nm CO2 lasers) is usually confined to the superficial layers, which are capable of regeneration (25). While superficial corneal burns can be intensely painful, they usually resolve in 2–3 days without sequelae. Both lasers are capable, with sufficient energy, of producing deeper injury with scarring and corneal opacification (25). Treatment of superficial corneal injury consists of topical antibiotics and an eye patch. There is no effective medical treatment for deeper injury and corneal transplantation may be the only hope for restoring vision. Surgical preparations used before laser surgery can also injure the cornea. Chlorhexidine, apart from being flammable, can cause severe keratitis with permanent opacification
88
Ammirati and Hruza
if allowed to come in contact with the cornea (26,27). Regardless of the treatment location, chlorhexidine should not be used before laser surgery since it could be potentially aerosolized in the laser plume. This vapor could injure the eyes of the patient, laser operator, or assistant if adequate laser smoke evacuation is not in use. 4.5.
Lenticular Injury
The human lens strongly absorbs UV-A and to a lesser extent visible and near-IR (760 –1400 nm) light (13,15). Visible and near-IR light is thought to damage the lens by conductive heating of the iris. If the energy is sufficient, acute exposure can produce an immediate burn. More commonly, the exposure is chronic and it can take years for the cataract to become evident. 5.
EYE PROTECTION
If there is any possibility of viewing a Class IIIb or Class IV laser beam, appropriate eye protection must be provided for all personnel and patients within the laser control area. OSHA’s Eye and Face Protection Standard [29CFR 1926.102 (b)(2)] addresses the safety of employees who work with lasers. An employer’s obligation to provide and pay for personal protective equipment is outlined in OSHA’s Personal Protective Equipment Standard (29CFR 1910.132 –138). To better understand eye protection requirements, the maximum permissible exposure (MPE) and the nominal hazard zone (NHZ) should be defined (2). MPE is the level of laser radiation to which a person may be exposed without damage to the eye or skin. The MPE will vary with laser wavelength, duration of exposure and pulse repetition and is expressed in joules per square centimeter or watts per square centimeter. ANSI Z-136.1 tables A3(a) and (b) list the MPE for specific wavelengths. Exposure to energy above these limits can result in tissue damage. The NHZ is the distance from the laser at which the level of direct, reflected, or scattered radiation exceeds the MPE. As such, it defines the space in which control measures are required. The NHZ is a function of the laser settings in use such as spot size, energy, and pulse duration. These parameters are often changed during a procedure and continual calculation of the NHZ would be unrealistic. To simplify this situation, the NHZ for Class IV lasers is defined as the entire surgery room. Laser protective eyewear (LPE) provides the primary means to guard against ocular injury and must be worn whenever the laser is enabled. To be effective, the LPE must be wavelength specific and have sufficient optical density (OD) for the laser in use. OD is a logarithmic function that defines the ability of a protective lens to absorb a specific wavelength: OD ¼ log10
incident light (in J=cm2 or W=cm2 ) transmitted light (in J=cm2 or W=cm2 )
For example, an OD of 4 allows 1/104 of the laser energy to be transmitted. Cutaneous lasers range from 308 to 10,600 nm and there is no single lens filter that will provide protection throughout this range of wavelengths without being opaque. A higher OD does not always mean improved safety (28). Lenses with higher OD values are often dark in color, which can limit color discrimination and visualization of the treatment area (29). Clearly, there must be a balance between maximal eye protection and visibility because compliance will be low if eyewear is difficult to see through.
Laser Safety Measures
89
There are a variety of reflective and absorbent optical filters available. A reflective filter allows the transmission of as much of the remaining visible spectrum as possible but may create potentially hazardous reflections. Other disadvantages of glass reflective filters are that they are heavy and if the coating is scratched, radiation may reach the eye. Absorbent filters molecularly convert, rather than reflect, laser energy. They can be made from polymeric materials, which weigh less, are easily molded into comfortable shapes, and are not affected by surface scratches (30). Their disadvantage is that they are easily cracked and can melt with sufficient heat. Any damage to the optical filter, be it reflective or absorptive, can lower the OD value in an unpredictable manner (31). Therefore, LPE should be handled carefully and examined prior to each use for cracks, scratches, or loose-fitting lenses. Do not rely on the color of the lens or style of the LPE to identify the level of protection, as this can be misleading. Different types of LPE often look alike and it is important to check the wavelength and OD prior to relying on them for protection. Some laser facilities have more than one laser in each room. In that case, color coded tape can be applied to the laser handpiece and matching LPE to minimize confusion. There are several styles of LPE available. Goggles can be worn over prescription glasses but must fit snugly if they are to be effective. The disadvantages of this style are that they may be cumbersome and can produce a tunnel vision effect. Spectacles resemble eyeglasses with side shields (Fig. 3.4). Wraps consist of a single lens, which is usually made from lightweight plastic and wraps across the eyes from temple to temple. While it is true that optical glass will filter wavelengths below 300 nm and above 2700 nm, prescription eyeglasses do not have side shields and therefore do not confer adequate protection (16). Class IV laser beams may be reflected by specular surfaces in the surgical field and still maintain sufficient energy to cause thermal damage. Metallic surfaces that appear dull and nonreflective may be specular to 10,600 nm CO2 light (12). Therefore, all jewelry should be removed from the field and the laser should not be aimed at any metallic or shiny surface. Metallic instruments or items that are needed in the field during treatment should be anodized (have a brushed or matte finish) to decrease the reflectivity of the beam. A black coating (ebonizing) augments anodizing but does not provide sufficient beam diffusion when used alone. Plastic devices can melt and should only be used if they are known to be laser-resistant.
Figure 3.4 Wavelength-specific laser eye protection. Note the side shields and prominently labeled optical density. These can be manufactured with prescription corrective lenses as well.
90
5.1.
Ammirati and Hruza
Patient Protection
Ideally, nonsedated patients should be offered the same eye protection as that worn by the operating staff. This allows them to see the actions taking place in the room and can reduce unnecessary anxiety. Nonsedated patients can also wear opaque mini goggles, with a few caveats. This type of LPE is often stiff and the elastic strap must be tightened until there is a lightproof seal around the eyes. The strap itself can be flammable and should be maneuvered away from the treatment area or “strapless” goggles can be taped into place. For infants and children, it may be necessary to cut the goggles at the nosepiece and individually tape them over the eyelids. Moistened gauze or Telfaw can be placed over the closed lids and under the mini goggles to add a second level of protection (32). Laser treatment on or near the eyelids requires corneal eyeshields (Fig. 3.5). After topical anesthetic drops (e.g., 0.5% tetracaine HCl ophthalmic solution) have been instilled onto the conjunctiva, the eyeshield concavity is lubricated with a water-based lubricant (e.g., Lacri-lubew) and carefully placed under the eyelid against the eyeball. Studies investigating the thermal response curves and rates of warming for various types of eyeshields have shown them to be variable (33). Metallic eyeshields provide the best protection from transmitted light and heat but can be highly reflective. To decrease the risk of beam reflection, the convex surface should be anodized. Plastic eyeshields, especially those of darker color, should be avoided since they tend to melt when struck with sufficient laser energy (34). Well-intentioned family members, present for emotional support, are also at risk for injury. Their lack of laser safety training further increases their risk and whenever possible they should be discouraged from staying for the procedure.
5.2.
Medical Surveillance
ANSI-Z136.1 requires preassignment medical surveillance exams for all laser personnel who will be exposed to Class IIIb or IV laser energy. This examination must be documented before participation in laser surgery and establishes the baseline ocular history, visual acuity, peripheral fields, and color vision. Any abnormal finding would warrant a dilated
Figure 3.5 Corneal eye shields. Note the anodized convex exterior surface to decrease specular reflection.
Laser Safety Measures
91
ophthalmologic exam and other tests as deemed appropriate. A second rationale for preassignment examinations is to identify certain personnel who may be at increased risk from laser exposure. This includes workers who use photosensitizing medications, which have been shown to lower the threshold for laser damage to the eye (35). Periodic examinations are not required for asymptomatic personnel but ANSI does require an examination after any suspected laser injury has occurred. At his/her discretion, an employer may elect to obtain an examination when employment is terminated to provide legal protection against future claims of injury.
6.
SKIN HAZARDS
Although the skin is more likely to be exposed to laser injury, it is not usually given the same priority as eye protection. This is because there is a vast difference in the magnitude of injury produced by a laser strike to the eye as compared to the skin. Depending on the energy and wavelength in use, lasers can produce cutaneous burns that range from superficial erythema to extensive blistering and charring. However, most skin injuries are relatively minor because an alert person will quickly remove the exposed skin from the path of the laser beam. A sedated patient, however, can suffer more severe skin burns since they will not reflexively withdraw from the laser impact. As a rule, when treating anesthetized patients, it is good practice to protect the surrounding skin with wet towels.
7.
TEETH HAZARDS
Dental enamel absorption is high in the UV and IR regions (36). When lasers are used around the lips and in the oral cavity, care must be taken that a stray laser beam does not damage or discolor tooth enamel or dental prosthetics (37,38). A moistened gauze or dental roll can be used as protection if the teeth are near the treatment field.
8.
FIRE HAZARDS
Class IV lasers can cause flash fires or electrical fires. A flash fire can result if the laser beam strikes a flammable material within the surgical field. An electrical fire would be one that occurs within the laser unit itself. To limit injury, each of these emergent situations requires an immediate response and personnel must be familiar with all safety protocols. 8.1.
Fire Prevention
A flash fire can occur if a direct or reflected beam ignites gauze, hair, cosmetics, or drapes within the surgical field (Fig. 3.6) (34). Nylon or rayon fabrics are especially hazardous since they can melt and adhere to the skin. To avoid this risk, all unnecessary material should be removed from the treatment site. Makeup is also flammable and must be removed before treatment begins. Drapes and gauze pads used in the field should be wet or nonflammable. If wet gauze or drapes are used, they should be periodically checked to make sure that they have maintained their moisture. One study found Telfaw pads to be more flame-resistant than gauze and their preferential use might be warranted (32). For small treatment areas, hair can be positioned away from the field with water-soluble lubricating gel (i.e., K-Yw Jelly). For larger areas, a wet towel should be used.
92
Ammirati and Hruza
Figure 3.6 Ignition of dry gauze by the continuous wave argon laser. (Ignition occurred within seconds.)
Alcohol readily ignites when exposed to the heat of a laser impact (39). Hair sprays and gels often contain alcohol, as do topical preparations such as chlorhexidine surgical scrub and some lidocaine gels. Iodophors may also ignite at high temperatures, especially if they accumulate near the operative field (40). The use of any potentially flammable preparation should be discouraged. If its use is absolutely necessary, it should be washed completely from the site before treatment begins. Methane release, during laser treatment of the anogenital area, also poses a fire hazard. A moist rectal tampon can be used to decrease this risk. Medical grade silicone can ignite when exposed to CO2 laser energy. This was first discovered during CO2 laser vaporization of silicone deposits in breast tissue (41). This “silicone flash” has now been experimentally produced by microdroplet silicone, which is the form used for dermal augmentation on the face (42). Even tiny fractions of silicone produced a visible flare with a flame extending as far as an inch from the experimental test site. This presents a theoretical concern and although it has not been shown in practice, it is unclear whether a history of silicone facial augmentation should be considered a relative contraindication to CO2 resurfacing. There have been several reports of ignition during the use of the pulsed dye laser treatment when supplemental oxygen was in use (32,39,43). Oxygen greatly increases the combustion potential of any flammable material, even those that are saturated with water (32,43). If possible, supplemental oxygen should be momentarily discontinued when any surgical laser is in use. Alternatively, spontaneous respiration with a laryngeal mask airway can be used (44). 8.2.
Fire Containment
During treatment, a bowl of water should be within reach of the laser operator at all times since an immediate response could limit the potential damage to the patient. A separate safety protocol is required if an electrical fire occurs within the laser unit itself. These situations require extreme caution and the staff should be trained to handle this emergency as well. It should be stressed that water must never be used on an electrical fire as this could lead to electrocution. A fire extinguisher should be available in each laser treatment room
Laser Safety Measures
93
or it can be attached to the side of the laser itself. The extinguisher of choice, for a laser unit electrical fire, is a halon fire extinguisher (45). Common dry chemical extinguishers emit a fine dust, which can damage laser optics or circuitry, and should not be used.
9.
ELECTRICAL AND MECHANICAL HAZARDS
The most lethal hazard associated with lasers is the high voltage that powers them. Most medical lasers operate on 220 or higher AC voltage. This is typically doubled or tripled by the laser exciter (power supply). Several deaths have occurred when persons working with the high-voltage portions of laser systems did not follow safety practices (2). Untrained personnel should never manipulate or access the laser power supply. If an emergent situation arises and it is absolutely necessary to access the power supply, first insure that the main power has been disconnected. Second, call for assistance and do not attempt repairs alone. In the event of high-voltage injury, a second person will be needed to call for emergency medical personnel and administer cardiopulmonary resuscitation until they arrive. Cutaneous lasers are designed to be portable but a significant jolt to the unit can result in misalignment of the laser head or optical fiber. Prior to beginning laser surgery the operator should verify the alignment of the laser beam and the integrity of the spot size. The Baggish 1 J test can be used for focused-beam CO2 lasers (46). To perform this test, the laser power is set to 10 W with an exposure duration of 100 ms. At these settings, 1 J of energy should be produced. A well-focused 1 J CO2 laser beam should penetrate through a standard wooden tongue depressor. If the beam does not penetrate, calibration is indicated. Visible and near-IR laser alignment can be checked by firing at an appropriately colored photopaper (i.e., red photopaper for 585 nm pulsed dye laser). The resultant laser spot on the photopaper should match exactly with the location of the alignment beam. The spot should also be of the appropriate diameter with its edges sharply defined and its center without “hotspots” (uneven burn patterns).
9.1.
Controlled Access
OSHA regulations state that access to the laser and entrance to the surgery room must be strictly controlled (47). The CDRH mandates that Class IIIb and IV lasers incorporate a key activated control switch (3). The laser must be rendered inoperable if the key is not in place. When the laser is not in use, the key should be removed from the control panel and stored in a secure location. The ANSI standards recommend that a door interlock system be used during laser procedures (2,48). While this may be effective in nonmedical settings, its use is impractical for most medical laser procedures. An interlock system would disengage the laser if the door to the laser room were opened. While this would provide safety for the person entering the room, it could compromise patient care since the operator may be at a critical point in the procedure. It is far better to post warning signs on the door when the laser is in use and train personnel to limit all nonessential entrance. Wavelength-specific eyewear can be hung next to the sign if unplanned entrance is necessary (Fig. 3.7). Laser warning signs should be promptly removed when the procedure is completed or their significance may be forgotten. Windows, doorways, and open portals, through which laser light might escape, must be adequately covered or shielded. Visible and near-IR laser wavelengths readily penetrate
94
Ammirati and Hruza
Figure 3.7 A laser warning sign should be prominently displayed on the door leading into the surgical suite. The sign should be removable and taken down when treatment has been completed. Laser-specific eye protection should be hung next to the sign to allow safe entrance once treatment has commenced.
window glass. If the windows are at eye level, opaque, laser-resistant coverings will be needed. To prevent accidental discharge of the laser, foot pedals are designed with protective housing (Fig. 3.8). To engage the laser, the foot must be purposely placed within the device and the pedal depressed. To limit any confusion, the smoke evacuator foot pedal is placed near the assistant, who is usually on the other side of the patient. When it is not in use, the laser should be placed in stand-by mode. This provides a second line of defense against accidental discharge.
Figure 3.8 Laser foot pedal on the left equipped with protective housing. This is compared to the unprotected smoke evacuator foot pedal on the right. The protective housing on the laser foot pedal decreases any risk for laser misfire.
Laser Safety Measures
10.
95
CHEMICAL HAZARDS
Some laser systems use toxic gases, organic dyes, and solvents that can be hazardous if not properly handled. Excimer lasers, which are not routinely used for cutaneous surgery, may contain toxic halogens mixed with an inert gas and special training is required to service these units (49). Dye lasers use a lasing medium that consists of a complex organic dye dissolved in an organic solvent. Limited animal studies have shown some laser dyes to be toxic, mutagenic (Ames/Salmonella assay), and possibly carcinogenic (50 – 52). Since specific data are limited, all dyes should be treated as hazardous chemicals. 10.1. Chemical Protection Impervious gloves and protective eyewear are to be used when handling laser dye and quencher solutions. If skin contact occurs, the area should be washed immediately with soap and water. Eye contact is a medical emergency and requires copious irrigation with water and prompt medical attention. In the case of accidental ingestion, the local poison control center should be contacted. Prolonged inhalation is also not recommended and persistent symptoms will require medical attention. OSHA’s Employee Right to Know Act of 1988 requires that employees who work with potentially hazardous materials have certain rights. This includes access to the material safety data sheet that accompanies each dye laser. This sheet will supply appropriate information pertaining to toxicity, personal protective equipment, and the storage of chemicals.
11.
ACCOUSTIC HAZARDS
The noise level of certain lasers, such as the Er:YAG, may be of sufficient intensity to warrant hearing protection during their use.
12.
LASER PLUME HAZARDS
A plume, consisting of smoke, vapor, and particulate debris, is generated whenever a laser ablates tissue. Depending on the type of medical procedure, the laser plume may contain carcinogens, mutagens, irritants, tissue fragments, potentially infectious viral particles, and bacteria (2). The hazard potential of this plume has been the subject of understandable concern as well as debate. In 1992, the EUREKA international project STILMED (Safety Technology in Laser Medicine) began systematic investigations of the chemical, particulate, and microbiological hazards of laser plume (53). Their final results were summarized and are available from SPIE—The International Society of Optical Engineering (see Table 3.1). 12.1. Organic Compounds The laser plume’s smell is nauseating and its particulate matter can cause eye, nose, and throat irritation. Chemical analysis of continuous wave CO2 and Nd:YAG laser plumes identified carbon monoxide, hydrogen cyanide, ammonia and more than 150 volatile organic compounds, including benzene, formaldehyde, and toluene (54 – 56). Extreme
96
Ammirati and Hruza
laser-generated temperatures split tissue molecules into free radicals, which catalyze the generation of these toxic compounds. If an oxygen donor, such as aerosolized water, is available, then the formation of free radicals and other harmful laser plume substances can be reduced (57). Wiping away charred tissue, prior to continued lasing, will also reduce the emission of toxic compounds (58). The particulate aerosol of the laser plume is known to have in vitro mutagenic, genotoxic, and clastogenic (disruption or breakage of chromosomes) potential (59,60). Laser-generated carcinogens are similar to those found in cigarette smoke and vaporization of 1 g of tissue produces the same amount of mutagenic smoke as smoking three to six cigarettes (60). While there is no epidemiologic evidence of increased malignancies in personnel chronically exposed to laser smoke, safe levels of ambient mutagens remain to be determined and unnecessary exposure should be avoided (61). 12.2.
Particulate Debris
The majority of CO2 laser-generated particles range from 0.1 to 0.8 mm in diameter (62). Particles of this size are easily deposited in the lower respiratory tract and can cause parenchymal damage (63). Experimental rats, when forced to breathe CO2 laser smoke for prolonged periods, developed congestive interstitial pneumonia, bronchiolitis, and emphysema (64). Similar experimental changes have been induced by the continuous wave 1064 nm Nd:YAG laser plume (65,66). 12.3.
Pathogenicity
The infectious potential of laser-generated cellular debris has been the focus of understandable concern. Early studies with the Nd:YAG and CO2 lasers failed to culture laser plume debris and it was hoped that the extreme temperatures generated by these lasers would sterilize any debris (67 –69). Recent findings, however, have been to the contrary (70 – 73), which may be due to different collection techniques as well as variations in the laser settings used (62,74). Transmission of human papilloma virus (HPV) from laser ablation of infected tissue remains a serious concern among laser surgeons. Infectious bovine papilloma virions and intact DNA from HPV have been recovered from the CO2 laser plume (75,76). The degree of risk that these findings represent in actual practice is not completely known. A comparative study of CO2 laser surgeons, who frequently treated HPV-infected lesions, failed to find an increased incidence of common warts (77). However, when grouped by anatomic site, CO2 laser surgeons were found to have a higher risk of acquiring nasopharyngeal papillomas. This is due to the ability of HPV types 6 and 11, which cause genital condyloma acuminata through contact, to induce nasopharyngeal papillomas after inhalation (78 –80). These findings also imply that there is a true infectious hazard, albeit small, from laser ablation of HPV-infected tissue and that strict adherence to protective measures is indicated. Transmission of human immunodeficiency virus (HIV) or hepatitis via the laser plume represents a serious potential hazard, but studies thus far have been limited (81 –84). Proviral HIV DNA and HIV p24 protein from CO2 laser smoke were detectable in culture at 14 days but were not sustained at 28 days (81). Examination of the Er:YAG laser plume, which failed to reveal HPV DNA (85), did recover infectious retrovirus (86). Hepatitis B virus, which can survive for 72 h outside the body, poses a theoretical risk during laser procedures but has not been studied. To date, there have been no cases of HIV or hepatitis transmission from a patient to a physician via laser plume. However,
Laser Safety Measures
97
since the degree of risk has not been clearly delineated and the consequences of infection are so severe, protective measures are a must. Additional concern surrounds the tissue debris that is ejected at supersonic speed by Q-switched lasers, such as the alexandrite, ruby, and Nd:YAG. Q-switched lasers cause a heat-induced explosion within tissue cells, which can liberate viable surface cells into the air at supersonic speeds. These ejection speeds are beyond the capture of a smoke evacuator and different protective measures will be needed (87). 12.4. Protection and Evacuation In 1996, NIOSH issued the Health Hazard Control, Control of Smoke from Laser/Electric Surgical Procedures (HC-11). This was the first federal statement calling for the evacuation of smoke generated by lasers and electrosurgery. In HC-11, NIOSH clearly identifies laser and electrosurgery smoke as a health hazard and provides guidelines for optimal evacuation. 12.5. Smoke Evacuators Smoke evacuation provides the first line of defense against laser plume hazards and there are several methods available. In-line wall suction filters have been used for small amounts of laser plume evacuation but are not recommended. They clog easily and the plume is exhausted elsewhere in the facility, usually without adequate filtration, and creates an airborne hazard (66). A high-efficiency laser smoke evacuator is a more reliable unit that consists of a vacuum, charcoal filter, high-efficiency particulate air (HEPA) filter, and ultra-low particulate air (ULPA) filter. The activated charcoal filter serves to trap toxic chemicals and noxious vapors. The HEPA filter traps particles as small as 0.3 mm in diameter with .99% efficiency. The ULPA filter captures 0.1 mm particles and this additional efficiency has a significant clinical impact. Recall that rats, when forced to inhale CO2 laser smoke, developed microscopic pulmonary changes (64). When laser smoke was filtered through an HEPA filter, prior to being inhaled, the rats developed similar but less severe pulmonary lesions. After a ULPA filter was added to the filtration system, no pathologic lung changes were observed (88). A high-efficiency smoke evacuator will only be effective when the nozzle is kept within 2 in. of the treatment site (89). Evacuation efficiency is dramatically reduced when the tube is held farther away (90). The vacuum tubing is changed after each patient and treated as biohazardous waste (81). Any lingering odor or smoke in the air suggests that the filter should be inspected and changed if necessary. Currently, there are two types of filter monitor systems available on laser smoke evacuators, pressure drop monitors, and time-based monitors (83). Pressure monitors measure the drop in pressure across the filter. When a critical pressure is reached, an indicator light signals that the filter should be changed. A time-based monitor will signal the need for a filter change after a preset period of use. Its signal may be premature if the vacuum has been left running while the laser was not engaged. To limit exposure to Q-switched laser-generated debris, a collecting cone or shield can be placed over the handpiece during use. The laser can also be fired through a transparent membrane, such as Cling Filmw or Vigilonw to reduce the ejection of particulate matter into the air (Fig. 3.9). Comparative studies with the Q-switched Nd:YAG laser found Cling Filmw to be superior to Tegadermw, Opsitew, or 2nd Skinw (91). Collecting cones and transparent membranes may reduce the ejected debris but not reliably eliminate it. Additional protective equipment such as gloves and laser masks are recommended.
98
Ammirati and Hruza
Figure 3.9 Ejected cellular debris trapped by a clear membrane. The Q-switched Nd:YAG laser was fired through acetate sheeting during laser treatment of a tattoo.
12.6.
Laser Masks
Laser plume particles 0.1 –0.8 mm in size are too small to be effectively filtered by a standard surgical mask (92). Specially designed laser masks trap particles down to 0.1 mm. To be effective, they must fit snugly and have a moldable nosepiece and flexible side panels. It is recommended that laser masks be changed after each case or if they become wet during the procedure. To achieve 0.1 mm particle filtration, laser masks use electrostatically charged synthetic fibers. Moisture can eliminate the electrostatic charge and compromise the filtration capacity of the mask (88).
REFERENCES 1. 2. 3. 4. 5. 6. 7.
8. 9.
Dierkesmann R, Huzly A. Side effects of endobronchial laser treatment. Endoscopy 1985; 17:49 – 53. American National Standards Institute. American National Standard for the Safe Use of Lasers. Orlando, FL: Laser Institute of America, 1993. US Department of Health and Human Services. Title 21 CFR, Subchapter J. Part 1040.10 Performance Standards for Laser Products. Sliney D, Trokel S. Safety standards and laser exposure limits. In: Sliney D, Trokel S, eds. Medical Lasers and Their Safe Use. New York: Springer-Verlag, 1993:87 – 94. Luttrull JK, Hallisey J. Laser pointer-induced macular injury. Am J Ophthalmol 1999; 127:95–96. Marshall J. The safety of laser pointers: myths and realities. Br J Ophthalmol 1998; 82:1335 – 1338. McHugh JD, Marshall J, Ffytche TJ, Hamilton AM, Raven A, Keeler CR. Initial clinical experience using a diode laser in the treatment of retinal vascular disease. Eye 1989; 3:516 – 527. Marshall J. Structural aspects of laser-induced damage and their functional implications. Health Phys 1989; 56:617 –624. World Health Organization. Lasers and Optical Radiation. Geneva: World Health Organization Press, 1982.
Laser Safety Measures 10. 11. 12. 13.
14. 15. 16. 17. 18. 19. 20. 21.
22. 23. 24. 25. 26. 27. 28. 29.
30. 31. 32. 33. 34. 35. 36.
99
Pitts D. The electromagnetic spectrum. In: Pitts D, Kleinstein R, eds. Environmental Vision. Boston: Butterworth-Heinemann, 1993:87 – 136. Sliney DH. Laser safety. Lasers Surg Med 1995; 16:215– 225. Wood RL Jr, Sliney DH, Basye RA. Laser reflections from surgical instruments. Lasers Surg Med 1992; 12:675– 678. Zuchlich J, Gagliano D, Chaney F, Stuck B, Zwick H, Edsall P, Lund D. Ocular effects of penetrating IR laser wavelengths. Proceedings SPIE Laser-Tissue Interaction VI, Vol. 2391, Bellingham, WA, 1995:112 – 125. Pitts D. Ocular effects of radiant energy. In: Pitts D, Kleinstein R, eds. Environmental Vision. Boston: Butterworth-Heinemann, 1993:151 – 208. Zuclich JA, Connolly JS. Ocular damage induced by near-ultraviolet laser radiation. Invest Ophthalmol Vis Sci 1976; 15:760 – 764. Sliney D, Wolbarsht M. Safety with Lasers and Other Optical Sources. New York: Plenum Press, 1980. Ham WT Jr, Clarke AM, Geeraets WJ, Cleary SF, Mueller HA, Williams RC. The eye problem in laser safety. Arch Environ Health 1970; 20:156 –160. Thach AB. Laser injuries of the eye. Int Ophthalmol Clin 1999; 39:13– 27. Rockwell R. Laser accidents: Reviewing thirty years of incidents. J Laser Appl 1994; 6:203–211. Decker C. Laser accident victim’s view. Laser Focus Aug 1977. Takahashi K, Lam TT, Fu J, Tso MO. The effect of high-dose methylprednisolone on laserinduced retinal injury in primates: an electron microscopic study. Graefes Arch Clin Exp Ophthalmol 1997; 235:723 – 732. Potthofer S, Foerster MH. Vitrectomy and autologous thrombocyte adhesion of an accidental macular hole caused by Nd:YAG laser. Br J Ophthalmol 1997; 81:803 –804. Thach AB, Lopez PF, Snady-McCoy LC, Golub BM, Frambach DA. Accidental Nd:YAG laser injuries to the macula. Am J Ophthalmol 1995; 119:767 – 773. Alhalel A, Glovinsky Y, Treister G, Bartov E, Blumenthal M, Belkin M. Long-term follow up of accidental parafoveal laser burns. Retina 1993:13:152– 154. Sliney D, Trokel S. Laser injury and potential hazards. In: Sliney D, Trokel S, eds. Medical Lasers and Their Safe Use. New York: Springer-Verlag, 1993:72 – 85. Varley GA, Meisler DM, Benes SC, McMahon JT, Zakov ZN, Fryczkowski A. Hibiclens keratopathy. A clinicopathologic case report. Cornea 1990; 9:341 –346. van Rij G, Beekhuis WH, Eggink CA, Geerards AJ, Remeijer L, Pels EL. Toxic keratopathy due to the accidental use of chlorhexidine, cetrimide and cialit. Doc Ophthalmol 1995; 90:7– 14. Boucek C, Freeman JA, Bircher NG, Tullock W. Impairment of anesthesia task performance by laser protection goggles. Anesth Analg 1993; 77:1232 – 1237. Teichman JM, Vassar GJ, Yates JT, Angle BN, Johnson AJ, Dirks MS, Thompson IM. Color vision deficits and laser eyewear protection for soft tissue laser applications. J Urol 1999; 161:874–880. Kaufman JG, Tucker R. Proper eye protection needed as lasers gain industry popularity. Occup Health Saf 1986; 55:76, 79. Tanner M. Increasing use, power of lasers make eye protection essential. Occup Health Saf 1990; 59:44 – 46. Epstein RH, Brummett RR Jr, Lask GP. Incendiary potential of the flash-lamp pumped 585-nm tunable dye laser. Anesth Analg 1990; 71:171– 175. Ries WR, Clymer MA, Reinisch L. Laser safety features of eye shields. Lasers Surg Med 1996; 18:309 – 315. Rohrich RJ, Gyimesi IM, Clark P, Burns AJ. CO2 laser safety considerations in facial skin resurfacing. Plast Reconstr Surg 1997; 100:1285 – 1290. Fraunfelder F. Drug Induced Ocular Side Effects and Drug Interactions. Philadelphia, PA: Lea & Febiger, 1976. Lueschner F, Lotriet CJ, Denner BF. Spectral reflectance and transmittance in dental enamel for UV, visible and NIR light. Proceedings SPIE Laser Interaction with Hard and Soft Tissue II, Vol. 2323, Bellingham, WA, 1995:317– 322.
100 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53.
54. 55. 56.
57.
58.
59.
60.
61. 62.
Ammirati and Hruza Pogrel MA, Muff DF, Marshall GW. Structural changes in dental enamel induced by high energy continuous wave carbon dioxide laser. Lasers Surg Med 1993; 13:89– 96. Shariati S, Pogrel MA, Marshall GW Jr, White JM. Structural changes in dentin induced by high energy, continuous wave carbon dioxide laser. Lasers Surg Med 1993; 13:543 – 547. Bean AK, Ceilley RI. Reducing fire risks of the flashlamp pumped 585-nm pulse dye laser. J Dermatol Surg Oncol 1994; 20:224. Rosio T. Basic laser safety. In: Roenigk R, Roenigk H, eds. Roenigk and Roenigk’s Dermatologic Surgery: Principles and Practice. New York: Marcel Dekker, Inc., 1996. Becker DW Jr. Laser silicone flash. Plast Reconstr Surg 1988; 81:600. Zager W, Huang J, McCue P, Reiter D. Laser resurfacing of silicone-injected skin: the “silicone flash” revisited. Arch Otolaryngol 2001; 127:418 – 421. Fretzin S, Beeson WH, Hanke CW. Ignition potential of the 585-nm pulsed-dye laser. Review of the literature and safety recommendations. Dermatol Surg 1996; 22:699 – 702. Epstein RH, Halmi BH. Oxygen leakage around the laryngeal mask airway during laser treatment of port-wine stains in children. Anesth Analg 1994; 78:486 –489. Ball K. Lasers: The Perioperative Challenge. 2nd ed. St. Louis, MO: Mosby, 1991. Sliney D, Trokel S. Laser checkout and demonstration procedures. In: Sliney D, Trokel S, eds. Medical Lasers and Their Safe Use. New York: Springer-Verlag, 1993. US Department of Labor. Guidelines for Laser Safety and Hazard Assessment: OSHA Instructional PUB 8-1.7, 1991. American National Standards Institute. American National Standards for the Safe Use of Lasers in the Health Care Environment. Orlando, FL: Laser Institute of America, 1996. Lorenz A. Gas handling safety for laser makers and users. Lasers Appl 1987; 6:69– 73. Mosovsky JA. Laser Dye Toxicity, Hazards and Recommended Controls. Livermore, CA: Lawrence Livermore National Laboratory, 1983. Kues H, Lutty G. Dyes can be deadly. Laser Focus 1975; 11:58 – 60. Anonymous. Lasers. In: Health & Safety Manual. California, CA: Lawrence Livermore National Laboratory, 1995:1 – 20. Woellmer W. Results of EUREKA project STILMED: transfer to standards. Proceedings APIE Laser-Tissue Interaction and Tissue Optics II, Vol. 2923, Bellingham, WA, 1996:189 – 193. Kokosa JM, Benedetto MD. Probing plume protection problems in the health care environment. Laser J Appl 1992; 4:39 – 43. Ott D. Smoke production and smoke reduction in endoscopic surgery: preliminary report. Endosc Surg Allied Technol 1993; 1:230– 232. Albrecht H, Hagemann R, Waesche W, Wagner G, Mueller G. Volatile organic components in laser and electrosurgery plume. Proceedings SPIE Laser Interaction with Hard and Soft Tissue, Vol. 2077, Bellingham, WA, 1994:310 – 317. Lademann J, Weigmann H, Meffert H, Sterry W. Radical formation during laser-tissue interaction. Proceedings SPIE Laser-Tissue Interaction and Tissue Optics II, Vol. 2923, Bellingham, WA, 1996:156 –163. Weigmann H, Lademann J, Meffert H, Sterry W. Permanent gases and highly volatile organic compounds in laser plume. Proceedings SPIE Laser-Tissue Interaction and Tissue Optics, Vol. 2923, Bellingham, WA, 1996:164 – 167. Plappert UG, Stocker B, Helbig R, Fliedner TM, Seidel HJ. Laser pyrolysis products— genotoxic, clastogenic and mutagenic effects of the particulate aerosol fractions. Mutat Res 1999; 441:29 – 41. Tomita Y, Mihashi S, Nagata K, Ueda S, Fujiki M, Hirano M, Hirohata T. Mutagenicity of smoke condensates induced by CO2-laser irradiation and electrocauterization. Mutat Res 1981; 89:145 – 149. Hunter JG. Laser smoke evacuator: effective removal of mutagenic cautery smoke. Aesthetic Plast Surg 1996; 20:177 – 178. Nezhat C, Winer WK, Nezhat F, Forrest D, Reeves WG. Smoke from laser surgery: is there a health hazard? Lasers Surg Med 1987; 7:376– 382.
Laser Safety Measures 63. 64. 65. 66. 67. 68. 69. 70.
71. 72. 73. 74.
75.
76. 77.
78.
79. 80. 81. 82. 83. 84. 85. 86. 87.
101
Schwab JA, Zenkel M. Filtration of particulates in the human nose. Laryngoscope 1998; 108:120 – 124. Baggish MS, Elbakry M. The effects of laser smoke on the lungs of rats. Am J Obstet Gynecol 1987; 156:1260 – 1265. Freitag L, Chapman GA, Sielczak M, Ahmed A, Russin D. Laser smoke effect on the bronchial system. Lasers Surg Med 1987; 7:283– 288. Wenig BL, Stenson KM, Wenig BM, Tracey D. Effects of plume produced by the Nd:YAG laser and electrocautery on the respiratory system. Lasers Surg Med 1993; 13:242– 245. Bellina JH, Stjernholm RL, Kurpel JE. Analysis of plume emissions after papovavirus irradiation with the carbon dioxide laser. J Reprod Med 1982; 27:268 – 270. Oosterhuis JW, Verschueren RC, Eibergen R, Oldhoff J. The viability of cells in the waste products of CO2-laser evaporation of Cloudman mouse melanomas. Cancer 1982; 49:61– 67. Mihashi S, Jako GJ, Incze J, Strong MS, Vaughan CW. Laser surgery in otolaryngology: interaction of CO2 laser and soft tissue. Ann N Acad Y Sci 1976; 267:263 – 294. Mullarky MB, Norris CW, Goldberg ID. The efficacy of the CO2 laser in the sterilization of skin seeded with bacteria: survival at the skin surface and in the plume emissions. Laryngoscope 1985; 95:186 – 187. Walker NP, Matthews J, Newsom SW. Possible hazards from irradiation with the carbon dioxide laser. Lasers Surg Med 1986; 6:84 – 86. McKinley IB Jr, Ludlow MO. Hazards of laser smoke during endodontic therapy. J Endod 1994; 20:558 – 559. Byrne PO, Sisson PR, Oliver PD, Ingham HR. Carbon dioxide laser irradiation of bacterial targets in vitro. J Hosp Infect 1987; 9:265 – 273. Kunachak S, Sithisarn P, Kulapaditharom B. Are laryngeal papilloma virus-infected cells viable in the plume derived from a continuous mode carbon dioxide laser, and are they infectious? A preliminary report on one laser mode. Laryngol J Otol 1996; 110:1031 –1033. Sawchuk WS, Weber PJ, Lowy DR, Dzubow LM. Infectious papillomavirus in the vapor of warts treated with carbon dioxide laser or electrocoagulation: detection and protection. J Am Acad Dermatol 1989; 21:41 – 49. Sawchuk WS, Felten RP. Infectious potential of aerosolized particles. Arch Dermatol 1989; 125:1689 – 1692. Gloster HM Jr, Roenigk RK. Risk of acquiring human papillomavirus from the plume produced by the carbon dioxide laser in the treatment of warts. J Am Acad Dermatol 1995; 32:436 – 441. Gissmann L, Wolnik L, Ikenberg H, Koldovsky U, Schnurch HG, zur Hausen H. Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc Natl Acad Sci USA 1983; 80:560– 563. Hallmo P, Naess O. Laryngeal papillomatosis with human papillomavirus DNA contracted by a laser surgeon. Eur Arch Otorhinolaryngol 1991; 248:425 – 427. Mounts P, Shah KV, Kashima H. Viral etiology of juvenile- and adult-onset squamous papilloma of the larynx. Proc Natl Acad Sci USA 1982; 79:5425 –5429. Baggish MS, Poiesz BJ, Joret D, Williamson P, Refai A. Presence of human immunodeficiency virus DNA in laser smoke. Lasers Surg Med 1991; 11:197– 203. O’Grady KF, Easty AC. Electrosurgery smoke: hazards and protection. J Clin Eng 1996; 21:149 – 155. Romig CL, Smalley PJ. Regulation of surgical smoke plume. AORN J 1997; 65:824 – 828. Winstin C. The effects of smoke plume generated during laser and electrosurgical procedures. Minim Invasive Surg Nurs 1994; 8:99 – 102. Hughes PS, Hughes AP. Absence of human papillomavirus DNA in the plume of erbium:YAG laser-treated warts. J Am Acad Dermatol 1998; 38:426 –428. Ziegler BL, Thomas CA, Meier T, Muller R, Fliedner TM, Weber L. Generation of infectious retrovirus aerosol through medical laser irradiation. Lasers Surg Med 1998; 22:37– 41. Voorhies RM, Lavyne MH, Strait TA, Shapiro WR. Does the CO2 laser spread viable braintumor cells outside the surgical field? J Neurosurg 1984; 60:819– 820.
102 88. 89. 90.
91. 92.
Ammirati and Hruza Baggish MS, Baltoyannis P, Sze E. Protection of the rat lung from the harmful effects of laser smoke. Lasers Surg Med 1988; 8:248– 253. Smith JP, Moss CE, Bryant CJ, Fleeger AK. Evaluation of a smoke evacuator used for laser surgery. Lasers Surg Med 1989; 9:276 – 281. Mihashi S, Ueda S, Hirano M, Tomita Y, Hirohata T. Some problems about smoke condensates induced by carbon dioxide laser irradiation. Procedings of the 4th Congress of the International Society for Laser Surgery, Tokyo, Japan, 1981:225 – 227. Pay AD, Kenealy JM. Laser transmission through membranes using the Q-switched Nd:YAG laser. Lasers Surg Med 1999; 24:48– 54. Kunachak S, Sobhon P. The potential alveolar hazard of carbon dioxide laser-induced smoke. J Med Assoc Thai 1998; 81:278 –282.
Section II: Laser Science and Instrumentation
4 Continuous Wave Lasers: Argon, Dye, KTP, Copper Vapor, Krypton Thomas O. McMeekin University of Rochester and State University of New York at Buffalo, Rochester, New York, USA
1. Continuous Wave Argon Laser 1.1. Laser Parameters 1.2. Indications—Port-Wine Stains 1.3. Perioperative Considerations 1.4. Telangiectasias 1.5. Other Vascular Lesions 1.6. Hemangiomas 1.7. Pigmented Lesions 2. Continuous and Quasicontinuous Argon-Pumped Tunable Dye Laser 2.1. Laser Parameters 2.2. Indications—Port-Wine Stains 2.3. Perioperative Considerations 2.4. Facial Telangiectasias 2.5. Argon-Pumped Tunable Dye Laser Pigmented Lesions 3. Copper Vapor Lasers/Copper Bromide Lasers 3.1. Laser Parameters 3.2. Indications—Port-Wine Stains 3.3. Perioperative Considerations 3.4. Facial Telangiectasia 3.5. Other Vascular Lesions 3.6. Pigmented Lesions 4. KTP Lasers 4.1. Laser Parameters 4.2. Indications—Port-Wine Stains/Telangiectasias 4.3. Perioperative Considerations 4.4. Hemangioma 5. Krypton Laser 5.1. Laser Parameters
106 106 106 108 109 110 110 112 112 112 112 113 113 114 114 114 116 117 117 117 118 119 119 120 121 121 123 123 105
106
McMeekin
5.2. Indications—Telangiectasia 5.3. Operative Considerations References
1. 1.1.
123 124 124
CONTINUOUS WAVE ARGON LASER Laser Parameters
Although the argon laser emits at six wavelengths from 457.9 to 514.5 nm, 80% of the total emissions occur at 488 and 514 nm. A filter can be used to limit the wavelength to green light at 514 nm, or all the blue-green light can be delivered by a fiber optic cable in a continuous beam. The fiber optic delivery cable comes with spot sizes of 0.1–1.0 mm, with a fluence range of 0–2.0 W. A scanner is available, but no cooling is built into the system. Optional cooling with ice pretreatment or using a commercial cooling chamber is available. The light can penetrate into tissue up to 1 mm, however, thermal injury in port wine stains is seen at ,0.5 mm. Argon light is well absorbed by both melanin and oxyhemoglobin. The argon laser is no longer manufactured, but an ophthalmic argon laser is made by Lumenis Laser Corporation (Palo Alto, CA).
1.2.
Indications—Port-Wine Stains
The argon laser was developed in the 1970s for the treatment of vascular lesions. Although the ruby laser and the CO2 laser antedated the argon laser, neither was greeted with the enthusiasm that heralded the first results published in 1976 in port-wine stains (1,2). This enthusiasm was partially due to the poor treatment options for port-wine stains which included radiation, cryosurgery, excisional surgery with grafting, tattooing with skin-colored pigments, dermabrasion, and electrosurgery. The optimism was also heightened by the now disproved theory that the blue-green light was specific for the chromophore oxyhemoglobin and would penetrate the necessary depth to coagulate the ectatic vessels in the vascular malformation. A trial-and-error approach characterized the experience over the first 5 years. Few attempts were initially made to study the histology and correlate the successes that were observed with prognostic factors or treatment parameters. The results of argon laser treatment of port-wine stains were essentially that 60– 75% of cases showed good to excellent results, only 10% showed complete disappearance, and 10% showed no response or only slight fading [see Fig. 4.1(a) and (b)] (3 –5). The risk of scarring varied from a low of 4% (6), to .50% (6), and with a survey of patient perceptions as high as 86%, when skin texture changes were included (7). Hypopigmentation was also common because of the high absorption of melanin at 514 nm (7). Particularly disturbing was the high incidence of scarring noted in children (7,8). The predictive values of age, color of the port-wine stain, and biopsy were helpful in defining prognostic parameters (8). Those patients over age 37, with purple-colored lesions, and a large target (large mean vascular area filled with erythrocytes) responded favorably (8). Darkly pigmented patients responded less than lighter skinned patients due to competitive absorption by melanin. A variety of manipulations to improve results included: prechilling the port-wine stain (9), using mechanical shutters and lower fluences (10), recommending test sites and observing for 2–4 months to predict outcome (11) and altering the treatment technique.
Continuous Wave Lasers
107
Figure 4.1 (a) Preoperative argon laser treatment of port-wine stain lip. (b) Postoperative argon laser treatment of port-wine stain lip.
Four treatment techniques were used to treat port-wine stains. A point-by-point or continuous technique with adjacent, but not overlapping spots (2), a striping technique utilizing parallel strokes that leaves a zebra look to the lesion while trying to minimize collateral heat damage (12), a dot or pointillistic technique delivering spots separated by 1 –2 mm (13), and, finally, a microspot tracing technique using a spot size equal to the blood vessel being photocoagulated (14). This latter technique proved to be tedious and time-consuming so that only small areas could be treated in a single session (15). Despite the attempts to improve clinical results, the argon laser was limited by the small spot sizes, the long pulse durations, and the short wave lengths (488 – 514 nm), which did not reach the depth necessary to coagulate the deeper vessels of port-wine stains (16). Histologic studies confirmed that the clinical finding observed with the argon lasertreated port-wine stains was the result of nonspecific coagulative necrosis of the superficial dermal ectatic blood vessels with subsequent fibrosis and small vascular channels replacing the superficial part of the lesion (16 – 18). The diffusion of heat collaterally caused nonspecific thermal damage leading to the potential of epidermal atrophy, depigmentation, dermal fibrosis, and scarring (19). The scarring was also more prominent in difficult areas such as the upper lip, nasolabial fold, angle of the jaw, and neck. The trunk responded less well than the face, the arms less well than the trunk, and the lower extremities responded poorly.
108
McMeekin
The role of argon laser therapy in the treatment of port-wine stains diminished with the development of lasers capable of selective photothermolysis (20) and the development of computerized robotized scanning devices (see section “Argon-Pumped Tunable Dye Laser”). The current role of argon laser treatment is for the treatment of nodules of hypertrophic port-wine stains in adults (Table 4.3). 1.3.
Perioperative Considerations
Preoperatively, laser patients should avoid sunlight for several weeks prior to argon irradiation or use total sunblocks such as zinc oxide or titanium dioxide. A representative consent form for laser surgery is included in Table 4.1. Topical anesthetics such as EMLA or lidocaine cream 30% can be used prior to intralesional anesthesia. Large lesions require either field blocks or intralesional lidocaine 1%. The use of epinephrine is not felt to alter the result of laser therapy of vascular lesions, and will prolong the duration of anesthesia. Toxicity with large quantities of topical or intralesional lidocaine must be avoided (21). Buffered lidocaine reduces the pain of injection and is recommended for larger areas. For the treatment of port-wine stains, a 1.0 mm spot is used with the handpiece held perpendicular to the skin at its focal length and 0.5– 0.8 W power. It is moved slowly enough to produce a white to grey response which represents thermal coagulation of tissue proteins and is the endpoint for port-wine stains. A continuous back-and-forth airbrushing method, either vertical, horizontal, or in concentric circles, is used. Solitary
Table 4.1 Consent Form for Laser Treatment of Vascular Lesions I certify that I have been informed by Dr. ________________ of the following: 1. The outcome of ________ laser therapy. 2. No guarantee of results has been made. 3. Possible side effects include hypopigmentation, hyperpigmentation, scarring, infection, and incomplete removal of lesion, discomfort, swelling, prolonged wound healing. 4. Alternative treatment methods including no treatment. 5. Treatment protocol, anesthesia requirements, laser safety and precautions necessary with laser goggles during procedure. For the treatment of _______________________________________. To minimize the chances of side effects and complications it is important that I follow all postoperative instructions carefully. I understand it may take multiple treatments to clear some lesions and no guarantee as to exact number of treatments has been made to me. I authorize the taking of photographs throughout the course of my laser treatment. These photographs may be used for the purpose of medical publication, education, and treatment decisions. I have been given the opportunity to ask questions, and have received satisfactory answers. I have read the contents of this consent and fully understand them before signing my name below. _______________________________________ Patient Signature
___________________ Date
_______________________________________ Witness Signature
___________________ Date
I have explained the above statements to the patient and answered all questions. _______________________________________ Physician Signature
___________________ Date
Continuous Wave Lasers
109
nodules can be coagulated, then the coagulum wiped away between subsequent passes until they flatten. If test sites are performed, an area representative of the entire lesion in the least conspicuous area is chosen. A 1 –2 cm area should be used for each fluence tested. Immediate postlaser irradiation, a topical antibiotic ointment or a bland healing ointment such as Aquaphor should be applied (Table 4.2). A semiocclusive dressing such as Opsite or Vigilon will speed wound healing and provide protection to the wound which takes several days to re-epithelialize. The patient may wash with soap and water twice daily and reapply the dressings until full healing occurs. Sunblocks are recommended for 2 months postoperatively to avoid hyperpigmentation. 1.4.
Telangiectasias
Telangiectasia treated with the argon laser lesions often results in complete disappearance of the vessels without significant sequelae [Fig. 4.2(a) and (b)] (22,23). Excellent results in linear ectatic vessels of the nose [Fig. 4.3(a) and (b)] (23), diffuse telangiectasia of rosacea (24), nevus araneus (25), and telangiectasia from scleroderma and radiation (23,24) were reported frequently with only one or two treatment sessions. Postrhinoplasty “red nose syndrome” has also been reported to respond to argon laser treatment, especially if superficial ectatic vessels were present (26). Although the success rate has been high in 65– 99% of patients with telangiectasia (2,24), the same problems with hypopigmentation, hyperpigmentation, recurrence of vessels, and depressed scars has been reported (27). To minimize these side effects, a small beam size and 50 ms shuttering has been recommended (15,28). With these caveats, the treatment of telangiectasia has been successful in the hands of skilled laser surgeons, making this application one of the remaining indications for argon laser therapy (Table 4.3). Higher power outputs are required for the shuttered method of treating linear telangiectasia. For a vessel 0.5 mm in diameter a laser spot of 0.5 mm should be used with a pulse duration of 0.03 s and 1 –3 W of power output or just enough to cause disappearance of the vessel without skin whitening. The vessels are traced with the handpiece perpendicular to the skin at the correct focal length.
Table 4.2 Patient Care Sheet for Post-Laser Treatment of Vascular Lesions 1. Wash twice daily with soap and water. Apply a topical antibiotic (Polysporin Ointment) or Aquaphor healing ointment. 2. Apply a semi-occlusive dressing after the ointment (Telfa or Vigilan) until the wound has healed (1 – 4 days). 3. If swelling occurs elevated use ice bag compresses several times daily for the first few days. 4. Take a nonaspirin analgesic such as Tylenol as needed should you experience any pain or discomfort. 5. Avoid direct sunlight for 2 months following laser treatment. 6. A sunscreen of 45 or higher (Solbar 50 or UVA Guard 45) or a titanium dioxide sunblock (PreSun for Sensitive Skin) should be used before sun exposure once the wound has healed. Sun-protective clothing and hats should be used when appropriate. 7. Avoid trauma to the area including contact sports until healing is complete. 8. Makeups are allowed immediately to camouflage the treated area, but care should be taken to avoid rubbing and irritation when removing. 9. Please call your physician if you have any questions or concerns regarding your postoperative care.
110
McMeekin
Figure 4.2 (a) Preoperative argon laser treatment of telangiectasias cheek. (b) Postoperative argon laser treatment of telangiectasias cheek.
Despite the success in facial telangiectasia, the treatment of lower extremity spider veins has been uniformly disappointing with worsening or no change in more than 49% of patients (29). 1.5.
Other Vascular Lesions
Many other benign lesions can be treated with the argon laser if they are vascular or have a vascular component. Cherry angioma (23), angiokeratoma (30), and venous lakes (24,31) all respond to continuous wave argon therapy, but may require several treatment sessions. Coagulation of the vascular lesion is the endpoint. Retraction or shrinkage of the lesion and superficial whitening of the epidermis occurs. Adenoma sebaceum (32,33), angiolymphoid hyperplasia (34), granuloma faciale (23), and Kaposi’s sarcoma (35) have also been treated with mixed results and a risk of scarring. 1.6.
Hemangiomas
Hemangiomas are the most common tumor of infancy and most commonly involve the head and neck. They usually develop after birth and undergo a rapid proliferative phase, followed by involution and regression. Many lesions leave fibro-fatty tissue and atrophy with telangiectasia as they resolve. Reconstructive surgery or treatment with
Continuous Wave Lasers
111
Figure 4.3 (a) Preoperative argon laser treatment of linear ectatic vessels nose. (b) Postoperative argon laser treatment of linear ectatic vessels nose.
the flashlamp pulsed dye laser at this late stage may lead to further improvement (35). Argon laser therapy has been used to treat these proliferative hemangiomas (36 – 39). The risks of scarring, inability to prevent the deeper component from continuing to proliferate, and the lack of depth of penetration (,1 mm) outweigh the potential benefit of treatment by argon laser (40). The treatment of choice for most hemangiomas that are superficial remains the flashlamp pulsed dye laser.
Table 4.3 Current Clinical Indications for Argon Laser Therapy 1. Nodules in mature port wine stains 2. Large linear telangiectasias of nose and face 3. Small vascular lesions: Angiokeratoma Cherry angioma Venous lakes 4. Small lesions with a vascular component: Angiolymphoid hyperplasia Adenoma sebaceum Granuloma faciale
112
1.7.
McMeekin
Pigmented Lesions
The majority of epidermal and dermal pigmented lesions can now be treated more selectively with Q-switched lasers (Chapters 10 – 13). A high complication rate of hypopigmentation and texture change accompanied the treatment of lentigines, cafe´ au lait, junctional nevi, seborrheic keratoses and nevus of Ota (41). Failure was noted in larger lesions of Becker’s nevi and cafe´ au lait (35). Tattoos are no longer treated with the argon laser due to the scarring noted and the new lasers (Chapter 24) capable of selective photothermolysis (42).
2. 2.1.
CONTINUOUS AND QUASICONTINUOUS ARGON-PUMPED TUNABLE DYE LASER Laser Parameters
The argon laser provides the power to an organic dye rhodamine, which can emit wavelengths from 488 to 638 nm. Most typically, the wavelength is tuned to 577 or 585 nm, where the absorption of oxyhemoglobin is maximal (20). Other wavelengths such as 540 nm have also been used to treat port-wine stains (43). The chromophores of melanin and oxyhemoglobin absorb the emitted light in varying degrees based on the selected wavelength. At 585 nm, the penetration of the light is approximately 1.0 mm. Spot sizes of 100 mm to 1.0 mm are available for fiber optic cable delivery. The beam can be delivered either in a continuous wave form, or mechanically shuttered to produce pulse durations from 20 ms to 2.0 s. Scanners are available with the Hexascan used the most extensively (44,45). Cooling is not available with the scanners, but a commercial cooling chamber can be adapted (cool laser optics, Westborough, MA). The argon-pumped tunable dye laser previously was manufactured by CoherentLihtan, but is no longer available. 2.2.
Indications—Port-Wine Stains
The development of the argon-pumped tunable dye laser paralleled the publication of the theory of selective thermolysis (20). Disappointment with argon laser therapy of port-wine stains was growing because of the high rate of scarring and the relative nonspecific coagulative necrosis observed (16). Early histologic studies of vessel damage at longer wavelengths (577 nm) showed more selective damage to vessels was feasible (46 –48). Two methods were developed to minimize collateral damage from the argon pumped tunable dye laser. The first was the use of low power, a small spot size, and a tracing technique previously described (section “Perioperative Considerations Under Continuous Wave Argon Laser”) (14,15). The second was a computerized scanner which gave precise control of dosimetry and allowed placement of small, 1 mm diameter treatment spots in nonadjacent locations in a grid. Using the tracing method, the early results published showed a good response in older patients with port-wine stains in over two-thirds [Figs. 4.4(a) and (b) and 4.5(a) and (b)], but a continued risk of hypopigmentation (15%), atrophic scarring (15%), and hypertrophic scarring (5%) (49). Other studies showed the argon pumped tunable dye laser to be as good as the argon laser in treating port-wine stains (50), or more effective (51). Children have also responded to this tracing method, but the average total treatment time per patient was 3 21 h (52). The use of scanners shortened the treatment times, but the development of more selective flash lamp pumped pulse dye lasers (PDLs) became the treatment of choice
Continuous Wave Lasers
113
Figure 4.4 (a) Preoperative argon pumped tunable dye laser treatment of port-wine stain cheek. (b) Postoperative argon pumped tunable dye laser treatment of port-wine stain cheek.
for children and adults (Chapters 7 and 23). Comparison studies of port-wine stains treated with a hexascan and the argon-pumped tunable dye laser at 585 nm vs. the PDL at 585 nm show greater lightening with the PDL in 40% after one treatment, with less hypopigmentation and hyperpigmentation (53).
2.3.
Perioperative Considerations
The preoperative planning and postoperative care are similar to the argon laser (see section “Continuous Wave Argon Laser”). For the tracing method, the argon-pumped tunable dye laser set at 577 nm is used with a 100 mm beam and power settings of 0.08–0.5 W. Using loupes of 8–10 power magnification vessels of 30–300 mm are traced using increasing power until the vessel disappears completely. The vessels are traced outward in concentric circles from a control point, with treatment sessions of 45–60 min, and areas covered averaging 1–2 in.2 (15). Retreatment can be performed after several months. With a hexascan, the suggested treatment parameters are 585 nm wavelength, 18–24 J/cm2 (depending on area, age of patient and vessel size) with 1–2 mm overlapping fields to prevent geometric patterning (45).
2.4.
Facial Telangiectasias
Comparison studies have also been done for facial telangiectasia (54,55). Using the tracing method and shuttered pulses, the flashlamp PDL had excellent results in 11 of 14 patients vs. just 4 of 14 with the tunable dye laser [Fig. 4.6(a) and (b)]. The purpura was a problem to 6 of 13 who preferred the tunable dye laser despite the poorer results (55). The same conclusions were reached in another study of facial telangiectasia using a robotized scanner and a tunable dye laser vs. the PDL. All patients in the pulsed dye laser treatment had 100% excellent results vs. 47% in the tunable dye group. Likewise, half the
114
McMeekin
Figure 4.5 (a) Preoperative argon pumped tunable dye laser treatment of port-wine stain neck. (b) Postoperative argon pumped tunable dye laser treatment of port-wine stain neck.
patients preferred the tunable dye due to the lower incidence of hyperpigmentation and lack of bruising (54). 2.5.
Argon-Pumped Tunable Dye Laser Pigmented Lesions
The results for pigmented lesions are similar to those of the argon laser. The use of the hexascan with the green light (514 nm) speeds up the treatment and clears lentigines in one or two treatments, and allows treatment of cafe´ au lait macules, nevus spilus, and Becker’s nevi (45). The longer pulse durations of 30 ms and the small relative spot size of 1 mm may limit the effectiveness in larger lesions. More selective wavelengths, and short pulse durations that approximate the thermal relaxation time of melanin makes the further use of this laser in pigmented lesions questionable (Chapter 26).
3. 3.1.
COPPER VAPOR LASERS/COPPER BROMIDE LASERS Laser Parameters
Both copper laser systems produce yellow light at 578 nm and green light at 511 nm by heating elemental copper or copper salts in the optical cavity. They differ only in the
Continuous Wave Lasers
115
Figure 4.6 (a) Preoperative argon pumped tunable dye laser treatment of telangiectasias nose. (b) Postoperative argon pumped tunable dye laser treatment of telangiectasias nose.
efficiency [1% copper bromide laser (CBL) vs. 0.5% copper vapor laser (CVL)] in energy conversion, the temperature at which they operate (6008C CBL and 16008C CVL) and the power output (CBL watts vs. CVL milliwatts). The light emitted is a train of 20 –40 ns high-energy pulses with pulse intervals of 63 ms and a frequency of 10– 16 kHz, with a peak power of 4 kW per pulse. Because the pulse intervals are too short for the targeted tissue (blood vessels) to thermally cool, the physiologic effect is a quasicontinuous pulse. The power output is generally measured as an average of the train of pulses. This quasicontinuous pulse train may be mechanically shuttered, used with a scanning device (see previous section) or used in a quasicontinuous mode to trace vessels. The light is delivered to a handpiece with spot sizes of 100 mm to 1.0 mm via a flexible quartz fiber. The chromophores for halide lasers are the same as argon, and argon PDLs, with absorption by melanin and oxyhemoglobin. The green band at 511 nm is used to target melanin, but the exposure times are longer than the thermal relaxation time of melanin. Q-switched lasers have since replaced the benign pigmented lesion applications of this laser. There were two manufacturers for the CVL: 1. 2.
Aesculap Meditec North America (Irvine, CA). Continuum Biomedical, Inc. [Livermore, CA (CBL)].
116
3.2.
McMeekin
Indications—Port-Wine Stains
At 578 nm, copper vapor laser light is mostly absorbed by oxyhemoglobin, and penetrates deeper than the argon laser. With melanin absorbing maximally at 300 –500 nm, the energy is less well absorbed by melanin. Histologically, the effects of this quasicontinuous laser on vessels is similar to other continuous wave lasers when used to trace vessels or treat port-wine stains freehand (56). More selective histology showing specific necrotic endothelial cells of ectatic vessels without rupture or hemorrhage while sparing epidermal and adjacent dermal structures was reported using a robotized scanner (57) and by mechanically shuttering the beam (58). Results comparing the argon laser to the copper vapor in treatment of port-wine stains are equivalent with the copper laser producing better fading (59). Thicker and darker port-wine stains with the so-called large vessels have been reported to respond well [Fig. 4.7(a) and (b)] (60). For subsequent treatments, the more selective pulsed dye lasers can be used to finish the smaller vessels. Excellent results were reported in 24% of 25 patients using the CVL with a hexascan and fluences of 12– 15 J/cm2. There was no response in 20% and adverse sequelae of hypopigmentation and scarring in 11 of 25 (60). The risk of hypopigmentation, especially in Fitzpatrick Type V skin, has been reported by several studies (61,62). CVL treatment of port-wine stains is not as selective in brown skin as compared to white skin. When treating brown skin, selection of minimal pulse widths and maximum power outputs are recommended (62). Two studies compared the CVL with a Hexascan and the flashlamp PDL in treatment of port-wine stains (63,64). The first found better fading of macular blanchable port-wine stains in the flashlamp PDL group without a significant difference in adverse reactions (63). An edge in clearing with the flashlamp PDL was also seen in the second study, but more adverse side effects such as hyperpigmentation were noted (64). It is generally felt that the PDL is safer, more effective and has an acceptable rate of side
Figure 4.7 (a) Preoperative copper vapor laser treatment of port-wine stain cheek. (b) Postoperative copper vapor laser treatment of port-wine stain cheek.
Continuous Wave Lasers
117
effects. It is noteworthy that copper vapor has been supplemented with PDL for port-wine stains except for port-wine stain nodules. 3.3.
Perioperative Considerations
The treatment of small lesions with the yellow light (578 nm) may not require anesthesia, but larger lesions or children require topical and/or field block anesthesia to minimize pain. The patient should avoid tanning preoperatively and caution should be used in Fitzpatrick skin types III –VI. Postoperatively, the wounds may occasionally blister or be edematous for several days. Ice packs, cool compresses, and topical antibiotic ointments are recommended routinely. Sun avoidance or sunblocks are advised for 2 months postoperatively. With magnifying loupes, the laser can be operated in a continuous tracing technique delivering 15,000 pulses per second with vessel disappearance at the end point. The actual dosimetry will depend on hand speed, the spot size, and average power settings. Typical port-wine stain settings for a 100 mm spot size would be 90 –140 mW for children under age 12; 120 – 180 mW for children age 12– 18; and 180 –260 mW for adults (65). For a field blanch or spot-by-spot method an entire contiguous area is treated using spot-byspot placement. Higher powers (25 – 50%) are required for the shuttered technique. Typically, a common setting is 0.2 s on and 0.2 s off. The endpoint again is vessel blanch or disappearance. Vessels are traced with treatment sessions varying from 5 –60 min (66). Typical settings for a CVL with a 150 mm spot size and a 600 mm optical fiber, using the above shuttering (0.2 s on, 0.2 s off ) were the lowest power (300 – 600 mW ) to achieve the end point (67). 3.4.
Facial Telangiectasia
One of the best indications for the CVL has been the treatment of facial telangiectasias [Fig. 4.8(a) and (b)]. The lack of purpura is a major factor in the success this treatment has enjoyed. Using the free-hand technique, one study of 20 patients showed good clearing in 18 of 20, with punctate scabbing seen in 50% and temporary hyperpigmentation in 15% [Fig. 4.9(a) and (b)] (67). The only nonresponders were the fine diffuse telangiectasias of rosacea, which respond better to PDL. Another study of 33 patients with telangiectasias had good to excellent results in two-thirds and only 19% with poor results (60). They also used the shuttered method with a 1 mm spot and pulse duration of 50– 200 ms. The nose and nasolabial fold were the most difficult areas with 7 of 33 showing atrophic scarring (60). Transient edema on the cheeks and eyelids lasting 1– 3 days was also observed. Similar transient edema has been reported in a study of 180 patients with almost 50% developing hypopigmentation (68). Good results were seen in 47% with further improvement to 86% seen in patients with combined CVL treatment and sclerotherapy of facial vessels (68). 3.5.
Other Vascular Lesions
Cherry angioma, venous lakes, and pyogenic granuloma have been reported to respond well to CVL treatment [Fig. 4.10(a) and (b)] (65). An advantage of quasicontinuous
118
McMeekin
Figure 4.8 (a) Preoperative copper vapor laser treatment of telangiectasias nose. (b) Postoperative copper vapor laser treatment of telangiectasias nose.
wave lasers such as the copper vapor in treating larger diameter vessels in venous malformations, as well as hypertrophic nodular port-wine stains, has been reported (69). Hemangiomas in the early proliferative phase have been treated with the CVL successfully with less than 1% risk of scarring (70). It is hypothesized that a photothermal reaction which provides a vasoconstrictive effect deeper than photothermolysis is responsible for some of the improvement (70). Other lasers such as the long-pulsed (1.5 ms) dye laser are more selective and have supplanted the CVL for the treatment of hemangioma as well as port-wine stains (Chapter 7). 3.6.
Pigmented Lesions
The green light band (511 nm) of the CVL may be used to treat benign pigmented lesions such as lentigines, freckles, dermatosis papulosa nigra, and seborrheic keratoses (71). Excellent results with few side effects were reported (71). A variable response is seen with larger lesions such as cafe´ au lait, Becker’s nevus, and melasma (72). Transient hyperpigmentation may be seen in up to 10%, which clears with hydroquinones (71). Other types of hyperpigmentation such as seen after sclerotherapy may respond in up to 69% of patients after one session with the CVL (73). The newer Q-switched lasers have replaced the copper vapor in treating pigmented lesions today.
Continuous Wave Lasers
119
Figure 4.9 (a) Preoperative copper vapor laser treatment of linear ectatic vessels nose. (b) Postoperative copper vapor laser treatment of linear ectatic vessels nose.
4. 4.1.
KTP LASERS Laser Parameters
The KTP laser is a frequency doubled Nd:YAG laser that produces a train of pulses at a frequency of 25,000 Hz at 532 nm wavelength. The 1064 nm light is converted to 532 nm
Figure 4.10 (a) Preoperative copper vapor laser treatment of hemangioma lip. (b) Postoperative copper vapor laser treatment of hemangioma lip.
120
McMeekin
with a KTP crystal (potassium titanyl phosphate). The Nd:YAG laser is continually pumped laser with a krypton arc lamp that is a switched type, producing nanosecond pulses. The light is delivered to the tissue via a fiberoptic cable (0.2 – 0.6 mm) with 1, 2, and 4 mm spot sizes. A scanner (Smartscan) is available, as is a cooling chamber. The quasicontinuous wave KTP laser, manufactured by Lasercope (San Jose, CA), has a modulated arc lamp that produces a greater average power (160 W) and can produce single pulses of 1 –50 ms, each composed of multiple nanosecond pulse trains. The 532 nm wavelength is near to one of oxyhemoglobin’s absorption peaks at 540 nm, and can be used to treat a variety of vascular cutaneous lesions.
4.2.
Indications—Port-Wine Stains/Telangiectasias
Histologically, the results from KTP laser are similar to argon laser, with obliteration of vessels in the upper dermis, dermal fibrosis, and normal re-epithelialization (74). Clinically, the results for port-wine stains are equivalent to CVL or the argon pumped tunable dye laser (75,76). The results on telangiectasia and port-wine stains have been good, producing vessel clearing with little to no purpura [see Figs. 4.11(a) and (b) and 4.12(a) and (b)] (77,78). Further comparison studies with the newer long PDLs and long pulse KTP lasers are needed (Chapters 7 and 9).
Figure 4.11 (a) Preoperative KTP laser treatment of telangiectasias nose/cheeks. (b) Postoperative KTP laser treatment of telangiectasias nose/cheeks.
Continuous Wave Lasers
121
Figure 4.12 (a) Preoperative KTP laser treatment of spider veins legs. (b) Postoperative KTP laser treatment of spider veins legs.
4.3.
Perioperative Considerations
The pre/postoperative considerations are similar to the argon and CVLs (see sections under “Continuous Wave Argon Lasers” and “Copper Vapor Lasers/Copper Bromide Lasers”). The treatment techniques vary. Using a 0.6 mm bore fiber passed directly into an hemangioma via a 20 gauge needle and 15 J of energy, hemangiomas can be treated. Using a 1 –4 mm spot at 5 W and 0.1 –1.0 s pulses with 0.2 s pulse duration generating a fluence of 127 J/cm2, nodular or adult port-wine stains can be treated. Finally, using a hexascan with fluences between 10 and 20 J/cm2 and pulse widths of 3 –5 ms, port-wine stains can be treated. A tracing technique similar to the copper vapor (see section under “Copper Vapor Lasers/Copper Bromide Lasers”) can be used for telangiectasia. 4.4.
Hemangioma
Intralesional bore fiber treatment of hemangiomas has been reported until shrinkage is seen or overlying heat is felt (79). About 92% of 12 patients had a greater than 50% reduction of hemangioma size, but only 8% maintaining this reduction at 6 months. Since one-third ulcerated after therapy and ulceration is associated with scar formation, this technique should be used with caution (40).
122
McMeekin
Figure 4.13 (a) Preoperative Krypton laser treatment of diffuse telangiectasia cheeks. (b) Postoperative Krypton laser treatment of diffuse telangiectasia cheeks.
Figure 4.14 (a) Preoperative Krypton laser treatment of matted telangiectasia cheeks. (b) Postoperative Krypton laser treatment of matted telangiectasia cheeks.
Continuous Wave Lasers
5. 5.1.
123
KRYPTON LASER Laser Parameters
Although the krypton laser has been used extensively in ophthalmology, it has more recently been introduced to dermatology. The krypton laser is a gas medium laser producing green light at 520 and 530 nm and yellow light at 568 nm. It is a continuous wave laser that can be shuttered to 50 ms pulses with pulse trains of 0.2– 10 s. It has two watts of green power and 1.0 W of yellow power in the HGM K1 Krypton Laser (HGM, Salt Lake City, UT). Selecting appropriate filters one can produce either yellow light at 568 nm, or green light with all three wavelengths. With all three wavelengths and a 1.0 mm spot, a fluence of 16 J/cm2 can be attained, which is enough to produce an endpoint of vessel disappearance. A digital autoscan is available. No external cooling chamber or spray are available. The chromophores are identical to the copper vapor previously discussed. 5.2.
Indications—Telangiectasia
Clinical studies using this laser are minimal. A retrospective questionnaire surveying 200 patients treated with the krypton laser in conjunction with microsclerotherapy found similar results to a CVL study by the same author (80). Sixty-four percent of patients had significant to total reduction in areas of their telangiectatic lesions, with 94% of
Figure 4.15 (a) Preoperative Krypton laser treatment of venous lake lip. (b) Postoperative Krypton laser treatment of venous lake lip.
124
McMeekin
patients reporting a better to much better appearance [Fig. 4.13(a) and (b)]. However, 11% of patients reported atrophic scarring. A second article describing the treatment technique for spider nevi [Figs. 4.14(a) and (b) and 4.15(a) and (b)], reported that a small scar is almost inevitable from krypton laser photocoagulation of these vessels, but was acceptable to the patients (81). Since PDLs rarely leave any scars, they remain the gold standard for the treatment of telangiectasias. Further study on the krypton lasers’ safety and efficacy in dermatology are needed. 5.3.
Operative Considerations
The preoperative and postoperative patient directions are similar to the other continuous wave lasers. The operative pain is less than with the CVL and only 13% require a local anesthetic (80). The technique for facial telangiectasia is to use the 1.0 mm spot and 50 ms pulse duration with exposure times of 0.1–0.2 s when treating central feeding arterioles of spider telangiectasia, or 0.2–0.4 s when used to treat linear telangiectasias, with powers of 1.8–2.5 W. Generally, all three wavelengths are used together to get sufficient energy to photocoagulate the vessels (80). Blanching of the epidermis is avoided and a visual and audible popping of the central vessel is an endpoint on spider telangiectasia (81).
REFERENCES 1. 2. 3. 4. 5. 6. 7. 8.
9. 10. 11. 12.
13.
Goldman L, Dfreffer R, Rockwell JR Jr, Perry E. Treatment of port wine marks by an argon laser. J Dermatol Surg 1976; 2:385 –388. Apfelberg DB, Maser MR, Lash H. Argon laser management of cutaneous vascular deformities. A preliminary report. West J Med 1976; 124:99 – 101. Touquet VL, Carruth JA. Review of the treatment of port wine stains with the argon laser. Lasers Surg Med 1984; 4:191 – 199. Silver L. Argon laser photocoagulation of the port wine stain haemangiomas. Lasers Surg Med 1986; 6:24 – 28, 52– 55. Dixon JA, Gilbertson JJ. Argon and neodynium YAG laser therapy of dark nodular port wine stains in older patients. Lasers Surg Med 1986; 6:5– 11. Masser MR, Sammut DP, Jones SG, Saxby PJ. Argon laser therapy of port wine stains— prediction of the effect by transcutaneous microscopy. Lasers Med Sci 1989; 4:237– 240. Dixon JA, Huether S, Rotering R. Hypertrophic scarring in argon laser treatment of port wine stains. Plast Reconstr Surg 1984; 73:771– 780. Noe JM, Barsky SH, Geer DE, Rosen S. Port wine stains and the response to argon laser therapy: successful treatment and the predictive role of color, age, and biopsy. Plast Reconstr Surg 65:130– 136. Gilchrest BA, Rosen S, Noe JM. Chilling port wine stains improves the response to argon laser therapy. Plast Reconstr Surg 1982; 69:278 – 283. Brauner G, Schliftman A, Cosman B. Evaluation of argon laser surgery in children under 13 years of age. Plast Reconstr Surg 1991; 87:37 – 43. Cosman B. Experience in argon laser therapy of port wine stains. Plast Reconstr Surg 1980; 65:119 – 129. Apfelberg DB, Flores JT, Maser MR, Lash H. Analysis of complications of argon laser treatment for port wine hemangiomas with reference to striped technique. Lasers Surg Med 1983; 2:357 – 371. Apfelberg DB, Smith T, Maser MR, Lash H. Dot or pointillistic method for improvement in results of hypertrophic scarring in the argon laser treatment of port wine hemangiomas. Lasers Surg Med 1987; 6:552 – 558.
Continuous Wave Lasers 14.
15.
16.
17. 18. 19.
20. 21. 22. 23. 24. 25. 26. 27. 28. 29.
30. 31. 32. 33. 34.
35. 36.
37.
125
Schreibner A, McCarthy WH. An improved method of removal of port wine stains, venule and capillary flares using an argon laser with minimal power, small spot and longer duration exposure. Lasers Surg Med 1984; 3:368– 371. Scheibner A, Wheeland RG. Argon-pumped tunable dye laser for facial port stain hemangiomas in adults—new technique using a small spot size and minimal power. J Dermatol Surg Oncol 1989; 15:277– 282. Tan OT, Carney JM, Margoli R, Seki Y, Bell J, Anderson RR, Parrish JA. Histologic responses of port-wine stains treated by argon, carbon dioxide, and tunable dye lasers. A preliminary report. Arch Dermatol 1986; 122:1016 –1022. Finley JL, Barsky SH, Geer DE, Kamat BR, Noe JM, Rosen S. Healing of port-wine stains after argon laser therapy. Arch Dermatol 1981; 117:486 – 489. Finley JL, Arndt KA, Noe J, Rosen S. Argon laser –port-wine stain interaction. Immediate effects. Arch Dermatol 1984; 120:613– 619. Greenwald J, Rosen S, Anderson RR, Harrist T, MacFarland F, Noe J, Parrish JA. Comparative histologic studies of the tunable dye (at 577 nm) laser and argon laser: the specific vascular effects of the dye laser. J Invest Dermatol 1981; 77:305 – 310. Anderson RR, Parrish JR. Selective photothermolysis precise microsurgery by selective absorption of pulsed radiation. Science 1983; 220:524 – 527. Goodwin D, McMeekin T. A case of lidocaine cream absorption from topical administration of 40% lidocaine cream. J Am Acad Dermatol 1999; 41:280– 281. Apfelberg DB, Maser MR, Lash H, Rivers JL. Progress report on extended clinical use of the argon laser for cutaneous lesions. Lasers Surg Med 1980; 1:71– 83. Arndt KA. Argon laser therapy of small cutaneous vascular lesions. Arch Dermatol 1982; 118:220 – 224. Achauer BM, Vanderkam VM. Argon laser treatment of telangiectasia of the face and neck: 5 years experience. Lasers Surg Med 1987; 7:495 –498. Tan OT, Gilchrest BA. Laser therapy for selected cutaneous vascular lesions in the pediatric population: A review. Pediatrics 1988; 82:652 –662. Noe JM, Finley J, Rosen S, Arndt KA. Postrhinoplasty “red nose”: differential diagnosis and treatment by laser. Plast Reconst Surg 1981; 67:661 – 664. Dolsky RL. Argon laser surgery. Surg Clin N Am 1984; 64:861 – 879. Cosman B. Role of retreatment in minimal-power argon laser therapy for port wine stains. Laser Surg Med 1982; 2:43 – 57. Apfelberg DB, Maser MR, Lash H, White DN, Flores JT. Use of the argon and carbon dioxide lasers for treatment of superficial venous varicosities of the lower extremity. Lasers Surg Med 1984; 4:221 – 231. Flores JT, Apfelberg DB, Maser MR, Lash H, White D. Angiokeratoma of fordyce: successful treatment with the argon laser. Plast Reconstr Surg 1984; 74:835– 838. Landthaler M, Haina D, Waidelich W, Braun-Falco O. Laser therapy of venous lakes (BeonWalsh) and telangiectasias. Plast Reconstr Surg 1984; 73:78 – 83. Janniger CK, Goldberg DJ. Angiofibromas in tuberous sclerosis: comparison of treatment by carbon dioxide and argon laser. J Dermatol Surg Oncol 1990; 16:317– 320. Arndt KA. Adenoma sebaceum: successful treatment with the argon laser. Plast Reconstr Surg 1982; 70:91 – 93. Cheney ML, Googe P, Bhatt S, Hibbard PL. Angiolymphoid hyperplasia with eosinophilia (histiocytoid hemangioma): evaluation of treatment options. Ann Otol Rhinol Laryngol 1993; 102:303 – 308. Dover JS, Arndt KA, Geronemus RG, Alora MBT. Illustrated Cutaneous and Aesthetic Laser Surgery. 2nd ed. Stamford, CT: Appleton and Lange, 2000:147 – 181. Apfelberg DB, Greene RA, Maser MR, Lash H, Rivers JL, Laub DR. Results of argon laser exposure of capillary hemangiomas of infancy—preliminary report. Plast Reconstr Surg 1981; 67:188 – 193. Hobby LW. Further evaluation of the potential of the argon laser in the treatment of strawberry hemangiomas. Plast Reconstr Surg 1993; 71:481 – 489.
126 38. 39. 40. 41. 42. 43. 44. 45. 46.
47. 48.
49. 50. 51. 52. 53.
54.
55. 56. 57.
58. 59.
60.
61.
McMeekin Achauer BM, Vanderkam VM. Argon laser treatment of strawberry hemangioma in infancy. West J Med 1984; 143:628– 632. Hobby LW. Visible light CW and quasi-CW laser treatment of superficial vascular lesions in children. Lasers Surg Med 1986; 6:16– 19. Goldman MP, Fitzpatrick RE. Cutaneous Laser Surgery. 2nd ed. St. Louis, MO: Mosby, 1999: 19– 178. McBurney EI. Clinical usefulness of the argon laser for the 1990s. J Dermatol Surg Oncol 1993; 19:359 – 362. Spicer MS, Goldberg DJ. Lasers in dermatology. J Am Acad Dermatol 1996; 34:1– 25. Hulsbergen-Henning JP, VanGemert MS. Port wine stain coagulation experiments with a 540-nm continuous wave dye laser. Lasers Surg Med 1983; 2:205– 210. Mondon S, Rotteleur G, Brunetaud JM, Apfelberg DB. Rationale for automatic scanners in laser treatment of port wine stains. Lasers Surg Med 1993; 13:113 – 123. McDaniel DH. Clinical usefulness of the hexascan. J Dermatol Surg Oncol 1993; 19:312 – 319. Anderson RR, Parrish JA. Microvasculature can be selectively damaged using dye lasers: a basic theory and experimental evidence in human skin. Lasers Surg Med 1981; 1:263 – 276. Anderson RR, Jaenicke KF, Parrish JA. Mechanisms of selective vascular changes caused by dye lasers. Lasers Surg Med 1983; 3:211 – 215. Greenwold J, Rosen S, Anderson RR, Harrist T, MacFarland F, Noe J, Parrish J. Comparative histological studies of the tunable dye (at 577 nm) laser and argon laser: the specific vascular effects of the dye laser. J Invest Dermatol 1981; 77:305 – 310. Lanigan SW, Cartwright P, Cotterill JA. Continuous wave dye laser therapy of port wine stains. Br J Dermatol 1989; 121:345 – 352. Malm M, Rigler R, Jurell G. Continuous wave (CW ) dye laser vs CW argon laser treatment of port wine stain (PWS). Scand J Plastic Reconstr Surg Hand Surg 1988; 22:241 – 244. Bandol Y, Yanai A, Tsuzuki K. Dye laser treatment of port-wine stains. Aesthetic Plast Surg 1990; 14:287 – 291. Scheibner A, Wheeland RG. Use of the argon-pumped tunable dye laser for port wine stains in children. J Dermatol Surg Oncol 1991; 17:735 – 739. Dover JS, Geronemus R, Stern RS, O’Hare D, Arndt KA. Dye laser treatment of port-wine stains: comparison of the continuous-wave dye laser with a robotized scanning device and the pulsed dye laser. J Am Acad Dermatol 1995; 32:237 –240. Ross M, Watcher MA, Goodman MM. Comparison of the flashlamp pulsed dye laser with the argon tunable dye laser with robotized handpiece for facial telangiectasia. Lasers Surg Med 1993; 13:374 – 378. Broska N, Martinho E, Goodman M. Comparison of the argon tunable dye laser in treatment of facial telangiectasia. J Dermatol Surg Oncol 1994; 20:749– 753. Tan OT, Stafford TJ, Murray S, Kurban AK. Histologic comparison of the pulsed dye laser and copper vapor laser effects on pig skin. Lasers Surg Med 1990; 10:552– 558. Neumann RA, Knobler RM, Leonhartsberger H, Gebhart W. Comparative histochemistry of port wine stains after copper vapor laser (578 nm) and argon laser treatment. J Invest Dermatol 1992; 99:160 – 167. Walker EP, Butler PH, Pickering JW, Day WA, Fraser R, Van Halewyn CN. Histology of port wine stains after copper vapor laser treatment. Br J Dermatol 1989; 121:217 – 223. Sheehan-Dare RA, Cotterill JA. Copper vapour laser treatment of port wine stains: clinical evaluation and comparison with conventional argon laser therapy. Br J Dermatol 1993; 128:546 – 549. Neumann RA, Leonhartsberger H, Bohler-sommeregger K, Knebler R, Kokoschka EM, Honigsmann H. Results and tissue healing after copper-vapour laser (at 578 nm) treatment of port wine stains and facial telangiectases. Br J Dermatol 1993; 128:306– 312. Haedersdal M, Wolf HC. Risk assessment of side effects from copper vapor and argon laser treatment: the importance of skin pigmentation. Lasers Surg Med 1997; 20:84 –89.
Continuous Wave Lasers 62. 63.
64.
65.
66. 67. 68. 69. 70. 71. 72.
73.
74. 75. 76. 77. 78. 79. 80. 81.
127
Chung JH, Koh WS, Youn JI. Histologic responses of port wine stains in brown skin after 578 nm copper vapor laser treatment. Lasers Surg Med 1996; 18:358– 366. Sheehan-Dare RA, Cotterill JA. Copper vapor laser (578 nm) and flashlamp-pumped pulsed dye laser (585 nm) treatment of port wine stains: result of a comparative study using test sites. Br J Dermatol 1994; 130:478 – 482. Dover JS, Geronemus R, Stern RS, O’Hare D, Arndt KA. Dye laser treatment of port wine stains: comparison of the continuous-wave dye laser with a robotized scanning device and the pulsed dye laser. J Am Acad Dermatol 1995; 32:237 – 240. Waner M, Dinehart S. Lasers in facial plastic surgery and reconstructive surgery. In: Davis RK, Sharpstrag S, eds. Lasers in Otolaryngology/Head and Neck Surgery. Philadelphia, PA: Saunders, 1989:156 – 191. McCoy SE. Copper bromide laser treatment of facial telangiectasia: results of patients treated over five years. Lasers Surg Med 1997; 2:329 – 340. Key JM, Waner M. Selective destruction of facial telangiectasia using a copper vapor laser. Arch Otolaryngol Head Neck Surg 1992; 118:509– 513. Thibault PK. Copper vapor laser and microsclerotherapy of facial telangiectases. J Dermatol Surg Oncol 1994; 20:48 – 54. Pickering JW, Walker RHB, Haleway CN. Copper vapor laser treatment of port wine stains and other vascular malformations. Br J Plast Surg 1990; 43:273– 282. Waner M, Suen JY, Dinchart S. Treatment of hemangiomas of the head and neck. Laryngoscope 1992; 10:1123– 1132. Dinchart SM, Waner M, Flock S. The copper vapor laser for treatment of cutaneous vascular and pigmented lesions. J Dermatol Surg Oncol 1993; 19:370– 375. Levine VJ, Lee MS, Geronemus RG, Arndt KA. Continuous-wave and quasi-continuous save lasers. In: Arndt KA, Dover JS, Olbricht SM, eds. Lasers in Cutaneous and Aesthetic Surgery Ch 5. Philadelphia, PA: Lippincott-Raven Publishers, 1997:67 – 107. Thibault P, Wlodanarczyk J. Postsclerotherapy hyperpigmentation. The role of ferritin levels and the effectiveness of treatment with the copper vapor laser. J Dermatol Surg Oncol 1992; 18:42 – 52. Apfelberg DB, Bailin P, Rosenberg H. Preliminary investigation of KTP/532 laser light in the treatment of hemangiomas and tattoos. Lasers Surg Med 1986; 6:38 – 42. Keller GS. Use of the KTP laser in cosmetic surgery. Am J Cosmetic Surg 1992; 9:177– 182. Routteleur G, Mordon S, Brunetaud JM. Argon 488 – 415, Nd:YAG 532, and CW dye 585 lasers for port wine stain treatment using the hexascan. Lasers Surg Med Suppl 1991; 3:68. Dierickx CC, Farinelli WA, Flotte T, Anderson RR. Effect of long pulsed 532 nm Nd:YAG laser on port wine stains. Lasers Surg Med Suppl 1996; 8:188. Be Silver, Livshots YL. Preliminary experience with the KTP/532 nm laser in the treatment of facial telangiectasia. Cosmetic Dermatol 1996; 9:61 – 64. Achauer BM, VanderKam VM, Celikoz B. Intralesional bore fiber laser treatment of hemangioma. Lasers Surg Med 1997; 9:41. Thibault PK. A patients questionnaire evaluation of krypton laser treatment of facial telangiectases—a comparison with the copper vapor laser. Dermatol Surg 1997; 23:37 – 41. Patel BC. The krypton yellow-green laser for the treatment of facial vascular and pigmented lesions. Semin Ophthalmol 1998; 13:158 –170.
5 Continuous Wave and Pulsed CO2 Lasers E. Victor Ross Naval Medical Center and University of California, San Diego, California, USA
1. Background 1.1. Physical Properties 1.2. Beam Profiles 1.3. Mechanically Shuttered Pulses and Superpulsing 1.4. Laser Spot Size 1.5. Delivery Systems 1.6. General Operating Principles 2. Laser – Tissue Interactions 2.1. Physics 2.2. Residual Thermal Damage 2.3. Clinical Examples of Laser – Tissue Interactions 2.3.1. High PD, Short Exposure Time 2.3.2. Long Exposures in CW Low –Medium PD Defocused Mode 2.3.3. Very Low PDs and Short Exposures 2.3.4. High PDs with Small Spots (0.1 – 0.3 mm), Used in Incisions 3. Comparison of the Resurfacing Lasers 3.1. UltraPulse 3.2. The SilkLaser 3.3. The NovaPulse 3.4. Nidek Unipulse 3.5. TruPulse 3.6. Summary of Resurfacing Systems 4. Wound Healing after CO2 Laser 5. Ultrastructure after CO2 LSR 6. Applications 6.1. Applications Where the Laser Performs Better Than Most Other Modalities 6.1.1. Trichoepitheliomas 6.1.2. Adenoma Sebaceum 6.1.3. Common Warts
131 131 131 132 133 133 134 134 134 135 138 138 139 140 140 141 142 142 143 143 144 144 144 145 145 146 147 147 148 129
130
6.1.4. Condyloma Acuminata 6.1.5. Nail Matrixectomy 6.1.6. Earlobe Keloids 6.1.7. Larger Keloids and Nonearlobe Keloids 6.2. Acne Keloidalis Nuchae 6.2.1. Pyogenic Granuloma 6.2.2. Actinic Cheilitis 6.2.3. Sebaceous Hyperplasia 6.2.4. Epidermal Nevi 6.2.5. Syringoma 6.2.6. Xanthelasma 7. Lesions that Might Be Treated Equally Well with Other Modalities 7.1. Seborrheic Keratoses 7.2. Dermatosis Papulosis Nigra 7.3. Neurofibromas 7.4. Steatocystomas 7.5. Pearly Penile Papules 7.6. Basal Cell Carcinoma 7.7. Bowen’s Disease 7.8. Hidradenitis Suppurativa 7.9. Scar Revisions 7.10. Chondrodermatitis Nodularis Helicus 7.11. Lymphangioma Circumscriptum 7.12. Nevus Sebaceous 7.13. Hydrocystoma 7.14. Histiocytoma or Xanthoma Disseminatum 7.15. Hailey – Hailey and Darier’s Disease 7.16. Kaposi’s Sarcoma 7.17. Tattoos 7.18. Disseminated Superficial Actinic Porokeratosis 7.19. Actinic Keratosis 8. Laser Sterilization 9. Technique Pearls 9.1. CW Vaporization 9.2. Cutting 10. Laser Safety Issues Specific to the CO2 Laser 11. New Developments 12. Pre- and Postoperative Considerations 12.1. Preoperative Considerations 12.1.1. Relative Contraindications 12.1.2. Preoperative Regimen 12.1.3. Postoperative Care 13. Conclusions References Appendix I: Sample Operative Note Appendix II: Consent Form Appendix III: Sample Postoperative Instructions Appendix IV: Patient Information Handout
Ross
150 150 151 151 152 152 153 154 155 156 156 157 157 157 157 158 158 159 159 159 159 160 160 160 160 160 161 161 161 162 162 162 162 162 163 163 164 164 164 164 165 165 165 166 176 177 178 178
Continuous Wave and Pulsed CO2 Lasers
1.
131
BACKGROUND
The CO2 laser was one of the first lasers to be used surgically. Since its invention by Patel in 1964, the laser’s strength is linked to its high absorption by water at 10.6 mm. The first published studies using the CO2 laser emphasized the device as a cutting tool with improved hemostatic capabilities over scalpel surgery, and typically the laser was used with a tightly focused beam (1). Subsequently, especially in dermatology, the laser has been used more as a defocused vaporizing or controlled heating tool. With the CO2 laser, one can simultaneously hold a coagulator, scalpel, and vaporizer, depending on the power density (2). 1.1.
Physical Properties
CO2 lasers are pumped electrically, that is, the laser cavity is excited by electrical discharges. All but one of the CO2 lasers presently used in cutaneous surgery are longitudinally excited, meaning that the pumping occurs at the ends of the sealed tube. One laser, the TruPulse (Tissue Technologies, Albuquerque, NM) is transversally excited, meaning that the electrical discharge occurs across the tube. Carbon dioxide lasers use a mixture of CO2 , N2 , and helium as the lasing medium. Doping of the CO2 gas with other elements, particularly nitrogen, increases the laser’s efficiency. There are multiple energy transitions for the CO2 laser, so that 10.6 mm is not the only possible emitted wavelength. The 10.6 mm photons are created when CO2 molecules drop from a higher-energy asymmetric stretching mode to a lower-energy stretching or bending mode. The wavelengths are longer than those in visible light lasers because the transitions are of the rotational/vibrational type, whereas the ruby laser, for example, involves moving electrons into higher and lower stages (electronic transitions) (3 – 8). The overall efficiency (5 –20% from the wall plug) of CO2 lasers is among the highest of all lasers. This efficiency is one reason why a room with a CO2 laser tends to get less hot than a room with a solid state laser, where the efficiency is less than 1%, and much of the remainder of the energy is wasted as heat (6). CO2 lasers are capable of a large range of powers. In medicine the range is usually 10 – 100 W continuous wave (CW) power, and up to 10,000 W peak power for pulsed applications. Conventional medical CO2 lasers develop about 50 W average power per meter length of the tube, so that a taller laser tower (the upright part of the laser) is associated with more power (6). 1.2.
Beam Profiles
Most CO2 laser beam profiles are Gaussian (TEM 00), which is a function of the way the beam is created in the laser cavity. The Gaussian beam profile is bell shaped, and because it tends to be stable and easy to propagate through an articulated arm, it is a desirable beam profile to have from an engineering perspective. However, the Gaussian beam profile also creates nonuniform local fluences at the skin surface (4,9,10). These nonuniformities, however, are typically mitigated by (1) the delivery device, (2) the user’s choice of fluences, and (3) the skin lesion itself. For example, scanners can be configured to deliver various degrees of overlap that decrease the effects of the “wings” of the Gaussian profile, creating a more uniform surface fluence. Also, the user can choose lower fluences (at or near the ablation threshold) in resurfacing that allow for fairly uniform heating across the spot. Finally, many skin lesions are bell-shaped, which naturally accommodates the bell-shaped beam profile if one is trying to ablate an exophytic lesion such as a verruca or an adnexal tumor.
132
Ross
The TruPulse laser runs multimode, so that it has a flatter beam profile. However, multimode beam profiles usually have a larger beam waist and are more difficult to focus to a uniform spot. Like the TruPulse, the Novapulse laser (Lumenis, Norwood, MA) beam profile is more flat-topped than Gaussian. In this case, the flatter beam profile is the result of mode mixing as the beam bounces along the inside walls of the hollow waveguide delivery device (11). Top hat profiles have been described as ideal, but it is the specific application and the skill of the physician that determines the “idealness” of a beam profile.
1.3.
Mechanically Shuttered Pulses and Superpulsing
Older CO2 lasers were either truly CW or operated at such a high frequency that the laser tissue interaction was, for all intents and purposes, CW. Early attempts to control laser exposure times involved the use of mechanical shutters to “chop” the pulse. The shortest possible exposures available with these devices were typically 50 –100 ms. Because the peak powers were low (the same as the average power, or 10– 30 W), the power densities were often subablative or marginally supra-ablative, and the only advantage was confinement of thermal injury to a level not observed with longer exposures (and higher fluences). The next generation of CO2 lasers used so-called “superpulsed (SP) technology”. Pulses were on the order of 50– 200 mJ and were delivered with varying repetition rates (50 –500 Hz). Sometimes they were delivered as couplets spaced very close together temporally. Unlike gated or mechanically shuttered pulses, however, these laser emissions were truly pulsed, that is, they were generated at the electrical source as pulsed exposures. These lasers delivered average powers similar to CW lasers, but the lasers were not “on” all of the time (Fig. 5.1). The older SP lasers only performed at very high repetition rates [so-called rapid superpulsed mode (RSP)], because of engineering limitations. The laser used a train of pulses, as few as 12, in trains of 50 ms or more. Even some newer SP lasers run only at repetition rates of 300 Hz, so that single-pulse ablation/heating is not
Figure 5.1 Differences between CW, mechanically shuttered, and RSP modes.
Continuous Wave and Pulsed CO2 Lasers
133
possible. Most SP lasers have a nonconstant pulse profile, so that the tail of the micropulse has a lower irradiance than the initial portion of the micropulse. This characteristic, and the rapid repetition rate, has contributed to levels of thermal damage not much lower than those of CW lasers. To minimize residual thermal damage (RTD) with RSP lasers, duty cycles should be low, or the repetition rate will be too high and thermal damage will accumulate (12 –14). Even though thermal damage was reduced somewhat by RSP lasers (typically by 10 – 30% using the same average power and fluence as in comparable CW applications) (15,16), it was not until the introduction of high-energy pulsed lasers with low repetition rates (single-pulse effects) and scanners that the full advantages of SP CO2 lasers were realized for defocused ablative and near-ablative applications (17,18). The term “UltraPulse,” used by a leading manufacturer, refers to a subset of superpulsed lasers with a rectangular pulse profile, capability of low repetition rates, and higher peak powers than older first-generation SP lasers. In a pulsed CO2 laser, there is a capacitor network that stores charge across the cavity electrode. Pulsed CO2 lasers can be excited by either direct current (DC) or radiofrequency (RF) power supplies. The RF laser develops high peak powers more easily than DC lasers, as RF excitation achieves and maintains the population inversion more efficiently within the cavity (see Chapter 2). Analogous to the ideal beam profile (top hat), the ideal temporal pulse shape should be rectangular, that is, the pulse is instantaneously turned on or off. The RF laser is the most capable of producing these “rectangular pulses” with a minimal tail. Most CO2 lasers in medicine are excited by a DC. The exceptions are the UP and Novapulse lasers, which are RF excited (11,13). For the remainder of the chapter, we will describe exposures as RSP mode, UltraPulse (UP) mode, or CW mode. We will refer to “mechanically shuttered” pulses simply as shorter exposures in CW mode.
1.4.
Laser Spot Size
Spot size can be estimated by irradiating a tongue blade for a brief period. However, these simple spot size measurements are sometimes deceptive, because they depend partly on the damage threshold of the target. For example, if one takes the UltraPulse laser and uses the 3 mm spot with very low pulse energy, only the center of the spot will be heated sufficiently, and the operator might mistakenly underestimate the spot size. Rigorous spot size measurements are made by profiling the beam by either moving a pinhole, using a knife edge, or using a dedicated beam profiler. The method allows one to see the point where the local power density is 14% of that at the center, which has arbitrarily been defined as the edge of the spot for a Gaussian beam.
1.5.
Delivery Systems
Usually, CO2 lasers work with a rigid articulated arm. The arm preserves the profile of the beam but sometimes results in cumbersome positioning between the operator and target. Arms may be fragile and mirrors may be knocked out of alignment during movement of the laser, making it imperative to test the laser on a tongue depressor prior to each use. Solid fiber delivery systems presently are impractical for IR radiation, as the materials are hygroscopic and not durable enough for pulsed laser systems (8,11). Hollow waveguide delivery devices will be discussed later.
134
1.6.
Ross
General Operating Principles
In general, when the CO2 laser runs in CW mode, a footswitch or mechanical shutter controls the total time on tissue. In CW mode the operator is using the laser in either a defocused or a focused manner. This is dependent on the distance between the skin and the handpiece. Most lasers have a focusing handpiece whose focal length is roughly 100 mm. The focal length is the distance from the end of the spatula tip to the lens. Normally, the focal plane is at the end of the tip. Longer focal lengths are usually associated with larger spots and greater depths of field. The depth of field is how much one can move the handpiece to and from the target and skin without significantly altering the spot size. The lens in the handpiece, which one can see by peering into the proximal portion of the handpiece, is usually made of zinc selenide, as standard glass absorbs CO2 energy. The lens focuses a somewhat collimated 7– 12 mm beam that has propagated from “knuckle to knuckle” to the distal end of the articulated arm. The operator can rapidly switch from a vaporizing to a heating mode (or vice versa) by moving the handpiece away from or toward the skin. As one pulls back from the skin, the beam is defocused. In this way, one can vary the power density according to the individual goals of the application. Some manufacturers provide handpieces with lenses that produce collimated beams, such as the TruSpot by Coherent. These allow the physician to work at varying distances from the skin surface with constant spot sizes. Regardless of the handpiece, one will see the greatest power density (PD) at the middle of the spot for Gaussian beams. The power density at the beam center is two times that of the average power density across the spot (12,19). It follows that one sees the greatest ablation at the center of the spot, and normally charring at the periphery.
2. 2.1.
LASER – TISSUE INTERACTIONS Physics
There are four important components in the CO2 laser – tissue interaction (20,21): 1. The propagation of the beam in tissue: When the CO2 laser beam impacts the skin surface, attenuation of the beam is guided by Beer’s law, which describes an exponential reduction in beam strength. Optical absorption and scattering determine the optical penetration depth (OPD) of the laser beam in the skin. The beam is rapidly attenuated (by about 85% within 40 mm) due to the high water content of the epidermis and dermis. This implies that if there is no ablation, the depth of the thermal effect will only be about 20 –40 mm if there is perfect thermal confinement (see Chapter 2) (22 –24). One might ask, if the beam is attenuated so much after only 20 –40 mm, why is there thermal damage and vaporization hundreds of micrometers and even millimeters into the skin? The reason is that Beer’s law describes only the optical attenuation of the beam. However, ablation and tissue heating during the pulse as well as postpulse heat conduction, result in deeper tissue injury. If there is significant ablation, the front (or boundary of the laser – tissue interaction) is constantly changing. In other words, the beam impact point is starting at increasing depths in the skin but still maintaining 20 – 40 mm of optical penetration beyond the front. 2. The instantaneous absorption of laser energy: The next step in laser – tissue interaction is conversion of laser irradiation to heat, which is instantaneous within the optical field. For all lasers, except ultra-SP lasers and the excimer laser, the major means of destroying tissue is the conversion of light to heat. The resulting heat deposition results
Continuous Wave and Pulsed CO2 Lasers
135
in either ablation or coagulation at the local level, depending mostly on the PD, or the time rate of energy delivery (W/cm2). Interestingly, the original PD ranges for CO2 lasers were chosen somewhat arbitra1 rily, but loosely based on the principle that it required 2.5 J over 10 s to convert 1 mm3 of water to steam. This required about 25 W average power (1). The threshold for tissue vaporization with the CO2 laser is about 100 –150 W/cm2, but at this low power density, there is much wasted heat with as much as 55% of the energy not used in ablation (12). It follows that the highest PD possible should be used that allows for control of the depth of injury. With standard CW lasers, the surgeon was forced to use a lower PD for control of vaporization depth, thereby increasing collateral thermal damage, or a higher PD for minimal RTD, but with more difficulty controlling the amount of removed tissue. One can think of the CO2 laser with high PD as delivering energy in such a rapid way that vaporization predominates over heating. In contrast, at lower irradiances of ,1000 W/cm2, heating predominates over vaporization (12,19). In both cases, the level of tissue destruction, which is the sum of depth of ablation plus residual thermal damage, will increase with exposure time. In the former case, the damage will be by tissue heating, and in the latter, by tissue vaporization. 3. The conduction of heat outside the OPD: This occurs on a much slower time scale than the aforementioned instantaneous heating due to absorption of the beam by tissue water and collagen. There is some absorption of 10.6 mm photons by dry collagen, but it is very small compared to tissue water. Because skin possesses high density and specific heat much like that of water, thermal diffusivity is high, and subsequently heat conduction is relatively poor. The temperature profiles deep to the OPD depend largely on the PD. If the energy is deposited before there is time for heat diffusion, thermal damage will be minimized (20,22,25 – 28). 4. Local denaturation of tissue: Finally, thermal damage is predicted from models that predict protein denaturation based on time – temperature combinations. This denaturation is based on integral equations where the denaturation is linearly dependent on time and exponentially dependent on temperature. In other words, by raising the temperature only by 10 – 208C, one requires only 1/10 the exposure time for equal denaturation (29).
2.2.
Residual Thermal Damage
Venugopalan and others have critically examined the various parameters that affect RTD in ablative and nonablative laser applications and have found the following (26): 1. Effect of ablation: Supra-ablative fluences and power densities are generally considered to be associated with less thermal damage than laser –tissue interactions without ablation. Theory predicts that if the ablation front outpaces the speed of heat conduction, thermal damage will be minimized. While this is true in principle and practice for prolonged irradiation times of .0.25 s, there are instances where the lack of ablation is associated with less injury than in those applications with ablation. For example, if one uses 3 J/cm2, one will observe less RTD at the base of the wound than at 10 J/cm2. The reason is that the total energy dose is less. Also, there is always a tail end of the penetrating beam as it is attenuated by tissue water. This “tail” fluence will not achieve ablation threshold, and therefore there will always be some RTD at the base of the ablation crater. To achieve large zones of thermal damage without ablation requires either overlapped low-energy pulses, or a low PD beam applied for times of over 50 ms (Fig. 5.2). The threshold for ablation is variable, and tends to increase with pulse duration and the strength
136
Ross
Figure 5.2 (a) Microscopic view of pigskin after a single 1 ms pulse at 8 J/cm2 laser with Gaussian beam profile. Note that there is less RTD at the edges of the wound due to lower energy at the beam edge. (b) In contrast, after 10 pulses at 1 Hz, there is ablation at the center of the wound, and the RTD has “built up” to be slightly greater at the wound edge. This sequence shows that subablative fluences only result in more RTD when the heating is cumulative. Ablation at the center of the crater limited the RTD to 80 mm.
of the tissue. The dermis has a higher threshold than the friable cellular epidermis (23,24,30). 2. Effect of pyrolysis: Pyrolysis refers to the thermal decomposition of organic compounds in the absence of O2 (31). The resulting char acts as a heat source for several seconds after laser exposure. As air is a better insulator than the underlying skin, heat tends to travel to deeper tissues. With continued heating of the char, one sees a flame or a bright spot at the surface (“flash” point 5008C) and smoke formation, as the gaseous molecules on the surface of the char undergo combustion. Simultaneously, continued heating of the solid char component can result in “white-hot” plasmas that are so bright that the surgeon will be tempted to turn his eyes away from the operative field. 3. Effect of a nonsquare pulse shape: With older SP lasers, the laser pulse typically had a sharp rise time, followed by a slow tail. Thus, the PD was not constant during the pulse, leading to more thermal damage than predicted. However, if the pulse is short-lived, and there is sufficient interpulse cooling, the tail should not be clinically important. 4. Effect of pulse duration: According to the literature the pulse duration should be shorter than the thermal relaxation time. Thermal damage will be minimized if the laser pulse is delivered faster than the time it takes a heated layer of water equal to the optical penetration depth to cool. This time is based on the geometry and dimensions of the target, which in this case is assumed to be a layer of water 30 mm thick. Although the thermal relaxation time is approximately 1 ms, this number is reported with widely different values, partly because different models are used to determine the time for cooling (32). Experimental data support this argument (Fig. 5.3), as Walsh et al. (28) showed that with longer pulses (50 vs. 0.6 ms), there was more RTD. However, Venugopalan et al. (25,26) argued that a more important contributor to the increase in RTD in Walsh’s study was the decrease in PD for the longer exposures. Furthermore, the increases in RTD observed by Walsh et al., were the result of up to 50 pulses (overlapping at 1 Hz); single-pulse effects would have most likely not shown such a dramatic difference in RTD as a function of pulse duration. In our own study, we showed that for single pulses over a range of 0.25– 10 ms, there were no significant increases in RTD for fluences of 1, 3, and 10 J/cm2 on the basis of pulse duration (30). However, this is only a 40-fold range of pulse durations. Studies with shorter pulsed lasers have shown (33), along with our on experiments, that with 60 – 120 ms pulses, thermal damage is reduced to about 30 –50 mm compared to the 70– 120 mm levels observed in
Continuous Wave and Pulsed CO2 Lasers
137
Figure 5.3 (a) RTD in pigskin after defocused CW CO2 laser beam (8 W, 2 mm spot, 0.5 s exposure, 115 J/cm2). Damage extends 500 mm deep to surface. (b) RTD is only about 90 mm after a 7 J/cm2 exposure with a pulse duration of 1 ms. (H&E stain, original magnification 100).
millisecond domain lasers. Moreover, Littler (34) found RTD intermediate between millisecond CO2 and erbium:YAG lasers with 130 ns CO2 laser pulses. The primary advantage of shorter pulses is (1) spatial confinement of thermal injury and (2) lowering of the ablation threshold. In general, the RTD with a very short pulse is roughly equal to two times the OPD, whereas that of longer pulses scales as the square root of the pulse duration assuming fluences above the damage threshold for tissue (28). 5. Power density: If one examines the study of Schomaker et al. (35) of RTD in CO2 laser surgery, there was no systematic association between PD and RTD over a range of 360 to 740,000 W/cm2. However, over this PD range, theory predicts only a 33% increase for the lowest PD over the highest PD. Dobry et al. (36) found that RTD and scar increased with PD in rats from 141 to 849 W/cm2. They used the same 0.1 s application times in all their experiments. It follows that the doses of energy were not the same, so that this study actually showed that increasing the fluence caused more RTD by increasing the wound depth. In practical terms, one must remember that by increasing the power, one only linearly increases the PD over any focal point in the beam profile, but by decreasing the spot size, because the area of a circle varies with the square of its radius, there is a quadratic increase in the PD at the impact site. Hobbs et al. (12) summarized that wound edge necrosis is minimized for PD .20,000 W/cm2 and exposures of about 0.1 ms. 6. Repetition rate: Early estimates of the critical repetition rate for minimizing thermal damage were as high as 1000 Hz. These rates, based on the inverse of the thermal relaxation time, which is the time for the target to cool to 37% of the peak temperature for the CO2 laser, were too high, as tissue requires more than 100 ms to cool completely before the next pulse. This is also known as the thermal recovery time. As long as ablation occurs, 20 Hz is the maximum rate that will limit RTD to near the theoretical minimum (25). Without ablation, the rate decreases to 1 – 5 Hz with the CO2 laser (37,38). Older RSP lasers showed that with high repetition rates, RTD was only modestly decreased vs. CW lasers (16,39,40). For vaporizing applications, Fitzpatrick (41)
138
Ross
noted that the RSP mode was most helpful when the total string of pulses was short (i.e., when the macropulse ,50 ms), regardless of the duty cycle and repetition rate. 7. Fluence: Kamat et al. (42,43) studied fluence effects and noted that there was increased RTD with increasing fluence. They found that the greatest effect was in the basal layer. Since heating should have been greatest at the upper epidermis, this was somewhat unexpected; however, the authors suggested that weaknesses in the lamina lucida might have played a role. They found selective epidermal damage for fluences of less than 10 J/cm2. In agreement with their results, we have experimentally found that for pulse durations ,10 ms fluence (and not power density or achievement of ablation) is a more important parameter in determining the extent of RTD; that is, lower fluences usually result in less RTD. 8. Plasmas: Plasmas have been observed with the CO2 laser (22,44,45) with fluences above 19 J/cm2 for 100 ns and 2 ms pulse durations. Plasmas are PD-dependent, generally requiring PD .107 W/cm2 in tissue, so that either increasing the fluence or decreasing the pulse duration will increase the likelihood of their formation. As plasmas absorb incoming energy and also create very high, although focal, surface temperatures of 10008C, they are generally undesirable. It follows that one should choose pulse duration/fluence combinations that avoid optical breakdown. 9. Temperature profiles in CO2 laser surgery: Choi et al. (46) measured the temperature profile at the surface with a pulsed CO2 laser and found experimentally that the thermal relaxation time was about 20– 40 ms (the time for the peak temperature to decay to 37% of the maximum). They found that temperatures increased from about 2208C (after one pulse) to 4008C after 15 pulses at 1 Hz and 3.5 J/cm2, without wiping. They noted carbonization after four pulses and a simultaneous sharp increase in temperature to 3508C. They also found tissue burning (combustion) after the 10th pulse. The high temperatures (.1008C) are due to water superheating and are not unexpected. They noted that the time for total tissue cooling (to baseline temperature) was about 150 ms. It should be noted that with continued low-PD charring, one might expect peak surface temperatures of about 10008C (47,48). 2.3.
Clinical Examples of Laser – Tissue Interactions
2.3.1. High PD, Short Exposure Time Laser resurfacing (LSR) is the best example of this scenario, where there is some vaporization (ablation) and a small residual zone of thermal damage. The zone of thermal damage is the result of both (1) subablative localized energy densities (at the base of the wound, as the beam is rapidly attenuated) and (2) heat conduction during and after the pulse. For typical fluences used in LSR, the following cascade of events, corroborated by both human and animal histologies, occurs with each pass. After the first pass, the entire epidermis, for fluences of 5 – 8 J/cm2 with a 1 ms domain laser is heated plus about 10 – 40 mm of the dermis. With lower fluences or with treatment with the ultra-short pulse Tru-pulse laser, thermal damage can be reduced to lower levels (10,30,49 – 52). At this point, the epidermis is normally wiped away with wet gauze, and the papillary dermis is exposed. However, there is a case to be made for not wiping. If one knows the extent of the injury after one pass and is confident that this level of injury will successfully reverse the skin pathology, wiping only serves to increase patient discomfort and prolong healing. More importantly, there appears to be a level of dermal thermal injury beyond which long-term hypopigmentation is almost inevitable in selected patients, especially appearing along the lateral cheeks and extending to the jawline. Thus,
Continuous Wave and Pulsed CO2 Lasers
139
one can titrate the injury according to the level of desired injury with one pass if one reliably knows the laser end points. For example, with the UP at 300 mJ and a density of 6, if the scans are laid down accurately, one can rely on complete epidermal denaturation and about 20 mm of dermal thermal damage. Of course, this is somewhat anatomy dependent, as in the thinner skin of the eyelids, neck, and temples, the thermal damage will extend deeper into the dermis. Thus, the same total thermal damage will result regardless of the delivery location. However, the level of dermal injury will increase in areas with a thinner epidermis. With the CO2 laser, once the denatured friable epidermis is wiped off, it takes many pulses to ablate the residual acellular dermis (53). With the typical Gaussian beam of the CO2 laser, there will be some ablation at 7 J/cm2 average fluence at the center of the spot, but very little at the perimeter. Overall, using this average fluence, the ablation is about 10 – 15 mm per pass, much less than was reported in the early days of LSR. Of course, as the average fluences reach 10, 15, and 20 J/cm2, the relative ratio of ablation to tissue heating will increase. That is, roughly the same RTD will result, but the amount of ablation per pass will increase, Depending on the patient’s pathology and age, one sees different surface characteristics after wiping the denatured epidermis. For younger patients with modest photodamage, normally a pink to red dermis is exposed. For an older patient with severe solar elastosis, one sees yellowing immediately. If the patient has either actinic keratoses (AKs) or incipient dysplasia, there is usually hyperemia and sometimes frank bleeding upon wiping. Often, vigorous wiping is helpful in unmasking early AKs that might not have been obvious from the surface prior to laser surgery. In these cases, it is wise to proceed with additional passes until there is mild yellowing. The RTD at the base of these wounds is often enough to remove the remainder of the AK. Fulton et al. (54) recently reported that the CO2 laser was inferior to dermabrasion for AKs and used examples of AKs and basal cell carcinomas (BCCs) recurring in LSR sites not long after laser surgery. He referred to the penetration depth of the laser as being the main limiting feature of this technique. This is true if one makes only one pass and does not wipe, a technique I do not advise when treating AKs. Once the AK is uncovered by wiping, however, the remaining lesion can be vaporized or heated to achieve a complete cure. 2.3.2. Long Exposures in CW Low – Medium PD Defocused Mode This is the so-called vaporization mode, which is actually a combination of simultaneous heating and vaporization, and is used for treating warts and other exophytic lesions where some tissue heating at the base of the wound is tolerated. Usually, one will encounter vaporization at the center of the spot and charring at the periphery. To decrease char, one must move in a pirouetting motion so that the char is not continuously heated. When the CO2 laser burns a hole in the skin, the mechanism for ablation is the rapid conversion of water to steam (23,55 – 57). In the epidermis, the fragility of this layer provides for easy ablation, as the water vapor easily escapes the intracellular space, typically carrying with it a solid residue of exploded cells. This debris will continue to be heated as it is carried off, thus one sees “burning” or combustion. The onset of vaporization by CW irradiation in this PD regime is not completely characterized, but Verdaasdonk et al. (47) studied it intensively. They found the following sequence at the tissue surface. Initially, there was slight tissue discoloration. Coincident with a “pop,” the surface was lifted slightly, suggesting boiling bubbles underneath. The sound was due to the rapid ejection of air through the ablation front (nozzle effect), like bursting a balloon. Next, a small black spot was noted in the center of the beam,
140
Ross
presumably from carbonization of the dehydrated tissue. Within a few tenths of a second, this charred zone expanded and a ring was formed. Next, the char underwent combustion, unveiling a new hydrated surface. Later, there were cyclical rings of carbonization and vaporization, following each other in rapid succession as a progressively deeper crater was formed. The temperature associated with the onset of ablation was around 150 – 2008C (48). In contrast to the above scenario, for lower PDs with long exposure times, the char is never “blown off” (either by vaporization of water below the char or by combustion), and there is deep heating beneath the skin surface, as temperatures .10008C may occur at the surface. Indeed, this can be observed occasionally in the treatment of warts and rhinophyma, where prolonged application times of .0.5 –1 s can result in a brownish color and finally deep blackening of the surface. With increased blackening, the char acts as a nearly perfect absorber, and the char becomes hotter and hotter. This is why using lower PDs for prolonged periods is usually not advisable, as it simply results in very deep “invisible” tissue heating. It is advisable in these cases to wipe the char, thus exposing hydrated tissue, so that additional vaporization can take place. 2.3.3. Very Low PDs and Short Exposures With this technique (also known as thermabrasion), the laser is used in low power mode at 1 – 5 W with a defocused beam with very short bursts of CW radiation of about 0.1 s, and a total fluence of 1 –5 J/cm2 (58). Although the thermal gradient is not steep, that is, the temperature decay as a function of depth is small, there is so little total heat that this is safe as long as one pass is made, and this application will typically restrict RTD to the epidermis and superficial papillary dermis. It is useful in lentigos and mild photodamage. The goal is to use short bursts of subablative PDs to heat a specific thickness of tissue. In the case of dermatosis papulosis nigra (DPN), for example, one can heat the tissue just to a level similar to that of the hyfercator of 0.5– 2 mm. The end point is slight whitening of the tissue. This technique is best reserved for those who do not have access to a pulsed CO2 laser (43,59). 2.3.4. High PDs with Small Spots (0.1 –0.3 mm), Used in Incisions Most skin surgeons do not use the CO2 laser in cutting mode, with the exception of eyelid surgery. In addition to the cumbersomeness of using the laser as a cutting tool including the need to work around the articulated arm, the need for a smoke evacuator, and the constant vigilance that is required not to inadvertently strike an innocent bystander target, the laser cannot be endorsed as a first choice for incisions because healing is delayed compared with scalpel incisions. It is therefore not recommended for most routine skin surgeries (60). The indications for using CO2 for cutting regardless of the mode, include: Bleeding disorders Where epinephrine is not indicated Vascular lesions (hemangiomas and scalp tumors) Infected surgical sites In patients with pacemakers or implanted defibrillators (58) The advantages, on the other hand, are ease of excision and a relatively bloodless field. The lack of perfect hemostasis is partly explained by the paucity of RTD in a standard excision with CO2 laser. Because the small spot sizes of 0.1– 0.3 mm allow for high PDs, thermal damage is minimal (61). Microscopically, one finds 90 mm of basophilic change and 100 – 500 mm of lateral glassy hypereosinophilic change on routine staining
Continuous Wave and Pulsed CO2 Lasers
141
(62 –64). It follows that high-flow vessels larger than 500 mm are likely to bleed after CO2 transection. In contrast, without blood flow, vessels up to 2 mm have been coagulated (55,65 –72). Also, Kaplan (personal communication) has noted that in adults the maximum coagulated vessel diameter is about 0.5 mm, but in children it is greater at about 1 –1.5 mm. One should note that minimizing RTD and achieving hemostasis are antagonistic (4). Ideally, one should choose the laser parameters with the least RTD that still achieves adequate control of bleeding. The amount of bleeding vs. other modalities such as diathermy and scalpel has been compared, and it appears that the CO2 laser performs as well as a cutting electrosurgical current. In our experience, however, we have found that a blended electrosurgical current achieves better hemostasis than a well-focused laser beam. Defocusing only works to stop bleeding when the bleeding is mild. Mullins et al. (73) found that by using suction ahead of the beam they could achieve better hemostasis. Another purported advantage of the CO2 laser is that it seals nerve endings (74), which presumably results in less postoperative pain than in scalpel excision.
3.
COMPARISON OF THE RESURFACING LASERS
There are over 10 lasers with resurfacing capabilities (Table) of lasers would be helpful. I will discuss the ones more commonly used. Most of these devices are also capable of CW operation. Alster et al. compared (75) four resurfacing lasers and found that they were similar in histologic and clinical outcomes. The same was true for clinical studies comparing the Sharplan SilkTouch and UltraPulse lasers (76 – 78). In another study, the TruPulse and UltraPulse were compared (79,80). Although the RTD was greater with the UltraPulse, the final cosmetic outcomes were similar. Kauvar et al. (51) studied the histology of superpulsed, SilkTouch, and UltraPulse lasers in human skin and found that after three passes, the SP and SilkTouch RTDs were both 150 mm, the UltraPulse RTD was 70 mm, and the CW laser RTD (10 W and 0.2 s exposure) was 400 mm. Many investigators have compared the various levels of RTD after three passes in LSR: a summary is provided in Table 5.1 (30,76,77,79,81,82). Table 5.1 Lasers with Resurfacing Capabilities
Typical “settings” UltraPulse (Lumenis, Norwood, MA) NovaPulse (Lumenis, Norwood, MA) SilkLaser (SilkTouch mode/ FeatherTouch mode) (Lumenis, Norwood, MA) TruPulse (Tissue Technologies, Albuquerque, NM) Unipulse (Nidek, Freemont, CA)
Typical safe fluence (J/cm2)
Typical RTD after two to three passes (mm)
Density 6, 300 mJ
7.5
90 – 110
Computer scanner E16, 7 W 18 W/36 W (with 200 mm handpiece)
6–7
60– 80
15/8
110/70
500 mJ
16– 18 W/20% overlap
5
50
14
70
142
3.1.
Ross
UltraPulse
The UltraPulse laser is one of the two most popular resurfacing systems (14,81,83–95). In its initial configuration, the laser was equipped with a 3 mm spot-size handpiece with a collimated beam (TruSpot). Typical pulse energies were 250–500 mJ giving a fluence of 3–7 J/cm2 in these first efforts at skin resurfacing with single short pulses of ,1 ms. With the addition of the computer pattern generator (CPG) in 1995, the laser became more popular and easier to use over larger surface areas. The CPG scans a 2.25 mm beam in an x–y fashion with varying user controllable degrees of overlap. The popularity of the system is borne out by the frequent reference in the literature to the proprietary laser settings as if everyone should know their significance. Frequently, one will see, for example, in the methods and materials of a paper, the laser settings referred to as 3–5–5, which refers to the pattern–size–density. The pattern is one of seven different geometric configurations including squares, triangles, circles, diamonds, and even a ring. The size refers to the number of spots laid down per scan, and does not represent an absolute dimensional value. For the square pattern the size is the square root of the number of spots in the scan. Thus, for a size 5, there are 25 spots in the scan. The density refers to the overlap between spots; for example, density 5 implies about 30% overlap, and is typically chosen because it allows for overlap of the wings of the Gaussian beam and thus a fairly uniform tissue effect across the scan. Density 9 is about 60% overlap and is usually only used for exophytic lesions where rapid ablation is required and the concern for thermal damage is minimal. The density is important in determining RTD. Ross et al. (37) showed that after three passes with 300 mJ with wiping between passes, the respective RTDs based on basophilic collagen changes were 70, 95, and 145 mm for densities of 3, 6, and 9, respectively. The UltraPulse can also be used in a quasicontinuous mode (CW on panel, 3000 Hz) for cutting with the 0.2 mm handpiece. A 1 mm handpiece can be used for treatment of small exophytic lesions such as syringomas either in UltraPulse or in CW mode.
3.2.
The SilkLaser
This is a CW laser coupled with a flashscanner that sweeps the beam over a microspot in approximately 1 ms in SilkTouch mode and 0.4 ms in FeatherTouch mode. The early models possessed only the SilkTouch mode. In this mode, the laser dwell time, that is, the time the microbeam is in contact with any local area of tissue, is about 1 ms. Arbitrarily, the device was used with a 125 mm (focal length) focusing handpiece which spiraled a 220 mm beam at the focal plane. Typical powers were 6– 7 W with a 3– 4 mm scan size and 0.2 s “on-time.” These settings resulted in fluences of 16 J/cm2 and RTD levels of about 80 – 120 mm after three passes. As this was slightly greater than that usually observed with the UltraPulse with a similar pass number, Sharplan introduced the FeatherTouch. The dwell time was reduced to 0.4 ms, and the thermal damage after three passes with FeatherTouch was reduced to about 50 –80 mm (96). The SilkLaser can be used with newer 200 and 260 mm focal length handpieces. These spiral 360 and 420 mm microbeams, respectively. Because of the larger beam, higher powers must be used to achieve the same local PDs as with the shorter handpiece. Typical recommended powers are 18 W in SilkTouch mode and 36 W in FeatherTouch mode. Modern versions of the scanner interface with the laser directly, so that once the user chooses the power and handpiece, the panel provides representative settings that have been found to be safe and effective in LSR. Overall, using the longer handpiece is preferable because the depth of focus is greater, that is although one still should hold the handpiece tip close to the skin, the
Continuous Wave and Pulsed CO2 Lasers
143
microbeam size will not change as significantly as when one uses the 125 mm handpiece. With this shorter handpiece, even holding the tip 2 mm above the skin surface can result in a 70% reduction in PD due to rapid divergence of the beam past the focal plane. In SilkTouch mode the laser beam overlaps on itself. This was due to the nature of the early device, where the laser and the scanner were not synchronized. This necessitated an “in and out” spiral to ensure complete coverage of all areas within the scan. With the FeatherTouch mode, there is only one spiral per pass, and the tangential velocity of the laser increases by about 1.3, thus the dwell time overall is decreased by about 60%. More importantly, because there is no overlap, RTD is significantly reduced. With the newer synchronized system, the panel gives suggested settings for power for a given handpiece and mode. For example, with the 125 mm handpiece (220 mm spot), the suggested laser power is 7 W, and for a given scan size such as 5 mm, the scan on-time is programmed for 0.43 s. For FeatherTouch mode with the same handpiece, the suggested power is 14 W, and for a 5 mm scan, the on-time is reduced to about 0.12 s. We have examined multiple tongue depressor impressions made by the laser with an operating microscope, and have confirmed that the SilkTouch mode does overlap almost, if not directly, on itself. This undoubtedly has contributed to the increase in RTD vs. the FeatherTouch mode as well as the increased fluence and slower tangential velocity. 3.3.
The NovaPulse
The NovaPulse can be used in pulsed or CW mode (75,97,98). This is an RF excited laser with 20 W average CW power capability and peak powers of upto 50 W in RSP mode. We have used the NovaPulse system for resurfacing, in which case it is coupled with either a 3 mm handpiece or a scanner, and found it to be a capable laser. The overall treatment times are somewhat longer than with the UltraPulse due to lower average powers for the NovaPulse. The laser scans a very small spot of 0.8 mm with the scanner. The pulse duration for a single pulse ranges from 50 to 1400 ms, depending on the pulse energy of 20 – 45 mJ. In other words, the duty cycle and average power increase slightly with each increase in pulse energy. The Nova Scan system generates a 3 mm spot size in a daisy pattern. A motor rotates the fiber tip, the 0.8 mm microspot, at about 1000 rpm 12 times to cover a 3 mm macrospot. For example, with a 6 W average power setting, the laser generates 360 mJ over 60 ms with a series of submillisecond pulses of about 30 mJ. A larger scanner, Dermascan, is also available with similar patterns and densities as the UltraPulse CPG. Depending on the application, the laser is capable of a number of programmed settings in CW (P programs) and pulsed (A, P, E, and F programs) modes. The unique feature of the NovaPulse laser is the delivery device, which is a proprietary hollow waveguide. The waveguide is a tube with a highly reflective coating on the inside wall. The waveguide is made of dielectric coated molybdenum encased in a stainless steel jacket. The laser beam enters at one end, and propagates down the guide into the handpiece. One problem with waveguides is that the transmission decreases from a maximum of about 85% to less than 40% if they are bent more than the arc of a basketball. This potentially introduces an unwanted variable into treatment if care is not taken by the operator (99,100). 3.4.
Nidek Unipulse
In skin resurfacing, the Unipulse (Nidek, Freemont, CA) scans a 1 mm spot at 100 –300 Hz with pulse energy ranging from 30 to 100 mJ depending on the pulse duration with a range from 200 to 800 ms. Typical operating parameters are 18 W average power and 20%
144
Ross
overlap between adjacent spots or about 60 mJ pulses for an average calculated fluence of 16 J/cm2. For younger, less photodamaged patients, the power can be reduced to 14– 16 W. The laser also offers an array of SP and CW modes that can be used with a range of focusing handpieces. Of the SP, Unipulse, modes, Mode I is a very high-duty cycle mode with relatively long on-times and short off-times. This mode is designed for coagulation. With increasing numbers (II –V), the duty cycle decreases and the peak powers increase. Also, there is more time for cooling between pulses. 3.5.
TruPulse
This laser is fundamentally different from the others in that it is transversally excited, meaning that the electrodes are placed across the tube. This allows for brief highenergy pulses of 60 –100 ms and pulse energies of up to 500 mJ (79,80,101,102). The laser only operates in pulsed mode: there is no CW availability. The laser produces a multimode beam called “mesa” mode or flat top beam. The beam size is roughly 2 2 mm with the scanning handpiece for resurfacing (103). A 0.2 mm handpiece is also available for cutting. Because of the short pulse duration, the laser produces peak powers of up to 10,000 W. 3.6.
Summary of Resurfacing Systems
All of the resurfacing systems above are capable of achieving a combination of ablation and RTD that is suitable for obtaining a good cosmetic outcome. The physician should become comfortable with one system and have another system as a backup. Each different laser system, and even different lasers of the same model type, usually has unique features and idiosyncrasies that should be mastered prior to use. One should always look closely at the skin surface during irradiation. I normally have the aiming beam turned off or dimmed during pulsing. If something seems odd, stop the procedure, go back to the tongue depressor, and recheck the beam. For example, a mirror in the articulated arm once deteriorated during a CO2 laser case and the only sign was that the skin surface showed a collage of crescents rather than circles with the UltraPulse CPG.
4.
WOUND HEALING AFTER CO2 LASER
Early studies of wound healing after CO2 laser treatment focused on incisional wounds (104 –106). These studies found a delay in epithelial migration at the wound surface and a delay in fibroblast migration. Presumably, the RTD associated with CO2 wounds produces the delayed inflammatory response that crescendoes somewhat later than scalpel wounds of similar depth (39,107– 115). Consistent with this delayed inflammatory response, and possibly the delayed deposition of new collagen, Pogrel et al. (114) showed that CO2 wounds were associated with greater amounts of hyaluronidase production vs. scalpel wounds after 3 weeks. Harmon et al. (116) studied erbium and CO2 wounds and showed more platelet cell adhesion molecule in the CO2 wounds 6 weeks after injury. All of these findings suggest that the initial thermal damage in CO2 laser injury modulates the healing response vs. wounds without thermal damage. Wound healing has been compared between CO2 laser, cautery, and scalpel surgery. Lunkenheimer et al. (106) examined minipig incisions and found that wounds that were left unsutured healed best after scalpel surgery, with fine scars after 16 days, whereas the laser wounds and cautery wounds tended to appear as oval dents “filled up” by
Continuous Wave and Pulsed CO2 Lasers
145
pinkish scars. They identified a microscopic transition zone “in a fairly unchanged condition that was particularly engaged in the process of tissue restoration.” Sloughing occurred above and within the transition zone. Hall examined sutured CO2 incisions and scalpel wounds and found that sutured laser wounds were weaker than scalpel wounds in rats after 21 days, but that by 40 days the wounds showed similar tensile strength. The delay in healing was blamed on the shedding of the eschar, which occurred around the sixth to eighth postoperative days just deep to the zone of basophilic staining collagen. Kamat et al., examined both sutured and unsutured human skin wounds after CW laser irradiation. They found that inflammation was delayed in laser wounds and that there was sloughing collagen, beneath which a new epidermis was formed (42). However, in deeper sutured wounds, there was also some entrapment of denatured collagen that remained unchanged and mummified for as long as 10 weeks after surgery. This study and our own results suggest that damaged collagen is handled differently in the skin depending on the depth of the damage, where superficially damaged collagen is more likely to be rapidly degraded within 1–2 weeks even when re-epithelialization has occurred over the specimen. In brief, CO2 laser-induced open wounds heal differently from wounds of similar depth with less than 75 mm RTD. They show delayed re-epithelialization and a different pattern of wound contraction. The wound contracts immediately, relaxes to a degree, and then undergoes a second contraction vs. dermatome, dermabrasion, or erbium:YAG laser wounds, which show little or no immediate contraction, then a one-time contraction and subsequent relaxation beginning about 2 –5 days after injury. Also, there is more fibroplasia per micrometer depth of injury and different patterns of enzymatic and cytokine activity in CO2 laser-induced wounds (50).
5.
ULTRASTRUCTURE AFTER CO2 LSR
Zweig et al. (61) studied both routine histology and electron microscopy in laser excisions and divided the zones ultrastructurally into two zones: (1) coagulation zone, where collagen fibers lost their periodicity, and (2) a transition region, where the periodicity of collagen fibers was partly retained. He also correlated the collagen changes seen in laser excisions with collagen changes after exposure to various controlled temperatures in a hot bath. In the bath, the minimum coagulation temperature was 738C, and the transition zone minimum temperature was 578C. Unfortunately, the exposures in the hot bath were for 160 s, much longer than the brief laser exposures. Undoubtedly, the temperatures required for similar collagen changes during short laser exposures would be much higher. More recently, Kirsch et al. (117) and Collawn et al. (118) have published separate studies on the ultrastructure of CO2 LSR with millisecond domain CO2 lasers. Kirsh et al., described two zones of damage, where Zone 2 represented a transition zone and, as in Zweig’s study, in this zone collagen fibers showed an increased cross-sectional area consistent with linear shrinkage. Zone I represented the tissue surface with more severely damaged fibers whose ultrastructure showed no distinct fibrillar component. Collawn et al., suggested that loss of the extracellular matrix rather than collagen shrinkage was responsible for the skin tightening seen during LSR.
6.
APPLICATIONS
The appeal of the CO2 laser is largely based on its utility, which increases rapidly with increasing physician skill. Since water is the chromophore, almost every skin lesion is a
146
Ross
potential target. However, one must examine the selectivity of the laser before deciding that it is a better choice than other wavelengths that either target discrete chromophores or allow for shallower tissue effects due to higher water absorption, such as the erbium:YAG laser. Unlike most of the other lasers in this book where selectivity is based on spatial confinement of injury to a discrete target the CO2 laser’s selectivity is based only on how precisely the block of ablated or heated tissue matches the dimensions of tolerability of the skin for scarring and dyspigmentation. As long as everything within the block of tissue vaporized or heated can be sacrificed without adverse side effects, the CO2 laser is an attractive “what you see is what you get laser.” Once the CO2 laser light impacts on the skin, there is immediate absorption, so that the injury is always top to bottom unless one irradiates the skin from the undersurface, which is a technique used by some physicians. For this reason, the CO2 laser demands a high level of operator practice and skill to achieve reliable results. It follows that with greater use, one finds that the laser is as good or nearly as good as some of the pigment selective or vascular selective lasers for particular lesions. In the ensuing discussion of applications, if not specified, wiping with either a H2O2 or a saline soaked gauze pad or applicator stick is done between serial passes with the CO2 laser. Also, in all applications using a defocused CW mode, the reader should assume that an “airbrush” technique was used for plaque-like lesions.
6.1.
Applications Where the Laser Performs Better Than Most Other Modalities (In Addition to Resurfacing—See Chapter 29)
Rhinophyma can be treated with excellent results with the CO2 laser in either the pulsed or the CW mode (Fig. 5.4). The author exclusively used the CW mode until recently.
Figure 5.4 (a) Rhinophyma preop. (b) Just after surgery, 8 – 20 W CW CO2 laser, 1 –4 mm spot, airbrush technique. (c) 12 Weeks after surgery note improved cosmesis and lack of scarring.
Continuous Wave and Pulsed CO2 Lasers
147
The advantage of this mode is that one can combine heating and vaporization by varying the spot size and power. By decreasing the former and increasing the latter, vaporization is observed, and the nose can be sculpted to its original shape. My recently adopted technique is to initiate treatment with 15–25 W in the defocused mode, using a pirouetting motion to vaporize the nose to a roughly desirable contour, followed by fine tuning in the UltraPulse mode. By using the high-energy short pulse mode at the end of the case, charring can be avoided and more of a “what you see is what you get” result is observed. One should use older photographs of the patient to guide the final silhouette. Also, one should periodically view the nose from different positions to ensure that the contour is even. Finally, no matter what method is used, occasionally one will encounter bleeding, in which case either aluminum chloride may be used or the laser can be used in the defocused mode for coagulation. One treatment end point is achieving the final nasal contour and another is using the sebaceous glands as a guide to treatment. Normally, if one can squeeze sebum from the glands near the end of the procedure, the ablation plane is not too deep. Several investigators have reported their experience in treating rhinophyma with the CO2 laser. Wheeland et al. (119) used a combined laser excision and vaporization approach, employing a focused 0.2 mm spot for excision with 15 W and an irradiance of about 50,000 W/cm2. The nose was grossly reshaped in this manner by cutting off the excess tissue. Next, they defocused the beam to 2 mm and decreased the power to about 4–5 W. This was used to gently smooth the remaining surface irregularities. Karim and Streitmann (120) retrospectively analyzed 20 patients after treatment with 12 W CW, using a combination of 0.2 mm spots for excision and defocused beams for vaporization. Simo and Sharma (121) reported three cases with good results. They used 5 W CW and a 1 mm spot to mark the perimeter of the field, then 15 W with a 2 mm spot to vaporize excess tissue. El-Azhary et al. (122) treated 30 patients with a 0.1 mm spot to excise, followed by a defocused beam at 15–20 W. They reported one case of scar and one case of leukoderma. 6.1.1.
Trichoepitheliomas
Both CW and UltraPulse lasers have been used to treat these lesions (123–127). Generally, the end point has been destruction to a level just below the adjacent skin surface. Deeper ablation results in scarring and more superficial ablation results in early recurrence. The typical laser settings in CW mode include 1–3 mm spot sizes and powers of 2–5 W. We have been using the 1 mm spot size in UltraPulse mode at 200–250 mJ, defocusing and focusing the beam to accommodate the skin dimensions and the ratio of ablation to heating. 6.1.2.
Adenoma Sebaceum
We have used both pulsed and CW lasers for these papules (Fig. 5.5). One can use the CO2 laser with a low power of 2 – 3 W and 1 –2 mm spot size with short application times of 0.25 – 0.5 s to gently vaporize/heat the papules so that they shrink over the subsequent few weeks. Alternately, one can use the pulsed laser to vaporize the lesions, but we have found that the pulsed mode results in mild bleeding in some areas. Once the exophytic portion of the lesions has been removed, the base at a different session 4 – 6 weeks later undergoes vascular lesion laser treatment. Janniger and Goldberg (128) performed a comparison study of argon and CO2 lasers (5 W, 2 mm CW) in a single-patient side-by-side study and found overall that the CO2 laser showed superior cosmetic results. We have similarly found that the CO2 laser works better than a vascular specific laser, at least for the exophytic component of the lesions. Boixeda et al. (129) compared CO2 , argon, and pulsed dye laser (PDL) in 10 patients and concluded that the CO2 laser overall was a better therapeutic tool.
148
Ross
Figure 5.5 (a) Tuberous sclerosis patient preop. (b) Six months after treatment of exophytic lesions with CW CO2 laser, 2 – 3 mm spot, 2– 4 W, 0.5– 1 s exposures.
6.1.3.
Common Warts
Even with the large armamentarium of available wart treatments, including interferon, 5-fluorouracil, imiquimod, as well as traditional therapies such as liquid nitrogen, some warts persist. Generally speaking, CO2 laser is not a first-line destructive therapy because the pain, while usually not severe, tends to be prolonged vs. cryosurgery. The healing time is prolonged, some scarring is very likely in most areas, and there is a requirement for injectable anesthesia. However, warts which have persisted over 1 year despite therapy, especially if they interfere with some aspect of the patient’s life (either functionally or through significant cosmetic disfigurement), are good candidates for CO2 laser treatment (Fig. 5.6). Advantages of CO2 laser therapy include precise control of the
Figure 5.6 (a) Periungal wart preop. (b) Immediately postop, note that the wound is carried out deep into the sulcus. (c) Four weeks postop there is no evidence of recurrence and the nailfold contour is returning to normal.
Continuous Wave and Pulsed CO2 Lasers
149
depth of injury, usually adequate hemostasis, immediate gratification of having the wart removed, and good “cure” rates. Technique: If a wart is very exophytic, I use higher PDs of 15 –20 W and a 2 mm spot size first, to vaporize the wart to a slightly raised level. The goal is to move quickly so as to minimize char. Residual debris is wiped away with moist gauze. At this point, a curet is use to separate the denatured tissue from the dermis. If the heating plane at the dermal – epidermal (DE) junction is sufficient, the wart will separate without much difficulty and the underlying dermal base will be only slightly heated. If one undertreats, the unheated remaining epidermis will still be attached to and interdigitated with the underlying dermis. Another pass will then need to be made, as attempting to forcibly separate the wart with the curet will result in unnecessary bleeding. Once the denatured wart is separated, the base should be heated gently with a lower power of 3– 5 W. Also, a rim 2 –5 mm from the clinically obvious wart should be heated. The underlying dermis can be identified by the appearance of skin lines or the observation of slight tissue shrinkage. CO2 laser treatment is often complicated by previous aggressive CO2 laser or liquid nitrogen therapy, and foci of wart can be intermixed with scar. Normally this requires that the entire previous treatment area be vaporized away. Otherwise, the recurrence rate will approach 100%. Periungal warts (Fig. 5.7) must be removed down to the level of the sulcus of the lateral nail fold (130 – 132). This requires that the physician be fairly aggressive in curettage. It is easy to stop the treatment too soon, mistaking the “hard” wart tissue in the nailfold for normal dermis. When the warty tissue has been completely removed the surface should be smooth and resist further curettage. One caveat: One should be careful not to continue to heat the remaining dermis in the nailfold, as often it is only hundreds of micrometers thick. Occasionally, one will expose focal fatty globules, which is an indication of too deep treatment. Bleeding can be a problem in wart treatment with the CW laser, particularly in the periungal area. We have found that use of a tourniquet greatly aids in hemostasis. For lesions where a tourniquet is not possible, pressure at the periphery of the lesion will usually slow down the bleeding enough so that a defocused beam can be applied to achieve hemostasis. Ashinoff et al. (133) found human papillomavirus (HPV) in 60% of SCC in the periungal region, therefore if the lesion in the nailfold is longstanding, a biopsy is warranted in adults. The literature contains many reports of CO2 laser treated verrucae. In a study by Street et al. (134) of recalcitrant periungal lesions, there was a 71% cure rate after 1 year, where the cure end point was the return of dermatoglyphic skin lines. Overall, long-term remission rates in CO2 laser wart treatment are difficult to assess; studies
Figure 5.7 (a) Preop view of a wart on the little toe. (b) 12 Weeks postop, note excellent result. Wart is still clinically resolved 1 year later.
150
Ross
have suggested 5-year cure rates of 50 – 80% (130,131,135 – 137). Patient satisfaction with CO2 laser treatment is good; Sloan et al. (138) found in a retrospective evaluation of resistant warts that 71% of patients would have the treatment again, with the major adverse effect being pain. If common verrucae are in a cosmetically compromising position, one can use interferon to complement the destructive effect of the laser (139). 6.1.4.
Condyloma Acuminata
The CO2 laser has been used extensively in the treatment of condylomata. Although the laser is effective in the removal of the clinical lesions, viral particles can be recovered after laser treatment in peripheral skin. The literature reports cure rates ranging from 31% to 95% (140 – 145), with higher recurrence rates with 16/18 vs. 6/11 HPV subtypes. Lassus et al. (146) reported good clinical clearing at 24 months of 50% of resistant condylomata in 38 males after three treatments (3– 5 W CW, 2 mm spot). However, only 26% of patients showed elimination of the HPV genome. They concluded that although CO2 laser is ineffective in eradicating the HPV genome from therapy-resistant penile warts, the treatment reduces the recurrence of atypical changes and visible warts. Ferenzcy et al. (147) found HPV as far away as 1.5 cm from the clinical lesion. Duus et al. (148) found higher rates of recurrence after CO2 laser vs. electrocautery in vulvar condylomata. Recently, it was reported (149) that in condylomata treated by CO2 laser, there was no change in T-cell subsets, that is, the ratio of suppressor to helper cells was not changed by clinical elimination of the wart by CO2 laser. The CO2 laser has been especially helpful in pediatric patients under general anesthesia. Johnson et al. (150) examined 17 children with condylomata in a retrospective analysis and found 4/17 with early recurrences (within 3 months) using RSP mode at 3 – 5 W and 2 mm spot. After retreatment of the four recurrences, only one recurred. Davis and Noble (151) treated multiple condylomata with CW CO2 laser and found that the recurrence rate was 9/20 with laser alone and only 3/14 with laser plus sublesional interferon alpha 2 beta. Technique: For multiple very small lesions, acetowhitening is performed just prior to the procedure. Next, the area is anesthetized with lidocaine. We use the laser in CW mode with powers from 3 to 8 W, using lower powers for smaller lesions (2 –3 mm papules) and higher powers for more extensive exophytic lesions. The gross raised portion of the lesion is vaporized using a defocused spot of 1 –3 mm. The beam is brushed over the wart until whitening occurs. Wiping with wet gauze should allow easy separation of the wart from the underlying dermis. Using magnification loupes, any residual wart can be vaporized, and the surface is rewiped; this series is repeated until slight shrinking of the surface is observed. Finally, a 5 –10 mm rim of clinically normal tissue is grayed with a low-power brushing technique. Some caveats: Bleeding can be a problem in the treatment of some larger lesions, especially in the perianal region. Stretching the skin surface during lasing will decrease the risk of bleeding. Gentle vs. vigorous wiping also tends to reduce the likelihood of disrupting the vessel walls. Finally, for some smaller lesions, with skill one can use one pass to eliminate the lesion, leaving the browned dome intact without wiping. This technique increases the recurrence rate, as a portion of the deeper wart might persist, but the cosmetic result is enhanced, particularly in pediatric patients, where making a second pass tends to result in scarring. 6.1.5. Nail Matrixectomy Like phenol and electrosurgical ablation, the CO2 laser can be used to eliminate the nail matrix conditions such as chronic ingrown nails (152).
Continuous Wave and Pulsed CO2 Lasers
151
Technique: The portion of the ingrown nail is removed with a nail splitter and hemostat, and the matrix visualized. Next the proximal nailfold skin is retracted and the laser is used in 0.5 s gated pulses in the 3 –5 W CW mode with a 1 mm spot. The area is allowed to heal by secondary intention. Complete ablation of the matrix sometime requires additional treatments. 6.1.6. Earlobe Keloids Earlobe keloids are particularly well suited to treatment with the CO2 laser. As long as most of the keloid is vaporized and care is taken in the postoperative period, we have found a low rate of recurrence and a high degree of patient satisfaction. We generally use the 3 mm handpiece with the UltraPulse laser with maximum pulse energy and a high repetition rate of 20 –40 Hz. We vaporize the lesion down to a point where one feels and sees very little keloid at the base. This requires many passes, so many that we do not count how many times we have treated one area but rather continue to vaporize until the area is contoured to a good end point. We generally use our thumb to push the keloidal tissue toward the laser handpiece. After many passes, one will begin to feel mild heating on the finger as the keloidal tissue is vaporized. The pulsed mode allows for relatively char-free tissue removal. However, because we do not try to avoid pulse stacking, the thermal damage is probably hundreds of micrometers deep rather than the 60 – 100 mm after traditional CO2 LSR for nonexophytic lesions. One can easily see the coarse collagen fibers in the keloid as the lesion is vaporized away. Remarkably, even though a substantial amount of tissue may be removed, we have not encountered any major loss of contour of the lower earlobe. Also, except for some mild hypopigmentation at the center of the laser site, the lesions tend to repigment after several months. In one patient we treated one keloid with the CO2 laser and the other with standard excisional surgery by shelling out the keloid and using the overlying skin as a graft and found the results to be as good or better on the laser treated side, with the laser treatment taking about a quarter of the time. For dumbell keloids, we generally ablate from both sides, leaving only a big-sized keloid remnant at the center. Conejo-Mir et al. (153) have reported that CO2 laser ablation plus interferon alpha 2 beta has resulted in better clearing than CO2 laser alone. Perilesional and sublesional interferon injections were performed three times a week for 3 weeks. As expected, earlobe keloids responded better than other sites. Stern and Lucente (154) found no difference in recurrence rates after CO2 vs. scalpel excision of earlobe keloids. Kantor et al. (155) excised 16 keloids, many of the “dumbell” type, on the ear with CO2 laser and found no recurrence after 6 months. They used a focused beam (0.1 – 0.2 mm) and closed the lesion anteriorly if the excision resulted in a through and through lesion. Although there were four early hypertrophic scars, these resolved with one to two IL injections of 40 mg/mL Triamcinolone acetonide. Recently imiquimod cream has been advocated postoperative after keloid excision vaporization. 6.1.7.
Larger Keloids and Nonearlobe Keloids
The literature shows considerable variability in the success of the CO2 laser in the treatment of keloids. Different investigators have used various techniques and postoperative interventions, so that advice based on sound prospective studies is generally lacking. Also, keloids have been removed both by laser excision and laser vaporization, and with and without primary closure in the case of laser excision. Despite all of these variables, some useful information can be summarized. Overall, studies have shown
152
Ross
that the CO2 laser probably offers little advantage over excisional surgery of keloids (156 –161), but in some cases the CO2 laser might represent the best option. Like most other laser surgeons, we have found that keloids in scalp and beard areas almost always recur if the lesions are merely vaporized to the level of the dermis. Stucker and Shaw (156) examined 37 patients with keloids that were excised with a 1 mm spot and 10 W. For nonearlobe keloids they found that with second-intention healing, 25/31 lesions recurred, usually at the edge of the wound, within 3– 4 weeks of treatment. They showed that aggressive early IL corticosteroid injections seemed to determine the final outcome more than the laser’s use as the excision modality. Lim and Tan (162) studied CO2 laser use for keloids and found that deltoid keloids allowed to granulate did no better with laser than after scalpel excision. Norris (159) followed 23 patients after laser excision of nonfacial keloids and likewise found a 100% recurrence rate after secondintention healing. He used 8– 14 W and a 0.75 mm spot and concluded that laser was no better than scalpel for recurrence. We have also treated some larger keloids with the CO2 laser, combining vaporization and excision with variable success. Typically, we have found that the keloids on the chest return, and have performed test sites on any patient where this treatment is entertained. In one patient, we removed several large keloids with postoperative radiation therapy (XRT), and after 1 year the keloid had not returned. One recently published study supports the use of the CO2 laser in some keloids. This is based on CO2 laser irradiation of cell cultures from normal and keloidal tissue (163). In this study, CO2 laser treatment was associated with higher levels of beta fibroblast growth factor (b-FGF) than untreated keloid controls. Because higher levels of b-FGF tend to inhibit excess collagen secretion, the authors felt that superpulsed CO2 laser exposure might be beneficial in the treatment of keloids. More recently, the same group has reported that in chest keloids, the laser tends to cause decreased b-FGF levels vs. untreated keloid controls whereas facial keloids showed the opposite pattern, suggesting that the lower b-FGF level might be responsible for the high rate of scar recurrence after CO2 laser treatment in the chest area (164). 6.2.
Acne Keloidalis Nuchae
We have treated the small papules of acne keloidalis nuchae with the CO2 laser, but have found that the recurrence rate is high unless the lesions are vaporized to the cutaneous fat and the hair follicles are destroyed. Unfortunately, at this level, blood vessels may be encountered that are larger than 0.5 mm and the lesions often bleed profusely, requiring electrosurgical coagulation. For larger plaques of acne keloidalis nuchae, we have used the CO2 laser as an excisional tool and found that bleeding was much better controlled by using a blended electrosurgical cutting device. Kantor et al. (165) treated eight patients with the CO2 laser and found that as long as the lesions were excised to the level of the fat, there were no recurrences. Lesions were allowed to heal by secondary intention. The primary advantage of the use of CO2 laser in acne keloidalis nuchae is hemostasis vs. cold steel. Related to the use for acne keloidalis nuchae, the CO2 laser has also been used to excise areas of dissecting cellulitis of the scalp, after which the wounds were allowed to heal by secondary intention (166). 6.2.1.
Pyogenic Granuloma
Pyogenic granulomas (PGs) (68,167 –169) respond well to CO2 laser vaporization, provided that the level of destruction is adequate (Fig. 5.8). The author has treated many PGs that have recurred after electrodesiccation and curettage (ED&C) and cryotherapy.
Continuous Wave and Pulsed CO2 Lasers
153
Figure 5.8 (a) Pyogenic granuloma preop, lesion had failed two ED&C attempts and one CO2 laser attempt. (b) Note depth of vaporization with CW CO2 laser, 1 – 3 mm spot, 5– 8 W. (c) Six months postop there is no recurrence and there is excellent restoration of the distal digit contour.
In most cases, the lesions have responded to CO2 laser in CW mode after only one treatment (Fig. 5.8). There have been reports of satellite lesion formation after treatment of PG, but only one case after CO2 laser treatment, and this occurred after laser excision, not vaporization (169). Technique: After injectable anesthesia, the lesion is vaporized with 3 –5 W power and a 2– 4 mm spot. Once the lesion is grossly flush with the surrounding skin, the denatured friable surface is curetted. Normally, this reveals a central feeder vessel surrounded by dermis or fibro-fatty tissue. At this point the vessel is vaporized using a more focused spot that is just large enough to accommodate the diameter of the vessel and the surrounding tissue is lightly grayed with a defocused beam. The key to effective one-time treatment is the depth of destruction. Patients who have been referred after treatment failure have invariably noted that the initial treatment had been more superficial. 6.2.2.
Actinic Cheilitis
Until recently the CW mode was used almost exclusively for widespread actinic cheilitis. Powers from 3 to 8 W using defocused 2– 4 mm beams were typically employed (18,157,170 – 178). The end point after the first pass in CW mode is white bubbling of the surface (opalescence). Higher powers will result in charring unless the handpiece is moved very quickly. This is wiped away with saline-soaked gauze. In mildly damaged areas, a bright pink papillary dermis is exposed. However, in areas where there is severe actinic damage, one sees a yellow-gray surface. Normally, an additional pass is performed in this area with a very low power of about 2 W for 0.5– 1 s. The importance of moving the handpiece in a rapid brushing manner cannot be overstated. When using the CW mode, the hand becomes a scanner, limiting the dwell time in a somewhat primitive manner, but one that becomes increasingly precise and reliable with practice.
154
Ross
Recently, Dufresne and Curlin (175) reviewed 140 patients in seven studies. They found 15 cases of scarring and an average of 21 days for healing. They found that there was a low failure rate and better results than with trichloroacetic acid peel. Clearly, there is much variability in the literature results, presumably at least partly due to variability in technique. Sexton (179) reported correctly that since actinic cheilitis is an epidermal lesion, the injury should be limited to this top layer of skin. Johnson et al. (180) used histology to correlate clinical and microscopic findings after laser treatment and found that there were three depth categories which could be matched to wound color. Superficial to deep, these colors were pink, white/gray, and white coarse. The authors advised remaining in the two most superficial planes. We have encountered the same planes. However, one can see various surface colors after even a first uniform “light” pass of the laser. It follows that the pretreatment variability in the depth of solar damage also determines the spectrum of surface colors. Accordingly, we suggest the whiter areas are those focal areas with the greatest clinical damage prior to treatment. Moreover, we suggest the lack of surface pinkness is not only due to deeper treatment, but also due to pre-existing fibrosis in these areas, as well as increased acanthosis and interdigitations between the lesion and the underlying dermis. Zelickson and Roegnik (171) treated 43 patients and found good results after one laser pass (3–5 W, CW, 2 mm spot). He encountered three small postoperative scars that resolved after treatment with IL triamcinolone acetonide. Robinson (172) found in a prospective study that the CO2 laser was a better choice than 5-fluorouracil or 50% trichloroacetic acid, with decreased recurrence rates vs. those modalities after 4 years. David (176) treated eight patients and found good results with a rapid laser sweep with 15 W and 3 mm spot. He wiped after one pass and then stopped unless there were persistent white areas. Fitzpatrick et al. (18) reported 35 patients treated with either RSP mode or CW mode. They found that if the length of the envelope of superpulses or the length of a mechanically shuttered CW “pulse” was limited to ,50 ms, there was no difference in outcomes between these two regimes. They also found that both CW and continuous SP modes resulted in the same incidence of side effects. Their conclusion was that the repetition rate of the RSP mode (250 Hz) was so high that there was insufficient time for interpulse cooling. More recently, we have used the UltraPulse laser in pulsed mode for actinic cheilitis. We do not feel the technique is necessarily better than our older CW technique, only more reproducible and safer. On the first pass, we use the 3 mm Tru-spot handpiece and a pulse energy of 350– 400 mJ. After wiping with wet gauze the epidermis is removed, after which a second pass is made with the pulse energy reduced to 250 mJ. Additional passes are made to areas with severe photodamage (Fig. 5.9). These areas are identified by a whitened surface. We have noted that H2O2 is useful in wiping after the first pass, as its application helps to identify residual epidermal fragments. In retrospect, we suspect that some of our early recurrences were due to incomplete removal of focal thickened epidermis when using saline-soaked gauze. With saline, the residual epidermis is more difficult to distinguish from the sometimes fibrotic dermis. The H2O2 causes the epidermis to whiten dramatically, and with gentle use of a curette, the epidermis can be separated from the dermis. 6.2.3.
Sebaceous Hyperplasia
This is one of the more rewarding lesions to treat. The 1 mm handpiece is used with the UltraPulse laser, and the distance between the skin and handpiece tip is varied to accommodate the size of the lesion, which is usually about 1 – 2 mm. A pulse energy of 200 mJ is used, and a few overlapping passes are made to expose the yellow fatty nodules. Once exposed, these punctate 0.5 mm lobules are treated with additional
Continuous Wave and Pulsed CO2 Lasers
155
Figure 5.9 (a) Preop view of 40-year-old white female (WF) with actinic cheilitis. (b) Immediately after treatment with two UltraPulse laser passes at 350 mJ with 3 m spot. (c) Appearance 4 weeks after treatment; note smooth surface.
pulses until they are either extruded are heated. The final result is a slight dell that resolves uneventfully in 1– 3 months. 6.2.4.
Epidermal Nevi
Although the histology suggests an epidermal lesion, there are abnormalities of the dermis that result in rapid recurrence if only the epidermis is removed. We have used electrodesiccation, dermabrasion, and the erbium:YAG laser, and have found that the CO2 laser and erbium:YAG lasers result in the best combination of excellent cosmesis and long remission. We use the UltraPulse laser in the initial pass, usually with the 3 mm handpiece and a pulse energy of 450 – 500 mJ. This results in epidermal ablation at the center of the spot, and after carefully heating the epidermis, the denatured epithelium can be wiped away. With magnifying loupes, the remaining areas of altered dermis can then be visualized. Usually, one can see fine papillomatosis where the epidermal nevus remains. At this point, we change to the 1 mm handpiece and ablate the remaining areas with pulse energies ranging from 150 to 250 mJ. The handpiece can be focused or defocused to either heat or ablate. As the handpiece is moved closer to the lesion, one increases the fluence and a louder pop is heard. After a few passes, the papillomatosis disappears and the area is smooth. We do not try to achieve complete removal of this surface finding, but rather “yellow” it slightly with the CO2 laser. The RTD is usually sufficient to obtain long-term remissions without significant scaring or pigmentation changes. In a recent study Cohen et al. (181) compared the CW CO2 laser and UltraPulse and found no significant differences in the two with respect to cosmesis or side effects. Losee et al. (182) used the FeatherTouch mode (120 W with 200 mm handpiece) to remove a large epidermal nevus. Hohenleutner and Landthaler (183) treated a large epidermal
156
Ross
nevus with 20– 25 W CW and a 2 – 3 mm spot with a good result. They used yellowing of the dermis and loss of papillations as an end point. Ratz et al. (184) treated 15 patients with epidermal nevi with 15 –20 W and a 2 mm spot and noted scarring on the torso. They subsequently decreased the power to 5 W and noted better results. 6.2.5.
Syringoma
Syringomas are another adnexal tumor that can be easily treated with the CO2 laser (Fig. 5.10). We have used both the CW mode at a low power of 1– 3 W, with 0.1 s mechanically shuttered “pulses,” as well as the UltraPulse mode with the 1 mm handpiece. We have found that the UltraPulse mode is more elegant in that one can ablate the lesions by 100– 200 mm increments. Our typical end point is removing about half to two-thirds of the whitish lesion. This results in a small dell in the skin that heals with minimal hypopigmentation and scarring. Dark-skinned patients should be warned that there will usually be some hyperpigmentation starting about 3 weeks after the procedure. This usually resolves within 2 –3 months with or without bleaching creams. We normally do a test site with one or two lesions prior to treating an entire area (185). Wang and Roenigk (186) treated multiple syringomas with the SilkTouch (5 W, 125 mm handpiece) laser with one to three passes with good results. Wheeland et al. (187) treated 25 patients using 5 W and 2 mm defocused mode. They used 0.1 s gated bursts for each lesion. Two to three passes were required to remove the glistening white tumor. Healing was complete within 7– 10 days. 6.2.6.
Xanthelasma
Xanthelasma has been treated with both the CW mode as well as the pulsed CO2 laser. Apfelberg et al. treated six patients with the superpulsed CO2 laser (188). They used magnification loupes and 10 W average power and focused the beam in the initial pass, followed by a defocused beam and curettage to remove any remaining yellow material. Alster and West (189) have reported treatment with the UltraPulse laser, and we have treated seven patients in the past 4 years with both erbium:YAG and pulsed CO2 lasers. Our approach is to use the 1 mm handpiece with the UltraPulse and defocus the beam in the initial pass to denature the epidermis, followed by a more focused beam to pick out the remaining yellow material. Typically, even when some material remains grossly, the subsequent fibrosis masks the yellow color well; furthermore, treatment to remove all of the pigment increases the risk of pitted scarring (Fig. 5.11).
Figure 5.10 (a) Syringomas preop in 25-year-old white male (WM). (b) Eight weeks after treatment. Some lesions were treated with the UltraPulse laser using 150 – 250 mJ pulses with 1 mm spot. Others were treated with CW CO2 laser at 2 W, 1 mm spot with 0.5– 1 s gated “pulses.”
Continuous Wave and Pulsed CO2 Lasers
157
Figure 5.11 (a) Xanthelasma preop. (b) Just after treatment with the UltraPulse laser at 200 – 350 mJ and 1 – 3 mm spot. Note that some yellow material remains at the end of treatment. (c) After 6 weeks, note good cosmetic result.
7. 7.1.
LESIONS THAT MIGHT BE TREATED EQUALLY WELL WITH OTHER MODALITIES Seborrheic Keratoses
The CO2 laser is a reasonable choice for treatment. We have treated patients with both CW and UltraPulse modes and have found that the pulsed mode results in faster healing and easier identification of end points (Fig. 5.12). The lesion can be vaporized away after many passes of the UltraPulse CO2 laser with 500 mJ and 3 mm spot size. Care should be taken near the base of the lesion so that unnecessary heating and subsequent pigmentation changes and scarring do not occur. Fitzpatrick et al. (17,18) treated seborrheic keratoses in both CW and RSP modes and found only a slight advantage in the RSP mode, once again supporting the concept that rapid overlapping pulses offer little advantage in RTD vs. conventional CW vaporization. 7.2.
Dermatosis Papulosis Nigra
We treat DPN with the 1 mm spot size with the UltraPulse laser. For smaller lesions, usually one 100–150 mJ pulse will desiccate the lesion adequately enough so that it falls off after a few days. Alternatively, the CW mode can be used at 1–2 W for 100–150 ms. 7.3.
Neurofibromas
We have used the UltraPulse laser, 1 –3 mm spots with pulse energies ranging from 200 to 500 mJ, and found that, after exposure of the dermis, the remaining tumor, which has a rubbery consistency, can be manually expelled by gentle pressure around the wound.
158
Ross
Figure 5.12 (a) A Seborrheic keratosis in the right infraorbital area preop. (b) Larger portion was treated with the UltraPulse laser at 400 mJ, 3 mm spot up, and three to five passes. The smaller portion, to the reader’s right, was treated with CW CO2 laser at 5 W and 2 –3 mm spot. (c) Both sites showed good results after 10 weeks.
Following this, additional passes of the laser vaporize the rubbery lesions, and the wounds are allowed to heal by secondary intention. The areas heal with slight hyperpigmentation, which resolves after 6 months. Roenigk and Ratz (190) used the CW CO2 laser with a 2 mm beam and power of 4– 6 W (160 W/cm2), in a similar manner. Becker (191) treated a patient with multiple pedunculated and sessile lesions. He used the cutting 0.2 mm spot to excise the stalks in the pedunculated lesions, and a defocused beam at 35 – 60 W CW while squeezing the rubber nodule outward to remove the sessile lesions. 7.4.
Steatocystomas
We have treated these tumors of the sebaceous glands by first piercing the central portion with the 1 mm spot in the UltraPulse mode, after which gentle pressure can be used to extrude the small wall, which can be vaporized with subsequent passes. The wounds are allowed to heal by second intention. Krahanbuhl et al. (192) treated a single patient in a similar fashion using the CW CO2 (1 mm spot and 5 W, 100 ms gated pulse) with good results. 7.5.
Pearly Penile Papules
We have treated two patients with this variant of angiofibromas. In one patient we used both UltraPulse and CW modes and found that the pulsed mode resulted in more bleeding and just as long a recovery period (193). As the additional thermal damage from CW application using low 1–3 W powers and short 0.25–0.5 s exposures did not result in a clinically relevant scar, we recommend this technique. Magid and Garden (194) also reported two cases treated successfully with CW laser (5 W, 0.1 s burst with a 1–2 mm spot).
Continuous Wave and Pulsed CO2 Lasers
7.6.
159
Basal Cell Carcinoma
Basal cell carcinoma (BCC) has been treated with the CO2 laser and curettage. In early reports the pulsed or CW laser replaced the hyfercater. Because no large studies have been performed, the role of this technique is unclear, particularly since the thermal damage induced by the hyfercater might be one reason for the relatively good success of traditional electrodesiccation and curettage. Superficial BCCs logically should have the best outcome with this technique. Wheeland et al. (195) reported the use of CO2 laser with curettage in the treatment of BCC. In this study, the CW laser was used in 52 patients for superficial lesions. They used powers of 4 – 5 W and 1 – 2 mm spot size that yielded a PD of 160– 510 W/cm2. The technique resulted in light charring at the skin surface, after which removal with H2O2 gauze showed a whitish yellow base. The base was then curetted, and this was repeated with the laser until the wound base was uniformly firm and no friability was observed. They found good overall cosmetic results with a hypertrophic scar rate of only 5% and no recurrence over a mean follow-up of 19 months. More recently, Kilmer and Chozen (196) reported the use of the UltraPulse laser in the treatment of BCCs, excluding those with a known infiltrative or morpheaform pattern. They used 450 mJ pulses with the 3 mm spot after curettage. In some patients, second passes were made. In subsequently excised specimens no tumor was found after laser treatment, and lesions followed clinically also did not show visible recurrence. Humphreys et al. (197) reported their experience with high-energy pulsed CO2 treatment of BCC and Bowen’s disease. They treated 30 tumors and found that BCC responded better than Bowen’s disease, whose full depth was not vaporized in excised specimens. Curettage was not performed in this study. Grobbelaar et al. (198) treated six BCC nevus syndrome patients, with up to 110 lesions treated in one session with the SilkTouch laser. The end point was the absence of punctate bleeding. Multiple passes were made, with wiping between passes. After a mean follow-up of 20 months, no clinical or histologic evidence of recurrence was noted. 7.7.
Bowen’s Disease
We have treated one patient with erythroplasia of Queyrat of the penis with the CO2 laser in UltraPulse mode (300 mJ, 3 mm spot, two passes) with excellent results. The patient had a poor response to Efudex. As with electrodesiccation and curettage, there is no margin control with this technique, so close clinical follow-up is required. Gordon and Robinson (199) recently reported laser vaporization of the finger for Bowen’s disease (3 W CW, 2–3 mm spot) with multiple passes. A postoperative biopsy showed no recurrence. 7.8.
Hidradenitis Suppurativa
Finley and Ratz (200) reported the use of the CW CO2 laser to excise axillary and inguinal lesions in seven patients with a power of 40 W and 0. 2 mm spot. The base of the wounds was lightly coagulated in the defocused mode. Time to healing by second intention ranged from 4 to 11 weeks. Only one recurrence was noted after 10 –27 months of follow-up. 7.9.
Scar Revisions
CO2 lasers have been used to resurface scars, both at the time of the excision (201,202) as well as after traumatic wounds. Like dermabrasion, the de-epithelialization of the scarred region appears to improve the excision line. Alster et al. (203) examined the use of the
160
Ross
UltraPulse CO2 laser alone vs. CO2 plus PDL in hypertrophic scars, and found that the addition of PDL helped in most cases. Grevelink and White (202) performed simultaneous LSR and punch excisions and found that the wounds healed well with minimal scarring. Their conclusion was that there was no need for the traditional 1 – 2 month delay between punch grafts/excisions and facial resurfacing. 7.10.
Chondrodermatitis Nodularis Helicus
Taylor (204) reported 11 patients treated with the CO2 laser in RSP mode. He vaporized the affected nodule and allowed the wounds to heal by secondary intention. He noted no recurrence after 2– 15 months. 7.11.
Lymphangioma Circumscriptum
Haas and Narurkar (205) recently reported the use of the UltraPulse laser where two to three passes were made or treatment was carried out until the point where no visible lymphatic drainage was observed. There was mild hypertrophic scarring but no recurrence in the same area after 2 years. Others have reported success with the CW CO2 laser for this condition (206). Because of the deep nature of the lesions, lesions usually recur regardless of the treatment modality. The author has treated two patients and has followed a patient treated with the CW CO2 laser. The CW treated patient had developed hypertrophic scarring; subsequent treatment with the UltraPulse laser (300 – 500 mJ) with multiple passes resulted in resolution of the majority of the nodules and only mild textural changes at the surface. As expected, at the periphery of the scarred areas and even within the scars, there were recurrences of the translucent nodules. 7.12.
Nevus Sebaceous
These usually broad-based plaques are vaporized with many passes to a level where most of the yellow papules embedded in the lesion are removed. The final result is a smooth pink surface. Healing is by secondary intention. Like epidermal nevi, attempts to ablate the lesion down to the reticular dermis will result in longer remission but also in a greater likelihood of scarring. Where resection is possible, because of the risk of BCC or BCC-like lesions developing in these lesions, excision should be strongly considered. Ashinoff (207) reported treatment of an extensive nevus sebaceous on the midface in a 10-year-old girl with 6 W CW power in the defocused mode in three separate sessions. The intention was to remove only the exophytic portion, as the case would have resulted in extensive scarring after surgery for definitive removal. 7.13.
Hydrocystoma
We have treated these with the UltraPulse laser with good results. Bickley et al. (208) reported a case treated with the CW CO2 laser (5 W, 2 mm spot). 7.14.
Histiocytoma or Xanthoma Disseminatum
Carpo et al. (209) reported treatment with an SP CO2 laser. We have also treated a case with the UltraPulse laser (Fig. 5.13). We used the 3 mm spot and 500 mJ pulse energy for lesions 3 mm in diameter. For smaller lesions, we used the 1 mm spot-size handpiece. This handpiece can be focused or defocused depending on the size of the lesion. Once the epidermis is removed, the yellow base of the lesions is seen. At this point the smaller
Continuous Wave and Pulsed CO2 Lasers
161
Figure 5.13 (a) Preop view of eruptive histiocytomas. (b) Six months after treatment with the UltraPulse laser at 200–350 mJ, 1– 3 mm spot, and multiple passes.
spot is used to ablate the remaining lesion. This will leave a depression if the lesion is completely removed. We have found that leaving about 20% of the lesion at the base results in a very nice cosmetic result without recurrences. 7.15. Hailey – Hailey and Darier’s Disease The author has only used the erbium:YAG laser for Hailey – Hailey disease, and has never treated a patient with the CO2 or erbium laser for Darier’s disease. However, there are reports of treatment with the CW CO2 laser for both of these dyskeratotic processes (210 –213). In one report (212) the CO2 laser was used defocused (2 mm spot, 10 W) to vaporize to a level without apparent disease, usually after two passes. In the case series, there were varying disease-free periods. The authors noted that the papillary dermis probably must be removed for long-term remission. More recently, Kruppa et al. (214) treated two patients with the SilkTouch system with good results (6 W, three passes with 125 mm handpiece). Christian and Moy (210) treated Hailey – Hailey disease with a short-dwelltime CO2 laser and showed that more passes resulted in superior outcomes. Touma et al. (213) used the UltraPulse laser for treatment of active lesions with success, and also found that prophylactic treatment of inactive lesions led to prolonged remissions in the majority of the treated areas. They also reported some mild scarring on the chest. 7.16. Kaposi’s Sarcoma Chun et al. (215) used the SilkTouch laser with 7 W and 6 mm scan size with good results on the penis. Kaplan (55) had reported the use of a CW CO2 laser many years earlier. 7.17. Tattoos The CW CO2 laser has been used to treat tattoos, but offers only slight advantages over other nonselective means of tattoo removal. The author had treated one large cosmetic
162
Ross
tattoo with the CW CO2 laser combined with urea paste, and found long-term erythema and mild textural change, along with incomplete pigment removal. Although sometimes very effective (2,216 –219), as a general rule, because of a 20 – 50% risk of hypertrophic scarring, the CO2 laser cannot be advocated as the treatment of choice, particularly if dedicated shorter-pulsed lasers are available (Q-switched lasers) in the patient’s geographic region. An exception is treating brown- and skin-colored tattoos. Often, these will darken after a test site treatment with a Q-switched laser (paradoxical ink darkening), in which case the CW or pulsed CO2 laser can be used to gently de-epithelialize the skin. The resulting extrusion of ink, particularly if repeated, can result in an excellent final cosmetic result (220). Use of the CO2 laser prior to Q-switched laser has been attempted (221). One study concluded that the disadvantages (textural changes, increased need for anesthesia, and infection) outweighed the modest improvement in tattoo lightening over Q-switched laser treatment alone. 7.18.
Disseminated Superficial Actinic Porokeratosis
We have treated one patient with extensive disseminated superficial actinic porokeratosis (DSAP) on the legs with the UltraPulse (400 mJ, 3 mm spot) with two passes. EMLA alone was used for anesthesia. After 3 months, there was no clinical evidences of recurrence and only mild hypopigmentation at the treatment site. 7.19.
Actinic Keratosis
Like DSAP, the lesions can be treated with an SP laser with multiple passes. Treatment should be aggressive enough so that the final surface is smooth, as we have observed two patients after full-face LSR who developed squamous cellcarcinoma in what appeared to be small actinic keratoses at the time of treatment. The squamous cellcarcinoma occurred within 12 weeks of LSR. 8.
LASER STERILIZATION
Laser wounds have been shown to support bacterial growth after treatment, that is, if implanted with bacteria, they show a higher rate of infection than similar scalpel wounds (222). In contrast, the CO2 laser has also been used to sterilize wounds. In these cases, the wound base is treated in the defocused mode, and this material is then excised by the laser, after which the wound is closed primarily. Wounds deliberately contaminated by Pseudomonas were shown in a rat study to be sterilized more completely than after an iodine scrub (223). Lee et al. (224) treated infected sterniotomy wounds with a CW CO2 laser, excised the eschar, and then closed the wounds with good results. Hinshaw et al. (225) reported the use of the CO2 laser to sterilize purulent wounds. They sterilized the base with a defocused beam, followed by laser excision and primary closure. Irrigation of the wound was an important contributor to the success of the procedure. 9. 9.1.
TECHNIQUE PEARLS CW Vaporization
In review of the CW applications described earlier, it becomes clear that most CO2 laser surgeons somewhat arbitrarily choose the power and pulse duration. Typically, the surgeon repeats the cycle of irradiation and inspection, continuing until almost or no
Continuous Wave and Pulsed CO2 Lasers
163
lesional tissue remains. Fleiming and Brody (226) proposed a more logical approach to the treatment of lesions with the CW CO2 laser. They cited several limitations in the empirical techniques commonly employed in the many publications cited earlier. (1) In many cases, the surgeon’s dependence on visual differentiation of normal from lesional tissue leads to possible overtreatment and scar, or undertreatment and rapid recurrence. (2) This technique is slow, because the cycle is repeated for each lesion. This was cited as a major drawback in a publication comparing electrosection and CW CO2 in the treatment of trichoepitheliomas (227). In Fleming and Brody’s study, they used a constant power in plotting the depth of the resulting crater as a guide in planning treatments. They noted that crater depth depended on fluence for the powers used (5–18 W and 1 mm spot). They found that the application time determined the crater depth for constant power and spot size. Based on their data and our own data with SP lasers, one can calculate an ablation depth of roughly 2500 mm for a fluence of 2000 J/cm2, as long as the irradiance is .1000 W/cm2, for example, a 10 W pulse delivered with a 1 mm spot and application time of 1 s. 9.2.
Cutting
The reader should note that 15 – 25 W will give a cutting depth of 3– 5 mm with a hand movement rate of 1.5 mm/s with a 0.3 mm spot (228). Also, wet gauze should always be used as a backstop so that the beam does not injure unintended targets (229). 10.
LASER SAFETY ISSUES SPECIFIC TO THE CO2 LASER
A primary area of concern is the eye, where the cornea can be injured. In one case, the cornea was damaged during LSR and required corneal transplant to restore vision (230). Eyeshields with the CO2 laser should be metal, as Ries et al. (231) showed that plastic shields will burn with prolonged CW irradiation. In the case of LSR lasers, although nine passes were required for shield perforation, melting of the surface was noted as early as the first pass. Also, Rohrich et al. (232) noted that plastic corneal protectors melted by the third pass and produced significant heat in LSR. Black surfaces have been advocated for laser surgery, but these may deteriorate after many passes. Roughened instruments are most effective but may not always be available. Therefore, protection of the eye should include side shields to prevent corneal injury from a reflection. Wood et al. (233) found that with the exception of silver finish polish, the hazard distances for laser reflections usually extend only to the immediate area of the operative field. The teeth should be covered during resurfacing, as dentin charring and cracking have been reported (234,235). Another area of concern is fire (236). Rohrich et al. (232) noted that dry but not wet gauze produced a flame with UltraPulse and SilkTouch irradiation. Wald et al. (237) found that the UltraPulse did not start a fire in an animal study, even with supplemental 6 L/min O2 close by (at 0.5 cm separation). However, the authors caution the reader that this is only so long as combustion does not occur. Other hazards peculiar to the CO2 laser are related to the plume. There are carcinogenic nitrosamines, and some particles are either too small to be filtered by the upper airway or too large to be removed from the alveoli. These particles can cause pulmonary fibrosis. The particulate matter in the plume has a mean diameter of 0.3 mm (238). Baggish et al. (239) found that rats showed interstitial lung changes after prolonged exposure to a CO2 plume. These changes were reduced with the use of an ultra-low-penetration air filter. Smoke evacuation systems have been reported to protect animals if they can trap particles of 0.3 mm or less (239). The smoke evacuator
164
Ross
should provide at least 40 CFM (cubic feet per minute) suction as the lower limit for efficient collection of debris. The nozzle should be ,1–2 cm from the treatment area (240). It has been shown that the CW laser plume contains viable bacterial spores at low irradiance (,500 W/cm2). Despite studies showing HIV in the laser plume, there appears to a low rate of infection transmission in experimental systems (241). Fader et al. (236) suggested that this is due to a low concentration of viral particles in the plume compared to a normal infective load, the use of adequate filtration and masks, or the fact that it is too early to tell. In Baggish et al.’s study (241), the PD was 500 W/cm2 and they studied DNA capture. This study showed that proviral HIV DNA was present in smoke. There was infection in cultured cells but the infection was not maintained. The study showed that most if not all of the potentially infectious debris was present in the plume. It is unclear whether HIV can be transmitted by inhalation. Garden et al. (242) found intact HPV DNA in the laser plume. Gloster and Roenigk (243) sent out a questionnaire and found that 5% of the respondents believed the plume had infected them. This percentage was not significantly different from the incidence of warts in the population. They did find a significantly higher incidence of nasopharyngeal lesions, which is consistent with the likelihood that inhalation is the primary means of transmission of the virus. They did not find a difference when a smoke evacuator was used, but admitted that the denominator was small for the unprotected group. Overall, they found that CO2 laser surgeons were no more likely to develop hand warts than their non-CO2 laser counterparts. Ideally, one should use a mask designed with a pore size no greater than 0.1 mm.
11.
NEW DEVELOPMENTS
At the time of writing, various strategies were being developed to reduce thermal damage with the CO2 laser, both in resurfacing and in incisional surgery. These strategies have included reducing the pulse duration, changing the repetition rate, employing computer scanners with temperature feedback (244), and using other wavelengths such as 9.6 mm (3). Also of current interest is the dependence of collagen shrinkage on wavelength. Presently, CO2 laser wavelengths have targeted water in the dermis and epidermis. However, using other wavelengths, one can target molecular bonds in the dermis. For example, Ellis et al. (245) found that 7.2 –7.4 mm was better than 10.6 mm in inducing collagen contraction, suggesting that selective protein absorption might provide a better clinical effect than water absorption. They also considered that collagen denaturation and contraction are not necessarily associated, so that collagen denaturation alone is not responsible for collagen shrinkage, or that collagen denaturation might look different with light microscopy at different wavelengths. Investigators are also studying metal templates that surround the incisional field. These devices conduct heat away from the site to reduce lateral thermal damage (246).
12.
PRE- AND POSTOPERATIVE CONSIDERATIONS
12.1. 12.1.1.
Preoperative Considerations Relative Contraindications
The ideal patient for treatment, regardless of disease, is either very dark or very light, as patients tend to return to their constitutive color after CO2 laser surgery. Bronzed patients with Type II and III skin are at high risk for permanent hypopigmentation with increasing depth of injury; this should be discussed with the patient within the context of likelihood
Continuous Wave and Pulsed CO2 Lasers
165
for cosmetic improvement. Whether the hypopigmentation is relative (i.e., lighter than the surrounding tanned untreated skin) or an absolute leukoderma is probably irrelevant, because the end result is similar potential line of demarcation. Any patient with decreased adnexal structures from previous radiation therapy or even laser hair removal or electrolysis should probably receive at least a test site. This advice is controversial for laser hair reduction, as there are no reports of compromised healing in CO2 laser induced areas previously treated with hair reduction lasers. The recommended minimum time interval between isotretinoin treatment and resurfacing (and vice versa) ranges from 6 months to 2 years (247,248). Weinstein found that two out of four cases of severe scarring in a review of 1925 CO2 resurfacing patients had received isotretinoin within 2 years. 12.1.2.
Preoperative Regimen
For adnexal tumors, test sites, and small-scar abrasions, no systemic or topical medications are prescribed. We have found that topical retinoids and bleaching preparations do not appear to alter the postoperative course. 12.1.3.
Postoperative Care
With the exception of excised wounds, in which sutures should be left in 3– 5 days longer than in scalpel wounds, wounds are left to heal by secondary intention and will heal optimally when kept moist and clean. Dressings will speed healing if they are changed (at least every 2 days). We have used Silon TSR (Biomedsciences, Allentown, PA) and Second Skin (SPENCO, Waco, TX), all with good results. The most important postoperative intervention is the use of a truly effective sunscreen. Until recently, we observed an almost 100% incidence of hyperpigmentation in our Hispanic and Asian patients, undoubtedly largely due to the omnipresent sun in southern California. The increase in color typically appears around Days 13 – 19, and has been most severe in areas with slightly deeper ablation (i.e., at the edge of discrete acne scars). While some of this increased color might be due to mechanical rubbing in making second passes with the CO2 laser, we have also routinely encountered this phenomenon after the erbium:YAG laser, where absolutely no wiping with gauze was performed. Most recently, we have observed a dramatic decrease in postinflammatory hyperpigmentation with the use of Total Block Sunscreen (Total Block, Fallene Ltd., King of Prussia, PA). In patients who have used this block, starting just after re-epithelialization is complete, we have noted a significant reduction in hyperpigmentation. More disturbing than the almost always temporary, especially on the face, postinflammatory hyperpigmentation, is the delayed onset of hypopigmentation after the CO2 laser in some cases. Laws et al. (249) examined the histology of a patient after CO2-induced loss of pigment and found that there were a normal number of melanocytes, but that they were simply not making melanin. Stuzin et al. (250) examined CO2 and phenol wounds in human skin and found postoperatively that epidermal melanocytes appeared to function normally in laser treated wounds. In the CO2 laser wounds there was a more regular distribution of melanosomes. In both wound types, there were melanocytes. In the phenol wounds, there simply was no melanin.
13.
CONCLUSIONS
It is interesting that in review of the vast literature of CO2 laser in skin, the laser has not enjoyed even greater popularity in dermatology. Particularly in CW and RSP modes, the laser is a very versatile tool whose uses are only limited by the creativity of the physician.
166
Ross
REFERENCES 1. 2. 3. 4.
5. 6. 7. 8. 9.
10. 11. 12.
13.
14. 15.
16.
17.
18.
19. 20. 21. 22.
Polanyi T. History of the CO2 laser in surgery. In: Andrews A, Polanyi T, eds. Microscopic and Endoscopic Surgery with the CO2 Laser. Boston: John Wright, 1982:1 – 25. McBurney EI. Carbon dioxide laser treatment of dermatologic lesions. South Med J 1978; 71(7):795– 797. Payne BP, Nishioka NS, Mikic BB, Venugopalan V. Comparison of pulsed CO2 laser ablation at 10.6 microm and 9.5 microm. Lasers Surg Med 1998; 23(1):1 – 6. Fisher J. Fundamentals of laser physics, optics, and operating characteristics for the physician. In: Wright V, FIsher J, eds. Laser Surgery in Gynecology. Philadelphia, PA: W.B. Saunders, 1993. Fisher JC. The medical laser: an indispensable tool of the physician and surgeon. Med Instrum 1983; 17(6):398– 400. Duley W. Gas lasers. In: Meyers R, ed. Encyclopedia of Lasers and Optical Technology. San Diego, CA: Academic Press, 1991:139. Hecht J. Understanding Lasers: An Entry Level Guide. New York: IEEE Press, 1994. Katzir A. Lasers and Optical Fibers in Medicine. San Diego, CA: Academic Press, 1993. Fisher J. Qualitative and quantitative tissular effects of light from important surgical lasers: optimal surgical principles. In: Wright V, FIsher J, eds. Laser Surgery in Gynecology. Philadelphia, PA: WB Saunders, 1993:58– 82. Ross EV, McKinlay JR, Anderson RR. Why does carbon dioxide resurfacing work? A review. Arch Dermatol 1999; 135(4):444– 454. Fisher J. Surgical Delivery Systems. In: Wright V, Fisher J, eds. Laser Surgery in Gynecology. Philadelphia, PA: WB Saunders, 1993:23– 41. Hobbs ER, Bailin PL, Wheeland RG, Ratz JL. Superpulsed lasers: minimizing thermal damage with short duration, high irradiance pulses. J Dermatol Surg Oncol 1987; 13(9):955– 964. Fisher J. The Concept, Calculation, and Surgical Importance of Power Density: Significance of Superpulsing. In: Wright V, Fisher J, eds. Laser Surgery in Gynecology. Philadelphia, PA: WB Saunders, 1993:41– 58. Fisher JC. Basic biophysical principles of resurfacing of human skin by means of the carbon dioxide laser. J Clin Laser Med Surg 1996; 14(4):193 – 210. Paulsen J. CO2 lasers thermal changes on laryngeal tissue after different application modes. In: Berlien H, Biamino G, Muller G, Ringelhan H, Schaldach B, eds. Safety and Laser Tissue Interaction. Berlin: SPIE, 1981. Hukki J, Lipasti J, Castren M, Puolakkainen P, Schroder T. Lactate dehydrogenase in laser incisions: a comparative analysis of skin wounds made with steel scalpel, electrocautery, superpulse – continuous wave mode carbon-dioxide lasers, and contact Nd:YAG laser. Lasers Surg Med 1989; 9(6):589– 594. Fitzpatrick RE, Ruiz-Esparza J, Goldman MP. The depth of thermal necrosis using the CO2 laser: a comparison of the superpulsed mode and conventional mode. J Dermatol Surg Oncol 1991; 17(4):340– 344. Fitzpatrick RE, Goldman MP, Ruiz-Esparza J. Clinical advantage of the CO2 laser superpulsed mode. Treatment of verruca vulgaris, seborrheic keratoses, lentigines, and actinic cheilitis. J Dermatol Surg Oncol 1994; 20(7):449 – 456. Reid R. Physical and surgical principles governing expertise with the carbon dioxide laser. Obstet Gynecol Clin North Am 1987; 14(2):513 – 535. Welch AJ, Motamedi M, Rastegar S, LeCarpentier GL, Jansen D. Laser thermal ablation. Photochem Photobiol 1991; 53(6):815– 823. Welch AJ, Gardner CM. Monte Carlo model for determination of the role of heat generation in laser-irradiated tissue. J Biomech Eng 1997; 119(4):489– 495. Walsh JT Jr, Deutsch TF. Pulsed CO2 laser tissue ablation: measurement of the ablation rate. Lasers Surg Med 1988; 8(3):264– 275.
Continuous Wave and Pulsed CO2 Lasers 23. 24. 25. 26.
27.
28. 29. 30.
31. 32. 33. 34. 35.
36. 37.
38.
39. 40.
41. 42. 43. 44. 45.
46.
167
McKenzie AL. How far does thermal damage extend beneath the surface of CO2 laser incisions? Phys Med Biol 1983; 28(8):905– 912. McKenzie AL. A three-zone model of soft-tissue damage by a CO2 laser. Phys Med Biol 1986; 31(9):967 –983. Venugopalan V, Nishioka NS, Mikic BB. The effect of CO2 laser pulse repetition rate on tissue ablation rate and thermal damage. IEEE Trans Biomed Eng 1991; 38(10):1049– 1052. Venugopalan V, Nishioka NS, Mikic BB. The effect of laser parameters on the zone of thermal injury produced by laser ablation of biological tissue. J Biomech Eng 1994; 116(1):62– 70. Venugopalan V, Nishioka NS, Mikic BB. Thermodynamic response of soft biological tissues to pulsed infrared-laser irradiation. Biophys J 1996; 70(6):2981– 2993 (published erratum appears in Biophys J 1996; 71(6):3530). Walsh JT Jr, Flotte TJ, Anderson RR, Deutsch TF. Pulsed CO2 laser tissue ablation: effect of tissue type and pulse duration on thermal damage. Lasers Surg Med 1988; 8(2):108 – 118. Anderson R. Laser tissue interactions. In: Goldman M, Fitzpatrick R, eds. Cutaneous Laser Surgery. St. Louis, MO: Mosby, 1999:1 – 19. Ross EV, Domankevitz Y, Skrobal M, Anderson RR. Effects of CO2 laser pulse duration in ablation and residual thermal damage: implications for skin resurfacing. Lasers Surg Med 1996; 19(2):123 –129. Fessenden R, Fessenden J. Organic Chemistry. Boston, MA: Willard Grant Press, 1979. Zweig A. A thermo-mechanical model for laser ablation. Appl Phys 1991; 70(3):1684– 1691. Sanders DL, Reinisch L. Wound healing and collagen thermal damage in 7.5-microsec pulsed CO(2) laser skin incisions. Lasers Surg Med 2000; 26(1):22 – 32. Littler C. The micrscopic effect of the nanosecond CO2 laser on ex-vivo human skin (abstract). Lasers Surg Med 1999; 11(suppl):27. Schomacker KT, Walsh JT Jr, Flotte TJ, Deutsch TF. Thermal damage produced by high-irradiance continuous wave CO2 laser cutting of tissue. Lasers Surg Med 1990; 10(1):74– 84. Dobry MM, Padilla RS, Pennino RP, Hunt WC. Carbon dioxide laser vaporization: relationship of scar formation to power density. J Invest Dermatol 1989; 93(1):75 – 77. Ross E, Barnette D, Glatter RD, Grevelink JM. Effects of overlap and pass number in CO2 laser skin resurfacing: a study of residual thermal damage, cell death, and wound healing. Lasers Surg Med 1999; 24(2):103– 112. Brugmans M, Kemper J, Gijsbers GH, van der Meulen FW, van Gemert MJ. Temperature response of biological materials to pulsed non-ablative CO2 laser irradiation. Lasers Surg Med 1991; 11(6):587– 594. Lanzafame RJ, Naim JO, Rogers DW, Hinshaw JR. Comparison of continuous-wave, chop-wave, and super pulse laser wounds. Lasers Surg Med 1988; 8(2):119 – 124. Bellina J, Meandzija M, Schillt V et al. Analysis of electronically pulsed versus quasicontinuous wave carbon dioxide lasers in an animal model. Am J Obstet Gynecol 1984; 150(8):934– 940. Fitzpatrick R. Carbon dioxide laser surgery. In: Goldman M, Fitzpatrick R, eds. Cutaneous Laser Surgery. St. Louis, MO: Mosby, 1999:279 – 337. Kamat BR, Carney JM, Arndt KA, Stern RS, Rosen S. Cutaneous tissue repair following CO2 laser irradiation. J Invest Dermatol 1986; 87(2):268 – 271. Kamat BR, Tang SV, Arndt KA, Stern RS, Noe JM, Rosen S. Low-fluence CO2 laser irradiation: selective epidermal damage to human skin. J Invest Dermatol 1985; 85(3):274–278. Green HA, Domankevitz Y, Nishioka NS. Pulsed carbon dioxide laser ablation of burned skin: in vitro and in vivo analysis. Lasers Surg Med 1990; 10(5):476 – 484. Green HA, Burd E, Nishioka NS, Bruggemann U, Compton CC. Middermal wound healing. A comparison between dermatomal excision and pulsed carbon dioxide laser ablation. Arch Dermatol 1992; 128(5):639 –645. Choi B, Barton JK, Chan EK, Welch AJ. Imaging of the irradiation of skin with a clinical CO2 laser system: implications for laser skin resurfacing. Lasers Surg Med 1998; 23(4):185 – 193.
168
Ross
47.
Verdaasdonk RM, Borst C, van Gemert MJ. Explosive onset of continuous wave laser tissue ablation. Phys Med Biol 1990; 35(8):1129– 1144. LeCarpentier GL, Motamedi M, McMath LP, Rastegar S, Welch AJ. Continuous wave laser ablation of tissue: analysis of thermal and mechanical events. IEEE Trans Biomed Eng 1993; 40(2):188– 200. Ross EV, Mowlavi A, Barnette D, Glatter RD, Grevelink JM. The effect of wiping on skin resurfacing in a pig model using a high energy pulsed CO2 laser system. Dermatol Surg 1999; 25(2):81– 88. Ross EV, Naseef GS, McKinlay JR et al. Comparison of carbon dioxide laser, erbium:YAG laser, dermabrasion, and dermatome: a study of thermal damage, wound contraction, and wound healing in a live pig model: implications for skin resurfacing. J Am Acad Dermatol 2000; 42(1, Pt 1):92 – 105. Kauvar AN, Waldorf HA, Geronemus RG. A histopathological comparison of “char-free” carbon dioxide lasers. Dermatol Surg 1996; 22(4):343 – 348. Cotton J, Hood AF, Gonin R, Beesen WH, Hanke CW. Histologic evaluation of preauricular and postauricular human skin after high-energy, short-pulse carbon dioxide laser. Arch Dermatol 1996; 132(4):425 –428. Walsh JT Jr, Deutsch TF. Pulsed CO2 laser ablation of tissue: effect of mechanical properties. IEEE Trans Biomed Eng 1989; 36(12):1195– 1201. Fulton JE, Rahimi AD, Helton P, Dahlberg K, Kelly AG. Disappointing results following resurfacing of facial skin with CO2 lasers for prophylaxis of keratoses and cancers. Dermatol Surg 1999; 25(9):729– 732. Kaplan I, Ger R, Sharon U. The carbon dioxide laser in plastic surgery. Br J Plast Surg 1973; 26(4):359– 362. Bailin PL. Lasers in dermatology—1983. Cleve Clin Q 1983; 50(2):53 – 55. Kirschner RA. Cutaneous plastic surgery with the CO2 laser. Surg Clin North Am 1984; 64(5):871– 883. Dover J, Arndt K, Geronemus R, Olbricht S, Noe J, Stern R. Illustrated Cutaneous Laser Surgery. Norwalk, CT: Appleton Lange, 1990. Herbich G. Epidermal changes limited to the epidermis of guinea pig skin by low-power carbon dioxide laser irradiation. Arch Dermatol 1986; 122(2):132– 133. Kaplan I, Ger R. The carbon dioxide laser in clinical surgery. A preliminary report. Isr J Med Sci 1973; 9(1):79 – 83. Zweig AD, Meierhofer B, Muller OM et al. Lateral thermal damage along pulsed laser incisions. Lasers Surg Med 1990; 10(3):262 –274. Pogrel M, McCracken KJ, Daniels TE. Histologic evaluation of the width of soft tissue necrosis adjacent to carbon dioxide laser incisions. Oral Surg Oral Med Oral Pathol 1990; 70(5):564– 568. Polanyi TG. Laser physics. Otolaryngol Clin North Am 1983; 16(4):753 –774. Hukki J, Lipasti J, Castren M, Puolakkainen P, Schroder T. Lactate dehydrogenase in laser incisions: a comparative analysis of skin wounds made with steel scalpel, electrocautery, superpulse – continuous wave mode carbon-dioxide lasers, and contact Nd:YAG laser. Lasers Surg Med 1989; 9(6):589– 594. Goldbaum AM, Woog JJ. The CO2 laser in oculoplastic surgery. Surv Ophthalmol 1997; 42(3):255– 267. Goldman L. Effects of new laser systems on the skin. Arch Dermatol 1973; 108(3):385– 390. Goldman L. Laser medical instrumentation. Med Instrum 1976; 10(2):125 – 129. Goldman L, Perry E, Stefanovsky D. A flexible sealed tube transverse radio frequency excited carbon dioxide laser for dermatologic surgery. Lasers Surg Med 1983; 2(4):317 – 322. Kaplan I, Ger R. The carbon dioxide laser in clinical surgery. A preliminary report. Isr J Med Sci 1973; 9(1):79 – 83. Kaplan I, Gassner S, Shindel Y. Carbon dioxide laser in head and neck surgery. Am J Surg 1974; 128(4):543 –544. Kaplan I. The CO2 laser in plastic surgery. Lasers Surg Med 1986; 6(4):385 – 386.
48.
49.
50.
51. 52.
53. 54.
55. 56. 57. 58. 59. 60. 61. 62.
63. 64.
65. 66. 67. 68. 69. 70. 71.
Continuous Wave and Pulsed CO2 Lasers 72. 73. 74. 75.
76. 77.
78. 79.
80.
81. 82. 83.
84.
85.
86. 87.
88. 89.
90. 91. 92.
93.
169
Kaplan I SATEB-BM. The CO2 laser in pediatric surgery. J Pediatr Surg 1984; 19(3):248– 257. Mullins F, Jennings B, McClusky L. Liver resection with the continuous wave carbon dioxide laser: some experimental observations. Am Surg 1968; 34(10):717– 722. Ascher P, Ingolitsch E, Walter G et al. eds. Ultrastructural Findings in CNS Tissue with CO2 Laser. Jerusalem: Jersalem Academic Press, 1978. Alster TS, Nanni CA, Williams CM. Comparison of four carbon dioxide resurfacing lasers. A clinical and histopathologic evaluation. Dermatol Surg 1999; 25(3):153 – 158, discussion 159. Bernstein E, Brown DB, Kenkel J, Burns A. Residual thermal damage resulting from pulsed and scanned resurfacing lasers. Dermatol Surg 1999; 25(10):739– 744. Ross EV, Grossman MC, Duke D, Grevelink JM. Long-term results after CO2 laser skin resurfacing: a comparison of scanned and pulsed systems. J Am Acad Dermatol 1997; 37(5, Pt 1):709 –718. Kauvar AN, Geronemus RG. Histology of laser resurfacing. Dermatol Clin 1997; 15(3):459– 467. Duke D, Khatri K, Grevelink JM, Anderson RR. Comparative clinical trial of 2 carbon dioxide resurfacing lasers with varying pulse durations. 100 microseconds vs 1 millisecond. Arch Dermatol 1998; 134(10):1240– 1246. Moy RL, Bucalo B, Lee MH et al. Skin resurfacing of facial rhytides and scars with the 90-microsecond short pulse CO2 laser. Comparison to the 900-microsecond dwell time CO2 lasers and clinical experience. Dermatol Surg 1998; 24(12):1390– 1396. Alster TS. Comparison of two high-energy, pulsed carbon dioxide lasers in the treatment of periorbital rhytides. Dermatol Surg 1996; 22(6):541 – 545. Alster TS, Kauvar AN, Geronemus RG. Histology of high-energy pulsed CO2 laser resurfacing. Semin Cutan Med Surg 1996; 15(3):189– 193. Apfelberg DB. The ultrapulse carbon dioxide laser with computer pattern generator automatic scanner for facial cosmetic surgery and resurfacing. Ann Plast Surg 1996; 36(5):522– 529. Bisaccia E, Sequeira M, Magidson J, Scarborough D. Surgical intervention for the aging face. Combination of mini-face-lifting and superficial carbon dioxide laser resurfacing. Dermatol Surg 1998; 24(8):821– 826. Fitzpatrick RE, Smith SR, Sriprachya-anunt S. Depth of vaporization and the effect of pulse stacking with a high-energy, pulsed carbon dioxide laser. J Am Acad Dermatol 1999; 40(4):615– 622. Fulton JE, Shitabata PK. CO2 laser physics and tissue interactions in skin. Lasers Surg Med 1999; 24(2):113 –121. Lowe NJ, Lask G, Griffin ME, Maxwell A, Lowe P, Quilada F. Skin resurfacing with the Ultrapulse carbon dioxide laser. Observations on 100 patients. Dermatol Surg 1995; 21(12):1025– 1029. Rosenberg GJ. Full face and neck laser skin resurfacing. Plast Reconstr Surg 1997; 100(7):1846– 1854. Ruiz-Esparza J, Barba Gomez JM, Gomez de la Torre OL, Huerta Franco B, Parga Vazquez EG. UltraPulse laser skin resurfacing in Hispanic patients. A prospective study of 36 individuals. Dermatol Surg 1998; 24(1):59– 62. Ruiz-Esparza J. A pictorial diary of complete healing in 6 days after UltraPulse laser skin resurfacing. Dermatol Surg 1998; 24(1):15 – 17. Seckel BR, Younai S, Wang KK. Skin tightening effects of the ultrapulse CO2 laser. Plast Reconstr Surg 1998; 102(3):872– 877. Shakespeare PG, Dewar AE, Carruth JA. Re: UltraPulse carbon dioxide laser with computer pattern generator for facial cosmetic surgery and resurfacing. Ann Plast Surg 1997; 38(5):547– 550. Trelles MA, David LM, Rigau J. Penetration depth of Ultrapulse carbon dioxide laser in human skin. Dermatol Surg 1996; 22(10):863– 865.
170
Ross
94.
Trelles MA, Rigau J, Mellor TK, Garcia L. A clinical and histological comparison of flashscanning versus pulsed technology in carbon dioxide laser facial skin resurfacing. Dermatol Surg 1998; 24(1):43– 49. Yang CC, Chai CY. Animal study of skin resurfacing using the ultrapulse carbon dioxide laser. Ann Plast Surg 1995; 35(2):154 –158. Carniol P. Laser resurfacing technique: feathertouch, SilkTouch, and SureTouch resurfacing lasers. In: Carniol P, ed. Laser Skin Rejuvenation. Philadelphia, PA: Lippincott-Raven, 1998:115 – 123. Koch RJ. Initial clinical evaluation of the NovaScan carbon dioxide laser handpiece. Dermatol Surg 1998; 24(3):369 –371. Hausfeld J. Laser Resurfacing Technique: Luxar. In: Carniol P, ed. Laser Skin Rejuvenation. Philadelphia, PA: Lippincott-Raven, 1998:123 – 135. Gannot I, Dror J, Calderon S, Kaplan I, Croitorn N. Flexible waveguides for IR laser radiation and surgery applications. Lasers Surg Med 1994; 14(2):184 – 189. Cossmann P, Romano V, Sporri S et al. Plastic hollow waveguides: properties and possibilities as a flexible radiation delivery system for CO2-laser radiation. Lasers Surg Med 1995; 16(1):66– 75. Bucalo BD, Moy RL. Quantitative comparison of inflammatory infiltrate and linear contraction in human skin treated with 90-microsecond pulsed and 900-microsecond dwell time carbon dioxide lasers. Dermatol Surg 1998; 24(12):1314– 1316. Smith KJ, Skelton HG, Graham JS, Hamilton TA, Hackley BE Jr, Hurst CG. Depth of morphologic skin damage and viability after one, two, and three passes of a high-energy, shortpulse CO2 laser (Tru-Pulse) in pig skin. J Am Acad Dermatol 1997; 37(2, Pt 1):204– 210. Bucalo B, Moy R. Laser resurfacing technique: TruPulse laser. In: Carniol P, ed. Laser Skin Rejuvenation. Philadelphia, PA: Lippincott-Raven, 1998:153– 161. Hall RR, Hill DW, Beach AD. A carbon dioxide surgical laser. Ann R Coll Surg Engl 1971; 48(3):181– 188. Hall RR. The healing of tissues incised by a carbon-dioxide laser. Br J Surg 1971; 58(3):222– 225. Lunkenheimer P, Druen B, Sowislo W, Weritz D, Freytag G, Dittrich H. Wound healing after scalpel, laser, and thermocautery surgery. In: Kaplan I, ed. 2nd International Symposium on Laser Surgery. Dallas, TX: Jerusalem Academy Press, 1977. Cochrane JP, Beacon JP, Creasey GH, Russell RC. Wound healing after laser surgery: an experimental study. Br J Surg 1980; 67(10):740– 743. Hambley R, Hebda PA, Abell E, Cohen BA, Jegasothy BV. Wound healing of skin incisions produced by ultrasonically vibrating knife, scalpel, electrosurgery, and carbon dioxide laser. J Dermatol Surg Oncol 1988; 14(11):1213– 1217. Jarmuske MB, Stranc MF, Stranc LC. The effect of carbon dioxide laser on wound contraction and epithelial regeneration in rabbits. Br J Plast Surg 1990; 43(1):40 – 46. Middleton WG, Tees DA, Ostrowski M. Comparative gross and histological effects of the CO2 laser, Nd-YAG laser, scalpel, Shaw scalpel and cutting cautery on skin in rats. J Otolaryngol 1993; 22(3):167– 170. Molgat YM, Pollack SV, Hurwitz JJ et al. Comparative study of wound healing in porcine skin with CO2 laser and other surgical modalities: preliminary findings. Int J Dermatol 1995; 34(1):42– 47. Nemeth AJ. Lasers and wound healing. Dermatol Clin 1993; 11(4):783 – 789. Pogrel MA, Yen CK, Hansen LS. A comparison of carbon dioxide laser, liquid nitrogen cryosurgery, and scalpel wounds in healing. Oral Surg Oral Med Oral Pathol 1990; 69(3):269– 273. Pogrel MA, Pham HD, Guntenhoner M, Stern R. Profile of hyaluronidase activity distinguishes carbon dioxide laser from scalpel wound healing. Ann Surg 1993; 217(2):196–200. Robinson JK, Garden JM, Taute PM, Leibovich SJ, Lautenschlager EP, Hartz RS. Wound healing in porcine skin following low-output carbon dioxide laser irradiation of the incision. Ann Plast Surg 1987; 18(6):499– 505.
95. 96.
97. 98. 99. 100.
101.
102.
103. 104. 105. 106.
107. 108.
109. 110.
111.
112. 113.
114. 115.
Continuous Wave and Pulsed CO2 Lasers 116. 117.
118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128. 129.
130. 131. 132. 133.
134. 135. 136. 137. 138. 139.
140.
171
Harmon C, Zelickson B, McBurney E, Yarborough J. Ultrastrucural and immunohistochemical comparison of CO2 resurfacing lasers (abstract). Lasers Surg Med 1998; 10(suppl):3. Kirsch KM, Zelickson BD, Zachary CB, Tope WD. Ultrastructure of collagen thermally denatured by microsecond domain pulsed carbon dioxide laser. Arch Dermatol 1998; 134(10):1255 –1259. Collawn SS, Boissy RE, Vasconez LO. Skin ultrastructure after CO2 laser resurfacing. Plast Reconstr Surg 1998; 102(2):509– 515. Wheeland R, Bailin PL, Ratz JL. Combined carbon dioxide laser excision and vaporization in the treatment of rhinophyma. J Dermatol Surg Oncol 1987; 13(2):172 –177. Karim A, Streitmann M. Excision of rhinophyma with the carbon dioxide laser: a ten-year experience. Ann Otol Rhinol Laryngol 1997; 106(11):952– 955. Simo R, Sharma V. Treatment of rhinophyma with carbon dioxide laser. J Laryngol Otol 1996; 110(9):841 –846. el-Azhary RA, Roenigk RK, Wang TD. Spectrum of results after treatment of rhinophyma with the carbon dioxide laser. Mayo Clin Proc 1991; 66(9):899 – 905. Rosenbach A, Alster TS. Multiple trichoepitheliomas successfully treated with a high-energy, pulsed carbon dioxide laser. Dermatol Surg 1997; 23(8):708 – 710. Buecker JW, Estes SA, Zalla JA. Multiple trichoepitheliomas treated with the carbon dioxide laser. J Ky Med Assoc 1986; 84(10):543– 544. Wheeland RG, Bailin PL, Kronberg E. Carbon dioxide (CO2) laser vaporization for the treatment of multiple trichoepithelioma. J Dermatol Surg Oncol 1984; 10(6):470 – 475. Sawchuk WS, Heald PW. CO2 laser treatment of trichoepithelioma with focused and defocused beam. J Dermatol Surg Oncol 1984; 10(11):905– 907. Gerretsen AL, Toonstra J. Carbon dioxide laser treatment of multiple tricho-epitheliomas. Br J Dermatol 1991; 125(3):284 –285. Janniger CK, Goldberg DJ. Angiofibromas in tuberous sclerosis: comparison of treatment by carbon dioxide and argon laser. J Dermatol Surg Oncol 1990; 16(4):317 – 320. Boixeda P, Sanchez-Miralles E, Azana JM, Arrazola JM, Moreno R, Ledo A. CO2 , argon, and pulsed dye laser treatment of angiofibromas. J Dermatol Surg Oncol 1994; 20(12):808– 812. Lim J, Goh CL. Carbon dioxide laser treatment of periungual and subungual viral warts. Australas J Dermatol 1992; 33(2):87– 91. Brauner GJ, Schliftman A. Laser surgery for children. J Dermatol Surg Oncol 1987; 13(2):178– 186. Sood S, Hruza G. Treatment of vuruca vulgaris and condyloma acunimatum with lasers. Dermatol Ther 2000; 13:90– 101. Ashinoff R, Li JJ, Jacobson M, Friedman-Kien AE, Geronemus RG. Detection of human papillomavirus DNA in squamous cell carcinoma of the nail bed and finger determined by polymerase chain reaction. Arch Dermatol 1991; 127(12):1813– 1818. Street M, Roenigk RK. Recalcitrant periungual verrucae: the role of carbon dioxide laser vaporization. J Am Acad Dermatol 1990; 23(1):115 – 120. Logan R, Zachary CB. Outcome of carbon dioxide laser therapy for persistent cutaneous viral warts. Br J Dermatol 1989; 121(1):99– 105. Apfelberg DB, Maser MR, Lash H, White DN. Efficacy of the carbon dioxide laser in hand surgery. Ann Plast Surg 1984; 13(4):320– 326. Taylor MB. Successful treatment of warts. Choosing the best method for each situation. Postgrad Med 1988; 84(8):126– 128, 131– 136. Sloan K, Haberman H, Lynde CW. Carbon dioxide laser-treatment of resistant verrucae vulgaris: retrospective analysis. J Cutan Med Surg 1998; 2(3):142 – 145. Petersen C, Nurnberg BM. Carbon dioxide laser vaporization combined with perilesionally injected interferon alfa-2b in the treatment of a hyperkeratotic verruca vulgaris on the upper eyelid. Arch Dermatol 1994; 130(11):1369– 1370. Baggish MS. Carbon dioxide laser treatment for condylomata acuminata venereal infections. Obstet Gynecol 1980; 55(6):711– 715.
172
Ross
141.
Baggish MS. Improved laser techniques for the elimination of genital and extragenital warts. Am J Obstet Gynecol 1985; 153(5):545– 550. Bellina JH. The use of the carbon dioxide laser in the management of condyloma acuminatum with eight-year follow-up. Am J Obstet Gynecol 1983; 147(4):375– 378. Ferenczy A. Laser therapy of genital condylomata acuminata. Obstet Gynecol 1984; 63(5):703– 707. Hahn GA. Carbon dioxide laser surgery in treatment of condyloma. Am J Obstet Gynecol 1981; 141(8):1000 –1008. Kryger-Baggesen N, Falck-Larson J, Hjortkjaer Pederson P. CO2-laser treatment of condylomata acuminata. Acta Obstet Gynecol Scand 1984; 63(4):341 –343. Lassus J, Happonen HP, Niemi KM, Ranki A. Carbon dioxide (CO2)-laser therapy cures macroscopic lesions, but viral genome is not eradicated in men with therapy-resistant HPV infection. Sex Transm Dis 1994; 21(6):297– 302. Ferenczy A, Mitao M, Nagai N et al. Latent papillomavirus and recurring genital warts. N Engl J Med 1984; 313:784. Duus B, Philipsen T, Christensen J, Lundvall F, Sondergaard J. Refractory condylomata acuminata: a controlled clinical trial of carbon dioxide laser versus conventional surgical treatment. Genitourin Med 1985; 61(1):59– 61. Petersen C, Munkvad S, Christiansen CB. CO2 laser eradication of recalcitrant condyloma acuminatum does not influence T-lymphocyte subsets. Acta Dermatol Venereol 1998; 78(5):389. Johnson P, Mirzai TH, Bentz ML. Carbon dioxide laser ablation of anogenital condyloma acuminata in pediatric patients. Ann Plast Surg 1997; 39(6):578 – 582. Davis B, Noble M. Initial experience with combined interferon-alpha 2B and carbon dioxide laser for the treatment of condylomata acuminata. J Urol 1992; 147(3):627– 629. Kaplan I, Labandter H. Onychogryphosis treated with the CO2 surgical laser. Br J Plast Surg 1976; 29(1):102– 103. Conejo-Mir J, Corbi R, Linares M. Carbon dioxide laser ablation associated with interferon alfa-2b injections reduces the recurrence of keloids. J Am Acad Dermatol 1998; 39(6):1039– 1040. Stern J, Lucente F. Carbon dioxide laser excision of earlobe keloids. A prospective study and critical analysis of existing data. Arch Otolaryngol Head Neck Surg 1989; 115(9):1107– 1111. Kantor G, Wheeland RG, Bailin P, Walker N, Ratz J. Treatment of earlobe keloids with carbon dioxide laser excision: a report of 16 cases. J Dermatol Surg Oncol 1985; 11(11):1063–1067. Stucker FJ, Shaw GY. An approach to management of keloids. Arch Otolaryngol Head Neck Surg 1992; 118(1):63– 67. Sinclair RJ, Sinclair PJ. Carbon dioxide laser in the treatment of cutaneous disorders. Australas J Dermatol 1991; 32(3):165 –171. Ries WR, Speyer MT. Cutaneous applications of lasers. Otolaryngol Clin North Am 1996; 29(6):915– 929. Norris JE. The effect of carbon dioxide laser surgery on the recurrence of keloids. Plast Reconstr Surg 1991; 87(1):44– 49; discussion 50 – 53. Friedman M, Gal D. Keloid scars as a result of CO2 laser for molluscum contagiosum. Obstet Gynecol 1987; 70(3, Pt 1):394– 396. Apfelberg D, Maser MR, White DN, Lash H. Failure of carbon dioxide laser excision of keloids. Lasers Surg Med 1989; 9(4):382– 388. Lim T, Tan W. Carbon dioxide laser for keloids. Plast Reconstr Surg 1991; 88(6):1111. Nowak K, McCormack M, Koch R. The effect of superpulsed carbon dioxide laser energy on keloid and normal dermal fibrblast secretion of growth factors: a serum free study. Plast Reconstr Surg 2000; 105:2039– 2048. Cheng E, Koch R. Regional differences in the secretion of growth factors by facial and chest fibroblasts utilizing blended CO2 and erbium YAG laser energy: a serum free study (abstract). Lasers Surg Med 2000; 12(suppl):11.
142. 143. 144. 145. 146.
147. 148.
149.
150. 151. 152. 153.
154.
155. 156. 157. 158. 159. 160. 161. 162. 163.
164.
Continuous Wave and Pulsed CO2 Lasers 165. 166. 167. 168. 169. 170. 171. 172. 173. 174. 175. 176. 177.
178. 179. 180.
181. 182. 183. 184. 185. 186. 187. 188. 189. 190.
173
Kantor G, Ratz J, Wheeland R. Treatment of acne keloidalis nuchae with carbon dioxide laser. J Am Acad Dermatol 1986; 14(2, Pt 1):263 –267. Glass L, Berman B, Laub D. Treatment of perifolliculitis capitis abscedens et suffodiens with the carbon dioxide laser. J Dermatol Surg Oncol 1989; 15(6):673 – 676. Modica LA. Pyogenic granuloma of the tongue treated by carbon dioxide laser. J Am Geriatr Soc 1988; 36(11):1036– 1038. Lee CT, Tham SN, Tan T. Initial experience with CO2 laser in treating dermatological conditions. Ann Acad Med Sing 1987; 16(4):713– 715. Blickenstaff RD, Roenigk RK, Peters MS, Goellner JR. Recurrent pyogenic granuloma with satellitosis. J Am Acad Dermatol 1989; 21(6):1241– 1244. Stanley R, Roenigk R. Actinic cheilitis: treatment with the carbon dioxide laser. Mayo Clin Proc 1988; 63(3):230– 235. Zelickson B, Roenigk R. Actinic cheilitis. Treatment with the carbon dioxide laser. Cancer 1990; 65(6):1307 –1311. Robinson JK. Actinic cheilitis. A prospective study comparing four treatment methods. Arch Otolaryngol Head Neck Surg 1989; 115(7):848– 852. Frankel DH. Carbon dioxide laser vermilionectomy for chronic actinic cheilitis. Facial Plast Surg 1989; 6(3):158– 161. Dufresne R, Garrett A, Bailin P, Ratz J. Carbon dioxide laser treatment of chronic actinic cheilitis. J Am Acad Dermatol 1988; 19(5, Pt 1):876 –878. Dufresne RG Jr, Curlin MU. Actinic cheilitis. A treatment review. Dermatol Surg 1997; 23(1):15– 21. David LM. Laser vermilion ablation for actinic cheilitis. J Dermatol Surg Oncol 1985; 11(6):605– 608. Alamillos-Granados FJ, Navai-Gias L, Dean-Ferrer A, Alonso del Hoyo JR. Carbon dioxide laser vermilionectomy for actinic cheilitis. J Oral Maxillofac Surg 1993; 51(2): 118 – 121. Ries W, Duncavage J, Ossoff R. Carbon dioxide laser treatment of actinic cheilitis. Mayo Clin Proc 1988; 63(3):294– 296. Sexton J. Carbon dioxide laser treatment for actinic cheilitis. J Oral Maxillofac Surg 1993; 51(8):953. Johnson T, Sebastien T, Lowe L, Nelson B. Carbon dioxide laser treatment of actinic cheilitis. Clinicohistopathologic correlation to determine the optimal depth of destruction. J Am Acad Dermatol 1992; 27(5, Pt 1):737– 740. Cohen E, Nouri K, Jimenez G, Weiss E. Treatment of verrucous epidermal nevi with UltraPulse CO2 laser. Lasers Surg Med (abstract) 2000; 12(suppl):15. Losee JE, Serletti JM, Pennino RP. Epidermal nevus syndrome: a review and case report. Ann Plast Surg 1999; 43(2):211 –214. Hohenleutner U, Landthaler M. Laser therapy of verrucous epidermal naevi. Clin Exp Dermatol 1993; 18(2):124 –127. Ratz JL, Bailin PL, Wheeland RG. Carbon dioxide laser treatment of epidermal nevi. J Dermatol Surg Oncol 1986; 12(6):567 – 570. Sajben F, Ross E. The use of the 1.0 mm handpiece in high energy, pulsed CO2 laser destruction of facial adnexal tumors. Dermatol Surg 1999; 25(1):41 – 44. Wang J, Roenigk H Jr. Treatment of multiple facial syringomas with the carbon dioxide (CO2) laser. Dermatol Surg 1999; 25(2):136– 139. Wheeland R, Bailin P, Reynolds O, Ratz J. Carbon dioxide (CO2) laser vaporization of multiple facial syringomas. J Dermatol Surg Oncol 1986; 12(3):225 – 228. Apfelberg DB, Maser MR, Lash H, White DN. Treatment of xanthelasma palpebrarum with the carbon dioxide laser. J Dermatol Surg Oncol 1987; 13(2):149 – 151. Alster T, West T. Ultrapulse CO2 laser ablation of xanthelasma. J Am Acad Dermatol 1996; 34(5, Pt 1):848 –849. Roenigk RK, Ratz JL. CO2 laser treatment of cutaneous neurofibromas. J Dermatol Surg Oncol 1987; 13(2):187– 190.
174
Ross
191.
Becker DW Jr. Use of the carbon dioxide laser in treating multiple cutaneous neurofibromas. Ann Plast Surg 1991; 26(6):582– 586. Krahenbuhl A, Eichmann A, Pfaltz M. CO2 laser therapy for steatocystoma multiplex. Dermatologica 1991; 183(4):294– 296. McKinlay JR, Graham BS, Ross EV. The clinical superiority of continuous exposure versus short-pulsed carbon dioxide laser exposures for the treatment of pearly penile papules. Dermatol Surg 1999; 25(2):124– 126. Magid M, Garden JM. Pearly penile papules: treatment with the carbon dioxide laser. J Dermatol Surg Oncol 1989; 15(5):552– 554. Wheeland RG, Bailin PL, Ratz JL, Roenigk RK. Carbon dioxide laser vaporization and curettage in the treatment of large or multiple superficial basal cell carcinomas. J Dermatol Surg Oncol 1987; 13(2):119 –125. Kilmer S, Chozen V. Ultrapulse laser treatment of basal cell carcinomas (abstract). Lasers Surg Med 1996; 8(suppl):36. Humphreys TR, Malhotra R, Scharf MJ, Marcus SM, Starkus L, Calegari K. Treatment of superficial basal cell carcinoma and squamous cell carcinoma in situ with a high-energy pulsed carbon dioxide laser. Arch Dermatol 1998; 134(10):1247– 1252. Grobbelaar AO, Horlock N, Gault DT. Gorlin’s syndrome: the role of the carbon dioxide laser in patient management. Ann Plast Surg 1997; 39(4):366 – 373. Gordon KB, Robinson J. Carbon dioxide laser vaporization for Bowen’s disease of the finger. Arch Dermatol 1994; 130(10):1250– 1252. Finley E, Ratz J. Treatment of hidradenitis suppurativa with carbon dioxide laser excision and second-intention healing. J Am Acad Dermatol 1996; 34(3):465 – 469. Greenbaum S, Rubin M. Surgical pearl: the high-energy pulsed carbon dioxide laser for immediate scar resurfacing. J Am Acad Dermatol 1999; 40(6, Pt 1):988– 990. Grevelink JM, White VR. Concurrent use of laser skin resurfacing and punch excision in the treatment of facial acne scarring. Dermatol Surg 1998; 24(5):527 – 530. Alster TS, Lewis AB, Rosenbach A. Laser scar revision: comparison of CO2 laser vaporization with and without simultaneous pulsed dye laser treatment. Dermatol Surg 1998; 24(12):1299– 1302. Taylor MB. Chondrodermatitis nodularis chronica helicis. Successful treatment with the carbon dioxide laser. J Dermatol Surg Oncol 1991; 17(11):862– 864. Haas AF, Narurkar VA. Recalcitrant breast lymphangioma circumscriptum treated by UltraPulse carbon dioxide laser. Dermatol Surg 1998; 24(8):893 – 895. Bailin PL, Kantor GR, Wheeland RG. Carbon dioxide laser vaporization of lymphangioma circumscriptum. J Am Acad Dermatol 1986; 14(2, Pt 1):257– 262. Ashinoff R. Linear nevus sebaceus of Jadassohn treated with the carbon dioxide laser. Pediatr Dermatol 1993; 10(2):189– 191. Bickley LK, Goldberg DJ, Imaeda S, Lambert WC, Schwartz RA. Treatment of multiple apocrine hidrocystomas with the carbon dioxide (CO2) laser. J Dermatol Surg Oncol 1989; 15(6):599– 602. Carpo B, Grevelink SV, Brady S, Gellis S, Grevelink J. Treatment of cutaneous lesions of xanthoma disseminatum with a CO2 laser. Dermatol Surg 1999; 25(10):751– 754. Christian M, Moy R. Treatment of Hailey-Hailey disease (or benign familial pemphigus) using short pulsed and short dwell time carbon dioxide lasers. Dermatol Surg 1999; 25(8):661– 663. Kartamaa M, Reitamo S. Familial benign chronic pemphigus (Hailey-Hailey disease). Treatment with carbon dioxide laser vaporization. Arch Dermatol 1992; 128(5):646–648. McElroy JA, Mehregan DA, Roenigk RK. Carbon dioxide laser vaporization of recalcitrant symptomatic plaques of Hailey-Hailey disease and Darier’s disease. J Am Acad Dermatol 1990; 23(5, Pt 1):893 – 897. Touma DJ, Krauss M, Feingold DS, Kaminer MS. Benign familial pemphigus (Hailey-Hailey disease). Treatment with the pulsed carbon dioxide laser. Dermatol Surg 1998; 24(12):1411– 1414.
192. 193.
194. 195.
196. 197.
198. 199. 200. 201. 202. 203.
204. 205. 206. 207. 208.
209. 210.
211. 212.
213.
Continuous Wave and Pulsed CO2 Lasers 214.
215.
216. 217. 218. 219. 220. 221. 222.
223. 224. 225.
226. 227. 228.
229. 230. 231. 232. 233. 234.
235. 236. 237.
175
Kruppa A, Korge B, Lasch J, Scharffetter-Kochanek K, Hunzelmann N. Successful treatment of Hailey-Hailey disease with a scanned carbon dioxide laser. Acta Dermatol Venereol 2000; 80(1):53– 54. Chun YS, Chang SN, Park WH. A case of classical Kaposi’s sarcoma of the penis showing a good response to high-energy pulsed carbon dioxide laser therapy. J Dermatol 1999; 26(4):240– 243. Apfelberg DB, Manchester GH. Decorative and traumatic tattoo biophysics and removal. Clin Plast Surg 1987; 14(2):243 –251. Apfelberg DB. Summary of carbon dioxide laser usage in plastic surgery. Scand J Plast Reconstr Surg 1986; 20(1):19– 24. Bailin PL, Ratz JL, Levine HL. Removal of tattoos by CO2 laser. J Dermatol Surg Oncol 1980; 6(12):997 –1001. Levine H, Bailin P. Carbon dioxide laser treatment of cutaneous hemangiomas and tattoos. Arch Otolaryngol 1982; 108(4):236 – 238. Herbich GJ. Ultrapulse carbon dioxide laser treatment of an iron oxide flesh-colored tattoo. Dermatol Surg 1997; 23(1):60– 61. Ort R, Anderson R, Arndt K, Dover J. CO2 laser resurfacing of tattoos prior to Q-switched laser treatment. 2000. Madden J, Edlich R, Custer J, Panek P, Thul J, Wangensteen O. Studies in the management of the contaminated wound. IV. Resistance to infection of surgical wounds made by knife, electrosurgery, and laser. Am J Surg 1970; 119(3):222– 224. al-Qattan MM, Stranc MF, Jarmuske M, Hoban DJ. Wound sterilization: CO2 laser versus iodine. Br J Plast Surg 1989; 42(4):380 – 384. Lee JS, Tarpley SK, Miller AS III. CO2 laser sterilization in the surgical treatment of infected median sternotomy wounds. South Med J 1999; 92(4):380 – 384. Hinshaw JR, Herrera HR, Lanzafame RJ, Pennino RP. The use of the carbon dioxide laser permits primary closure of contaminated and purulent lesions and wounds. Lasers Surg Med 1987; 6(6):581– 583. Fleming MG, Brody N. A new technique for laser treatment of cutaneous tumors. J Dermatol Surg Oncol 1986; 12(11):1170– 1175. Shaffelburg M, Miller R. Treatment of multiple trichoepithelioma with electrosurgery. Dermatol Surg 1998; 24(10):1154– 1156. Karbe E, Beck W, Englisch G, Konigsmann H, Kramer H, Peterson W, eds. Experimental Surgery with Neodymium, Holmium, CO, and CO2 Lasers. Jerusalem: Jerusalem Academic Press, 1975. Lee MS, Hunt M, Richards S. Wet gauze in CO2 laser resurfacing. Australas J Dermatol 1999; 40(4):230– 231. Widder RA, Severin M, Kirchhof B, Krieglstein GK. Corneal injury after carbon dioxide laser skin resurfacing. Am J Ophthalmol 1998; 125(3):392– 394. Ries WR, Clymer MA, Reinisch L. Laser safety features of eye shields. Lasers Surg Med 1996; 18(3):309 –315. Rohrich RJ, Gyimesi IM, Clark P, Burns AJ. CO2 laser safety considerations in facial skin resurfacing. Plast Reconstr Surg 1997; 100(5):1285 – 1290. Wood RL Jr, Sliney DH, Basye RA. Laser reflections from surgical instruments. Lasers Surg Med 1992; 12(6):675– 678. Anic I, Segovic S, Katanec D, Prskalo K, Najzar-Fleger D. Scanning electron microscopic study of dentin lased with argon, CO2 , and Nd:YAG laser. J Endod 1998; 24(2):77– 81. Lobene R, Bhussry B, Fine S. Interaction of carbon dioxide laser radiation with enamel and dentin. J Dent Res 1968; 47(2):311– 317. Fader DJ, Ratner D. Principles of CO2/erbium laser safety. Dermatol Surg 2000; 26(3):235– 239. Wald D, Michelow BJ, Guyuron B, Gibb AA. Fire hazards and CO2 laser resurfacing. Plast Reconstr Surg 1998; 101(1):185– 188.
176
Ross
238.
Nezhat C, Winer W, Nezhat F, Forrest D, Reeves W. Smoke from laser surgery: is there a health hazard? Lasers Surg Med 1987; 7(4):376 – 382. Baggish MS, Elbakry M. The effects of laser smoke on the lungs of rats. Am J Obstet Gynecol 1987; 156(5):1260 –1265. Smith JP, Moss CE, Bryant CJ, Fleeger AK. Evaluation of a smoke evacuator used for laser surgery. Lasers Surg Med 1989; 9(3):276–281. Baggish M, Poiesz B, Joret D, Williamson P, Refai A. Presence of human immunodeficiency virus DNA in laser smoke. Lasers Surg Med 1991; 11(3):197 – 203. Garden JM, MK OB, Shelnitz LS et al. Papillomavirus in the vapor of carbon dioxide lasertreated verrucae. J Am Med Assoc 1988; 259(8):1199– 1202. Gloster HJ, Roenigk R. Risk of acquiring human papillomavirus from the plume produced by the carbon dioxide laser in the treatment of warts. J Am Acad Dermatol 1995; 32(3):436– 441. Howard J, Arango P, Ossoff J, Ossoff RH, Reinisch L. Healing of laser incisions in rat dermis: comparisons of the carbon dioxide laser under manual and computer control and the scalpel. Lasers Surg Med 1997; 20(1):90 – 96. Ellis DL, Weisberg NK, Chen JS, Stricklin GP, Reinisch L. Free electron laser infrared wavelength specificity for cutaneous contraction. Lasers Surg Med 1999; 25(1):1 – 7. Spector N, Reinisch L, Spector J, Ellis DL. Free-electron laser and heat-conducting templates: a study of reducing cutaneous lateral thermal damage. Lasers Surg Med 2002; 30(2):117 – 122. Weinstein C, Ramirez OM, Pozner JN. Postoperative care following CO2 laser resurfacing: avoiding pitfalls. Plast Reconstr Surg 1997; 100(7):1855– 1866. Weinstein C. Carbon dioxide laser resurfacing. Long-term follow-up in 2123 patients. Clin Plast Surg 1998; 25(1):109 –130. Laws RA, Finley EM, McCollough ML, Grabski WJ. Alabaster skin after carbon dioxide laser resurfacing with histologic correlation. Dermatol Surg 1998; 24(6):633 – 636. Stuzin JM, Baker TJ, Baker TM, Kligman AM. Histologic effects of the high-energy pulsed CO2 laser on photoaged facial skin. Plast Reconstr Surg 1997; 99(7):2036 –2050, discussion 2051– 2055.
239. 240. 241. 242. 243.
244.
245. 246. 247. 248. 249. 250.
APPENDIX I: SAMPLE OPERATIVE NOTE Procedure: CO2 Laser Ablation (Removal) Indication: Adnexal tumor Location: Face Procedure: The patient was counseled regarding the risks and potential benefits of the procedure. After giving informed consent, the skin was hydrated with a wet towel for 10 min. Ninety minutes before surgery, a thick layer of EMLA cream was applied to the treatment site. The cream was removed just prior to surgery. Just before surgery, metal eye shields were placed after instillation of anesthetic eyedrops. The face was cleansed with Septisol solution to include a 2 cm perimeter of untreated skin. A Gentian violet pen was used to demarcate the nodules to be treated. The entire treatment area was surrounded with wet towels and the hair was wetted with sterile saline. Approximately 0.2 cm3 of 2% lidocaine with 1:1,000,000 epinephrine was injected intradermally just deep to each lesion. The lesions were treated with 175–250 mJ with the UltraPulse laser. The 1 mm spot size was used to ablate the lesion to a level where only stippled remnants of the base were observed. Bacitracin ointment was applied, and written and verbal postoperative instructions were provided. The patient will be followed up in 7–10 days. After treatment, the eye shields were removed, and postoperatively, antibiotic ointment was placed over the lesions. The patient was counseled regarding postoperative care and will return within 48 h for evaluation,
Continuous Wave and Pulsed CO2 Lasers
177
dressing removal, and wound cleansing. The patient was discharged from the clinic in good condition.
APPENDIX II: CONSENT FORM Name I understand that Dr. will perform carbon dioxide laser surgery on my (specify location) . I understand laser surgery consists of removing a bump on my skin. I understand that despite the ability of the device to precisely remove skin, the following restrictions apply to the treatment: 1. 2.
3. 4. 5. 6.
The goal is improvement rather than perfection. There is no guarantee that the anticipated results will be achieved. There will be significant swelling, oozing, and crusting, which may last for 1 – 2 weeks. In some cases redness may persist for up to 1 year, particularly in hot weather or after exercising. Improvement may continue as time elapses after treatment. The final result may not be apparent for up to 1 year. If additional improvement is desired after this time, it may be possible to re-treat areas, at additional cost. Although pain management is a primary concern during treatment, some mild transient discomfort may occur, especially “stinging” after the procedure. Generally, the carbon dioxide laser results in skin improvement. However, there is no guarantee that the results will be permanent. In rare cases, the skin can even look worse than before treatment. This may or not be due to one of the complications or consequences of laser surgery. These are outlined below.
I understand that the following complications, although infrequent, can occur after CO2 laser treatment: 1.
2. 3. 4.
Scarring: This can occur in the form a raised or depressed red area with change in skin texture. Over time these may turn white. It is important that any prior history of abnormal scarring is reported. Infection: Despite preventive measures, infection may occur, and additional medications may be necessary for treatment. Color changes: There is a risk of temporary or permanent dark or light changes to the skin. The likelihood of side effects will be decreased by my strict adherence to written postoperative instructions. Besides caring for the wound, avoiding sunlight exposure is critical, especially in the first 12 weeks after surgery.
Alternatives to carbon dioxide laser treatment are: accepting the present skin condition, use of cosmetics, or application of other procedures, including dermabrasion, erbium laser treatment, or surgical excision (cutting the skin lesion out). I have read this form and have been given the opportunity to discuss any questions I may have regarding the nature and aims of this procedure. Patient Witness
Date Date
Surgeon
Date
178
Ross
APPENDIX III: SAMPLE POSTOPERATIVE INSTRUCTIONS 1.
2. 3.
4. 5.
6.
7. 8.
Immediately after treatment, an antibiotic with or without a dressing will be applied. Any dressing will be removed 1 –2 days after treatment. The dressing should be left alone until your follow-up visit. Avoid strenuous exercise for 10 days. Walking before sunrise and after sundown is recommended. There may be swelling after treatment, especially around the eyes (they may even be closed shut for 1 day). This will resolve within 3 days. An ice pack may be placed over swollen sites once the dressing has been removed. This may be done as often as 5 –10 min every hour while awake. Sleeping with your head elevated may reduce swelling (use two pillows). For the next 1–3 days, the wound should be cleaned at home by applying a dilute vinegar solution (about one teaspoon vinegar in one cup water) with a cloth or gauze. After soaking with this for 10–15 min, any excess crusts can be gently removed by using a Q-tip. Cleaning should be done often enough to keep the face clear of cumulated debris. This may require three to five sessions per day for the first 3 days. Occasionally, pinpoint bleeding may occur; this can be stopped by applying gentle pressure for several minutes. After cleaning the wound, a petrolatum-type ointment or antibiotic ointment should be applied. You are encouraged to allow shower water to irrigate the wound. Hair can be washed at the same time, preferably only with baby shampoo until after 5 days. You should not apply soaps to the open skin. Once the skin is healed (no open areas), your normal soap may be resumed. Before cleaning your face, you should wash your hands with an antibacterial soap (e.g., Dial or Safeguard) to avoid contamination of the treatment area. We will normally want to see you for follow-up visits weekly for the first 3 weeks after treatment. Call the office immediately for any rash, fever, or severe pain. These may be early signs of infection.
After 1 Week 1. After 1 week normally, the skin will be healed enough for you to be able to venture outside. When outside, the face should be covered with a broadspectrum sunscreen (at least SPF 15) and the head covered with a broad-brim hat. Total block 60 (Fallene Ltd., King of Prussia, PA) is recommended. It is most important to avoid any sun exposure as long as the skin is pink. Even a brief trip across the parking lot without protection can result in dark brown splotches. 2. A green concealer can be used to neutralize residual redness. A flesh-tone foundation can then be applied to conceal the green tone. 3. A light moisturizer can be applied ad lib (Curel, Moisturel, or Purpose) 4. Apply a steroid cream every night if your doctor prescribes it for redness. APPENDIX IV: PATIENT INFORMATION HANDOUT The carbon dioxide laser has become a popular method for skin surgery. By precisely removing and gently heating skin wrinkles, for example, new healthier skin will appear during the healing period. Also, the contour of acne scars can be improved. Other benign skin bumps can also be removed with the carbon dioxide laser. The carbon
Continuous Wave and Pulsed CO2 Lasers
179
dioxide laser has been the most popular machine used to peel the skin. Although it works well, the heat generated causes prolonged healing. Often, 10 days to 2 weeks are required before crusts completely resolve and you can comfortably return to work. Also, often red skin is noted up to 4 months after surgery. Sometimes only a cream application is required for skin numbing, but usually an injection (with a needle—like at the dentist’s office) will be required to make you comfortable during the laser surgery. At the consultative visit, you will be counseled about the risks and benefits of carbon dioxide laser surgery. Representative photographs will be shown. If you are interested in carbon dioxide laser treatment, a date will be scheduled for surgery and a handout specific for your skin condition type of surgery will be provided.
6 Er:YAG Lasers Ulrich Hohenleutner and Michael Landthaler University of Regensburg, Regensburg, Germany
1. Introduction 2. Laser – Tissue Interaction 2.1. Er:YAG Laser Physics 2.2. Laser – Tissue Interaction 2.3. Ablation Efficacy 2.4. Residual Thermal Damage 2.5. Laser Plume and Noise 3. Commercially Available Er:YAG Lasers 4. Er:YAG Laser Treatment 4.1. General Treatment Considerations and Contraindications 4.2. Treatment Techniques 4.3. Anesthesia 4.4. Pre- and Perioperative Care 4.5. Postoperative Care 4.6. Wound Healing and Side Effects 5. Treatment Results 5.1. Skin Resurfacing (Rhytides, Actinically Damaged Skin) 5.1.1. Er:YAG Lasers Alone 5.1.2. Comparisons/Combinations of Er:YAG and CO2 Laser 5.2. Pigmentory Abnormalities 5.3. Acne Scars 5.4. Other Skin Lesions 6. Conclusion References
1.
181 182 182 182 183 183 184 186 186 187 188 189 189 189 190 190 190 191 192 192 193 193 194 194
INTRODUCTION
The introduction of Er:YAG lasers has considerably broadened the therapeutic possibilities for skin disorders. Er:YAG lasers allow an extremely precise but superficial ablation of the skin with considerably faster healing and reduced side effects compared to the CO2 laser. 181
182
Hohenleutner and Landthaler
Their ablative effect is comparable to mechanical dermabrasion, but the technique is simpler to perform without the risk of injury from the high-speed rotating fraises. In areas of loose or thin skin like lips or eyelids, where even pulsed CO2 lasers carry a considerable risk of scarring, Er:YAG lasers are safe and effective. This chapter will present an overview of the laser–tissue interaction of Er:YAG lasers, their clinical applicability, therapeutic indications, and results, and the general considerations in Er:YAG laser therapy.
2. 2.1.
LASER – TISSUE INTERACTION Er:YAG Laser Physics
Like neodymium:YAG lasers, Er:YAG lasers are solid state lasers that mostly are flash lamp pumped. The laser medium is a crystal rod consisting of yttrium aluminum garnet that is doped with erbium. Er:YAG lasers emit light at 2940 nm wavelength, which is in the near-infrared spectrum. Like Nd:YAG lasers, they can be Q-switched (1), but most Er:YAG lasers for clinical applications work in the so-called free-running mode. Typical pulse times are 250 ms (250–350 ms). During this macropulse, Er:YAG lasers emit a chain of highenergy, 1 ms short pulses, so-called spikes (1,2). For clinical applications, the light of the Er:YAG laser usually is transmitted to the operating field by mirror arms and focusing lens handpieces, rather than via the usual quartz fibres because they absorb the Er:YAG lasers’ wavelength. 2.2.
Laser – Tissue Interaction
At 2940 nm, water has an absorption maximum. The absorption coefficient of water at this wavelength is approximately 13,000 cm21 (3–5). Additionally, the wavelength of the Er:YAG laser is very close to an absorption maximum of collagen at 3030 nm (6). Therefore, skin containing 70– 80% water has an absorption coefficient of approximately 8000 – 9000 cm21 at 2940 nm (1,3,4). In comparison, at the wavelength of CO2 laser radiation (10,600 nm), the absorption coefficient of water is approximately 790 cm21 (5). This very high absorption of the Er:YAG laser radiation in skin directly explains the precise and effective ablation properties of Er:YAG lasers. The irradiated light is absorbed in very small tissue volumes that are maximally heated and explosively vaporized. The theoretical skin penetration depth of Er:YAG laser radiation is 1 mm (3 – 5), as stated before. This penetration depth cannot explain the highly effective tissue vaporization that is possible with these lasers. Experimental ablation efficacies in skin of up to 200 mm and more per pulse (at 80 J/cm2) (1) have been observed. These ablation depths, nevertheless, can be explained by the model of dynamic vaporization and by the changed optical properties of water at high temperatures and high pressures (1,3,4). During a high-irradiance laser pulse, small layer after small layer of skin is irradiated and maximally heated while the more superficial layers are vaporized (4). The high temperatures and high pressures in the thin tissue layers change the optical properties of water and, consecutively, of the tissue. The water absorption decreases by two orders of magnitude (3) and allows a higher penetration depth of the laser radiation, which increases the ablation efficacy. Additionally, water vapor is nearly transparent for Er:YAG laser radiation (1). Therefore, the ejected particles and the vapor that are in the laser beam during the ablating macropulse cannot significantly weaken the incident irradiation. Hence, tissue layer after tissue laser is effectively removed, the particles are ejected at supersonic speed (1), and a deep tissue ablation becomes possible.
Er:YAG Lasers
183
These dynamic optical properties of water during infrared laser ablation (3) also explain the typical residual thermal damage zones of 10– 50 mm that are seen with Er:YAG lasers. With static optical properties and a theoretical penetration depth of 1 mm, these residual thermal damage zones would be limited to exactly this penetration depth and not exceed 1 mm. 2.3.
Ablation Efficacy
The threshold for ablation of skin with Er:YAG lasers in free-running mode with a pulse time around 250 ms is 1.5 J/cm2 (0.7 – 1.7 J/cm2) (2,7 –9). At fluences up to 20 J/cm2, the ablation per pulse strongly increases with the irradiant fluence. This has been demonstrated in many in vitro studies using pig or human skin (3,8 –10). Above 20 J/cm2, the ablation efficacy increases more slowly, but still linearly with the fluence (3). Above 60 J/cm2, the additional ablation that is achievable by an increase of the fluence further decreases (3). The application of multiple consecutive pulses to the same spot of tissue (“pulse stacking”) leads to decreased ablation efficacy and increased thermal damage. Although Hibst and Kaufmann (8) could not observe this effect at repetition frequencies of 1 Hz and 1 mm spot size, in our own study with repetition rates of 7 – 10 Hz we could clearly demonstrate this effect for 3 –4 mm spot sizes (9). The thermal damage zone was clearly dependent on the number of pulses applied and increased from 25 mm with less than 10 pulses to 100 mm with 40 pulses. This effect was confirmed by Ross et al. (11), who observed a 12-fold increase of thermal necrosis due to pulse stacking. In clinical application, pulse stacking, as defined by 100% overlap of pulses, is prevented by the sweeping motion of the handpiece over the skin that is used for most indications. Even at higher repetition frequencies, 100% pulse overlap is improbable when using this technique, and even if two or three pulses should be applied on the same spot, the thermal coagulation depth is not yet increased (see later). The ablation efficacy of skin with Er:YAG lasers at above-threshold fluences is between 2.5 and 6 mm per pulse per 1 J/cm2 (1,8 – 10). For example, with 1 mm spot size at 5 J/cm2 the ablation is about 10 mm per pulse (1,9) and increases to 20 mm at 10 J/cm2 and to 60 mm at 20 J/cm2 (1). To estimate the ablation depth per pass (in mm) for clinical purposes, it is recommended to multiply the applied fluence by 4 (12). These high ablation rates result in a relatively fast and effective ablation of skin in vivo. With typical clinical settings of 5 J/cm2 and repetition rates of 10 Hz, 20 – 60 mm of tissue is vaporized with one to two passes; with three passes, the vaporization increases to 80– 120 mm (13). In contrast to CO2 lasers, an increased number of passes with Er:YAG lasers does not lead to a decreased ablation efficacy (14 –16). With CO2 lasers, after several passes the tissue becomes increasingly dehydrated due to the fluid sealing effect of the coagulation zones, which can amount to up to 200 mm (17 – 20). Due to the lack of water, the skin can no more be vaporized and is only heated, which further increases the coagulation damage (16). With Er:YAG lasers, due to the minimal coagulation zones, there is no dehydration of tissue, hence no limit to tissue vaporization (14 –16). 2.4.
Residual Thermal Damage
Compared to the CO2 laser, the main advantage of Er:YAG lasers is the minimal to almost absent residual thermal damage in the skin. Many studies, either in vitro or in vivo, have clearly demonstrated that with output parameters as they are used in clinical application
184
Hohenleutner and Landthaler
(fluences up to 25 J/cm2, spot sizes up to 6 mm, repetition frequencies up to 20 Hz), the zone of residual thermal damage as visualized by collagen denaturation is typically about 10 – 30 mm and does not exceed 50 mm (2,9,10,12,13,17,21 – 24). Even with up to 10 passes at fluences of 14 – 24 J/cm2, the thermal necrosis remains constant at 15– 40 mm (14). Compared to the CO2 laser, this dramatically reduced thermal damage leads to reduced healing times, reduced postlaser erythema, and a lower frequency of side effects. Nevertheless, for the clinical effect of wrinkle reduction, the reduced coagulation of collagen and elastic fibers is a disadvantage. Some studies directly comparing Er:YAG and CO2 lasers for rhytides showed that although the Er:YAG laser leads to faster healing and reduced side effects, wrinkle improvement was better and more prolonged with the CO2 laser (17,25 –29). For non-skin-resurfacing indications, the nearly complete absence of residual thermal damage makes the Er:YAG laser the more precise and safer tool. Nevertheless, this holds true only for relatively superficial and not strongly vascularized skin lesions. The main disadvantage of the Er:YAG lasers in skin ablation is their inability to stop bleeding. Due to the absence of coagulation, there is a profuse capillary bleeding as soon as the papillary dermis with its superficial vessel loops is reached (2,7). This bleeding considerably interferes with further ablation in a clinical setting. Further ablation is only possible when the bleeding has stopped, since the blood film on the tissue prevents any further vaporization. Therefore, the clinical applicability of Er:YAG lasers for deeper vaporization, cutting, or the treatment of highly vascularized skin lesions (e.g., common or genital warts) is limited. Some Er:YAG lasers provide subablative pulses at subthreshold energy densities or with longer pulse times which produce a coagulation effect similar to CO2 lasers and are hemostatic. With pulse lengths up to 700 ms, decreased bleeding was noted without increasing residual thermal damage (30). Other authors, nevertheless, found that with subthreshold, longer pulses (“heating pulses”) the thermal damage zones increase up to 80 mm (31) and 100 mm, respectively (32). In contrast to ablative (above-threshold) pulses, “pulse stacking” with subablative pulses leads to greatly increased residual thermal damage, which can reach 200 mm (33). These increased coagulation zones lead to more hemostasis in the operating field and also to prolonged healing times and increased side effects compared to the pure ablative mode. In the clinical setting, these subablative pulses, provided by some Er:YAG lasers (Table 6.1), are used to produce a larger zone of thermal damage, with CO2 laser like clinical effects. The resultant “collagen shrinkage” and “collagen remodeling” have improved the long-term efficacy of Er:YAG laser skin resurfacing (34,35).
2.5.
Laser Plume and Noise
Several studies have demonstrated that the CO2 laser plume may carry infectious particles and is hazardous for the lungs due to the particle size (36 – 40). Regarding the Er:YAG laser plume, only one study exists so far. Hughes and Hughes (41) could not demonstrate HPV-DNA in the Er:YAG laser plume when treating human warts. Possibly, the intensive fragmentation and heating that occur when tissue is explosively vaporized and the particles are ejected at supersonic speed (1) prevent the survival of infectious particles in the Er:YAG laser plume. Nevertheless, until further data are available, it is recommended that infectious patients (hepatitis B and C, HIV) should not be treated with ablative lasers including Er:YAG lasers (7) since the risk of disseminating the infection cannot be totally excluded.
TM
2
No
–15 Hz –15 Hz –50 Hz
250 ms 350 ms
–1.2 J/pulse
2 J/pulse
45 W 100 ms–200 ms (Nd:YAG) ND ND
0.1– 45 W (Nd:YAG) –2 J/pulse
–2 J/pulse
500 ms
ND
–20 Hz
–45 Hz
1– 4 Hz
a ND ¼ no data available. Note: This table may be incomplete and implies no recommendation for specific machines!
Wavelight GmbH BuraneTM, www.wavelight-laser.net Wavelight GmbH SuperbTM, www.wavelight-laser.net
Sciton ProfileTM, www.sciton.com
Yes
–15 Hz
100/300/750/ 1000 ms 250 ms
2 J/pulse
Laserscope VenusTM Laser System, www.laserscope.com Limmer Laser UNILAS 2940, www.limmermt.com Lynton Lasers Ltd. SkinlightTM, www.lyntlaz.demon.co.uk Lynton Lasers Ltd. Skinlight PlusTM, www.lyntlaz.demon.co.uk Sciton ContourTM, www.sciton.com
–1 J/pulse
No
–20 Hz
300 ms
0.8 J/pulse
Yes
Yes
ND
Yes
No
ND
ND
2.5–3.5–5 mm, focused
2, 3, 4, 6, 10 mm, focused
Collimated, 4 mm
Focused, 1.5– 7 mm
Focused, 1.5– 7 mm
Focused, 1.2– 5 mm
Collimated, 3/5/7 mm
Focused, –10 mm collimated and contact fibers also available Focused, 1–8 mm
IrradiaTM, www.irradia.se
Yes
1 J/pulse
Fotona FidelisTM, www.fotona.de –50 Hz
ND
Yes
ND
ND
–3 J/pulse 100, 300, 750, 1000 ms
Focused, 1–10 mm
No
–28 Hz
250 ms
0.8–1–1.2 mm and 1–10 mm focused ND
Focused, 1.5– 5 mm fiber
Handpiece and spot size
–2 J/pulse
No
No
Yes
Long pulses (subablative)
–15 Hz
–28 Hz
–20 Hz
Repetition rate
250 ms
250 ms
ND
a
Pulse length
–1.2 J/pulse
–2 J/pulse
4–40 J/cm
Output
Asclepion-Meditec MCL 29 DermablateTM, www.asclepion.com Asclepion-Meditec DermablateTM, www.asclepion.com Fotona NovalisTM, www.fotona.si
Asclepion-Meditec Derma Star , www.asclepion.com Asclepion-Meditec Dermablate HareTM, www.asclepion.com
Company, web address
Table 6.1 Commercially Available Nd:YAG Lasers
ND
ND
Available
Integrated
ND
ND
ND
Available
ND
ND
ND
Available
ND
Available
ND
Scanner
Built-in Nd:YAG/KTP laser at 532 nm Variable coagulation depths up to 100 mm Built-in Nd:YAG for hair and vascular lesions
Cutting handpiece available
Built-in ruby and KTP 532 nm lasers Desktop size
Smoke evacuation in handpiece Built-in ruby laser for hair removal
Additional handpiece for hair transplant holes
Specialities
Er:YAG Lasers 185
186
Hohenleutner and Landthaler
Safety considerations as well as the prevention of unpleasant odors make an effective smoke evacuation device absolutely necessary for Er:YAG laser as well as for CO2 laser treatment. Another problem that is specific to the Er:YAG laser is the typical cracking noise that is associated with the explosive skin vaporization. Especially with higher fluences and high repetition rates, the resulting hammering noise is not unlike machine gun fire and can be quite bothersome (7). Depending on the distance to the treatment field, the noise intensity can reach levels that can possibly damage the ears [at least with chronic exposure (42)]. Therefore, for extensive procedures, the use of ear protection is recommended or at least should be taken into consideration.
3.
COMMERCIALLY AVAILABLE Er:YAG LASERS
As solid state lasers, Er:YAG lasers normally are reliable machines without high running expenses. Due to internal cooling circulation systems, they are air cooled and run on 110 or 220 V. In contrast to CO2 lasers, where different pulse lengths and different scanners lead to significantly different laser – tissue interactions and coagulation zones, the various commercially available Er:YAG lasers, at least with respect to their ablative pulses, produce similar effects on skin. This has been shown in a study by Alster (13), who performed a clinical and histological evaluation of six different Er:YAG lasers for skin resurfacing. Nevertheless, the Er:YAG laser machines offer different options for subablative pulses. Subthreshold pulses are available alone or in (fixed) combination with ablative pulses, and the irradiation parameters can be chosen either directly as fluence and/or pulse length or as the desired depth of coagulation. Also, the machines are different regarding their technical equipment. Output energies up to 2 J per pulse, spot sizes up to